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Tumour profiling tests to guide adjuvant chemotherapy
decisions in early breast cancer: a systematic review and
economic analysis
Sue Harnan,1* Paul Tappenden,1 Katy Cooper,1 John Stevens,1
Alice Bessey,1 Rachid Rafia,1 Sue Ward,1 Ruth Wong,1
Robert C Stein2,3 and Janet Brown4
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2University College London Hospitals Biomedical Research Centre, London, UK
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4Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
*Corresponding author s.harnan@sheffield.ac.uk
Background: Breast cancer and its treatment can have an impact on health-related quality of life and
survival. Tumour profiling tests aim to identify whether or not women need chemotherapy owing to their
risk of relapse.
Objectives: To conduct a systematic review of the effectiveness and cost-effectiveness of the tumour
profiling tests oncotype DX® (Genomic Health, Inc., Redwood City, CA, USA), MammaPrint® (Agendia, Inc.,
Amsterdam, the Netherlands), Prosigna® (NanoString Technologies, Inc., Seattle, WA, USA), EndoPredict®
(Myriad Genetics Ltd, London, UK) and immunohistochemistry 4 (IHC4). To develop a health economic
model to assess the cost-effectiveness of these tests compared with clinical tools to guide the use of
adjuvant chemotherapy in early-stage breast cancer from the perspective of the NHS and Personal Social
Services.
Design: A systematic review and health economic analysis were conducted.
Review methods: The systematic review was partially an update of a 2013 review. Nine databases were
searched in February 2017. The review included studies assessing clinical effectiveness in people with
oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, stage I or II cancer with
zero to three positive lymph nodes. The economic analysis included a review of existing analyses and the
development of a de novo model.
Results: A total of 153 studies were identified. Only one completed randomised controlled trial (RCT)
using a tumour profiling test in clinical practice was identified: Microarray In Node-negative Disease may
Avoid ChemoTherapy (MINDACT) for MammaPrint. Other studies suggest that all the tests can provide
information on the risk of relapse; however, results were more varied in lymph node-positive (LN+) patients
than in lymph node-negative (LN0) patients. There is limited and varying evidence that oncotype DX and
MammaPrint can predict benefit from chemotherapy. The net change in the percentage of patients with
a chemotherapy recommendation or decision pre/post test ranged from an increase of 1% to a decrease
of 23% among UK studies and a decrease of 0% to 64% across European studies. The health economic
analysis suggests that the incremental cost-effectiveness ratios for the tests versus current practice are
broadly favourable for the following scenarios: (1) oncotype DX, for the LN0 subgroup with a Nottingham
Prognostic Index (NPI) of > 3.4 and the one to three positive lymph nodes (LN1–3) subgroup (if a predictive
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benefit is assumed); (2) IHC4 plus clinical factors (IHC4+C), for all patient subgroups; (3) Prosigna, for
the LN0 subgroup with a NPI of > 3.4 and the LN1–3 subgroup; (4) EndoPredict Clinical, for the LN1–3
subgroup only; and (5) MammaPrint, for no subgroups.
Limitations: There was only one completed RCT using a tumour profiling test in clinical practice.
Except for oncotype DX in the LN0 group with a NPI score of > 3.4 (clinical intermediate risk), evidence
surrounding pre- and post-test chemotherapy probabilities is subject to considerable uncertainty. There is
uncertainty regarding whether or not oncotype DX and MammaPrint are predictive of chemotherapy
benefit. The MammaPrint analysis uses a different data source to the other four tests. The Translational
substudy of the Arimidex, Tamoxifen, Alone or in Combination (TransATAC) study (used in the economic
modelling) has a number of limitations.
Conclusions: The review suggests that all the tests can provide prognostic information on the risk of relapse;
results were more varied in LN+ patients than in LN0 patients. There is limited and varying evidence that
oncotype DX and MammaPrint are predictive of chemotherapy benefit. Health economic analyses indicate
that some tests may have a favourable cost-effectiveness profile for certain patient subgroups; all estimates
are subject to uncertainty. More evidence is needed on the prediction of chemotherapy benefit, long-term
impacts and changes in UK pre-/post-chemotherapy decisions.
Study registration: This study is registered as PROSPERO CRD42017059561.
Funding: The National Institute for Health Research Health Technology Assessment programme.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
vi
Contents
List of tables xi
List of figures xvii
List of boxes xix
List of supplementary material xxi
List of abbreviations xxiii
Plain English summary xxvii
Scientific summary xxix
Chapter 1 Background and definition of the decision problem 1
Condition and aetiology 1
Aetiology, pathology and prognosis 1
Epidemiology and incidence 3
Significance in terms of ill health (burden of disease) 3
Measurement of disease 3
Current service provision 4
Management of early-stage breast cancer 4
Use of adjuvant chemotherapy 4
Current guidelines 4
Description of technologies under assessment 6
Gene expression profiling tests 7
Immunohistochemical-based tests 7
Summary of tumour profiling tests included in the assessment 7
Current usage of tumour profiling tests in the NHS 11
Description of the decision problem 11
Interventions 11
Comparators 12
Population and important subgroups 12
Outcomes 13
Aims and objectives of the assessment 13
Chapter 2 Clinical evidence 15
Methods 15
Identification of studies 15
Inclusion and exclusion criteria 16
Study selection process 19
Data extraction 19
Quality assessment 20
Data presentation and synthesis 21
Results 21
Quantity of evidence 21
Overview of results 22
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Results: oncotype DX 23
Development: oncotype DX 23
Prognostic performance: oncotype DX 24
Chemotherapy benefit: oncotype DX 33
Clinical utility: oncotype DX 41
Results: MammaPrint 46
Development: MammaPrint 46
Prognostic performance: MammaPrint 46
Chemotherapy benefit: MammaPrint 54
Clinical utility: MammaPrint 57
Results: Prosigna 67
Prognostic performance: Prosigna 67
Results: EndoPredict and EndoPredict Clinical 68
Development: EndoPredict and EndoPredict Clinical 68
Prognostic performance: EndoPredict and EndoPredict Clinical 68
Results: IHC4 79
Development and analytic validity: IHC4 79
Prognostic performance: IHC4 and IHC4+C 79
Results: all tests compared with each other 90
Results: decision impact studies 90
Decision impact: study and patient characteristics 90
Decision impact: results 92
Summary and discussion of decision impact studies 98
Anxiety and health-related quality of life 98
Oncotype DX 98
MammaPrint 98
EndoPredict 102
Prosigna 102
Discussion 102
Conclusions 102
Time-to-test results 102
Chapter 3 Cost-effectiveness 103
Independent economic evaluation 103
Scope of the External Assessment Group economic analysis 103
Model structure 105
Evidence sources used to inform the model parameters 107
Methods for model evaluation 117
Model verification and validation 118
Cost-effectiveness results 120
Comparison between the Genomic Health model, the current External
Assessment Group model and the previous External Assessment Group
model (lymph node negative, clinical intermediate-risk subgroup) 138
Discussion 140
Chapter 4 Discussion and conclusions 145
Statement of principal findings 145
Clinical effectiveness: principal findings 145
Cost-effectiveness: principal findings 146
Strengths and limitations of the assessment 147
Strengths and limitations in the clinical evidence base 147
Strengths and limitations relating to the health economic analysis 148
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Uncertainties 149
Generalisability 149
Implications for service provision 149
Suggested research priorities 150
Acknowledgements 151
References 153
Appendix 1 Additional tables for Chapter 1 199
Appendix 2 Literature search strategies 201
Appendix 3 Table of excluded studies with rationale 225
Appendix 4 Summary of the clinical review 227
Appendix 5 Results: all tests compared with each other 235
Appendix 6 Review of existing economic analyses published since National
Institute for Health and Care Excellence Diagnostics Guidance 10 279
Appendix 7 Review and critical appraisal of economic analyses provided by test
manufacturers 291
Appendix 8 External Assessment Group model input parameter tables 299
Appendix 9 External Assessment Group post-test chemotherapy use survey
disseminated to UK Breast Cancer Group members 309
Appendix 10 Modelled chemotherapy use with and without tumour profiling
tests (External Assessment Group model) 311
Appendix 11 External Assessment Group cost-effectiveness acceptability curves 313
Appendix 12 Additional economic analyses undertaken after submission of the
original External Assessment Group report 321
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix
List of tables
TABLE 1 Summary of technologies included in the assessment 8
TABLE 2 The PROBAST quality criteria and scoring 20
TABLE 3 Oncotype DX prognostic performance: DRFS, DRFI and DFS 26
TABLE 4 Oncotype DX: additional prognostic value over clinicopathological
factors or comparator tests 30
TABLE 5 Oncotype DX RSPC, discrimination, reclassification and additional
prognostic value 34
TABLE 6 The prediction of chemotherapy responsiveness by oncotype DX:
reanalyses of RCT data 36
TABLE 7 The prediction of chemotherapy responsiveness by oncotype DX:
observational studies 38
TABLE 8 Clinical utility results: oncotype DX 43
TABLE 9 Prognostic performance of MammaPrint: DRFS/DRFI 48
TABLE 10 Prognostic performance of MammaPrint for patients at high or low
clinical risk 51
TABLE 11 Additional prognostic value for DRFS/DRFI: MammaPrint 52
TABLE 12 Prediction of chemotherapy responsiveness: MammaPrint 56
TABLE 13 Clinical utility of MammaPrint (MINDACT) 59
TABLE 14 Clinical utility of MammaPrint (RASTER study): DRFI in node-negative
patients 62
TABLE 15 Clinical utility of MammaPrint (RASTER study): additional prognostic
value in node-negative patients 64
TABLE 16 Clinical utility of MammaPrint (RASTER study): DRFI in node-positive
patients 66
TABLE 17 Prognostic performance of Prosigna: DRFS/DRFI 69
TABLE 18 Additional prognostic value for DRFI/DRFS: Prosigna 72
TABLE 19 Prognostic performance of EndoPredict and EPClin: DRFS/DRFI 75
TABLE 20 Additional prognostic value for DRFI/DMFS: EndoPredict and EPClin 77
TABLE 21 Characteristics of prognostic studies: IHC4 and IHC4+C 80
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi
TABLE 22 Prognostic performance of IHC4: DRFS and DRFI 84
TABLE 23 Additional prognostic value, all outcomes: IHC4 85
TABLE 24 Prognostic performance of IHC4+C: DRFI 89
TABLE 25 Additional prognostic value, all outcomes: IHC4+C 91
TABLE 26 Decision impact results: oncotype DX 93
TABLE 27 Decision impact results: EndoPredict (EPClin) 95
TABLE 28 Decision impact results: IHC4+C 96
TABLE 29 Decision impact results: Prosigna 96
TABLE 30 Decision impact results: MammaPrint 97
TABLE 31 Study and patient characteristics: anxiety and HRQoL 99
TABLE 32 Results: anxiety and HRQoL 100
TABLE 33 Scope of the EAG economic analysis 103
TABLE 34 Evidence sources used in the model 108
TABLE 35 Studies available to inform chemotherapy use conditional on test results 112
TABLE 36 Distributions used in EAG probabilistic analyses 118
TABLE 37 List of DSAs undertaken for each test 119
TABLE 38 Central estimates of cost-effectiveness: oncotype DX vs. current
practice – probabilistic model 121
TABLE 39 Probability of optimality: oncotype DX vs. current practice 121
TABLE 40 Deterministic sensitivity analyses: oncotype DX vs. current practice 122
TABLE 41 Central estimates of cost-effectiveness: IHC4+C vs. current practice –
probabilistic model 125
TABLE 42 Probability of optimality: IHC4+C vs. current practice 125
TABLE 43 Deterministic sensitivity analyses: IHC4+C vs. current practice 127
TABLE 44 Central estimates of cost-effectiveness: Prosigna vs. current practice –
probabilistic model 129
TABLE 45 Probability of optimality: Prosigna vs. current practice 129
TABLE 46 Deterministic sensitivity analyses: Prosigna vs. current practice 130
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xii
TABLE 47 Central estimates of cost-effectiveness: EPClin vs. current practice –
probabilistic model 132
TABLE 48 Probability of optimality: EPClin vs. current practice 132
TABLE 49 Deterministic sensitivity analyses: EPClin vs. current practice 133
TABLE 50 Central estimates of cost-effectiveness: MammaPrint vs. current
practice (mAOL) – probabilistic model 135
TABLE 51 Probability of optimality: MammaPrint vs. current practice (mAOL) 135
TABLE 52 Deterministic sensitivity analyses: MammaPrint vs. current practice
(mAOL) 136
TABLE 53 Summary of structural assumptions and evidence sources 139
TABLE 54 Comparison of ICERs generated using the current EAG model, the
previous EAG model and the Genomic Health model (LN0 NPI > 3.4 subgroup) 141
TABLE 55 Incidence of breast cancer per 100,000 people in England, by age
group and sex (2014) 199
TABLE 56 Breast cancer risk prediction tools 199
TABLE 57 Summary of risk categorisation and prognostic and predictive
(of chemotherapy benefit) ability across tests 228
TABLE 58 Characteristics of prognostic studies: multiple tests 236
TABLE 59 Quality assessment of prognostic studies: multiple tests 239
TABLE 60 Prognostic performance of multiple tests: DRFI/DMFS/DRFS 241
TABLE 61 Prognostic performance of multiple tests: OS 246
TABLE 62 Additional prognostic value (likelihood ratio χ2 values): multiple tests 250
TABLE 63 Additional prognostic value (C-indices and multivariable analyses):
multiple tests 252
TABLE 64 Characteristics of microarray studies 258
TABLE 65 Microarray results: HRs 262
TABLE 66 Microarray results: C-index (AUC) data 267
TABLE 67 Microarray results: additional prognostic value 271
TABLE 68 Percentage in each risk category and kappa statistics between tests 276
TABLE 69 Existing economic evaluations: analytic scope 281
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 70 Existing economic evaluations: modelling approach and assumptions
regarding predictive benefit and chemotherapy 283
TABLE 71 Evidence sources used in the Genomic Health model 293
TABLE 72 Risk of distant recurrence and the benefit (RR) of chemotherapy 293
TABLE 73 Parameter values in the LN+ analysis 294
TABLE 74 Parameter values for MammaPrint, EndoPredict score, EPClin and
Prosigna 294
TABLE 75 Results of the Genomic Health model: oncotype DX vs. standard care
and other comparator tests 296
TABLE 76 Risk classification probabilities using oncotype DX, Prosigna, IHC4+C
and EPClin (TransATAC) 299
TABLE 77 Risk classification probabilities using MammaPrint (MINDACT) 299
TABLE 78 The 10-year distant recurrence rates by risk classification for oncotype DX,
Prosigna, IHC4+C and EPClin 300
TABLE 79 Calculation of 5-year DMFS probabilities by clinical/genomic risk group
and chemotherapy use 301
TABLE 80 Baseline chemotherapy probabilities by risk group [provided by NCRAS
(Dr Kwok Wong, Senior Cancer Analyst, National Cancer Registration and
Analysis Service, 28 June 2017)] 302
TABLE 81 Summary of post-test chemotherapy probabilities conditional on risk
classification 302
TABLE 82 Estimates of adjuvant chemotherapy benefit applied in the EAG model 302
TABLE 83 Summary of EQ-5D health state valuations in identified studies 303
TABLE 84 Health utilities applied in the EAG model 304
TABLE 85 Test costs assumed in the EAG analysis 304
TABLE 86 Adjuvant chemotherapy costs applied in the EAG model 305
TABLE 87 Endocrine therapy costs applied in the EAG model 306
TABLE 88 Cusumano et al. post-test chemotherapy probabilities (node negative
and node positive) 306
TABLE 89 Penault-Llorca et al. post-test chemotherapy probabilities (LN0) 306
TABLE 90 Baseline probability of chemotherapy adjusted by oncotype DX Breast
Recurrence Score (LN0, intermediate clinical risk) 306
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
TABLE 91 Risk classification probabilities and 10-year DMFI probabilities for RSPC
(from TransATAC analysis) 307
TABLE 92 Prosigna risk classification and distant metastases probabilities derived
from Gnant and Filipits (LN+) 307
TABLE 93 EndoPredict Clinical risk classification and distant metastases
probabilities derived from Dubsky et al. (LN+) 307
TABLE 94 MammaPrint risk classification and distant metastases probabilities
derived from van ’t Veer et al. (LN0) 307
TABLE 95 Cost-effectiveness of chemotherapy vs. no chemotherapy 321
TABLE 96 The QALY shortfall analysis: oncotype DX (prognostic benefit only) 322
TABLE 97 The QALY shortfall analysis: oncotype DX (predictive benefit) 322
TABLE 98 The QALY shortfall analysis: IHC4+C 323
TABLE 99 The QALY shortfall analysis: Prosigna 324
TABLE 100 The QALY shortfall analysis: EPClin 324
TABLE 101 The QALY shortfall analysis: MammaPrint 325
TABLE 102 Hazard ratios for chemotherapy benefit by oncotype DX risk score
based on naive indirect comparisons of Study B20, Study B14 and TransATAC 327
TABLE 103 Additional analyses of oncotype DX vs. usual practice including
chemotherapy benefit based on naive indirect comparisons of Study B20, B14
and TransATAC: LN0, NPI > 3.4 subgroup 327
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
List of figures
FIGURE 1 Five-year net survival, by age, for women in England: 2009–13 2
FIGURE 2 Five-year relative survival, by stage, for women aged 15–99 years in
the former Anglia Cancer Network: 2002–6 2
FIGURE 3 Diagnosis and management pathway in breast cancer 5
FIGURE 4 The PRISMA flow diagram 21
FIGURE 5 The EAG model: decision tree component 105
FIGURE 6 The EAG model: state-transition model component 106
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii
List of boxes
BOX 1 Main issues relating to the Genomic Health model identified by the EAG 297
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix
List of supplementary material
Report Supplementary Material 1 Comparison of TransATAC data with other study data
(risk classification and prognosis)
Report Supplementary Material 2 Narrative synthesis and additional tables from Chapter 2,
Results: oncotype DX
Report Supplementary Material 3 Narrative synthesis and additional tables for Chapter 2,
Chemotherapy benefit: oncotype DX and RSPC
Report Supplementary Material 4 Narrative synthesis and additional tables for Chapter 2,
Clinical utility: oncotype DX
Report Supplementary Material 5 Narrative synthesis and additional tables from Chapter 2,
Results: MammaPrint
Report Supplementary Material 6 Narrative synthesis and additional tables for Chapter 2,
Results: Prosigna
Report Supplementary Material 7 Narrative synthesis and additional tables for Chapter 2,
Results: Endopredict and EndoPredict Clinical
Report Supplementary Material 8 Narrative synthesis and additional tables for Chapter 2,
Development and analytic validity: IHC4
Report Supplementary Material 9 Additional tables for Chapter 2, Results: decision impact
studies
Report Supplementary Material 10 Microarray data relating to one test only
Supplementary material can be found on the NIHR Journals Library report project page
(www.journalslibrary.nihr.ac.uk/programmes/hta/163003/#/documentation).
Supplementary material has been provided by the authors to support the report and any files
provided at submission will have been seen by peer reviewers, but not extensively reviewed. Any
supplementary material provided at a later stage in the process may not have been peer reviewed.
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
List of abbreviations
ABCSG Austrian Breast and Colorectal
Cancer Study Group
AE adverse event
AiC academic in confidence
AML acute myeloid leukaemia
AOL Adjuvant! Online
ASCO American Society of Clinical
Oncology
ATAC Arimidex, Tamoxifen, Alone or in
Combination
AUC area under the curve
BCS Edinburgh Breast Conservation
Series
BCSS breast-cancer-specific survival
BNF British National Formulary
CALGB Cancer and Leukemia Group B
cDNA complementary deoxyribonucleic
acid
CE Conformité Européenne
CEAC cost-effectiveness acceptability
curve
CHF congestive heart failure
CI confidence interval
CLP clinical linear predictor
CRD Centre for Reviews and
Dissemination
CTS clinical treatment score
DBCG Danish Breast Cancer
Cooperative Group
DCIS ductal carcinoma in situ
DFS disease-free survival
DG diagnostics guidance
DMFI distant metastasis-free interval
DMFS distant metastasis-free survival
DNA deoxyribonucleic acid
DRFI distant recurrence/relapse-free
interval
DRFS distant recurrence/relapse-free
survival
DSA deterministic sensitivity analysis
EAG External Assessment Group
EBCTCG Early Breast Cancer Trialists’
Collaborative Group
EPClin EndoPredict Clinical
EQ-5D EuroQol 5-Dimensions
ER oestrogen receptor
ER– oestrogen receptor negative
ER+ oestrogen receptor positive
FACT-B Functional Assessment of Cancer
Therapy – Breast cancer
FACT-G Functional Assessment of Cancer
Therapy – General
FFPE formalin fixed, paraffin embedded
G-CSF granulocyte colony-stimulating
factor
GEICAM Grupo Español de Investigación
en Cáncer de Mama
GEO gene expression omnibus
GEP gene expression profiling
HCHS Hospital and Community Health
Service
HER2 human epidermal growth factor
receptor 2
HER2– human epidermal growth factor
receptor 2 negative
HER2+ human epidermal growth factor
receptor 2 positive
HR hazard ratio
HR+ hormone receptor positive
HRQoL health-related quality of life
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii
HTA Health Technology Assessment
ICER incremental cost-effectiveness
ratio
IDFS invasive disease-free survival
IES Intergroup Exemestane Study
IHC immunohistochemistry
IHC4 immunohistochemistry 4
IHC4+C immunohistochemistry 4 plus
clinical factors
IPD individual patient data
ITT intention to treat
LN+ lymph node positive
LN0 lymph node negative
LN0–3 zero to three positive lymph
nodes
LN1–3 one to three positive lymph
nodes
LN1micro one lymph node micrometastasis
LNmicro lymph node micrometastases
LYG life-year gained
mAOL Modified Adjuvant! Online
MDS myelodysplastic syndromes
MeSH medical subject heading
MINDACT Microarray In Node-negative
Disease may Avoid
ChemoTherapy
mRNA messenger ribonucleic acid
NCBI National Centre for
Biotechnology Information
NCCN National Comprehensive Cancer
Network
NCIC National Cancer Institute of
Canada
NCRAS National Cancer Registration and
Analysis Service
NHS EED NHS Economic Evaluation
Database
NICE National Institute for Health and
Care Excellence
NPI Nottingham Prognostic Index
NSABP National Surgical Adjuvant
Breast and Bowel Project
OPTIMA Optimal Personalised Treatment
of early breast cancer usIng
Multi-parameter Analysis
OPTIMA Prelim Optimal Personalised Treatment
of early breast cancer usIng
Multi-parameter Analysis
preliminary
OR odds ratio
OS overall survival
PAI-1 plasminogen activator inhibitor 1
PAM50 Prediction Analysis of Microarray
50
PAS Patient Access Scheme
PR progesterone receptor
PR+ progesterone receptor positive
PRISMA Preferred Reporting Items
for Systematic Reviews and
Meta-Analyses
PROBAST Prediction model study Risk Of
Bias ASsessment Tool
PSA probabilistic sensitivity
analysis
PSS Personal Social Services
pT pathological tumour stage
QALY quality-adjusted life-year
RASTER MicroarRAy-prognoSTics-in-
breast-cancER
RCT randomised controlled trial
RFI recurrence/relapse-free interval
RFS recurrence/relapse-free survival
RNA ribonucleic acid
ROR risk of recurrence
ROR-C risk of recurrence based on
Prediction Analysis of Microarray
50 subtype information plus
tumour size
LIST OF ABBREVIATIONS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxiv
ROR-P risk of recurrence based on
Prediction Analysis of Microarray
50 subtype information plus
proliferation score
ROR-PT risk of recurrence based on
Prediction Analysis of Microarray
50 subtype information plus
proliferation score plus tumour
size
ROR-S risk of recurrence based on
Prediction Analysis of Microarray
50 subtype information
ROR-T risk of recurrence based on
Prediction Analysis of Microarray
50 subtype information plus
tumour size
RR relative risk
RSPC recurrence score–pathology–
clinical
RT-PCR reverse transcription-polymerase
chain reaction
RT-qPCR reverse transcription-quantitative
polymerase chain reaction
ScHARR School of Health and Related
Research
ScHARR-TAG School of Health and Related
Research Technology
Assessment Group
SE standard error
SEER Surveillance, Epidemiology, and
End Results
STAI State–Trait Anxiety Inventory
STO-3 Stockholm Tamoxifen-3
SWOG Southwest Oncology Group
TAILORx Trial Assigning Individualized
Options for Treatment (Rx)
TC docetaxel and cyclophosphamide
TEAM Tamoxifen vs Exemestane
Adjuvant Multinational
TransATAC Translational substudy of the
Arimidex, Tamoxifen, Alone or in
Combination
TRANSBIG Translating molecular knowledge
into early breast cancer
management: building on the
BIG (Breast International Group)
network for improved treatment
tailoring
UKBCG UK Breast Cancer Group
uPA urokinase plasminogen activator
WSG West German Study Group
WSG-AGO-Doc West German Study Group
epirubicine and
cyclophosphamide-Doc
WTP willingness to pay
Note
This monograph is based on the Technology Assessment Report produced for NICE. The full
report contained a considerable number of data that were deemed confidential. The full report
was used by the Appraisal Committee at NICE in their deliberations. The full report with each
piece of confidential data removed and replaced by the statement ‘confidential information
(or data) removed’ is available on the NICE website: www.nice.org.uk.
The present monograph presents as full a version of the report as is possible while retaining
readability, but some sections, sentences, tables and figures have been removed. Readers
should bear in mind that the discussion, conclusions and implications for practice and research
are based on all the data considered in the original full NICE report.
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Plain English summary
B reast cancer is the most commonly diagnosed cancer in women in England and Wales. Breast cancer,and its treatment, can have an impact on a person’s health-related quality of life and survival. Tumour
profiling tests are used before chemotherapy. They test small samples of a patient’s tumour (removed
during surgery) to find out whether the genes in it mean that a person has a high or low risk of the
disease returning (relapse). If the risk is low, the patient may be able to avoid having chemotherapy and,
therefore, avoid its side effects. Some tests might also be able to identify which patients will respond to
chemotherapy.
This study looked at the evidence for five tumour profiling tests. A total of 153 studies were identified.
This study considered the results and the quality of the studies to find out if the tests are helpful. Most
studies had design flaws (e.g. some patients had already had chemotherapy) that meant that the studies
were of low quality overall. The results suggest that all of the tests can give information on the risk of
relapse; however, some tests may be less useful in patients whose disease has spread to the lymph nodes
(lymph node-positive disease). There was limited and varying evidence about whether or not two of
these tests can also predict which patients will respond to chemotherapy.
This study also looked at whether or not these tests represent good value for money for the NHS through
cost-effectiveness analyses. The analyses showed that some of the tests may represent a good use of NHS
resources for some patient groups; however, there was still a lot of uncertainty about this.
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Scientific summary
Background
Breast cancer is the most commonly diagnosed cancer in women in England and Wales. In 2014, 55,222
new cases of breast cancer were diagnosed. Treatment usually involves surgery to remove the primary
tumour and any involved lymph nodes; this may be followed by radiation therapy, endocrine therapy and/or
chemotherapy with or without trastuzumab (Herceptin®, Roche Products Ltd) depending on tumour and
patient variables. A proportion of patients also receive neoadjuvant therapy prior to surgery. Although
chemotherapy can reduce the likelihood of cancer recurrence and death for women with breast cancer, it may
have considerable adverse effects. Improved information on a patient’s risk of recurrence (i.e. prognostic risk)
and/or likely response to chemotherapy (i.e. predictive benefit) may help target chemotherapy to those
patients who will benefit the most. Avoiding chemotherapy in patients at low risk of recurrence, who would
therefore obtain limited absolute benefit, avoids the unpleasant side effects of chemotherapy and reduces
expenditure on both the chemotherapy itself and the treatment of these adverse effects. Tumour profiling
tests aim to improve the use of chemotherapy in breast cancer by improving the categorisation of patients
in accordance with risk and the identification of those patients who will gain most benefit from chemotherapy.
Objectives
The overall aim of the assessment was to address the question ‘Do tumour profiling tests used for
guiding adjuvant chemotherapy decisions in patients with early-stage breast cancer represent a clinically
effective and cost-effective use of NHS resources?’. This includes an update of the systematic review
and cost-effectiveness analysis that informed National Institute for Health and Care Excellence (NICE)
Diagnostics Guidance (DG) 10.
The objectives of the assessment were to:
l conduct a systematic review of the published evidence on the effectiveness and cost-effectiveness of
five tumour profiling tests with or without clinicopathological factors [EndoPredict® (Myriad Genetics
Ltd, London, UK), oncotype DX® (Genomic Health, Inc., Redwood City, CA, USA), MammaPrint®
(Agendia, Inc., Amsterdam, the Netherlands), immunohistochemistry 4 (IHC4) and Prosigna®
(NanoString Technologies, Inc., Seattle, WA, USA)] to guide decisions about adjuvant chemotherapy
l develop a health economic model to assess the cost-effectiveness associated with the use of tumour
profiling tests compared with current prognostic tools to guide the use of adjuvant chemotherapy in
early-stage breast cancer from the perspective of the NHS and Personal Social Services (PSS).
Methods
This report was commissioned by the National Institute for Health Research Health Technology Assessment (HTA)
programme as project number 16/30/03. A registered protocol of the systematic review (CRD42017059561) is
available on the PROSPERO website: www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017059561
(accessed 10 May 2018).
Clinical evidence review methods
A systematic review was undertaken, which included results from a search of nine databases in February
2017 plus other sources including a review published in 2013. The review included studies assessing
clinical effectiveness of the five tumour profiling tests to guide decisions about adjuvant chemotherapy in
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people with early-stage breast cancer, with a focus on those with hormone receptor-positive (HR+), human
epidermal growth factor receptor 2-negative (HER2–) stage I or II cancer with zero to three positive lymph
nodes. Outcomes included prognostic performance (whether or not recurrence and survival outcomes differ
between test risk groups), prediction of chemotherapy benefit (whether or not effect of chemotherapy
differs between test risk groups), clinical utility (the impact of prospective use of the test on recurrence and
survival) and decision impact (changes in chemotherapy recommendations pre/post test).
Cost-effectiveness methods
The External Assessment Group (EAG) undertook a review of existing economic analyses published since
NICE DG10. The EAG also reviewed and critically appraised economic analyses of oncotype DX, MammaPrint
and EndoPredict, which were provided during the course of the appraisal.
In addition, the EAG developed a de novo health economic model to assess the cost-effectiveness of
oncotype DX, MammaPrint, Prosigna, EndoPredict Clinical (EPClin) and IHC4 plus clinical factors (IHC4+C),
each compared with current practice. The health economic analysis was undertaken from the perspective
of the NHS and PSS and was largely based on the model developed to inform NICE DG10. The EAG model
adopts a hybrid decision tree/Markov structure. The model parameters were informed by a number of
sources, including a bespoke analysis of the Translational substudy of the Arimidex, Tamoxifen, Alone or
in Combination (TransATAC) trial, the Microarray In Node-negative Disease may Avoid ChemoTherapy
(MINDACT) trial, a bespoke analysis of the National Cancer Registration and Analysis Service data set, a
bespoke survey disseminated by the UK Breast Cancer Group (UKBCG), the NHS England Access Scheme
Database, standard costing sources and other literature.
Results
Clinical evidence results
The review included 153 studies across all five tests and across all outcomes listed in the NICE scope.
Four of these were data sets provided by a company as commercial-in-confidence or academic-in-
confidence data and could not be presented in this report.
Among studies of lymph node-negative (LN0) patients receiving endocrine monotherapy, percentages of
patients categorised as high risk ranged from 9% to 33% across all five tests. In lymph node-positive (LN+)
patients, three tests [Prosigna/ROR-PT (risk of recurrence based on Prediction Analysis of Microarray 50
subtype information plus proliferation score plus tumour size), EPClin and IHC4+C] categorised far more
(38% to 76%) LN+ patients than LN0 patients as high risk among studies of endocrine monotherapy,
whereas oncotype DX categorised a similar number as high risk in the LN0 and LN+ groups. However,
oncotype DX categorised more patients as low risk in LN+ than other tests (57% in oncotype DX vs. 4%
to 28% in other tests), but with worse 10-year distant recurrence/relapse-free survival/distant recurrence/
relapse-free interval outcomes (82% in oncotype DX vs. 95% to 100% in other tests).
In terms of prognostic performance, all tests had statistically significant prognostic power in unadjusted
analyses in LN0 and LN+ populations. However, recurrence score–pathology–clinical (RSPC) was only
validated in LN0 patients in a cohort that had been used in part to derive oncotype DX, and unadjusted
analyses using clinical cut-off points were not reported in the validation sets for IHC4 or IHC4+C. All tests
provided additional prognostic information in addition to the most commonly used clinicopathological
factors and in addition to clinical treatment score and Nottingham Prognostic Index (NPI) in LN0, although
data were not reported by risk group for oncotype DX. Results were more varied in LN+ patients.
There was some evidence of differential chemotherapy benefit between risk groups for oncotype DX,
as shown by significant interaction tests between risk group and chemotherapy treatment in unadjusted
analyses. Adjusted interaction tests were significant/borderline significant in the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B20 study (LN0 patients, significant in HER2– patients), whereas in the
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Southwest Oncology Group (SWOG)-8814 (LN+ patients), they were significant when adjusted for some
clinicopathological variables individually, but not when adjusting for ER determined by Allred status. However,
part of the NSABP B20 cohort was the derivation cohort for oncotype DX and this may bias results in favour of
observing an interaction. Oncotype DX RSPC (oncotype DX plus age, tumour size and grade) was prognostic
but not statistically significantly predictive for chemotherapy benefit and was not tested in an entirely
independent validation cohort.
Evidence relating to the ability of MammaPrint to predict benefit from chemotherapy was extremely limited.
Although the effect of chemotherapy was significant in high-risk groups and not significant in low-risk
groups, interaction tests between risk groups and chemotherapy treatment were not significant, suggesting
that there was no statistically significant difference in the effect of chemotherapy between risk groups.
The MINDACT randomised controlled trial (RCT) for MammaPrint was, at the time of writing, the only RCT
to have reported (in full) the use of a test in clinical practice compared with clinical practice only. It reported
that, for patients with a high Modified Adjuvant! Online (mAOL) score (clinical risk) and a low MammaPrint
risk, chemotherapy gave a non-significant absolute benefit of 1.5% in 5-year distant metastasis-free survival
(DMFS) (p = 0.267). This met the primary objective in that the lower bound of the 95% confidence interval
for 5-year DMFS in the no-chemotherapy group was ≥ 92%. This finding was interpreted by the authors
as implying that patients who had a high clinical risk but a low MammaPrint risk could potentially avoid
chemotherapy. In patients who were low-mAOL with a high MammaPrint risk, chemotherapy gave an
absolute benefit of 0.8%. This could be interpreted to mean that MammaPrint would not be a useful
test in mAOL low-risk patients, as it would not alter treatment decisions.
For oncotype DX and MammaPrint, evidence from observational, non-comparative studies assessing the
impact of the test used prospectively in clinical practice suggested that recurrence/survival outcomes in
low-risk groups were acceptable even with low rates of chemotherapy. There was no similar evidence
relating to the other tests.
Decision impact studies reported that the percentage of patients with any change in chemotherapy
recommendation or decision pre/post test ranged from 27% to 49% across UK studies (these included
oncotype DX, EndoPredict and IHC4+C) and from 5% to 70% across European studies (these included all
tests except IHC4). The net change in the percentage of patients with a chemotherapy recommendation or
decision pre/post test ranged from an increase of 1% to a decrease of 23% among UK studies and from a
change of 0% to a decrease of 64% across European studies.
Concordance between tests was not fully reviewed as it was not within the scope of the assessment,
but one UK study [Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis
preliminary (OPTIMA Prelim)] that compared oncotype DX, MammaPrint, Prosigna and IHC4 concluded
that although tests assigned similar proportions of patients to low/intermediate- and high-risk categories,
test results for an individual patient could differ markedly depending on which test was used.
Data relating to anxiety and health-related quality of life (HRQoL) were limited as most studies did not
include a comparator, instead adopting a pre–post test design. Anxiety generally reduced post test, but it
is unclear if this would happen equally after a treatment decision made in accordance with clinical factors.
HRQoL improved in some analyses.
Microarray studies support conclusions from studies using the commercial versions of the assays in
suggesting that oncotype DX, MammaPrint and EndoPredict can discriminate between high- and low-risk
patients regardless of lymph node status (there were no relevant microarray studies for EndoPredict or IHC4).
Cost-effectiveness results
The EAG’s base-case model suggests the following results.
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Oncotype DX
Within the subgroup of LN0 patients with a NPI of ≤ 3.4, the incremental cost-effectiveness ratio (ICER) for
oncotype DX versus current practice is expected to be £122,725 per quality-adjusted life-year (QALY) gained
(£34,245 per QALY gained assuming a predictive benefit). Within the subgroup of LN0 patients with a NPI
of > 3.4 and the one to three positive lymph nodes (LN1–3) subgroup, oncotype DX is expected to be
dominated by current practice (conversely, oncotype DX dominates current practice if a predictive benefit is
assumed). The results generated using the EAG model are primarily driven by the modelled reduction in the
use of adjuvant chemotherapy using the oncotype DX test. When based on the same evidence sources,
the Genomic Health, Inc. (Redwood City, CA, USA) model produces broadly similar results.
IHC4 plus clinical factors
Within the subgroup of LN0 patients with a NPI of ≤ 3.4, the ICER for IHC4+C versus current practice is
expected to be £2654 per QALY gained. Within the subgroup of LN0 patients with a NPI of > 3.4 and the
LN1–3 subgroup, IHC4+C is expected to dominate current practice.
Prosigna
Within the subgroup of LN0 patients with a NPI of ≤ 3.4, the ICER for Prosigna versus current practice is
expected to be £91,028 per QALY gained. Within the subgroup of LN0 patients with a NPI of > 3.4 and
the LN1–3 subgroup, the ICERs for Prosigna versus current practice are £26,058 and £28,731 per QALY
gained, respectively.
EndoPredict Clinical
Within the subgroup of LN0 patients with a NPI of ≤ 3.4, the ICER for EPClin versus current practice is
expected to be £147,419 per QALY gained. Within the subgroup of LN0 patients with a NPI of > 3.4,
the ICER for EPClin versus current practice is expected to be £46,788 per QALY gained. Within the LN1–3
subgroup, the ICER for EPClin versus current practice is expected to be £21,458 per QALY gained.
MammaPrint
Within the overall MINDACT population, the ICER for MammaPrint versus current practice is expected to
be £131,482 per QALY gained. Within the mAOL high-risk subgroup, MammaPrint is expected to be
dominated by current practice. Within the mAOL low-risk subgroup, the ICER for MammaPrint versus
current practice is expected to be £414,202 per QALY gained.
Discussion
Strengths and limitations in the clinical evidence base
The evidence base was large but included only one RCT of a test being used in clinical practice compared
with usual clinical practice that had reported results in full (MINDACT, for MammaPrint). A number of
reanalyses of RCTs, which are generally considered to be high-quality sources of data, were also included
in the reviews of prognosis and prediction of chemotherapy benefit. However, nearly all studies excluded
patients who did not have enough tissue sample, meaning that patients with small tumours are, in theory,
likely to be under-represented.
Many studies were funded by industry and this should be borne in mind when interpreting the evidence
base.
Many studies were observational in nature, and these are subject to confounding, whereby exclusion of
patients who received chemotherapy is likely to introduce bias as these patients are likely to be systematically
different in terms of known (and potentially unknown) prognostic variables. Equally, studies that included
patients who received chemotherapy may underestimate prognostic effect.
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There were some key gaps in the literature for IHC4+C and RSPC. Notably, IHC4+C and RSPC have only
been validated in one cohort each, and this was not entirely independent in the case of RSPC. There are
known problems with conducting the analyses required for IHC4, and it is unclear whether or not the
absolute IHC4 values obtained would be similar across centres.
Much of the evidence base relates to unadjusted analyses, which do not address the crucial question of
whether or not a test has additional value over clinicopathological factors. When adjusted analyses were
conducted, the clinicopathological variables included were not always consistent and it is unclear if all
important factors were included in all analyses.
There were relatively limited data relating to the ability of oncotype DX and MammaPrint to predict benefit
from chemotherapy, and some of the analyses conducted were also subject to criticisms about adjustment
for relevant confounders and use of the derivation cohort. This means that there remains uncertainty
about whether or not the tests are associated with a predictive benefit from chemotherapy.
The evidence base relating to the impact of tests on treatment decisions (decision impact studies) was limited
in that use of chemotherapy differs across countries and there were no UK studies for two of the tests
(MammaPrint and Prosigna) and only one UK study for another two of the tests (EndoPredict and IHC4+C).
Strengths and limitations relating to the health economic analysis
The EAG model has a number of strengths:
l For all tests, risk classification and DMFS probabilities are derived from the same source (TransATAC
or MINDACT).
l Within the LN0 intermediate-risk subgroup (NPI of > 3.4, analysis of three-level tests), the probability
of receiving chemotherapy with and without the test is based on the NHS England Access Scheme
Database; this is likely to best reflect how the three-level tumour profiling tests would be used in clinical
practice in England.
l The model structure is consistent with that of other published models of tumour profiling tests: when
similar data inputs are used, the EAG model produces similar results to the previous EAG model and the
Genomic Health model.
l Extensive deterministic sensitivity analyses have been conducted to explore the impact of uncertainty on
the model results.
The model is also subject to several limitations, most of which stem from uncertainties in the evidence base.
The main limitations and uncertainties relating to the cost-effectiveness analysis are:
l With the exception of oncotype DX in the subgroup of LN0 patients with a NPI of > 3.4 (clinical
intermediate risk), the evidence surrounding the pre- and post-test chemotherapy probabilities is
subject to considerable uncertainty. This has the propensity to influence the conclusions regarding the
cost-effectiveness of all tests.
l There is uncertainty regarding whether or not oncotype DX and MammaPrint are predictive of
chemotherapy benefit; the inclusion of such effects are likely to strongly influence economic conclusions
drawn from the analysis.
l The analysis of MammaPrint is based on a different data source to that used in the other four tests.
l The TransATAC study, which was used to estimate test risk classification and DMFS probabilities, was
the derivation study for IHC4. For this reason, there is potential for the overestimation of prognostic
performance for this test.
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Implications for service provision
The per-test costs for Prosigna provided by NanoString Technologies (used in the EAG economic analyses)
are based on an efficient level of throughput. This may not hold if centres do not undertake the
anticipated number of tests (e.g. in smaller centres or if multiple tumour profiling tests are available).
Furthermore, as NanoString Technologies does not offer a centralised testing service, local testing services
will need to be established.
The IHC4 test is not currently commercially available. Standardisation of IHC4 and quality assurance
programmes are required before this test may be used routinely within the NHS.
Suggested research priorities
l There is uncertainty regarding whether or not oncotype DX and MammaPrint are predictive of
chemotherapy benefit. Further studies that adjust for all relevant clinicopathological factors in validation
cohorts are required.
l There is limited evidence demonstrating long-term impacts resulting from the use of the five tumour
profiling tests. Future studies assessing the comparative long-term impact of the tests compared with
risk prediction tools commonly used in clinical practice would be valuable.
l There is uncertainty regarding the cost-effectiveness of all five tests included in the NICE scope.
It is noteworthy that under the assumption of no predictive chemotherapy benefit the inclusion of
additional data collected through the NHS England Access Scheme Database has a significant impact
on the conclusions previously drawn from the oncotype DX analysis within NICE DG10 (moving from an
ICER of £22,572 per QALY gained to a situation in which oncotype DX is dominated in the subgroup
of LN0 patients with a NPI of > 3.4). Additional UK-based data collection relating to pre- and post-test
chemotherapy use for EPClin, IHC4+C, Prosigna and MammaPrint may be important in reducing
existing uncertainty surrounding the cost-effectiveness of these tests.
Study registration
This study is registered as PROSPERO CRD42017059561.
Funding
Funding for this study was provided by the HTA programme of the National Institute for Health Research.
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Chapter 1 Background and definition of the
decision problem
This chapter is largely reproduced, with updates when necessary, from the study by Ward et al.
1
Contains information licensed under the Non-Commercial Government Licence v2.0.
Condition and aetiology
Breast cancer is the most commonly diagnosed cancer in women in England and Wales. In 2014, 55,222
new cases of breast cancer were diagnosed.2 Treatment usually involves surgery to remove the primary
tumour and any involved lymph nodes; this may be followed by radiation therapy, endocrine therapy and/or
chemotherapy with or without trastuzumab depending on tumour and patient variables. A proportion of
patients also receive neoadjuvant therapy prior to surgery.
Aetiology, pathology and prognosis
Aetiology
The causes of breast cancer are not completely understood. A range of risk factors have been identified,
including genetic, hormonal and lifestyle factors.3
It has been estimated that 12% of women with breast cancer have one affected family member and
1% have two or more affected family members.4 Genetic predisposition is mediated by high-penetrance
genes such as BReast CAncer 1 (BRCA1) and BReast CAncer 2 (BRCA2), which are responsible for around
80–90% of hereditary cancers, and low-penetrance genes, which confer both increased and decreased risk.3
Environmental and lifestyle factors as well as genetic factors influence breast cancer risk. Asian migrants to
the West have increased levels of risk compared with the indigenous population, whereas Asian Americans
born in the West have incidence rates approximating the US average.5 Lifestyle and environmental factors
thought to increase risk include hormonal factors such as taking the oral contraceptive pill or hormone
replacement therapy, higher age of menopause, early age of menarche, late age of first birth and not giving
birth. Factors that decrease risk include higher folate intake, higher number of pregnancies, breastfeeding
and younger age at first birth.3 Obesity increases the risk of breast cancer in postmenopausal women.6
The picture is less clear for premenopausal women, for whom the risk may be lower but prognosis is poorer.
Physical activity in adolescence and young adulthood confers a decreased risk of breast cancer,7 which may
be mediated hormonally.
Pathology
Breast cancer starts with genetic changes in a single cell or a small group of cells in the epithelia of the
ducts or the lobules of the breast. The genetic change allows cells to reproduce uncontrollably, resulting
in a tumour. Tumours that have not yet spread to surrounding tissue are known as ‘carcinoma in situ.’
Once it has spread to the surrounding tissue, a tumour is known as ‘invasive’. More rapid growth and
spread occurs once a blood supply is secured. Cancer spreads via the lymphatic system or the bloodstream.
Lymphatic spread is usually first to the axillary lymph nodes. Spread via the bloodstream can lead to distant
metastases in the bone or viscera that are incurable.
The presence or absence of axillary lymph node metastases is a key indicator of disease and prognosis and
adjuvant therapy is, in part, planned based on their presence and extent.8 They are caused by a single
cell or a small number of cells detaching from the main tumour, travelling via the lymphatic system and
establishing themselves in the tissue of the axillary lymph nodes. Axillary metastases occur in approximately
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1
41% of cases;9 prognosis is better when there is no axillary spread. When metastases are present, axillary
clearance is indicated in order to prevent further spread and ensure local disease control.
Prognosis
Overall, the 5-year, age-standardised survival rate for women with breast cancer is 86.3%.10 Survival varies
with age (Figure 1) and stage of disease (Figure 2).
Other factors can also affect prognosis. Clinicians may use tools such as the Nottingham Prognostic Index
(NPI),12 Predict (University of Cambridge, Cambridge, UK) or Adjuvant! Online (AOL) (University of Texas
Health Sciences Center, San Antonio, TX, USA) to predict disease course and treatment options, although
it should be noted that AOL is in the process of being updated and is not currently available. These tools
take into account different patient and tumour factors and may give different risk predictions for the same
patient.
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In general, good prognosis is associated with small tumour size, lymph node-negative (LN0) status,
younger age, oestrogen receptor positive (ER+) status and progesterone receptor positive (PR+) status.
Overexpression of human epidermal growth factor receptor 2 (HER2) is associated with poorer prognosis.
Epidemiology and incidence
Incidence varies most in accordance with sex. Women are considerably more likely to develop breast
cancer than men. For both sexes, incidence varies with age (see Appendix 1, Table 55). Over 81% of cases
occur in women aged ≥ 50 years. Based on 2014 data, the highest incidence rates for women were
reported in those in the 60- to 70-year age group.13
Incidence varies with ethnicity. Asian, Chinese and black ethnic groups and those with mixed heritage have
a lower incidence of breast cancer than the white ethnic group in England; the rate ratios are 0.65, 0.75,
0.49 and 0.58, respectively, when compared with the white group.14
Based on data for the period 2006–10, the incidence of female breast cancer was highest in the least
deprived 20% of the population; however, the more deprived group had statistically significantly higher
mortality.15 It is unclear why this is, but may be due to lower levels of screening compliance, worse overall
general health status and lower levels of treatment attributable to access and compliance issues.
Significance in terms of ill health (burden of disease)
Breast cancer is the second largest cause of cancer deaths in women, after lung cancer, with an
age-standardised mortality rate of 34.6 per 100,000 women. In 2014, breast cancer caused 11,360 deaths
of women in the UK.2
Measurement of disease
Breast cancer has few obvious symptoms and can easily go undetected for a few years. Among the more
noticeable symptoms are a palpable lump in the breast, a change in breast shape and skin appearance or
changes to the nipple, such as inversion, a rash or discharge.
A suspicious breast mass may be identified through screening, or via presentation to a general practitioner.
Women between the ages of 50 and 70 years are routinely invited to attend regular screening; the NHS is
currently in the process of extending the programme as a trial, offering screening to some women aged
47–73 years. A recent case–control study within the NHS England breast screening programme reported
that attendance at breast screening resulted in a breast cancer mortality reduction of 39% [odds ratio (OR)
0.61, 95% confidence interval (CI) 0.44 to 0.85] after self-selection correction.16 Screening increases the
proportion of tumours detected in the early, more curable stages.
The breast mass and axillary areas are investigated clinically through palpation and by mammography or
ultrasonography, and the status of the tumour is confirmed by histology of a percutaneous tissue biopsy.
Staging of the disease depends on tumour size, the number of involved lymph nodes and the presence or
absence of distant metastases. Tumour size and axillary metastases can be estimated by clinical examination
and imaging techniques, but definitive status is achieved through surgery. Those with small tumours and
no axillary metastases have the best prognosis, whereas those with distant metastases are considered
incurable. Patients with high-risk early-stage breast cancer also undergo computerised tomography of the
chest and abdomen and a bone scan to assess any distant metastases.
Current methods for staging of breast cancer
Three main factors are used to stage breast cancer: (1) tumour size, (2) metastases to the regional lymph
nodes and (3) distant metastases. The tumour/node/metastases (TNM) staging system was developed and is
maintained by the American Joint Committee on Cancer and the Union for International Cancer Control.17
The T stage is classified in accordance with the size of the tumour and degree of local infiltration, the N stage is
classified in accordance with the number and location of metastases to the lymph nodes in the axilla, between
the ribs (internal mammary nodes) and above or below the collarbone (supraclavicular and infraclavicular
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nodes), and the M stage is classified by the presence of metastases beyond the breast and regional lymph
nodes (see Table 56, Appendix 1). Early-stage breast cancer is generally defined as cancer that has not spread
beyond the breast or the ipsilateral axillary lymph nodes and is confined to stages I, II or IIIA.
Current service provision
Management of early-stage breast cancer
Patients diagnosed with early-stage breast cancer currently follow the diagnosis/treatment pathway shown
in Figure 3.
Use of adjuvant chemotherapy
Since 2002, the National Institute for Health and Care Excellence (NICE) has recommended that women
at intermediate or high risk of recurrence (ROR) who have not had neoadjuvant chemotherapy should
normally be offered a multi-agent chemotherapy that includes anthracyclines.18 Chemotherapy is defined
as the use of cytotoxic medications with the intention of preventing cancer recurrence in patients. It should
be noted that, for the purposes of this assessment, chemotherapy does not include other forms of systemic
therapy, such as endocrine treatments or targeted biological therapy (e.g. trastuzumab).
Meta-analyses of randomised clinical trials by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
have indicated that the use of adjuvant chemotherapy (chemotherapy following surgery) is associated with
a reduction in the risk of cancer recurrence and death in women with early-stage breast cancer.19 However,
chemotherapy is associated with considerable adverse events (AEs). Short- and long-term AEs will affect
a proportion of patients receiving chemotherapy, imposing additional costs and reducing health-related
quality of life (HRQoL). Short-term AEs that happen during chemotherapy are usually temporary and
reversible. The most common AEs include nausea, vomiting, mouth soreness, diarrhoea, tiredness, hair loss
and temporary lowering of the blood counts. Long-term AEs, such as damage to the heart, and a small
increase in the risk of leukaemia are not reversible. Although chemotherapy may prevent relapse in some,
not all women with early-stage breast cancer will benefit and many women remain recurrence-free at
10 years without chemotherapy. However, a subset of patients with a ‘good’ prognosis may still develop
recurrence after curative surgery and adjuvant therapy. This presents a considerable challenge to clinicians
in estimating prognosis and making the most appropriate therapeutic decisions relating to whether or not
to use adjuvant chemotherapy in women with early-stage breast cancer.
Improved information on a patient’s ROR (i.e. prognostic risk) and/or likely response to chemotherapy
(i.e. predictive benefit) may help target chemotherapy to those patients who will benefit the most.
Avoiding chemotherapy in patients at low ROR, who would therefore obtain limited benefit, avoids the
unpleasant side effects of chemotherapy and reduces expenditure on both the chemotherapy itself and
the treatment of these adverse effects.
Current guidelines
The NICE Clinical Guideline 809 indicates that adjuvant therapy should be considered for all patients with
early invasive breast cancer after surgery, based on assessment of the prognostic and predictive factors,
the potential benefits and side effects of the treatment. Historically, clinicopathological factors, such as
patient age, tumour size, nodal involvement, histological grade, oestrogen receptor (ER) expression, HER2
overexpression and comorbidities, have been assessed and considered alongside patient preference. The
NICE guideline9 indicates that decisions regarding adjuvant therapy should be made following discussion of
these factors with the patient and recommends consideration of the use of AOL to support estimations of
individual prognosis and the absolute benefit of adjuvant treatment for patients with early invasive breast
cancer. Although there is variation between centres, the NPI and Predict are also commonly used
as the basis for many local guidelines on decisions regarding whether or not to use chemotherapy for
patients with early-stage breast cancer. These risk prediction tools include different patient and tumour
characteristics and may give different predictions for the same patient (see Table 56, Appendix 1).
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FIGURE 3 Diagnosis and management pathway in breast cancer. For postmenopausal women whose tumours are
greater than grade 1, many centres also use adjuvant bisphosphonates for up to 3 years. Patients may also be
treated with adjuvant radiotherapy depending on whether they have had a wide local excision or mastectomy
and depending on the characteristics of the primary tumour; this may include radiotherapy to not only the breast
but also the chest wall, supraclavicular fossa and lymph node and axillar. Neoadjuvant treatment may include
Pertuzumab (Perjeta®, Roche Products Ltd) and trastuzumab. Adjuvant chemotherapy may be given alongside
biological therapy. Reproduced with permission from Ward et al.1 Contains information licensed under the
Non-Commercial Government Licence v2.0. FISH, fluorescence in situ hybridisation.
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The NICE CG809 does not make specific reference to the use of tumour profile tests to aid decision-making.
However, the NICE Diagnostics Guidance (DG) 10 on tumour profiling20 recommends oncotype DX as an
option for guiding adjuvant chemotherapy decisions for people with ER+, LN0, HER2- early-stage breast
cancer at intermediate (clinical) risk if oncotype DX is likely to help in the decision of whether or not to use
adjuvant chemotherapy.
Adjuvant! Online
The AOL computer program is designed to provide estimates of the benefits of adjuvant endocrine therapy
and chemotherapy. The current version of AOL does not include HER2 status and the potential benefit of
trastuzumab. Patient and tumour characteristics are entered into the program and provide an estimate of
the baseline risk of mortality or relapse for patients without adjuvant therapy. Information about the
efficacy of different therapy options are derived from the EBCTCG meta-analyses in order to provide
estimates of reduction in risk at 10 years of breast-cancer-related death or relapse for selected treatments.
These estimates are then provided on printed sheets in simple graphical and text formats to be used in
consultations. At the time of writing this report (October 2017), AOL was in the process of being updated
and was not accessible.
Nottingham Prognostic Index
The NPI is a composite prognostic parameter involving both time-dependent factors and aspects of biological
aggressiveness. The NPI score is based on a combination of tumour grade, lymph node involvement and
tumour size. To calculate the score, add numerical grade (1, 2 or 3), lymph node score (negative = 1, 1–3
nodes = 2, > 3 nodes = 3) and 0.2 × tumour size in cm. Patients can be divided into three prognostic groups
on the basis of the NPI: a good prognosis group (NPI of ≤ 3.4), a moderate prognosis group (3.4 < NPI < 5.4)
and a poor prognosis group (NPI of > 5.4).
Predict (version 2.0)
Predict (version 2.0) is an online computer program designed to help women with breast cancer and their
doctors make informed decisions about treatment with chemotherapy or endocrine therapy following
breast cancer surgery. Predict version 2.0 was developed using data from > 5000 women with breast
cancer from England and has been tested on data from another 23,000 women with breast cancer from
around the world. Patient and tumour characteristics are entered into the program, which provides an
estimate of the overall survival (OS) for patients with or without adjuvant hormone therapy, adjuvant
chemotherapy and trastuzumab.
Clinical opinion suggests that there is variation in clinical practice between NHS trusts in the UK, with
some centres using single risk prediction tools and others using multiple tools in combination, in addition
to other clinical parameters.
Description of technologies under assessment
Tumour profiling tests aim to improve the use of chemotherapy in breast cancer by improving the
categorisation of patients in accordance with ROR or death, and by identifying those patients who will
gain most benefit from chemotherapy. Tests predicting the ROR in a specific population are likely to be
used after surgery, in conjunction with other information available about tumour size, grade, nodal status
and other factors to guide the use of adjuvant chemotherapy. Tests that require samples to be sent away
for central review, following surgery, may introduce a short delay (of up to 3 weeks) before the decision
can be taken on whether or not to offer chemotherapy.
Five tests were identified in the final NICE scope21 and are included in this assessment: four are based on
gene expression profiling [EndoPredict® (Myriad Genetics Ltd, London, UK), oncotype DX® (Genomic Health,
Inc., Redwood City, CA, USA), MammaPrint® (Agendia, Inc., Amsterdam, the Netherlands) and Prosigna®
(NanoString Technologies, Inc., Seattle, WA, USA)] and one is based on immunohistochemistry 4 (IHC4).
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Gene expression profiling tests
Gene expression profiling tests investigate the expression of specific panels of genes (also known as gene
profiles or gene signatures). They do this by assessing the identity and number of messenger ribonucleic acid
(mRNA) transcripts in a specific tissue sample. As only a fraction of the genes encoded in the genome of a
cell are expressed by being transcribed into mRNA, gene expression profiling provides information about
the activity of genes that give rise to these mRNA transcripts. Given that mRNA molecules are translated
into proteins, changes in mRNA levels are ultimately related to changes in the protein composition of the
cells, and consequently to changes in the properties and functions of tissues and cells (both normal and
malignant) in the body. Gene expression profiling tests work by making use of different techniques to
measure mRNA levels in breast cancer specimens including real-time reverse transcription-polymerase chain
reaction (RT-PCR) and deoxyribonucleic acid (DNA) microarrays.
There are various ways of preparing the ribonucleic acid (RNA), and different protocols may be used to
prepare the specimens [e.g. formalin-fixed, paraffin-embedded (FFPE), snap-frozen and fresh samples].
The tests included in this assessment use FFPE tissue and do not require the use of fresh samples. Furthermore,
there are varying algorithms that can be used to combine the raw data to obtain a summary measure.
All of these factors can affect the reproducibility and reliability of gene expression profiling tests. These
tests provide an estimate of the ROR.
Immunohistochemical-based tests
Immunohistochemistry (IHC) markers are being developed to provide similar information to that given by
gene expression profiling tests. Some of these tests offer the advantage of using existing IHC technology
(such as ER and HER2 markers) that is routinely available in all UK pathology departments, although
methods for quantifying these markers in the format required for the test may not be routinely available.
Summary of tumour profiling tests included in the assessment
The key features of the five tests are summarised in the following sections and in Table 1.
EndoPredict (Myriad Genetics)
EndoPredict is a Conformité Européenne (CE)-marked assay that is designed to assess the risk of distant
recurrence within 10 years of initial diagnosis. The test is intended for use in premenopausal and
postmenopausal women with early-stage breast cancer with all of the following clinical features:
l oestrogen receptor positive
l human epidermal growth factor receptor 2 negative (HER2–)
l lymph node negative (no positive nodes) or lymph node positive (LN+) (up to three positive nodes).
EndoPredict measures the expression of 12 genes: three proliferation-associated genes, five hormone
receptor-associated genes, three reference (normalisation) genes and one control gene.
EndoPredict requires RNA samples extracted from FFPE breast cancer tissue. The test can be conducted in a
local laboratory using a VERSANT® kPCR Amplification Detection Module (Siemens Healthcare Diagnostics
Inc, Erlangen, Germany). Alternatively, FFPE samples can be submitted to a Myriad Genetics pathology
laboratory in Munich that is accredited by the Deutsche Akkreditierungsstelle, a national accreditation
body for Germany.
The test process involves using a reverse transcription-quantitative polymerase chain reaction (RT-qPCR),
in which target mRNAs are reverse transcribed, amplified and simultaneously detected. The raw data are
then exported to online evaluation software (EndoPredict Report Generator; Myriad Genetics Ltd, London,
UK), which performs a quality check and calculates the EndoPredict score and the EndoPredict Clinical
(EPClin) score. The EndoPredict score is a number on a scale from 0 to 15, is the molecular score only and
is not the final test result. An EndoPredict score of < 5 indicates a low risk of distant disease recurrence in
the next 10 years. An EndoPredict score of ≥ 5 indicates a high risk of distant disease recurrence in the
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TABLE 1 Summary of technologies included in the assessment
Features
Test
EndoPredict
(Myriad Genetics) MammaPrint (Agendia)
Oncotype DX
(Genomic Health)
Prosigna
(NanoString Technologies) IHC4
Purpose Recurrence risk Recurrence risk and
chemotherapy benefit
Recurrence risk and
chemotherapy benefit
Recurrence risk and intrinsic
subtype
Recurrence risk
Description 12-gene assay (eight cancer
genes; RT-qPCR) plus clinical
factors
70-gene array (microarray) 21-gene assay (16 cancer
genes; RT-qPCR)
50-gene assay (50 cancer genes;
direct mRNA counting) plus
clinical factors
4 IHC tests (ER, PR, HER2,
Ki-67). IHC4+C includes
IHC4 plus clinical factors
Testing location Local laboratory or test service
(Germany)
Test service (the Netherlands) Test service (USA) Local laboratory or test service
(UK)
Local laboratory
Stage Early stage Early stage (stage I or II) Early stage (stage I or II) Early stage (stage I to IIIA) Early stage
Lymph node status LN0 and LN+ (up to three
positive)
LN0 or LN+ (up to three
positive)
LN0 or LN+ (up to three
positive)
LN0 and LN+ LN0 and LN+ (1 to three
positive nodes)
Hormone receptor status ER+ ER+ or ER– ER+ ER+ ER+
HER2 status Negative Negative or positive Negative Negative Negative or positive
Menopausal status Premenopausal and
postmenopausal
Premenopausal and
postmenopausal
Premenopausal and
postmenopausal
Postmenopausal Postmenopausal
Test result Low risk or high risk Low risk or high risk Low risk, intermediate risk
or high risk
Low risk, intermediate risk or
high risk
Intrinsic subtype
Low risk, intermediate risk
or high risk
Assumptions Score assumes 5 years of
hormonal treatment
Assumes no therapy Score assumes 5 years of
hormonal treatment
Score assumes 5 years of
hormonal treatment
Score assumes 5 years of
hormonal treatment
Commercially available
in England?
Yes Yes Yes Yes No
Cost £1500 £2326 (based on conversion
from Euros to pounds sterling)
£2580 (excludes PAS) £1650 (kit cost only) £202.52 (inflated to
2016 values)
ER–, oestrogen receptor negative; LN+, lymph node positive; PR, progesterone receptor.
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8
next 10 years. The EPClin score is calculated by adding clinical data about tumour size and nodal status
to the EndoPredict score. From the EPClin score, the probability of metastasis formation within 10 years
is estimated, assuming 5 years of hormonal treatment. The EPClin score (cut-off point of 3.3) provides
a single low-/high-risk cut-off point; the threshold was set such that women with a low-risk result
(EPClin score of < 3.3) have a < 10% risk of developing distant metastases over the next 10 years. It takes
approximately 2 days to obtain the test results if the test is done in-house. If samples are sent away for
testing, the turnaround time for the central service is 4 to 5 working days.
MammaPrint (Agendia)
MammaPrint is a CE-marked microarray that is designed to assess the risk of distant recurrence within 5
and 10 years and whether or not a woman would benefit from chemotherapy. The test is intended for use
in premenopausal and postmenopausal women with stage I or II breast cancer with the following clinical
features:
l tumour size of ≤ 5 cm
l lymph node negative or positive (up to three positive nodes).
The test can be used irrespective of ER and HER2 status; that is, it can be used for tumours that are
ER negative (ER–) or ER+ and HER2– or human epidermal growth factor receptor 2 positive (HER2+).
MammaPrint measures the expression of 70 genes, including genes associated with seven different parts
of the metastatic pathway: (1) growth and proliferation, (2) angiogenesis, (3) local invasion, (4) entering
the circulation, (5) survival in the circulation, (6) entering organs from the circulation and (7) adaption to
the microenvironment at a secondary site. The MammaPrint test is offered as an off-site service. In Europe,
samples are sent for analysis at the Agendia laboratory in Amsterdam, the Netherlands. The test requires
a FFPE breast cancer tissue sample from a surgical specimen or core needle biopsy.
The test process involves isolation of RNA from a FFPE sample followed by reverse transcription of the mRNA
to get complementary DNA (cDNA). The cDNA is amplified and labelled before being hybridised (bound) to
the diagnostic microarray. The microarray is washed and then scanned using an Agilent Technologies, Inc.
DNA microarray scanner (Santa Clara, CA, USA). The scan file is analysed using Agilent Technologies, Inc.
Feature Extraction Software (Santa Clara, CA, USA) and an algorithm is used to calculate the correlation of
the sample profile to a ‘low risk’ template profile on a scale of –1.000 to +1.000 with a cut-off point of 0.
The threshold was set such that women with a low-risk result have a 10% risk of developing distant
metastases over the next 10 years without any adjuvant hormone therapy or chemotherapy. Test results are
available to health-care professionals within 10 days of submitting the sample.
Oncotype DX Breast Recurrence Score (Genomic Health)
Oncotype DX is designed to assess the risk of distant recurrence within 10 years and predict the likelihood
of benefit from chemotherapy. The test also reports the underlying tumour biology: ER, progesterone
receptor (PR) and HER2 status. The test is intended for use in premenopausal and postmenopausal women
with stage I or II breast cancer that has the following clinical features:
l lymph node negative or positive (up to three positive nodes)
l oestrogen receptor positive
l human epidermal growth factor receptor 2 negative.
Oncotype DX quantifies the expression of 21 genes. Of these, 16 are cancer-related genes correlated with
distant recurrence/relapse-free survival (DRFS) and five are reference genes for normalising the expression
of the cancer-related genes. This information is used to calculate the Breast Recurrence Score.
Oncotype DX is offered as a test service to the NHS. Samples are processed centrally at the Genomic
Health laboratory in the USA, which is accredited by the American Association for Laboratory Accreditation
and the College of American Pathologists. The test requires a FFPE breast cancer tissue sample from a
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biopsy or surgical resection, which can be sent as a paraffin-embedded block or as 15 unstained charged
slides. The test process is based on RT-qPCR. The test gives a recurrence score of between 0 and 100,
which is used to quantify the 10-year risk of distant recurrence, assuming 5 years of hormonal (endocrine)
therapy. Based on current cut-off points for the oncotype DX test, a score of < 18 indicates low risk of
distant recurrence, a score between 18 and 30 indicates intermediate risk and a score of ≥ 31 indicates
high-risk. It should be noted that a number of studies, including the ongoing Trial Assigning Individualized
Options for Treatment (Rx) (TAILORx) study,22 are testing the use of different cut-off points for oncotype DX.
The recurrence score may also predict the benefit of chemotherapy. The oncotype DX results are typically
reported within 7–10 days after the sample is received at the laboratory.
The oncotype DX Breast Recurrence Score can be combined with clinical and pathological factors
(tumour size, tumour grade and patient age) using the recurrence score–pathology–clinical (RSPC)
calculator; however, this calculator has not been validated.
Prosigna (NanoString Technologies)
Prosigna is a CE-marked assay designed to assess DRFS at 10 years. The test is intended for use in
postmenopausal women with early-stage breast cancer that is:
l lymph node negative or positive (up to three positive nodes)
l oestrogen receptor positive
l human epidermal growth factor receptor 2 negative.
The test requires RNA extracted from a FFPE breast tumour tissue sample and is done using the nCounter®
analysis system (NanoString Technologies, Inc., Seattle, WA, USA). The test process involves fluorescent
probe pairs that hybridise to the mRNA; the fluorescence is then detected by the nCounter Digital Analyzer
(NanoString Technologies, Inc., Seattle, WA, USA).
Prosigna is based on the Prediction Analysis of Microarray 50 (PAM50) gene signature.23 It measures the
expression levels of 50 genes used to classify patients into one of four breast cancer subtypes. It also
measures the expression of eight housekeeping genes used for signal normalisation, six positive controls
and eight negative controls. Prosigna classifies samples into the following breast cancer subtypes based on
their PAM50 gene expression signatures: luminal A, luminal B, HER2-enriched or basal-like. A ROR score,
representing the risk of distant recurrence within 10 years (assuming 5 years of hormonal treatment), is
then derived from an algorithm based on the results of the PAM50 gene signature plus clinicopathological
factors. Four versions of the ROR score exist in the research setting: (1) ROR based on PAM50 subtype
information (ROR-S), (2) ROR-S based on PAM50 information plus proliferation score (ROR-P), (3) ROR-S
plus tumour size (ROR-T or ROR-C) and (4) ROR-S plus proliferation score and tumour size [PAM50 subtype
call, proliferation score and ROR score (ROR-PT)]. The proliferation score is based on a subset of the
PAM50 genes associated with the proliferation pathway.
The Prosigna test uses ROR-PT and therefore includes the PAM50 breast cancer subtype, tumour size and
proliferation score. Nodal status is also used in converting the score into a risk category. The ROR score is
a numerical score on a scale of 0 to 100. Based on this score and the nodal status, samples are classified
into risk categories:
l node negative: low risk (score of 0–40), intermediate risk (score of 41–60) or high risk (score of 61–100)
l node positive (up to three positive nodes): low risk (score of 0–15), intermediate risk (score of 16–40)
or high risk (score of 41–100).
This assessment includes all studies assessing ROR-PT, whether they use the commercial Prosigna test
(using the nCounter system) or other methods (such as RT-qPCR). However, studies assessing ROR-S
(subtype), ROR-T/ROR-C (subtype and tumour size) or ROR-P (subtype and proliferation score) are excluded.
Studies are also excluded if they only assess PAM50 breast cancer subtypes (luminal A, etc.) rather than
ROR-PT score.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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IHC4 test
Immunohistochemistry 4 is a laboratory-developed test that combines the results of four IHC-measured
parameters. The test can be combined with clinical and pathological features; this is known as IHC4 plus
clinical factors (IHC4+C). The test is designed to quantify the risk of distant recurrence in breast cancer
patients, assuming 5 years of endocrine therapy. The test is intended for use in postmenopausal women
with early-stage breast cancer with the following clinical features:
l oestrogen receptor positive
l lymph node negative or positive (up to three positive nodes).
The components of the test are four immunohistochemical assays: ER, PR, HER2 and the proliferation
marker Ki-67. The IHC4 test is currently used within the Royal Marsden Breast Cancer Unit service, but it
has been suggested that the test could be run in local NHS laboratories if quality assurance programmes
for the individual assays were in place. IHC4 uses FFPE breast tumour tissue samples and IHC techniques
that are universally available in NHS pathology departments. ER and HER2 markers are commonly
measured in NHS laboratories, although methods for quantifying these markers in the format required for
the test may not be routinely available. Although PR and Ki-67 markers are not routinely measured in
breast tumour tissue samples, the assays are commonly available for use if needed. The quantitative
assessment of Ki-67 required for the IHC4 test is not currently conducted in most NHS laboratories and,
therefore, further training for pathologists and biomedical scientists is likely to be needed.
The IHC4+C test involves an algorithm that calculates a risk score for distant recurrence based on the
results of the four IHC assays and clinical factors including age, nodal status, tumour size and tumour
grade. The algorithm has been published and validated24,25 and is freely available, and a calculator is
available for use on request. A distant recurrence score of < 10% is categorised as low risk for distant
recurrence at 10 years, a score of ≥ 10% but < 20% is categorised as intermediate risk and a score of
≥ 20% is categorised as high risk for distant recurrence at 10 years. At the Royal Marsden NHS Foundation
Trust, the test is processed with an average estimated turnaround time of 1 week; however, results may be
made available in 2 working days if they are urgently required.
Current usage of tumour profiling tests in the NHS
A previous systematic review and economic evaluation (Ward et al.1) published in 2013 considered the
clinical effectiveness and cost-effectiveness of tumour profiling tests compared with current prognostic
tools in guiding the use of adjuvant chemotherapy in people with early-stage breast cancer in England and
Wales. This report informed the NICE decision to approve the use of oncotype DX as an option for guiding
adjuvant chemotherapy decisions for people with ER+, LN0, HER2– early-stage breast cancer assessed to
be at intermediate ROR of breast cancer after surgery. The use of the other tumour profiling tests in the
NHS remains limited (mainly to clinical trial use).
Description of the decision problem
This assessment aims to assess whether or not tumour profiling tests used for guiding adjuvant
chemotherapy decisions for people with early-stage breast cancer represent a clinically effective and
cost-effective use of NHS resources.
Interventions
The following tumour profiling tests are included, in combination with current decision-making:
l EndoPredict and EPClin
l MammaPrint
l oncotype DX Breast Recurrence Score and oncotype DX breast RSPC
l Prosigna (or ROR-PT, which is equivalent)
l IHC4 and IHC4+C.
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Comparators
The comparator for the assessment is standard UK practice for chemotherapy decision-making, which may
include any tool, or clinical and pathological features, used to assess risk. Clinicopathological tools used in
current practice include Predict, NPI and AOL. The use of these tools varies between centres.
Population and important subgroups
The intended population for the assessment relates to people with ER+ (and/or PR-positive), HER2–,
early-stage breast cancer (stages I or II) with zero to three positive lymph nodes (LN0–3).
In practice, it was anticipated that many potentially relevant studies would include a broader population.
Therefore, all relevant studies of early-stage breast cancer were eligible for inclusion, and the findings
are interpreted with reference to how closely the study population matched the intended population.
The following subgroups are considered within this assessment:
l people with LN0 cancer, people with micrometastases in the lymph nodes and people with one to three
positive lymph nodes (LN1–3)
l premenopausal and postmenopausal women
l people predicted to be at low, intermediate or high risk using a risk assessment tool or using clinical
and pathological features
l males and females
l people of different ethnicities.
These tests will only have an impact on the health of patients if they lead to changes in patient
management. This is most likely to happen in populations in which the decision of whether or not to offer
chemotherapy is currently uncertain. One such group is patients with ER+, LN0, HER2– early-stage breast
cancer for whom prognostic variables suggest that they are at intermediate risk. The definition of this
‘intermediate group’ is not clear cut. Clinical advice suggests that patients with a NPI of ≤ 3.4 are typically
considered at low risk either using current prognostic tools (except for a few very young women with
aggressive early-stage breast cancer) or based on the new tests and are unlikely to receive chemotherapy;
therefore, their management is unlikely to change. Few patients with ER+, LN0, HER2– early-stage breast
cancer will have a NPI of > 5.4 and, therefore, those with a NPI of > 3.4 can be considered as being at
intermediate risk. Some LN+ patients may also be considered to be at intermediate risk.
Current treatment protocols indicate that women with HER2+, ER– early-stage breast cancer or with more
than three positive nodes are likely to receive chemotherapy in most centres in England. Although the use
of tumour profiling tests might be able to spare a proportion of these patients from chemotherapy, the
evidence base for the use of these tests in this population is more limited and clinical opinion, therefore,
considered the assessment of these tests in this population to be a lower priority; this population was
therefore excluded from the NICE scope. Currently, patients with micrometastases who are clinically
managed as LN0 patients are excluded from NHS-funded testing using oncotype DX, even if they fall
within the intermediate-risk group. Patients with micrometastases are included in the NICE scope.
Patients with ER+, HER2– early-stage breast cancer, who either are LN0 or have one to three positive
nodes, are therefore considered to be an important population in which to assess these tests, given the
current evidence base. The scope therefore focuses on the ER+, HER2– population with zero to three
lymph nodes. Within this population, an important subgroup consists of patients at clinically intermediate
risk for whom the decision about whether or not to offer chemotherapy is not clear cut.
BACKGROUND AND DEFINITION OF THE DECISION PROBLEM
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Outcomes
The clinical effectiveness review considers the clinical effectiveness of the tests in relation to the following
broad categories (these are described further in Chapter 2, Methods, which also lists the relevant study
designs for each outcome):
l Analytic validity (i.e. the ability of the test to accurately and reliably measure the expression of mRNA or
proteins by breast cancer tumour cells). Owing to time constraints, it was not possible to conduct a full
review of analytic validity for all tests. A rapid review of IHC4 was conducted.
l Prognostic ability (i.e. the degree to which the test could accurately predict the risk of an outcome such
as disease recurrence and discriminate patients with different outcomes).
l Prediction of chemotherapy benefit (i.e. whether or not the effect of chemotherapy vs. no
chemotherapy on patient outcomes differs between test risk groups).
l Clinical utility (this is defined differently throughout the prognostic literature); here, we define clinical
utility studies as those that assess the ability of the test to affect patient outcomes (e.g. recurrence and
survival) through the prospective use of the test to guide treatment decisions.
l Decision impact (i.e. how the tests influence decision-making in terms of which patients will be offered
or administered chemotherapy; this design does not include follow-up of clinical outcomes such as
recurrence or survival). The review included only UK and European studies because chemotherapy rates
differ widely between European and non-European countries.
l Health-related quality of life and anxiety.
l Time-to-test results.
Assessment of the above outcomes involves making comparisons (between study groups or between risk
groups for the test) in terms of clinical patient outcomes such as recurrence and survival. Key clinical
outcomes included for this purpose are listed in Chapter 2, Methods.
The outcomes of interest for the economic evaluation are the morbidity and mortality associated with
invasive breast cancer and its treatment. Outcomes from the model are expressed in terms of the
incremental cost per quality-adjusted life-year (QALY) gained.
Aims and objectives of the assessment
The overall aim of the assessment is to address the question ‘Do tumour profiling tests used for guiding
adjuvant chemotherapy decision in patients with early-stage breast cancer represent a clinically effective
and cost-effective use of NHS resources?’. This includes an update of the systematic review and
cost-effectiveness analysis1 undertaken to inform NICE DG10.20
The objectives of the assessment are to:
l conduct a systematic review of the published evidence on the effectiveness and cost-effectiveness of
the five tumour profiling tests
l develop a health economic model to assess the cost-effectiveness associated with the use of tumour
profiling tests compared with current prognostic tools to guide the use of adjuvant chemotherapy in
early-stage breast cancer from the perspective of the NHS and Personal Social Services (PSS).
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Chapter 2 Clinical evidence
A systematic review was undertaken to assess the effectiveness of tumour profiling tests for guidingadjuvant chemotherapy decisions in early-stage breast cancer. The methods of the systematic review
are described in Methods. The results of the review are reported in Results.
Methods
This report contains reference to confidential information provided as part of the NICE appraisal process.
This information has been removed from the report and the results, discussions and conclusions of the
report do not include the confidential information. These sections are clearly marked in the report.
A registered protocol of this systematic review (CRD42017059561) is available on the PROSPERO website
at www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017059561 (accessed 10 May 2018).
The review was conducted following the general principles recommended in the Centre for Reviews
and Dissemination (CRD)’s guidance,26 in the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement,27 in the NICE Diagnostic Assessment Programme manual28 and by
the Cochrane Prognosis Methods Group.29
The protocol included a mapping stage, following which minor amendments were made to the inclusion
criteria and review methods in consultation with NICE and clinical advisors in order to focus the evidence
review to studies of most relevance to the decision problem.
Identification of studies
This systematic review search provided an update to the previous systematic review (by Ward et al.1)
conducted for NICE DG10.20 The search strategy was adapted to retrieve clinical studies and systematic
reviews of five tumour profiling tests (with or without clinicopathological factors) in early-stage breast
cancer management: EndoPredict, oncotype DX, MammaPrint, IHC4 and Prosigna.
The search approach involved:
l searching of electronic databases
l contact with experts in the field
l scrutiny of bibliographies of retrieved papers
l identification of relevant studies from the previous review by Ward et al.1 conducted for NICE DG1020
(see below)
l references included within the evidence dossiers provided by the manufacturers to NICE.
Electronic database searches
The search strategy comprised medical subject headings (MeSHs) or Emtree thesaurus terms and free-text
synonyms for ‘breast cancer’ combined with the individually named tumour profiling tests. Searches were
translated across databases and were not limited by language. Searches for oncotype DX, MammaPrint,
IHC and Prosigna were limited by publication date from 2011 (the search date in the review by Ward
et al.,1 because these tests were included in this review), whereas no date limits were applied to EndoPredict
(as it was not included in the review by Ward et al.1).
The search strategies are presented in Appendix 2. Literature searching was undertaken in February 2017
in the following electronic databases and trials registries:
l MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations (via Ovid): 1946 to present.
l EMBASE (via Ovid): 1974 to 24 February 2017.
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l Cochrane Database of Systematic Reviews (via Wiley Interscience): 1996 to present.
l Database of Abstracts of Reviews of Effects (via Wiley Interscience): 1995 to 2015 (until close
of database).
l Cochrane Central Register of Controlled Trials (via Wiley Interscience): 1995 to present.
l Health Technology Assessment (HTA) Database (via Wiley Interscience): 1995 to 2016 (until close
of database).
l NHS Economic Evaluation Database (via Wiley Interscience): 1995 to 2015 (until close of database).
l Science Citation Index Expanded (via Web of Science): 1900 to present.
l Conference Proceedings Citation Index – Science (via Web of Science): 1990 to present.
l World Health Organization International Clinical Trials Registry Platform (http://apps.who.int/trialsearch/;
accessed 19 January 2017) (no date limit applied).
l American Society of Clinical Oncology (ASCO) (via Web of Science) (date range searched: 2011–17).
l European Society for Medical Oncology (via Web of Science) (date range searched: 2011–17).
Supplementary searches
References of relevant systematic reviews, primary studies and company submissions were checked to
identify additional studies.
Inclusion and exclusion criteria
The inclusion and exclusion criteria for selecting studies are described in the following sections.
Population and setting
The intended population included people with ER+ (and/or PR-positive), HER2–, early-stage breast cancer
(stages I or II) with LN0–3.
In practice, it was anticipated that many potentially relevant studies would include a broader population.
Therefore, all relevant studies of early-stage breast cancer were eligible for inclusion. When subgroups
were reported for the intended population (described above), these were used in the assessment. When
no subgroups were reported, the study was included and the findings were interpreted with reference to
how closely the study population matched the intended population.
The following subgroups were considered within this assessment:
l people with LN0 cancer, people with micrometastases in the lymph nodes and people with LN1–3
l premenopausal and postmenopausal women
l people predicted to be at low, intermediate or high risk using a risk assessment tool or using clinical
and pathological features
l males and females
l people of different ethnicities.
This assessment focuses on the use of tumour profiling tests to guide decisions about adjuvant
chemotherapy. The use of these tests to guide endocrine therapy decisions, or decisions about
neoadjuvant chemotherapy (to shrink the tumour before surgery), was not evaluated.
Interventions
The following tumour profiling tests were included:
l EndoPredict and EPClin
l MammaPrint
l oncotype DX Breast Recurrence Score and oncotype DX Breast RSPC
l Prosigna (or ROR-PT, which is equivalent)
l IHC4 and IHC4+C.
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Commercial versus in silico tests
Studies were included if they assessed the commercially available versions of the tests. For IHC4, as there is
no commercially available version of the test, any methodology was included. In addition, some studies used
in silico (electronic database) versions of tests using publicly available genetic databases, usually based on
whole-genome-expression microarray data. Owing to uncertainty about their similarity to the commercially
available tests, these studies were analysed separately. It was beyond the scope of the review to ascertain the
quality of the methods used or the degree of overlap between cohorts for these in silico studies.
Comparators
The comparator for the assessment is standard UK practice for chemotherapy decision-making. This was
taken to include combinations of clinicopathological factors (e.g. within multivariable models), plus
clinicopathological risk tools used in the UK, including Predict, the NPI and AOL. The clinical treatment
score (CTS), a combination of commonly used clinicopathological variables, was also included as a
comparator even though it is not commonly used in practice as a tool, because it is used in a number of
key studies and includes a set of variables that are used in practice.
Other non-UK local or national guidelines, such as St Gallen and the National Comprehensive Cancer
Network (NCCN) guidelines, were excluded when a study also reported comparisons with Predict, NPI or
AOL, but were otherwise included.
Relevant comparators within individual studies varied in accordance with the study type:
l Studies assessing prognostic performance. No comparator is needed as the aim is to compare outcomes
between risks groups for the test being studied.
l Studies assessing prediction of chemotherapy benefit. No comparator is needed as the aim is to
compare the effect of chemotherapy between risks groups for the test being studied.
l Clinical utility studies. The relevant comparator is standard clinical practice as defined in the first
paragraph of this section.
l Decision impact studies. The relevant comparator is standard clinical practice as above (for pre-test
chemotherapy decisions).
Outcomes and study designs
The clinical effectiveness review considers the clinical effectiveness of the tests in relation to the following
broad categories:
l Analytic validity (i.e. the ability of the test to accurately and reliably measure the expression of mRNA or
proteins by breast cancer tumour cells). Owing to time constraints, it was not possible to conduct a full
review of analytic validity for all tests. A rapid review of IHC4 was conducted.
l Prognostic performance (i.e. the degree to which the test can accurately predict the risk of an outcome
such as disease recurrence and discriminate patients with different outcomes). This is usually assessed
by conducting the test on stored tumour samples for which longer-term patient outcome data are
available, but when the test did not influence treatment. Study designs include –
¢ Reanalysis of randomised controlled trial (RCT) data.
¢ Analysis of prospective or retrospective cohorts in which the test did not influence treatment.
l Prediction of chemotherapy benefit (i.e. whether or not the effect of chemotherapy vs. no chemotherapy
on patient outcomes differs between test risk groups). This is usually assessed by conducting the test on
stored tumour samples for which longer-term outcome data are available. Study designs include –
¢ Reanalysis of RCTs in which some patients received chemotherapy and some did not.
¢ Analysis of prospective or retrospective cohorts in which some patients received chemotherapy and
some did not. These could include cohorts in which the test did or did not influence practice.
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l The difference between absolute and relative benefit should be noted: for a test that is prognostic, a
difference in absolute benefit of chemotherapy between groups would be expected, whereas for a test to
be considered predictive of chemotherapy benefit, a difference in relative benefit should be seen. As an
example, if distant recurrence rates in the test high-risk group were 30% without chemotherapy and
20% with chemotherapy, the absolute benefit of chemotherapy would be 10%. Likewise, if distant
recurrence rates in the test low-risk group were 3% without chemotherapy and 2% with chemotherapy,
the absolute benefit of chemotherapy would be 1% (i.e. much smaller). However, the relative benefit
would be the same in both groups [relative risk (RR) of 0.67, i.e. chemotherapy reduces recurrence by
one-third]. If the test is predictive of chemotherapy benefit, the RR would be expected to be different in
different risk groups.
l Clinical utility: this is defined differently throughout the prognostic literature. Here, we define clinical
utility studies as those that assess the ability of the test to affect patient outcomes (such as recurrence
and survival) through the prospective use of the test to guide treatment decisions (the study may be
prospective or retrospective, but use of the test should have been prospective, i.e. used in clinical
practice rather than conducted on stored tumour samples). Study designs include –
¢ RCTs randomising patients to chemotherapy guided by the test or guided by a comparator
(e.g. clinical practice).
¢ Observational studies reporting clinical outcomes for patients whose treatment was guided by the
test. As these studies do not have a comparator, we are primarily interested in outcomes for patients
with low-risk disease, who, as a group, have mostly avoided chemotherapy. The observation of good
outcomes in this group could, alongside other evidence, support the avoidance of chemotherapy in
this group.
l Decision impact (i.e. how the tests influence decision-making in terms of which patients will be offered
chemotherapy). Clinical advice to the External Assessment Group (EAG) suggests that chemotherapy
rates differ between countries, with lower rates in the UK and Europe than in the USA. The review
therefore included only UK and European studies. Study designs include –
¢ Studies assessing change in chemotherapy recommendations and/or decisions before and after use of
the test (this design does not include follow-up of clinical outcomes such as recurrence or survival).
l Health-related quality of life and anxiety. Study designs include –
¢ Studies assessing impact of the test versus usual practice on HRQoL and anxiety.
¢ Studies assessing HRQoL and anxiety before and after test use.
l Time-to-test results: studies assessing the time taken to obtain test results.
l Concordance: concordance is defined in this review as the degree to which tests assign the same
patients to the same risk groups. Such studies do not report long-term outcomes. A full systematic
review of studies that only assess concordance between tests (with no patient outcome data) was
beyond the scope of this assessment. However, the Optimal Personalised Treatment of early breast
cancer usIng Multi-parameter Analysis preliminary (OPTIMA Prelim) study30 was included as a key
example of concordance between tests.
Clinical patient outcomes
Assessment of clinical utility, prognostic ability and prediction of chemotherapy benefit involves making
comparisons (between study groups or between risk groups for the test) in terms of clinical patient
outcomes. Key clinical outcomes included for this purpose are listed below. Standard definitions for breast
cancer outcomes, defined by Hudis et al.,31 are given below, although these are not always consistently or
clearly defined in study reports. Within this review, DRFS and distant recurrence/relapse-free interval (DRFI)
CLINICAL EVIDENCE
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have been combined in some sections where insufficient detail was provided in study reports to distinguish
between them. The standard definitions for breast cancer outcomes are:
l distant recurrence/relapse-free survival, also referred to as distant metastasis-free survival (DMFS) or
distant disease-free survival (DFS) – events include distant recurrence and death from any cause
l distant recurrence/relapse-free interval, also referred to as distant metastasis-free interval (DMFI) –
events include distant recurrence and death from breast cancer
l recurrence/relapse-free survival (RFS) – events include ipsilateral, locoregional or distant invasive recurrence
and death from any cause [not contralateral disease, non-breast cancers or ductal carcinoma in situ (DCIS)]
l recurrence/relapse-free interval (RFI) – events include ipsilateral, locoregional or distant recurrence and
death from breast cancer (not contralateral disease, non-breast cancers or DCIS)
l invasive disease-free survival (IDFS) – events include ipsilateral, locoregional or distant invasive
recurrence, contralateral and non-breast cancers, and death from any cause (not DCIS)
l disease-free survival – events include ipsilateral, locoregional or distant recurrence, DCIS, contralateral or
non-breast cancers, and death from any cause
l breast-cancer-specific survival (BCSS) – events include breast cancer death only
l overall survival – events include death from any cause only
l disease-related morbidity and mortality
l chemotherapy-related morbidity and mortality.
For the above clinical outcomes, studies were only included if follow-up was ≥ 5 years for survival
outcomes (OS and BCSS) or ≥ 3 years for other outcomes.
The following outcomes were excluded:
l locoregional recurrence (i.e. within the region of the original tumour), because chemotherapy decisions
will mainly impact distant recurrence and survival
l clinician confidence and patient decisional conflict relating to decision impact of the test (this is beyond
the scope of this assessment)
l prediction of benefit from one type of chemotherapy versus another (the assessment is restricted to
benefit of chemotherapy vs. no chemotherapy).
Studies not published in the English language were included if sufficient PICOS (population, intervention,
comparator, outcome, study design) data could be extracted from non-English-language full-texts or from
an existing English language abstract. Non-peer-reviewed reports or abstracts were only included if the
data were presented in a succinct and accessible manner (e.g. a manuscript prepared for submission to a
journal), if sufficient methodological details were reported to allow critical appraisal of the study quality
and if results were reported in sufficient detail.
Study selection process
All records retrieved from the search were exported into a reference management database [EndNote
version X7; Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA]. After deduplication,
titles/abstracts were assessed for relevance, followed by examination of full texts of potentially includable
studies. Study selection was conducted by one reviewer, with discussion between two reviewers for any
studies giving rise to uncertainty. A 10% sample was checked by a second reviewer early in the process to
ensure mutual understanding of study inclusion and to correct if necessary.
Data extraction
A data extraction form was constructed in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA)
and piloted using two examples of each study design. Data were extracted by one reviewer and checked
by a second reviewer. Disagreements were resolved by discussion. Study authors were contacted for any
missing or ambiguous data when time allowed. When multiple publications related to the same patient
cohort, or when pooled analyses were identified, the references selected for inclusion were those that
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provided the most complete follow-up and the most useful clinical outcomes (DRFS or DRFI were preferred
based on clinical advice and use in the health economic model; see Chapter 3), avoiding double-counting
of patients/cohorts when possible.
Quality assessment
The methodological quality of included studies was assessed using quality assessment tools relevant to the
study design. Quality assessment was undertaken by one reviewer and checked by a second reviewer.
The quality and design of studies was considered within the narrative synthesis of results.
For clinical utility studies (for which the highest level of evidence is a RCT of the test vs. usual practice),
quality was assessed using the Cochrane risk-of-bias tool for RCTs.32
For studies assessing prognostic ability and prediction of chemotherapy benefit, quality was assessed using
relevant criteria selected from the draft Prediction model study Risk Of Bias ASsessment Tool (PROBAST)
(Dr Robert Wolff, Kleijnen Systematic Reviews Ltd, January 2017, personal communication). The PROBAST
tool has been developed specifically for use in systematic reviews of prediction models by the Cochrane
Prognosis Methods Group,29 but is not yet validated or published. Criteria were selected on the basis of
relevance to this review. Table 2 shows the quality criteria used in this assessment and how they were scored.
Studies assessing decision impact, analytic validity and HRQoL/anxiety were not quality assessed owing to
time constraints.
TABLE 2 The PROBAST quality criteria and scoring
Number Criterion Scoring
Risk-of-bias questions
1 Is the study design appropriate? Yes (prognosis): reanalysis of RCT or cohort or nested case control AND
patients did not receive chemotherapy
Yes (predicting chemotherapy benefit): RCT or reanalysis of RCT
No (prognostic): non-nested case control or case series AND/OR some/all
patients had chemotherapy
No (predicting chemotherapy benefit): patients not randomised to
chemotherapy vs. no chemotherapy
2 Are all eligible patients
included?
Yes: all eligible patients from trial or consecutive eligible patients from
prospective registry
No: some eligible patients excluded (e.g. not sent for testing, insufficient
tissue, test failures, missing data, AND/OR non-prospective registry)
Unclear: if unclear
4 Were test assessors blinded to
clinical outcomes?
Yes: blinded
No: not blinded
Unclear: if unclear
6 Was the outcome definition
standardised or defined a priori?
Yes: reported outcomes that were standardised (e.g. DRFS, OS) or defined
a priori
No: outcomes non-standardised and not defined a priori
Unclear: if either item unclear
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Data presentation and synthesis
Data were summarised and presented as tabular and narrative syntheses. Meta-analysis was not considered
appropriate owing to significant heterogeneity between studies. Interpretation of the evidence base was
conducted with reference to published hierarchies for predictive studies33–35 and with regard to the ability of
the study design to adequately address the decision problem. Interpretation of results also considered how
closely the study population matched the intended population, the methodological quality of the studies
and the treatment received by patients (in terms of endocrine therapy and chemotherapy).
Results
Quantity of evidence
Figure 4 is the PRISMA flow diagram for study selection. The database searches and searches of other
sources identified a total of 2330 unique references to screen. Of these, 1797 were excluded at the title/
abstract stage and 533 full-text articles were screened, of which 380 were excluded (reasons are listed in
Appendix 3). In total, 153 references were included in the assessment.
TABLE 2 The PROBAST quality criteria and scoring (continued )
Number Criterion Scoring
Applicability questions
3 Does the patient spectrum
match the review question?
Yes: all patients in scope (HR+, HER2–, LN0–3)
Mostly: < 20% out of scope
No: > 20% out of scope
Unclear: if unclear
5 Is the test as per the decision
problem?
Yes: same as commercially available tests or IHC4 conducted as per
Cuzick et al.25
No: different from commercially available tests (e.g. FFPE vs. fresh samples,
test methods)
Records identified
through database
searching
(n = 2279)
Additional records
identified through
other sources
(n = 51)
Records screened as
title and/or abstract
(n = 2330)
Records excluded at
title/abstract stage
(n = 1797)
Full-text articles assessed
for eligibility
(n = 533)
Full-text articles excluded,
with reasons
(n = 380)
• Population not relevant, n = 40
• Intervention not relevant, n = 27
• Comparator not relevant, n = 3
• Outcome not relevant, n = 146
• Study type not relevant, n = 34
• Could not obtain, n = 2
• No novel data, n = 128Articles included in
assessment report
(n = 153)
FIGURE 4 The PRISMA flow diagram.
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There are numerous Translational substudies of the Arimidex, Tamoxifen, Alone or in Combination (TransATAC)
publications that met the criteria for the review.25,36–44 ATAC45 was an international trial, which evaluated
anastrozole alone, tamoxifen alone, and the combination of both treatments in breast cancer patients.
Recruitment ended in 2006. TransATAC was a series of translational studies utilising samples and data
from the ATAC trial. Throughout the report we present data provided by the TransATAC team as personal
communications (Ivana Sestak, Queen Mary University of London, July 2017, personal communication) to the
EAG, provided on request from the EAG, which restricts to UK patients in the tamoxifen arm, with hormone
receptor-positive (HR+), HER2– and LN0–3 patients.46 Subsequently, a very similar analysis was published by
the TransATAC team.47 Some concerns were expressed during the NICE consultation about the suitability of
the TransATAC bespoke analysis and its comparability with other sources of data, and these are addressed in
Report Supplementary Material 1.
Overview of results
To orientate the reader to the broad sweep of the evidence and to facilitate interpretation of the detailed
evidence base, a summary of the results is provided in Appendix 4. A more complete summary of DRFS/
DRFI/DFS data for each test is then provided in section Results: oncotype DX through to Time-to-test results,
with more detailed narrative syntheses (including outcomes OS and BCSS) in Report Supplementary
Material 2–10. We have separated the evidence into the following broad categories:
l Development – a description of the development of the test. A full review of analytic validity was not
possible owing to time constraints. A rapid review of IHC4 was conducted.
l Prognostic performance – studies reporting on the ability of the test to predict ROR and/or survival.
The most commonly reported data are Kaplan–Meier estimates of risk of outcome per test risk group
and hazard ratios (HRs) between groups, although a small number of studies report C-index data
[which, in this case, are identical to the area under the curve (AUC)] and likelihood ratios. In keeping
with the majority of studies, we first present unadjusted data, and separately report analyses (usually
multivariable Cox proportional hazards models) that adjust for clinicopathological factors, which show
whether or not the test potentially has prognostic value over clinicopathological variables. The C-index
is a measure of the goodness of fit of a model with binary outcomes (in this case, it is identical to the
AUC). A value of < 0.5 indicates a poor model, a value of 0.5 indicates that the model is no better than
chance, a value of > 0.7 indicates a good model, a value of > 0.8 indicates a strong model and a value
of 1 indicates a perfect model.48
l Chemotherapy benefit – studies in this category compare treatment benefit across risk categories,
and most commonly reanalyse RCT data in which patients were randomised to chemotherapy or no
chemotherapy, and conduct a test for the interaction between treatment and tumour profiling test
risk group. The interaction test tells us whether or not the tumour profiling test is able to predict a
differential treatment effect by risk group. We have also included any observational studies that report
treatment benefit across risk categories, with or without interaction tests, with appropriate caveats
about the possibility of confounding in such studies. Note that the difference between absolute benefit
and relative benefit, as described in Data extraction, is of critical importance.
l Clinical utility – studies reporting the impact on patient outcomes (such as recurrence and survival) of the
prospective use of the test to guide adjuvant chemotherapy treatment decisions. Ideally, such studies
would randomise patients to treatment guided by the test or to treatment guided by usual clinical
practice; however, given the paucity of RCT evidence, the inherent ethical issues with randomising all
patients to chemotherapy and issues with powering such studies, observational studies have also been
included in this section.
l Decision impact – studies that report the impact of test results on actual chemotherapy decisions or
recommendations. Such studies do not report long-term follow-up of patients.
There were no data available for clinical utility for Prosigna, EndoPredict or IHC4. Chemotherapy benefit
only applies to MammaPrint and oncotype DX, as only these tests claim to be able to identify patients who
will benefit from chemotherapy, rather than just those patients who are at high risk of relapse. For this
CLINICAL EVIDENCE
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reason, the clinical review comprises the following main sections in Chapter 2, each with a number of
relevant subheadings:
l Overview of results.
l Results: oncotype DX (additional data in Report Supplementary Material 2–4).
¢ Development: oncotype DX.
¢ Prognostic performance: oncotype DX.
¢ Chemotherapy benefit: oncotype DX.
¢ Clinical utility: oncotype DX.
l Results: MammaPrint (additional data in Report Supplementary Material 5).
¢ Development: MammaPrint.
¢ Prognostic performance: MammaPrint.
¢ Chemotherapy benefit: MammaPrint.
¢ Clinical utility: MammaPrint.
l Results: Prosigna (additional data in Report Supplementary Material 6).
¢ Prognostic performance: Prosigna.
l Results: EndoPredict and EndoPredict Clinical (additional data in Report Supplementary Material 7).
¢ Development: EndoPredict and EndoPredict Clinical.
¢ Prognostic performance: EndoPredict and EndoPredict Clinical.
l Results: IHC4 (additional data in Report Supplementary Material 8).
¢ Development and analytic validity: IHC4.
¢ Prognostic performance: IHC4 and IHC4+C.
l Results: decision impact studies (additional data in Report Supplementary Material 9).
l Anxiety and health-related quality of life.
l Time-to-test results.
Additional sections that appear in Report Supplementary Material are:
l Report Supplementary Material 1: Comparison of TransATAC data to other study data (risk classification
and prognosis).
l Report Supplementary Material 8: Narrative synthesis and additional tables for IHC4 analytical validity.
l Appendix 5: results: all tests compared with each other:
(a) studies reporting more than one test
(b) microarray studies
(c) concordance.
Results: oncotype DX
Development: oncotype DX
See Report Supplementary Material 2 for a description of the development of oncotype DX.
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Prognostic performance: oncotype DX
Study characteristics: oncotype DX
Oncotype DX was validated in 11 distinct data sets. Seven were reanalyses of RCTs [the National Surgical
Adjuvant Breast and Bowel Project (NSABP) B14,49 B2050 and B2851,52 trials; the Southwest Oncology
Group (SWOG) trial 8814;53 the Eastern Cooperative Oncology Group E219754,55 trial; UK patients from the
TransATAC37,46 trial; and a French trial, PACS0156] and four were retrospective cohort studies (one from the
USA,57 two from China58,59 and one from Japan60). All studies recruited patients with either ER+ or HR+
tumours, but only TransATAC37,46 and one Chinese study58 recruited or reported a subgroup of exclusively
HER2– patients. Two studies (TransATAC37,46 and the SWOG 8814 trial)53 recruited only postmenopausal
patients.
The test was designed to predict outcomes in patients who received 5 years of endocrine therapy without
chemotherapy. Only three studies treated patients with endocrine monotherapy, although it was not
always clear if this was for 5 years; of these, one study recruited mixed lymph node status patients and
reported separate analyses for LN0 and LN+ patients,37,46 one recruited LN0 patients49 and one recruited
LN+ patients.53 Of the remaining studies, one treated some patients with endocrine monotherapy and
some with endocrine therapy and chemotherapy (LN0 patients50), two treated all patients with endocrine
therapy and chemotherapy (one study recruited mixed lymph node status patients54,55 and one recruited
LN+ patients51,52) and one treated all patients with chemotherapy and some with endocrine therapy
(LN+ patients).56 The retrospective studies treated patients in accordance with usual practice (without
oncotype DX) with varying levels of endocrine therapy and chemotherapy.57–60 The total number of patients
included was 4929. A detailed narrative synthesis of study characteristics is provided in Report Supplementary
Material 2. Study characteristics data are presented in Report Supplementary Material 2, Table 1.
Two studies did not report how oncotype DX was conducted (PACS01 study56 and Russell et al.57). In all
but three other cases, the test was conducted on fixed, paraffin-embedded tissue by Genomic Health
using the commercial oncotype DX assay. The three exceptions were the two studies from China in which
the test was not carried out by Genomic Health58,59 and the study by Paik et al.,49 as Paik et al. (2006)50
described the assay used in Paik et al. (2004)49 as being ‘a preliminary version of the RT-PCR assay (lacking
standardized reagents, calibrators, and controls)’. In these three studies, the equivalence of the tests to the
commercially offered oncotype DX assay is unknown.
Quality assessment: oncotype DX
Quality assessment is summarised in Report Supplementary Material 2. All studies were validation studies.
Only three studies37,46,49,53 used an appropriate study design, as eight50–52,54–59 included patients who had
been treated with chemotherapy or did not report the proportion of patients treated with chemotherapy.
Undertreatment with endocrine therapy and overtreatment with chemotherapy both have the potential to
affect recurrence and may alter the observed HRs for outcomes between risk groups. No studies included
all eligible patients and only three37,46,53,54 stated that they blinded test assessors to patient outcomes.
A lack of blinding is likely to have a low impact as the test is objective. There are concerns about patient
spectrum bias in all studies, mainly owing to the retrospective nature of the studies and the exclusion of
tumour samples with insufficient tissue probably leading to the loss of patients with smaller tumours.
The potential loss of patients with small tumours is of unknown concern, as it is unknown whether or
not the test would have a different prognostic performance in these patients.
Results: oncotype DX
The following is a summary of key results from the review. A detailed narrative synthesis of all study results
is provided in Report Supplementary Material 2.
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Distribution of patients by risk group: oncotype DX
Data are presented in Table 3. The proportion of patients classified as being at low risk ranged from 48%60
to 64%46 in LN0 cohorts and was generally lower, ranging from 36%51,52 to 57%,46 in LN+ cohorts. The
proportion of patients who were classified as being at intermediate risk ranged from 20%60 to 27%46 in
LN0 cohorts, and was generally higher in LN+ cohorts, ranging from 30%56 to 34%.51,52 The proportion of
patients who were classified as being at high risk ranged from 9% to 33% in LN0 patients and was similar
among LN+ patients, ranging from 11% to 32%. The number of patients who are likely to be prescribed
chemotherapy on the basis of their test results will, to a large extent, depend on how intermediate-risk
patients are handled and whether or not they would be handled in the same way in the LN0 and LN+ groups.
Prognostic performance, unadjusted analyses: oncotype DX
Data are presented in Table 3. The 10-year DRFI rates in low-risk LN0 patients treated with endocrine
monotherapy ranged from 93% to 97% (three studies46,49,60), and was similar when 100% patients
received endocrine therapy and chemotherapy (96%, one study50). LN+ patients had much lower 10-year
DRFI rates: 82% (one study46) with endocrine monotherapy and 81% (one study51,52) when 100% of
patients received endocrine therapy and chemotherapy. The 10-year DRFI rates in LN0 intermediate-risk
patients treated with endocrine monotherapy ranged from 86% to 100% (three studies46,49,60), and
was similar when 100% of patients received endocrine therapy and chemotherapy (89%, one study50).
LN+ intermediate-risk patients had much lower 10-year DRFI rates: 75% (one study46) with endocrine
monotherapy and 65% (one study51,52) when 100% of patients received endocrine therapy and
chemotherapy. The 10-year DRFI rates in LN0 high-risk patients treated with endocrine monotherapy
ranged from 70% to 77% (three studies46,49,60), and was higher when 100% of patients received
endocrine therapy and chemotherapy (88%, one study50). LN+ high-risk patients treated with endocrine
monotherapy had similar 10-year DRFI rates to LN0 patients, at 69% (one study46); in studies in which all
patients received endocrine therapy and some or all received chemotherapy, the DRFI was lower, at 56%
(one study51,52). All the DRFI rates in this paragraph exclude one study from China, which appeared an
outlier with very low DRFI rates (Sun et al.59). The study from Japan60 also reported some unusual results
in that intermediate-risk patients had better DRFI than low-risk patients (e.g. 10-year DRFI rate was 97%
and 100%, respectively). It is unclear if, for both of these studies,59,60 the unusual results are due to small
sample sizes (n = 9859 and n = 20060), differences in treatment practices in Japan and China compared with
Western countries or differences in ethnicity.
Despite confounding from treatment, the studies reporting prognostic performance data reported largely
statistically significant differences between high-risk and low-risk groups, whether through HRs or through
analyses of event rates per group, and this was the case regardless of lymph node status. However, differences
between the intermediate-risk group and the high- or low-risk groups were not always statistically significant,
particularly in the LN+ population (see Table 3).
Two studies reported a C-index (AUC). One study54,55 was in LN+/LN0 patients and the other was in LN0
patients.58 In both cases, the C-index was 0.69, which indicated that the model was better than chance at
placing patients into appropriate risk categories and nearly reaches the cut-off point for a ‘good’ test of 0.7.48
Data for OS, BCSS, RFS and RFI can be found in Report Supplementary Material 2. These data support
observations for DRFS, DRFI and DFS.
Additional prognostic value, adjusted analyses: oncotype DX
Data are presented in Table 4. The analyses that reported multivariable Cox proportional hazards models
that were adjusted for clinicopathological variables generally indicated that the prognostic performance of
oncotype DX had additional benefit over these factors, as HRs remained significant in most analyses (the
exception being RFS and OS analyses by Toi et al.60). This was consistent regardless of lymph node status
and variables adjusted for, which included age, tumour size and LN status (when applicable) in all cases
and grade in most cases (Toi et al.60 and Sun et al.59 being the exceptions). However, covariates included
in multivariate analyses varied, and it is not clear if all important covariates were included in all analyses.
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TABLE 3 Oncotype DX prognostic performance: DRFS, DRFI and DFS
Reference
(first author
and year) Cohorts Population
Nodal
status ET/chemotherapy
Cut-off
points
Percentage of patients per
group
DRFS/DRFI/DFS: % risk of outcome (95% CI)
DRFS/DRFI/DFS: HR (95% CI)0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High 0–5 years 0–10 years
DRFS
a
LN0, variable ET and chemotherapy
Gong 201658
(n = 153)
SYSMH,
CCSYU and
3rd HNC
100% HR+,
100% HER2–
LN0 100% ET; 79%
chemotherapy
NR 49 26 25 0–5 years:
l High vs. low: 2.2 (1.11 to 4.30);
p = 0.004
l High vs. intermediate: 1.9
(0.55 to 6.47); p= 0.108
l Intermediate vs. low: 1.0
(0.67 to 1.52); p= 0.953
l C-index (AUC) 0.685 (95% CI
0.540 to 0.830)
DRFI
LN0/+
Variable ET and chemotherapy
Sun 201159
(n = 93)
a
HAAMMS 100% HR+,
86% HER2–
LN+/
LN0
LN+/LN0, 75.3%
ET, 80.6%
chemotherapy
18–30 37 31 32 5.5 years median follow-up
l Low vs. high: p < 0.001
l Inter vs. high: p = 0.003
5.5 years median
follow-up, RS
50-point
Difference: 2.35
(1.58 to 3.49);
p < 0.001
LN0
100% ET monotherapy
Paik 2004,49
Tang 201161
and Wolmark
201652
(n = 668)
NSABP B-14 100% ER+,
HER2+/HER2–,
% NR
LN0 100% ET 18–30 51 22 27 97.9
(95.6 to 99.0)
b
90.8
(84.7 to 94.5)
b
77.9
(71.1 to 83.4)
b
93.2
(90.4 to 96.0)
85.7
(79.7 to 91.7)
69.5
(62.6 to 76.4)
RS 50-point
difference: 6.04
(3.88 to 9.41);
p < 0.001
b
Intermediate
vs. low: 2.21
(1.28 to 3.81)
High vs. low:
3.8 (2.36 to
6.1); p< 0.001
Log rank p < 0.001
b
p < 0.001 high vs. low
5–10 years:
95.2
(92.1 to 97.2)
b
5–10 years:
94.4
(88.0 to 97.5)
b
5–10 years:
89.2
(82.4 to 93.4)
b
5–10 years:
RS 50-point
difference – 1.55
(0.81 to 2.97);
p = 0.20
b
Log rank p= 0.06
b
high vs. low
5–15 years:
93.3
(89.6 to 95.7)
b
5–15 years:
88.1
(79.9 to 93.1)
b
5–15 years:
86.4
(79.0 to 91.3)
b
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Reference
(first author
and year) Cohorts Population
Nodal
status ET/chemotherapy
Cut-off
points
Percentage of patients per
group
DRFS/DRFI/DFS: % risk of outcome (95% CI)
DRFS/DRFI/DFS: HR (95% CI)0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High 0–5 years 0–10 years
Toi 201060
(n = 200)
8 Japanese
hospitals
100% ER+,
HER2 NR
LN0 100% ET 18–30 48 20 33 96.7
(90.0 to 98.9)
100 (NR) 75.2
(62.2 to 84.3)
50-point
increase: 6.20
(2.27 to 17.0);
p< 0.001p < 0.001 log rank (low vs. high)
Sestak
201746 (data
request) and
Dowsett
201037
(n = 829)
TransATAC 100% HR+,
100% HER2–,
postmenopausal
LN0 100% ET 18–30 64 27 9 99.1 (NR) 94 (NR) 88.9 (NR) 94.9 (NR) 87.7 (NR) 77.2 (NR) Intermediate
vs. low: 6.37
(2.27 to 17.87)
High vs. low:
12.39 (4.05 to
37.89)
Intermediate
vs. low: 2.67
(1.53 to 4.68)
High vs. low:
5.43 (2.84 to
10.35)
100% ET+ chemotherapy
Paik 200650
(n = 424)
NSABP B-20 100% ER+,
HER2+/HER2–
LN0 100% ET and
chemotherapy
18–30 51 21 28 95.6
(92.7 to 98.6)
89.1
(82.4 to 95.9)
88.1
(82.0 to 94.2)
Variable ET and chemotherapy
Sun 201159
(n = 57)
a
HAAMMS 100% HR+,
86% HER2–
LN0 75.3% ET, 80.6%
chemotherapy
18–30 – – – 84.4
(77.2 to 91.6)
72.6
(62.1 to 83.1)
41.7
(27.5 to 55.9)
57.9
(41.4 to 74.4)
43.0
(23.7 to 62.3)
20.8
(4.4 to 37.2)
p = 0.02
LN+
100% ET monotherapy
Sestak 201746
(data request)
and Dowsett
201037
(n= 219)
TransATAC 100% HR+,
100% HER2–,
postmenopausal
LN1–3 100% ET 18–30 57 32 11 95.9 (NR) 84.8 (NR) 83.6 (NR) 81.8 (NR) 75.4 (NR) 68.6 (NR) Intermediate
vs. low: 3.84
(1.31 to 11.23)
High vs. low:
4.45 (1.19 to
16.58)
Intermediate
vs. low: 1.66
(0.86 to 3.23)
High vs. low:
2.35 (0.99 to
5.60)
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TABLE 3 Oncotype DX prognostic performance: DRFS, DRFI and DFS (continued )
Reference
(first author
and year) Cohorts Population
Nodal
status ET/chemotherapy
Cut-off
points
Percentage of patients per
group
DRFS/DRFI/DFS: % risk of outcome (95% CI)
DRFS/DRFI/DFS: HR (95% CI)0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High 0–5 years 0–10 years
Variable ET and chemotherapy
Wolmark
201652 and
Mamounas
201251
(n = 1065)
NSABP-28 100% ER+,
HER2 NR
LN+ 100%
chemotherapy
and ET
18–30 36 34 30 91.6
(88.3 to 94.0)
81.2
(76.8 to 84.9)
70.3
(64.9 to 75.1)
80.9
(76.4 to 84.6)
c
64.9
(59.6 to 69.7)
c
55.8
(50.0 to 61.2)
c
RS 50-point
difference: 4.22
(2.93 to 6.07);
p < 0.001
Log rank p < 0.001 p < 0.001
5–10 years:
88.3
(84.3 to 91.4)
5–10 years:
79.9
(74.7 to 84.2)
5–10 years:
79.3
(73.1 to 84.3)
5–10 years,
RS 50-point
Difference: 1.66
(1.05 to 2.61);
p = 0.04
Log rank p= 0.02
Penault-
Llorca 201456
(n = 530)
PACS01 100% HR+ LN+ 100%
chemotherapy,
74.2% ET
NR 39 30 31 93.7
(89.4 to 96.3)
87.3
(81.0 to 91.6)
69.3
(61.5 to 75.8)
p < 0.001 7.7 years median
follow-up, RS 50-
point difference:
4.1 (CI NR);
p < 0.001
Sun 201159
(n = 35)
a
HAAMMS 100% HR+,
86% HER2–
LN+ LN+/LN0, 75.3%
ET, 80.6%
chemotherapy
18–30 62.5
(45.4 to 79.6)
66.7
(51.0 to 82.4)
16.7
(7.9 to 25.5)
62.5
(45.4 to 79.6)
33.3
(8.5 to 58.1)
16.7
(7.9 to 25.5)
p = 0.038
DFS
d
LN+
100% ET monotherapy
Albain
201053
(n = 148)
SWOG-
8814
100% HR+,
91% HER2–,
postmenopausal
LN+,
100%
LN > 3,
37%
100% ET 18–30 37 31 32 – – – 60 49 43 RS 50-point
difference: 2.64
(1.33 to 5.27);
p=0.006)
Assumption of
proportional
hazards not met
(p=0.0016)
0–5 years: HR
5.55 (2.32 to
3.28); p=0.0002
5–10 years: HR
0.86 (0.27 to
2.74); p=0.80
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Reference
(first author
and year) Cohorts Population
Nodal
status ET/chemotherapy
Cut-off
points
Percentage of patients per
group
DRFS/DRFI/DFS: % risk of outcome (95% CI)
DRFS/DRFI/DFS: HR (95% CI)0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High 0–5 years 0–10 years
Variable ET and chemotherapy
Penault-
Llorca 201456
(n = 530)
PACS01 100% HR+ LN+ 100%
chemotherapy,
74.2% ET
NR 39 30 31 90.8
(86.0 to 94.1)
84.9
(78.3 to 89.6)
64.6
(56.7 to 71.4)
7.7 years median
follow-up, RS 50-
point difference:
3.3 (CI NR);
p < 0.001
p< 0.001
Wolmark
201652 and
Mamounas
201251
(n = 1065)
NSABP-28 100% ER+,
HER2 NR,
menopausal
status NR,
female NR
LN+ 100%
chemotherapy and
ET
18–30 36 34 30 75.8
(71.1 to 79.8)
57.0
(51.6 to 61.9)
48.0
(42.3 to 53.4)
p < 0.001
LN status NR
ET and chemotherapy NR
Russell
201657
(n = 135)
University of
South
Florida and
Morton Plan
Hospital
100% ER+,
HER2– NR,
menopausal
status NR,
female NR
NR NR – usual
practice guided by
MammaPrint
NR 53 26 21 4.5 years median
follow-up:
Mantel–Cox
log-rank test
l Intermediate
vs. low:
p=0.760
l High vs. low:
p=0.036
l Intermediate
vs. high:
p=0.072
3rd HNC, Third Hospital of Nanchang City; ET, endocrine therapy; HAAMMS, Hospital Affiliated Academy of Military Medical Science, Beijing; NR, not reported; RS, recurrence score; SYSMH, Sun Yat-sen Memorial Hospital (Cancer Centre of
Sun Yat-sen University).
a Outcome described as DRFS, but the definition is for DRFI as it excludes contralateral disease, locoregional relapse, other primary cancers and non-breast-cancer deaths.
b From Wolmark et al.52
c These data are from Mamounas et al.51 The same data are reported in the company submission62 as DRFS. As DRFI is defined and reported in Wolmark et al.,52 we have assumed Mamounas et al.51 is correct in calling this DRFI.
d The definition of DFS is unclear for all studies.
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TABLE 4 Oncotype DX: additional prognostic value over clinicopathological factors or comparator tests
Reference (first author
and year) Cohorts Population Nodal status ET/chemotherapy
Cut-off
point Outcome Test or comparator
a
Multivariable Cox proportional hazards model (adjusted for
clinicopathological factors
a
): HR (95% CI) unless otherwise stated
LN+/LN0, 100% ET and chemotherapy
Goldstein 200854 and
Sparano 201255 (n = 465)
E2197 (ECOG trial) 100% HR+, 44% HER2–,
premenopausal/
postmenopausal
LN0, 56.5%
LN1–3, 43.5%
All ET and
chemotherapy,
40% aromatase
inhibitor
18–30 RFI Oncotype DX vs.
clinicopathological factors
a
5 year:54
HR (RS 50-point difference):
2.12 (0.97 to 4.65, p = 0.06)
b
3.13 (1.60 to 6.14, p = 0.0009)
b
10 year55
HR (RS 50-point difference):
2.27 (1.04 to 4.97, p NR)
Oncotype DX vs. integrator
based on AOL
b
5 year:54 for 50-point difference using central grade:
l RS HR: 2.51 (95% CI 1.71 to 3.70); p < 0.001
l Integrator HR: 1.51 (95% CI 1.07 to 2.13); p = 0.02
For 50-point difference using local grade:
l RS HR: 2.64 (95% CI 1.80 to 3.87); p < 0.001
l Integrator HR: 1.34 (95% CI 0.94 to 1.91); p = 0.11
Interaction term was not significant indicating effect of RS is largely
independent of the level of the integrator
100% HR+,
100% HER2–
NR 5 year:54 C-index (AUC):
l RS: 0.69
l Integrator (central grade): 0.61
l Integrator (local grade): 0.56
Sestak 2017 (data
request)46 and Dowsett
201037 (n= 774)
TransATAC 100% HR+, 100%
HER2–, postmenopausal
LN+/LN0 100% ET 18–30 DRFI Increase in likelihood ratio χ2 over comparator
Oncotype DX vs. CTS 10 year: 15.22 (p = 0.0001)
Oncotype DX vs. NPI 10 year: 11.89 (p = 0.0006)
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Reference (first author
and year) Cohorts Population Nodal status ET/chemotherapy
Cut-off
point Outcome Test or comparator
a
Multivariable Cox proportional hazards model (adjusted for
clinicopathological factors
a
): HR (95% CI) unless otherwise stated
LN0, 100% ET monotherapy
Paik 200449 and Tang
201161 (n= 668)
NSABP B-14 100% ER+, HER2+/
HER2–, % NR
LN0 100% ET 18–30 DRFI Increase in likelihood ratio χ2 over
clinical factors
a
or comparator
Multivariable Cox proportional
hazards model (adjusted for
clinicopathological factors
a
)
Oncotype DX vs.
clinicopathological factors
a
l Cox proportional hazards model 1:
33.7, p<0.001
l Cox proportional hazards model 2:
15.2, p<0.001
l Cox proportional hazards
model 3:
c
NR
RS 50-point difference:
Cox proportional hazards model 1:
3.21 (2.23 to 4.61) p<0.001
Cox proportional hazards model 2:
2.81 (1.70 to 4.64) p<0.001
Cox proportional hazards
model 3:
c
2.34 (1.56 to 3.5);
p < 0.001
DRFI Multivariable Cox proportional hazards model (adjusted for
clinicopathological factors
a
)
Oncotype DX vs. AOL
d
Cox proportional hazards model 4 (only AOL and RS):
l AOL: 1.93 (1.27 to 2.91); p= 0.002
l RS 50-point difference: 2.83 (1.91 to 4.18); p< 0.001
Oncotype DX vs. AOL and
clinicopathological factors
b
Cox proportional hazards model 5 (AOL, RS, age, tumour size, grade):
l AOL: 0.86 (0.45 to 1.62); p= 0.636
l RS: 2.37 (1.58 to 3.55); p < 0.001
Toi 201060 (n= 200) 8 Japanese
hospitals
(unnamed)
100% ER+, HER2 NR,
menopausal status NR,
% female NR
LN0 100% ET 18–30 DRFI Oncotype DX vs.
clinicopathological factors
a
RS 50-point difference: 6.03 (2.17 to 16.7); p< 0.001
RFI RS 50-point difference: 3.38 (1.32 to 8.69)
RFS RS 50-point difference: 2.09 (0.84 to 5.20)
OS RS 50-point difference: 2.67 (0.93 to 7.62)
Sestak 2017 (data
request)46 and Dowsett
201037 (n= 591)
TransATAC 100% HR+, 100% HER2–,
postmenopausal
LN0 100% ET 18–30 DRFI Increase in likelihood ratio χ2 over comparator
Oncotype DX vs. CTS 5 year: 10.03 (p = 0.002) 10 year: 10.64 (p = 0.001)
Oncotype DX vs. NPI 5 year: 9.62 (p= 0.002) 10 year: 8.82 (p = 0.003)
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TABLE 4 Oncotype DX: additional prognostic value over clinicopathological factors or comparator tests (continued )
Reference (first author
and year) Cohorts Population Nodal status ET/chemotherapy
Cut-off
point Outcome Test or comparator
a
Multivariable Cox proportional hazards model (adjusted for
clinicopathological factors
a
): HR (95% CI) unless otherwise stated
LN0, variable ET and chemotherapy
Sun 201159 (n = 57) HAAMMS 100% HR+, 86% HER2–
(7.5% unclear)
LN0 75.3% ET, 80.6%
chemotherapy
18–30 DRFS RS (not Genomic Health)
vs. clinicopathological
factors
a
RS 1-point difference: 1.03 (1.01 to 1.06); p = 0.017
LN+, variable ET and chemotherapy
Penault-Llorca 201456
(n = 530)
PACS01 100% HR+ LN+ 100%
chemotherapy,
74.2% ET
NR NR, assume
DRFI
Oncotype DX vs.
clinicopathological factors
a
p < 0.001
Sun 201159 (n = 35) HAAMMS 100% HR+, 86% HER2–
(7.5% unclear)
LN+ 75.3% ET, 80.6%
chemotherapy
18–30 DRFS RS (not Genomic Health) RS 1-point difference: 1.03 (1.00 to 1.07); p = 0.039
Sestak 2017 (data
request)46 and Dowsett
201037 (n= 183)
TransATAC 100% HR+, 100% HER2–,
postmenopausal
LN+ 100% ET 18–30 DRFI Increase in likelihood ratio χ2 over comparator
Oncotype DX vs. CTS 5 year: 3.29 (p= 0.07) 10 year: 3.56 (p = 0.06)
Oncotype DX vs. NPI 5 year: 2.47 (p= 0.1) 10 year: 2.14 (p = 0.1)
Wolmark 201652 and
Mamounas 201251
(n = 1065)
NSABP-28 100% ER+, HER2 NR,
menopausal status NR,
female NR
LN+ 100%
chemotherapy and
ET
18–30 DFS, DRFI,
OS
Oncotype DX vs.
clinicopathological factors
a
p < 0.001
ECOG, Eastern Cooperative Oncology Group; ET, endocrine therapy; HAAMMS, Hospital Affiliated Academy of Military Medical Science, Beijing; RS, oncotype DX recurrence score.
a Adjusted for:
l Goldstein et al.54 – number positive nodes, tumour size, age, HER2 status, grade.
l Paik et al.49 – Cox proportional hazards model 1 adjusted for age and tumour size; Cox proportional hazards model 2 adjusted for age, tumour size, tumour grade, HER2 amplification, amounts of oestrogen and progesterone-receptor
protein; Cox proportional hazards model 3 adjusted for age, tumour size, grade.
l Penault-Llorca et al.56 – treatment, age, tumour size and grade, number of positive nodes, surgery type and Ki-67 status.
l Sun et al.59 – unclear if all clinicopathological factors kept in the analysis: age, tumour size, nodal status, ER, PR, HER2, ET, chemotherapy, St Gallen criteria,63 RS.
l Toi et al.60 – age and clinical tumour size.
l Wolmark et al.52/Mamounas et al.51 – does not specify which covariates were included for which outcomes, but selected from treatment, age, tumour size, tumour grade, number of positive nodes and type of surgery.
b First Cox proportional hazards model used centrally determined disease grade, second Cox proportional hazards model used locally determined disease grade.
c Reported in Tang et al.44
d In this analysis, the Cox proportional hazards model only included oncotype DX and an integrator based on AOL, where the integrator was adjusted to 5-year outcomes rather than AOL’s 10-year outcomes.
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The use of the 50-point difference in the adjusted analyses of prognostic performance indicated that the
recurrence score may be prognostic over clinicopathological factors, but does not provide information
about the clinical significance of the 18–30 recurrence score cut-off points.
The likelihood ratio χ2 in the TransATAC data set was statistically significantly higher for oncotype DX than
for CTS or NPI only for LN0 patients [10-year DRFI likelihood ratio χ2 10.64 (p = 0.001) and 8.82 (p = 0.003),
respectively], while the difference was not statistically significant for LN+ patients [3.56 (p = 0.06) and 2.14
(p = 0.1), respectively].46 Compared with AOL, and with a model based on AOL but with 5-year outcomes,
oncotype DX also appeared to provide additional prognostic information (see Table 4).49,61
Oncotype DX RSPC
Data are presented in Table 5. One study (Tang et al.44) derived the RSPC score in a meta-analysis of
NSABP B-14 and TransATAC (LN+/LN0; n = 1735), and performed a limited validation in NSABP B-20 (LN0;
n = 625), which included 233 patients used to derive the oncotype DX recurrence score. For this reason,
both NSABP B-14 and B-20 data were used to derive part of the algorithm. Based on the NSABP B-14
analysis set, the oncotype DX RSPC algorithm (oncotype DX plus age, tumour size and grade) appeared to
provide additional prognostic information over oncotype DX and over clinicopathological variables, and
was able to classify more patients into a low-risk category than oncotype DX while maintaining a roughly
equivalent rate of distant recurrence in the low-risk group. In the NSABP B-20 cohort, RSPC had prognostic
value in a univariate analysis.
Conclusion: oncotype DX and RSPC prognostic performance
Seven reanalyses of RCTs and four retrospective cohort studies were included, with a total of 4929 patients.
The generalisability of the evidence base to the decision problem is uncertain owing to the loss of patients
with insufficient tumour samples. Generally, when comparing LN0 patients with LN+ patients, similar numbers
were at high risk, but more were at low risk in LN0 cohorts, and more at intermediate risk in LN+ cohorts.
How many patients would be prescribed chemotherapy would depend in large part on how intermediate
patients are handled. The 10-year DRFI rates suggest that patients in the LN0 low-risk group46,49,60 are at very
low ROR (10-year DRFI range 93–97%) in the absence of chemotherapy, and patients in the intermediate risk
group may be at somewhat higher risk (10-year DRFI range 86–100%). In the LN+ study using endocrine
monotherapy, patients were generally at higher risk of recurrence than LN0 patients in both the low and the
intermediate categories (10-year DRFI < 85% and ≤ 75%, respectively). Unadjusted analyses indicated that
oncotype DX had prognostic power (statistically significant differences between low-risk and high-risk groups)
across various recurrence outcomes, regardless of lymph node status. HRs between the intermediate-risk
group and the high- or low-risk groups were not always statistically significant. Oncotype DX provided
additional prognostic information over the most commonly used clinicopathological variables (age, grade, size
and nodal status) regardless of lymph node status (although it was not always clear if all relevant variables
had been included in the analyses), and over CTS and NPI in LN0 (but not LN+) patients. On the basis of
proportions classified as low risk and DRFI rates, RSPC may outperform oncotype DX in LN0 patients, but
these data are from the derivation cohort, with only limited validation data from a cohort (NSABP B-20)
that included patients who were used to derive one of its constituent parts (oncotype DX Breast Recurrence
Score), and it has not been tested in premenopausal or LN+ patients.
Chemotherapy benefit: oncotype DX
Chemotherapy benefit relates to the ability of the test to predict which patients will respond to chemotherapy,
and can be assessed by considering whether or not the effect of chemotherapy versus no chemotherapy on
patient outcomes differs in accordance with the test score (e.g. by comparing HRs or p-values between risk
groups). Formal assessments of chemotherapy benefit include interaction tests that assess whether or not
the difference is statistically significant. The results of the review are summarised here, and a full narrative
synthesis is provided in Report Supplementary Material 3.
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TABLE 5 Oncotype DX RSPC, discrimination, reclassification and additional prognostic value
Reference
(first author
and year) Cohorts Population
Nodal
status ET/chemotherapy
Cut-off
point Outcome Test
% of patients per group
Discrimination
Reclassification
Additional
prognostic
value, difference
in likelihood
ratio χ2
% 10-year DRFI (95% CI)
HR,
p-value
Low
risk
Intermediate
risk
High
risk Low risk
Intermediate
risk High risk
Node negative and node positive
Tang 201144
l B-14: n = 647
l TransATAC:
n = 1088
l B-20: n = 625
NSABP,
B-14 and
TransATAC
meta-analysed
ER+, HER2+/
HER2–,
% NR
LN0 (B-14);
LN+/LN0
(TransATAC)
100% ET 12–20%
risk
DRFI
10 years
RSPC 64 18 18 93.5 (91.5
to 95.5)
82.4 (77.1
to 87.7)
73.8 (68.4
to 79.2)
HR/CI NR,
p < 0.001
with
increasing
risk group
RSPC vs. RS: DRFI risks
not significantly different
between RS and RSPC
within each risk group
(p = 0.68, p = 0.27 and
p = 0.42 for low-,
intermediate- and
high-risk groups)
RS intermediate-risk
patients (n = 272):
l 16.9% high-risk
RSPC
l 55.1% low-risk RSPC
RS low-risk patients
(n = 783):
l 1.9% high-risk RSPC
l 8.9% intermediate-
risk RSPC
RS high-risk patients
(n NR):
l 28.6% intermediate-
risk RSPC
l Other differences NR
RSPC vs. oncotype
DX RS: 76.9,
p< 0.001
RSPC vs. grade,
tumour size, age:
45.4, p < 0.001
RS 54 27 19 94.1 (92.2
to 96.0)
86.2 (81.9
to 90.5)
70.5 (63.4
to 76.5)
HR/CI NR,
p < 0.001
with
increasing
risk group
NSABP and
B-20
ER+, HER2+/
HER2–,
% NR
LN0 100% ET; 64%
chemotherapy
RSPC RSPC: 2.43,
p < 0.001
RS: 2.22,
p < 0.001
ET, endocrine therapy; LN, lymph node; NR, not reported; RS, oncotype DX recurrence score.
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Study design and patient characteristics
Five data sets, reported across 10 published references44,50,53,61,64–69 and one academic-in-confidence (AiC)
manuscript (see Report Supplementary Material 3, Table 3), have conducted analyses that assess the ability
of oncotype DX to predict the benefit of chemotherapy. Two were reanalyses of RCTs: the American
(NSABP) B-20 study (n = 651) in LN0 was reported by Paik et al.,50 Tang et al.61 and Tang et al.;44 and
the American SWOG 8814 study (n = 367) in LN+ patients (38% had four or more lymph nodes) was
reported by Albain et al.53 In both trials, patients were randomised to tamoxifen only, or tamoxifen plus
cyclophosphamide. NSABP-B20 did not select participants by HER2 status, but an analysis of HER2– patients
was provided as a personal communication (Professor Tang via NICE, University of Pittsburgh, personal
communication, February 2018) as part of the NICE assessment process. SWOG-881453 recruited patients
with any HER2 status (12% were HER2+) and all patients were postmenopausal. Both reanalyses had high
attrition rates (72% and 60%, respectively), owing to missing clinical variables, missing samples, insufficient
tissue and test failures.
The three remaining studies were observational64–67,70 (total approximately 44,000 with some double-counting).
Two LN0 studies were from the USA [MD Anderson Center, n = 1424;64,65 Surveillance, Epidemiology,
and End Results (SEER) registry, n = 40,13467] and one study recruiting a mix of LN+ and LN0 patients was
from Israel [Clalit Health Services one lymph node micrometastasis (LN1micro)–LN3, n = 620; LN0–LN1micro,
n = 159466]. Additional analyses were provided to the EAG as AiC data but cannot be reported here.
Patients were treated in accordance with local routine practice in conjunction with their oncotype DX score.
Quality assessment
Report Supplementary Material 3, Table 4, presents the quality assessment of the included studies. Among
the RCTs, neither trial scored well on every item. The key concerns included the use of the derivation cohort
in Paik et al.50/Tang et al.61 and high attrition rates in both trials. The comparison of baseline characteristics
between patients included in the analysis and those excluded from the analysis showed differences in patient
age at recruitment (Paik et al.49) and tumour grade. (Paik et al.50).
The three observational studies64–67,69 are limited by their non-randomised design, whereby patients
who received chemotherapy are likely to be systematically different in terms of known (and potentially
unknown) prognostic variables (e.g. age) and treatment effect modifiers to those who did not, leading to
a high risk of confounding. They also only recruited patients for whom an oncotype DX test had been
ordered and it is unclear how this may have affected the patient spectrum and generalisability to the
decision problem. However, owing to their prospective use of the test in clinical practice, three studies
blinded the test assessors to the long-term outcomes.64–69
Results
Both RCT reanalysis studies showed that unadjusted HRs for the effect of chemotherapy versus no
chemotherapy on survival and recurrence outcomes were most favourable in the higher-risk groups. HRs
were generally statistically significant in high-risk groups but not in low- or intermediate-risk groups. In the
B20 study (LN0 patients),44,50,61 unadjusted HRs for 10-year DRFI in the low-, intermediate- and high-risk
groups were 1.31, 0.61 and 0.26, respectively. HRs restricted to HER2– patients (adjusted and unadjusted)
showed the same pattern (Table 6; Professor Tang, personal communication). However, it is interesting to
note that absolute differences (for chemotherapy vs. no chemotherapy) were very small in the low- and
intermediate-risk groups (1.1% and 1.8%, respectively, both favouring no chemotherapy), although they
were greater in the high-risk group (27.6% favouring chemotherapy).
In SWOG-8814 (LN+),53 DRFI was not reported. HRs for 10-year DFS for low-, intermediate- and high-risk
groups, adjusted for number of positive nodes, were 1.02, 0.72 and 0.59, respectively.
Unadjusted interaction tests were statistically significant for 10-year DRFI and OS in NSABP B-20 (LN0)
(p = 0.031 and p = 0.011, respectively).50,61 Albain et al.53 (LN+) found that the effect of recurrence score
on treatment varied over time and that recurrence score is a treatment effect modifier in the first 5 years
(interaction p-value 0.029) but not after 5 years (interaction p-value 0.580).
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TABLE 6 The prediction of chemotherapy responsiveness by oncotype DX: reanalyses of RCT data
Study Outcome
% recurrence free, absolute benefit HR for chemotherapy vs. no chemotherapy (95% CI) Interaction tests
Low Intermediate High Low Intermediate High Unadjusted Adjusted
NSABP-B20: LN0, ER+
(n = 651)
Paik 2006,50
Tang 201161 and
Professor Tang,
personal communication
10-year DRFI unadjusted,
HER2– unadjusted,
HER2– adjusted
a
Chemotherapy:
95.6%
No chemotherapy:
96.8%
Absolute difference:
1.1%
Chemotherapy:
89.1%
No chemotherapy:
90.9%
Absolute difference:
1.8%
Chemotherapy: 88.1%
No chemotherapy: 60.5%
Absolute difference:
27.6%
1.31 (0.46 to
3.78); p= 0.61
1.21 (0.41 to
3.55); p= 0.73
1.18 (0.40 to
3.53); p= 0.76
a
0.61 (0.24 to
1.59); p= 0.39
0.78 (0.29 to
2.11); p= 0.62
0.67 (0.24 to
1.87); p= 0.44
a
0.26 (0.13 to
0.53); p< 0.001
0.21 (0.08 to
0.53); p< 0.001
0.20 (0.07 to
0.52); p= 0.001
a
Interaction
(continuous RS)
p= 0.031 or
p= 0.038 (Tang
201161 and Paik
200650)
Interaction
a
(continuous RS)
adjusted for age, tumour size,
grade, ER and PR:
l All patients: p= 0.035,
0.039, 0.068
b
l HER2–: p= 0.007, 0.018, 0.022
b
10-year DFS 0.91
(0.57 to 1.45)
0.79
(0.43 to 1.47)
0.41
(0.23 to 0.71)
p= 0.082
10-year OS 1.37
(0.63 to 3.01)
0.94
(0.4 to 2.25)
0.31
(0.16 to 0.60)
p= 0.011
SWOG-8814: LN+,
HR+, HER2+/HER2–
(n = 367)
Albain 201053
10-year DFS Chemotherapy:
64%
No chemotherapy:
60%
Absolute difference:
4%
Chemotherapy: 55%
No chemotherapy: 43%
Absolute difference: 12%
1.02 (0.54 to
1.93); p= 0.97
c
0.72 (0.39 to
1.31); p= 0.48
c
0.59 (0.35 to
1.01); p= 0.033
c
Interaction (continuous RS) adjusted
for positive nodes:
l All years: p= 0.053
c
l 0–5 years: p= 0.029
c
l 5–10 years: p = 0.58
c
Interaction (continuous RS) adjusted
for each of age, ethnicity, size,
grade, PR, P53, HER2: significant
(p =NR)
Interaction adjusted for Allred-
scored ER: p = 0.15
0- to 5-year DFS 1.34
(0.47, 3.82)
c
0.95
(0.43, 2.14)
c
0.59 (0.32, 1.11)
c
5- to 10-year DFS 0.88
(0.38, 1.92)
c
0.52
(0.21, 1.27)
c
0.60 (0.22, 1.62)
c
10-year BCSS Chemotherapy: 73%
No chemotherapy: 54%
Absolute difference: 19%
p = 0.56 p = 0.89 p= 0.033
c
10-year OS Chemotherapy: 68%
No chemotherapy: 51%
Absolute difference: 17%
1.18 (0.55 to
2.54); p= 0.68
c
p = 0.63
log-rank
0.84 (0.40 to
1.78); p= 0.65
c
p = 0.85
log-rank
0.56 (0.31 to
1.02); p = 0.057
c
p= 0.027
log-rank
Interaction (continuous RS):
c
l All years: p= 0.026
l 0–5 years: p= 0.016
l 5–10 years: p = 0.87
NR, not reported; P53, tumour protein p53; RS, recurrence score.
a Adjusted for age, tumour size, grade, ER and PR.
b p-values correspond to analyses using different assessments of tumour grade.
c Adjusted for number of positive nodes (1–3 vs. ≥ 4).
Note
Bold font denotes statistically significant analyses.
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Interaction tests adjusted for clinicopathological factors in NSABP-B20 were borderline significant for the full
cohort for DRFI (p = 0.035, p = 0.039 and p = 0.068 for different methods of assessing tumour grade),50
(Professor Tang, personal communication), whereas for the HER2– subgroup, the equivalent analyses were
statistically significant (p = 0.007, p = 0.018 and p = 0.022) (Professor Tang, personal communication). The
EAG report71 stated that it was unclear whether or not all factors were adjusted for simultaneously in B20;
however, a personal communication with the biostatistician (Professor Tang, personal communication)
confirmed that this was the case. Interaction tests in SWOG-8814 adjusted individually for each of age,
ethnicity, tumour size, grade, PR, P53 and HER2 were also statistically significant (p = not reported). Initially,
the EAG interpreted this as a model including all clinicopathological variables; however, clarification from the
authors in a personal communication (Professor Barlow, University of Washington School of Public Health,
personal communication, March 2018) stated that each variable was included in a separate model. An
interaction test adjusted for Allred-scored ER status was not significant (p = 0.15). No interaction test that
included all clinicopathological variables together was available.
The oncotype DX cut-off point below which chemotherapy could be avoided was reported to be
approximately 20 in SWOG-8814,53 but NSABP B-20 authors could not determine a cut-off point as there
was no point below which chemotherapy did not confer an advantage.50,61
The analyses and available data were subject to some criticisms in the context of this decision problem.
First, it was not clear whether or not all stratification factors used in randomising patients to treatment were
included in the interaction test model. Second, categorising the continuous oncotype Breast Recurrence
Score into risk groups may lead to loss of information and has the potential to create spurious interactions
between recurrence score and chemotherapy benefit due to imbalances in clinicopathological variables
between risk groups. Third, none of the analyses were conducted in the clinically-intermediate-risk patient
group of interest to the decision problem; in particular, it is plausible that even if there is no chemotherapy
benefit for clinically-low, oncotype DX-low patients, there could be benefit for clinically-intermediate (NPI of
> 3.4) oncotype DX-low patients. Fourth, patients from the no-chemotherapy arm of the B20 study were
used to derive the oncotype DX score. Therefore, oncotype DX may be overfitted in this study arm (i.e.
recurrence rates may be artificially low in oncotype low-risk patients and artificially high in oncotype DX
high-risk patients). This could lead to an overestimate of chemotherapy benefit because the chemotherapy
arm was not used in derivation; therefore, recurrence rates in this arm may show less separation between
the low- and high-risk groups. A more thorough discussion of this and other quality issues is provided in
Report Supplementary Material 3.
Other potential biases in the reanalyses of RCTs included attrition of samples, exclusion of patients owing
to missing data for covariates and inclusion of HER2+ patients (applies only to SWOG-8814 LN+ patients),
who are out of the scope of this assessment.
Observational studies: results
Data are presented in Table 7. From the three observational cohort studies,64–67,69,70 evidence was
mixed and at high risk of confounding, because patients who received chemotherapy were likely to be at
higher risk of recurrence than patients who did not. Only one study reported an interaction test between
recurrence score categories and chemotherapy treatment, and this was statistically significant (p = 0.03),
but only adjusted for grade, tumour size, age and race (omitting ER and PR),67,70 and for recurrence score
as a continuous variable (p < 0.001). The other two studies only reported HRs for chemotherapy versus
no chemotherapy in intermediate- and high-risk patients,64–66,69 and in one study these were statistically
non-significant, even after adjustment for confounders.64,65 In the other study,66,69 patients with LN0/LN1micro
did not appear to receive benefit from chemotherapy in the intermediate group (DRFI for chemotherapy vs.
no chemotherapy: 94.4% vs. 94.7%, respectively), whereas those in the high-risk group did (DRFI for
chemotherapy vs. no chemotherapy: 86.7% vs. 78.9%, respectively). In the LN1micro–LN3 subgroup,
patients did appear to receive benefit from chemotherapy in the intermediate-risk group (DRFI for
chemotherapy vs. no chemotherapy: 97.8% vs. 90.4%, respectively); data for high risk patients were not
reported. A more detailed narrative is provided in Report Supplementary Material 3.
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TABLE 7 The prediction of chemotherapy responsiveness by oncotype DX: observational studies
Reference (first author and year) Study Outcome
Cut-off
point
Prediction of chemotherapy benefit: chemotherapy vs. no
chemotherapy
Additional predictive value, adjusted HR, chemotherapy vs.
no chemotherapy (95% CI)
Low RS Intermediate RS High RS Low RS Intermediate RS High RS
Barcenas 201764
Le Du 201565
Median follow-up: 58 months
HR+, HER2–, LN0, Stage I–II, had
oncotype DX test
All risk groups, all years: n= 1424
Diagnosed 2005 to 2011 and included in
K–M analysis:
l Intermediate RS: n = 547
l High RS: n= 142
MD Anderson
Center, USA
5-year DRFS 11–25 NR Actuarial 5-year rate:
l Chemotherapy 96% (95% CI
87% to 99%)
l No chemotherapy 96% (95% CI
94% to 98%)
HR NR, p = 0.97
HR NR, p= 0.74 NR 1.25 (0.32 to 4.92);
p = 0.746
a
0.67 (0.16 to 2.78);
p = 0.584
a
18–30 NR NR NR NR, too few events 0.80 (0.23 to 2.71);
p = 0.716
0.32 (0.07 to 1.47);
p = 0.143
5-year DRFS
b
18–30 NR Stage 1 disease, intermediate risk
(RS 18–30) only
b
(HRs NR):
l pT1a (n= 13), NR
l pT1b (n = 95) p = 0.752
l pT1c (n = 246)
p= 0.020
NR NR NR NR
5-year IDFS 11–25 NR Actuarial 5-year rate:
l Chemotherapy 89% (95% CI
80% to 94%)
l No chemotherapy 93% (95% CI
90% to 95%)
HR NR, p = 0.35
HR NR, p= 0.56 NR 1.64 (0.73 to 3.71);
p = 0.233
a
0.67 (0.21 to 2.07);
p = 0.483
a
18–30 NR NR NR 1.09 (0.14 to 8.62,
p= 0.938)
0.78 (0.34 to 1.80);
p = 0.571
0.50 (0.13 to 2.02);
p = 0.334
5-year RFS 11–25 NR Actuarial 5-year rate:
l Chemotherapy 95% (95% CI
86% to 98%)
l No chemotherapy 96% (95% CI
94% to 98%)
HR NR, p = 0.75
HR NR, p= 0.94 1.46 (0.41 to 5.23);
p = 0.564
a
0.78 (0.17 to 3.52);
p = 0.748
a
18–30 NR NR NR NR, too few events 0.98 (0.32 to 3.06);
p = 0.975
NR
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Reference (first author and year) Study Outcome
Cut-off
point
Prediction of chemotherapy benefit: chemotherapy vs. no
chemotherapy
Additional predictive value, adjusted HR, chemotherapy vs.
no chemotherapy (95% CI)
Low RS Intermediate RS High RS Low RS Intermediate RS High RS
5-year OS
c
11–25 NR Actuarial 5-year rate:
l Chemotherapy 98% (95% CI
91% to 99%)
l No chemotherapy 98% (95% CI
96% to 99%)
HR NR, p = 0.91
HR NR, p= 0.18 NR 2.19 (0.44 to 11.0);
p = 0.340
a
0.28 (0.04 to 2.05);
p = 0.209
a
18–30 NR NR NR NR, too few events 0.86 (0.15 to 4.91);
p = 0.861
0.13 (0.01 to 1.30);
p = 0.082
Stemmer 201666
Stemmer 201669
Median follow-up: 6 years
ER+, HER2–, had oncotype DX test
N0/1micro: n= 1594
LN1micro–LN3: n= 627
e
Clalit Health
Services,66
Israel
5-year DRFI
d
18–30 NR LN0/1micro:
l Chemotherapy (38%): 94.4%
l No chemotherapy (62%): 94.7%
LN0/1micro:
l Chemotherapy
(11%): 86.7%
l No chemotherapy
(89%): 78.9%
NR
18–30 NR LN1micro–LN3 (% DRF):
l Chemotherapy (40%): 97.8%
l No chemotherapy (60%): 90.4%
NR
11–25 NR LN1micro–LN3 (% DRF):
l Chemotherapy (18%): 97.3%
l No chemotherapy (82%): 95.9%
NR NR
5-year BCSS
d
18–30 NR LN1micro–LN3:
l Chemotherapy (40%): 98.9%
l No chemotherapy (60%): 96.3%
NR NR
11–25 NR LN1micro–LN3:
l Chemotherapy (18%): 100%
l No chemotherapy (82%): 98.8%
NR NR
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TABLE 7 The prediction of chemotherapy responsiveness by oncotype DX: observational studies (continued )
Reference (first author and year) Study Outcome
Cut-off
point
Prediction of chemotherapy benefit: chemotherapy vs. no
chemotherapy
Additional predictive value, adjusted HR, chemotherapy vs.
no chemotherapy (95% CI)
Low RS Intermediate RS High RS Low RS Intermediate RS High RS
Petkov 201670
Roberts 201667
Roberts 201768
Follow-up: 38 months
HR+, HER2–, LN0
f
n = 40,134
SEER registry,
USA
Actuarial
5-year BCSS
c
18–30 NR Multivariable model
g
including chemotherapy treatment: RS
remained significantly prognostic for 5-year BCSS for both
chemotherapy-treated and untreated (or unknown) patients, but
strength of association between RS categories and BCSS attenuated
for those with chemotherapy reported as ‘yes’ (p = 0.03 for
covariate-adjusted interaction) vs. those reported as ‘no/unknown’.
Similar analysis with RS as continuous variable also significant both
with and without adjustment for covariates (p< 0.001 for both)
BCSM, breast cancer specific mortality; DR, distant recurrence; K–M, Kaplan–Meier; LN, lymph node; NR, not reported; pT, pathological tumour stage; RS, oncotype DX recurrence score.
a Adjusted for age at diagnosis, tumour size, grade, histological subtype, LVI, type of surgery and endocrine therapy. Covariates producing unstable estimates were removed. Ki-67 was removed owing to too many missing values.
b Data from Le Du et al.,65 in which only stage I disease patients were included; 17 intermediate patients were also in the TAILORx study.22
c OS and BCSS data do not meet the inclusion criteria as follow-up was < 5 years.
d Converted to DRFI from DR; converted to BCSS from BCSM.
e Note overlap between LN0–1micro and LN1micro–LN3 analyses.
f HR+ by oncotype DX and by IHC; HER2 status by oncotype DX.
g Adjusted for grade, tumour size, age and race.
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RSPC results
Recurrence score–pathology–clinical results were derived in TransATAC and NSABP B-14,44 and validated in
NSABP B-20.44 Only LN0 data were available. An interaction test was non-significant (p = 0.10), with a
standardised HR of 0.65 (95% CI 0.39 to 1.09) (data not tabulated).44
In practice, it is unlikely that chemotherapy decisions would be made on oncotype DX scores independent
of clinicopathological variables. Evidence relating to the ability of the test to predict chemotherapy benefit
over and above routinely collected clinicopathological variables was provided in both RCT data sets in the
adjusted interaction tests.50,53,61 Interestingly, Tang et al.61 tested the ability of AOL to predict benefit from
chemotherapy in a large cohort of 1952 patients, and found it to have predictive ability for OS. However,
the inclusion of clinicopathological variables alongside recurrence score in the RSPC algorithm resulted in
a loss of predictive ability (p = 0.10), indicating that the incorporation of clinicopathological factors may
reduce prediction of chemotherapy benefit; therefore, if chemotherapy decisions are based on an informal
consideration of clinicopathological factors alongside the oncotype DX score, this may reduce any predictive
ability of oncotype DX in clinical practice.
Conclusion: oncotype DX and RSPC chemotherapy benefit
In conclusion, there is some evidence from two reanalyses of RCTs to suggest that oncotype DX may predict
benefit from chemotherapy, and that benefit from chemotherapy is highest in oncotype DX high-risk patients.
Unadjusted interaction tests between oncotype DX risk group and chemotherapy benefit were mainly
statistically significant. Adjusted interaction tests were borderline significant in the LN0 NSABP B20 study
(significant in HER2– patients), whereas in the LN+ SWOG-8814 study they were significant when adjusted
for some clinicopathological variables individually, but not when adjusting for ER determined by Allred status.
Only data from the derivation cohort (NSABP B-20) were available for LN0 patients and this may have biased
the results. The RSPC algorithm (oncotype DX plus age, tumour size and grade) showed a non-significant
interaction test between chemotherapy benefit and RSPC risk group, and also used the NSABP B-20 data set.
Three observational cohort studies were at high risk of confounding; one reported a statistically significant
interaction test but this was only adjusted for limited factors. If predictive ability was assumed, it is unclear
below which exact cut-off point patients could avoid chemotherapy (although one study suggests that this is
a recurrence score of 20), as chemotherapy benefit is uncertain in the intermediate-risk group. Although
TAILORx22 (an ongoing RCT comparing long-term outcomes in patients treated with usual care vs. patients
treated with usual care in conjunction with oncotype DX) will address the issue of whether or not low- and
intermediate-risk patients can avoid chemotherapy, it is unclear to what extent it will address the question of
whether or not the test can predict chemotherapy benefit. Considering the limitations of the available data,
the EAG concludes that there remains uncertainty surrounding whether or not oncotype DX is associated
with a predictive benefit of chemotherapy (i.e. a difference in relative effect by genomic risk group) and,
if so, that there is uncertainty in the likely magnitude of this predictive effect within the clinical subgroups
considered in this appraisal.
The TAILORx study22 reported during the course of the assessment, and included some data relating to
chemotherapy benefit prediction. The EAG prepared a preliminary appraisal of this evidence, which can
be accessed via the NICE website.72
Clinical utility: oncotype DX
In this review, clinical utility relates to the impact of the prospective use of the test on patient outcomes
such as survival and recurrence. The ideal study design would be a RCT in which patients are randomised
to treatment guided by the test or treatment in accordance with usual practice. Observational studies
(either prospective or retrospective) in which patients received the test prospectively in clinical practice are
at a higher risk of bias from confounding. Such studies cannot address the question of whether or not the
test can improve patient outcomes relative to usual practice. They can, however, reveal something about
the ability of the test to identify a group of patients at very low ROR who could avoid chemotherapy. Data
relating to risk in intermediate- and high-risk categories are, without a no-test comparator arm, difficult to
interpret in the context of clinical utility. Therefore, we have focused on outcome data in low-risk patients
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and the use of chemotherapy in all groups. A full narrative synthesis of results can be found in Report
Supplementary Material 4.
Study and patient characteristics
Five data sets reported across nine publications22,65,66,68,69,73–75 and one AiC manuscript were included.
Study characteristics are presented in Report Supplementary Material 4. Two studies had a prospective
trial design (within RCTs),22,73,74 and the remainder were retrospective analyses of observational data. One
further study, the SEER registry,67,68 did not meet the inclusion criteria for the review in that only survival
outcomes with < 5 years follow-up were reported, but it reported useful data on certain subgroups of
interest to the review (micrometastases and race) and is presented here due to the paucity of other data
relating to there characteristics.
Only one study (TAILORx)22 randomised patients (HR+, HER2– and LN0) to treatment guided by the test or
treatment in accordance with usual practice. Women with recurrence scores of < 11 were assigned to endocrine
therapy only, whereas women with recurrence scores of 11–25 were randomised to either endocrine
therapy plus chemotherapy or endocrine therapy only. As of July 2017, this study had only reported results
for the low-risk (recurrence score of < 11) group (n = 1626). Data for this group are effectively prospective
observational data. The study reported in full in June 201876 and the EAG prepared a preliminary appraisal
of this evidence, which can be accessed via the NICE website.72
The West German Study Group (WSG) PlanB73,74,77 trial (n = 3198) is also a prospective RCT, but does not aim
to assess the clinical utility of oncotype DX, as it randomises clinically high-risk patients {pathological tumour
stage (pT)1–T4c; LN+, or LN0 with a risk factor [≥ pT2, grade 2/3, high urokinase plasminogen activator
(uPA)/plasminogen activator inhibitor-1 (PAI-1), aged < 35 years or HR-negative]} with 0–3 positive lymph
nodes with a recurrence score of ≥ 12 to two different sorts of chemotherapy. However, a translational
research aim was to assess the ROR in patients with recurrence scores of < 12 who were not treated with
adjuvant chemotherapy. This group is, again, effectively a prospective observational cohort.
There were three retrospective cohorts in which patients were treated using oncotype DX,65,66,69,75 and one
further retrospective cohort that did not meet the inclusion criteria for the review.67,70 The total number of
patients included in these retrospective analyses is ≈54,000 (some double-counting from the Clalit Health
Services cohort).66,69 Patients were ER+, HER2– and must have had an oncotype DX test (it was unclear
how patients were selected for testing, and this may have introduced spectrum bias). Two studies recruited
only LN0 to lymph node micrometastases (LNmicro) patients,65,75 and one reported LN0-LNmicro69 and
patients with micro metastases or between one and three lymph node metastases (LNmicro–LN3).66,69
The study that did not meet the inclusion criteria recruited patients with LN0–3, and is included as it
subgrouped patients in accordance with age (40–85 years), lymph node status (LN0, LNmicro–LN3,
LNmicro only) and race (black, white, other).67,70
Quality assessment
The highest level of evidence for clinical utility is a RCT of treatment guided by the test versus treatment
guided in accordance with usual practice. Assessment with the Cochrane risk-of-bias tool for RCTs
indicates that all studies are of too poor quality to meet this aim.
Results: oncotype DX clinical utility
Data relating to the clinical utility of oncotype DX are presented in Table 8. A more detailed narrative
synthesis is provided in Report Supplementary Material 4. All studies report data relating to recurrence or
survival, but differences in cut-off points (recurrence score of < 11, < 12 and < 18), patient populations
(clinically high risk, LN0 or LN+), treatment regimens (some patients had chemotherapy in some studies)
and outcome measures (DRFS, DFS, DRFI, BCSS and OS) precluded a meaningful meta-analysis.
Across the studies in which chemotherapy was delivered in accordance with usual practice using
oncotype DX, chemotherapy rates in patients at low risk (recurrence score of < 18) ranged from 1%69 to
CLINICAL EVIDENCE
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TABLE 8 Clinical utility results: oncotype DX
Study, first
author and year Study design Patients Subgroup Treatment
Outcome
(5 years)
Cut-off
point
a
Risk group, % risk of outcome (95% CI)
Comparison
Adjusted HR
(95% CI)
b
Low Intermediate High
DRFS/DRFI/IDFS
LN0, cut-off point RS 18–30
Clalit Health
Services, Stemmer
201669
R ER+, HER2–, had
oncotype DX test
LN0–1micro,
n = 159469
l RS < 18: 1%
l RS 18–30: 26%
l RS > 30: 89%
DRFI 18–30 99.5 (98.4
to 99.8)
98.8 (97.2
to 99.4)
93.1 (87.1
to 96.3)
MD Anderson,
Le Du 201565
R ER+, HER2–,
stage 1, had
oncotype DX test
LN0/LNmicro,
n = 1030
Chemotherapy per
group:
l RS < 18: 6.4%
l RS 18–30: 42.7%
l RS > 30:89.8%
DRFS 18–30 95.9 (93.0
to 97.6)
c
NR 76.4 (59.2
to 87.1)
c
p < 0.0001 l High vs. low: 2.20
(0.90 to 5.36);
p = 0.083
l Intermediate vs.
low: 1.88
(0.96 to 3.68);
p = 0.066
l High vs.
intermediate: 1.17
(0.54 to 2.51);
p = 0.690
Memorial Sloan
Kettering, Wen
201775
R ER+, HER2–,
stage 1 and 2,
had oncotype DX
test, low RS
LN0 or LNmicro,
n = 1406
Chemotherapy:
l RS < 18: 12%
DRFI < 18 99.6%
d
LN0, cut-off point RS 11 (or 12)–25
Memorial Sloan
Kettering, Wen
201775
R ER+, HER2–,
stage 1 and 2,
had oncotype DX
test, low RS
LN0 or LNmicro,
n = 1406
Chemotherapy:
l RS < 18: 12%
DRFI < 11 99.9%
d
TAILORx, Sparano
201522
P HR+, HER2–,
tumour size
e
LN0, n= 1626 100% endocrine
therapy
DRFS < 11 99.3 (98.7
to 99.6)
IDFS < 11 93.8 (92.4
to 94.9)
LN+, cut-off point RS 18–30
Clalit Health
Services, Stemmer
201666
R ER+, HER2–, had
oncotype DX test
LN1micro–LN3,
n = 62766
Chemotherapy per
group:
l RS < 18: 7%
l RS 18–30: 40%
l RS > 30: 90%
DRFI 18–30 96.8 (NR) 93.4 (NR) 83.6 (NR)
LN1micro, n= 27066 DRFI 99.3 (NR) 89.2 (NR) 80.6 (NR)
continued
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TABLE 8 Clinical utility results: oncotype DX (continued )
Study, first
author and year Study design Patients Subgroup Treatment
Outcome
(5 years)
Cut-off
point
a
Risk group, % risk of outcome (95% CI)
Comparison
Adjusted HR
(95% CI)
b
Low Intermediate High
LN+, cut-off point RS 11–25
Clalit Health
Services, Stemmer
201666
R ER+, HER2–, had
oncotype DX test
LN1micro–LN3,
n = 62766
l RS < 11: 7%
l RS 11–25: 18%
l RS > 25: 81%
DRFI 11–25 95.1 (NR) 96.1 (NR) 86.8 (NR)
LN1micro, n= 27066 97.8 (NR) 95.9 (NR) 83.9 (NR)
LN+/LN0, cut-off point RS 12–25
WSG PlanB,
f
Nitz 201773,74,77
P Clinically high-
risk,
g
HR+, HER2–
patients
LN0–3,73 n = 2642 l RS < 12 endocrine
therapy only;
RS ≥ 12,
chemotherapy plus
endocrine
therapy
IDFS 12–25 94.2 (91.2
to 97.3)
h,i
94.3 (92.8
to 95.8)
h
84.2 (80.6
to 87.8)
h
HR= 2.33 (1.73 to
3.14); p< 0.001
j
For continuous score
(100–75th vs. 0–25th
percentiles): 1.73
(1.21 to 2.47);
p = 0.001
BCSS and OS
LN0, cut-off point RS 18–30
Clalit Health
Services, Stemmer
201669
R ER+, HER2–, had
oncotype DX test
LN0–1micro,
n = 159469
l RS < 18: 1%
l RS 18–30: 26%
l RS > 30: 89%
BCSS 18–30 99.9 (99.0
to 100.0)
98.5 (97.1
to 99.2)
90.6 (84.5
to 94.4)
SEER registry,
Petkov 2016,70
Roberts 201667
R HR+, HER2–
k
LN0, 40–84 years
of age, n= 38,568
LN0, 40–85 years:
l RS < 18: 7%
l RS 18–30: 34%
l RS > 25: 69%
BCSS < 5 years 18–30 99.6 (99.4
to 99.7)
98.6 (98.3
to 98.9)
95.6 (94.4
to 96.6)
l Intermediate
vs. low: HR 3.1
(2.3 to 4.3)
l High vs. low: HR
11.0 (7.8 to 15.5)
l All: p < 0.001
l Intermediate
vs. low: HR 3.0
(2.1 to 4.2)
l High vs. low: HR
7.8 (5.3 to 11.6)
l All: p < 0.001
LN0, black,
n = 2890
BCSS < 5 years 18–30 99.2 (0.28) 98.2 (0.58) 94.3 (2.17) p < 0.0001
LN0, white,
n = 33,684
BCSS < 5 years 18–30 99.6 (0.07) 98.6 (0.15) 95.6 (0.61) p < 0.0001
LN0, other race,
n = 3321
BCSS < 5 years 18–30 99.8 (0.15) 99.2 (0.36) 95.3 (1.89) p < 0.0001
LN0, cut-off point RS 11–25
SEER registry,
Petkov 2016,70
Roberts 201667
R HR+, HER2–
k
LN0, all ages,
n = 40,134
Chemotherapy per
group: NR
BCSS < 5 years 11–25 99.6 (99.4
to 99.8)
99.3 (99.2
to 99.4)
96.4 (95.6
to 97.0)
p < 0.001
TAILORx, Sparano
201522
P (RCT) HR+, HER2–,
tumour size,
e
n= 1629
LN0 100% endocrine
therapy
OS < 11 98.0 (97.1
to 98.6)
N/A N/A N/A
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Study, first
author and year Study design Patients Subgroup Treatment
Outcome
(5 years)
Cut-off
point
a
Risk group, % risk of outcome (95% CI)
Comparison
Adjusted HR
(95% CI)
b
Low Intermediate High
LN+, cut-off point RS 18–30
Clalit Health
Services, Stemmer
201666
R ER+, HER2–, had
oncotype DX test
LN1micro–LN3,
n = 62766
Chemotherapy per
group:
l RS < 18: 7%
l RS 18–30: 40%
l RS > 30: 90%
BCSS 18–30 99.1 (NR) 97.4 (NR) 86.9 (NR)
LN1micro, n= 27066 BCSS 18–30 99.3 (NR) 96.8 (NR) 83.9 (NR)
SEER registry,
Petkov 2016,70
Roberts 201667
R HR+, HER2–
k
LNmicro–LN3, all
ages, n = 4691
LN1–3:
l < 18: 23%
l 18–30: 47%
l > 25: 75%
BCSS < 5 years
m,n 99.0
(98.0 to
99.5)118
97.7 (95.9
to 98.7)
85.7 (76.2
to 91.6)
p < 0.001
LN1–3, black,
n = 328
BCSS < 5 years
m,n 18–30 99.4 (0.56) 98.9 (1.12) 91.3 (8.31) p = 0.4117
LN1–3, white,
n = 4,021
BCSS < 5 years
m,n 18–30 99.0 (0.39) 97.6 (0.75) 84.1 (4.21) p < 0.0001
LN1–3, other race,
n = 320
BCSS < 5 years
m,n 18–30 98.5 (1.53) 99.1 (0.92) 100 (0) p = 0.8427
LNmicro, n = 282068 NR BCSS < 5 years
m,n 98.9 (97.4
to 99.6)
99.1 (97.9
to 99.6)
84 (74.1
to 90.4)
LN+, cut-off point RS 11–25
Clalit Health
Services, Stemmer
201666
R ER+, HER2–, had
oncotype DX test
LN1micro–LN3,
n = 62766
l RS < 11: 7%
l RS 11–25: 18%
l RS > 25: 81%
BCSS 11–25 98.0 (NR) 99.0 (NR) 90.4 (NR)
Ln1micro, n= 27066 BCSS 97.8 (NR) 98.8 (NR) 89.3 (NR)
SEER registry,
Petkov 2016,70
Roberts 201667
R HR+, HER2–
k
LNmicro–LN3, all
ages, n = 4691
LN1–3:
l < 18: 23%
l 18–30: 47%
l > 25: 75%
BCSS < 5 years
m,n 11–25
l
99.0 (98.0
to 99.5)118
97.7 (95.9
to 98.7)
85.7 (76.2
to 91.6)
p < 0.001
BCD, breast cancer death; FFR, freedom from recurrence of breast cancer; K–M, Kaplan–Meier; N/A, not applicable; NR, not reported; P, prospective; R, retrospective; RS, oncotype DX recurrence score.
a Range of intermediate group (e.g. where cut-off points were < 18, 18–30 and > 30 for low, intermediate or high, respectively, this is shown as 18–30).
b Adjustments: Le Du 2015: not reported; Stemmer: age, tumour size, grade; Nitz 2017: nodal status, tumour size, grade, ER, PR, Ki-67, IHC4; SEER registry: age, grade, tumour size, race.
c Median follow-up 58 months.
d Median follow-up 46 months.
e Tumour size 1.1–5 cm or 0.6–1.0 cm in intermediate- or high-risk tumours.
f Overall survival data not presented here as follow-up was < 5 years. Nitz et al. 201777 published after searches, but only added 95% CIs to data already available from conference abstracts.
g HER2–; pT1–T4c; LN+ [or LN0 with a risk factor (CpT2, grade 2/3, high uPA/PAI-1, < 35 years, or HR-negative)].
h 55-month follow-up.73
i These data for 348/404 patients with RS of < 12, in whom chemotherapy was omitted after a protocol amendment.
j Assume low risk vs. intermediate/high risk.
k HR+ by oncotype DX and by IHC; HER2 status by oncotype DX.
l 98.7% (95% CI 97.1% to 99.4%) for LN1–3.
m Clinical advice to the EAG stated that for survival outcomes, a minimum of 5-year data were required. These data are presented as an exception as they are included in Genomic Health’s submission, and it presents data on micrometastases and
by number of lymph nodes, and analyses relating to race.
n Follow-up 38 months.
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12%75 (four studies65,67,69,70,75) in LN0 patients and from 7% to 23% (two studies66,67,70) in LN+ patients.
In intermediate-risk (recurrence score of 18–30) patients, chemotherapy rates ranged from 26%69 to 43%65
(three studies65,69,75) in LN0 patients and from 40%66 to 47%67,70 (two studies66,67,69) in LN+ patients. These
data perhaps indicate that lymph node status was considered in treatment decisions, although no formal
comparison has been made. In high-risk patients, chemotherapy rates were similar in LN0 (90%65 and 89%69)
and LN+ patients (90%).66
Studies generally reported different outcomes [5-year DRFS (n = 2),22,65 DRFI (n = 2),66,69,75 IDFS (n = 2),22,73,74,77
BCSS (n = 3)66,67,69,70 and OS (n = 1)22], making comparisons across studies difficult. For outcomes including
recurrence (DRFS, DRFI and IDFS), low-risk patients with recurrence scores of < 1865,66,69,75 had outcomes
ranging from 95.9%65 (5-year DRFI) to 99.6%75 (5-year DRFI) in LN0 patients (n = 3) and 97%66 (5-year DRFI)
in LN+ patients, whereas low-risk patients with recurrence scores of < 11 had outcomes of 94%22 (5-year
IDFS) and 99.9%75 (5-year DRFI) in LN0 (n = 2)22,75 and 95%66 (5-year DRFI) in LN+ patients (n = 1).66
Clinical advice to the EAG suggests that these levels of recurrence are acceptable in a low-risk population.
It was beyond the scope of the assessment to determine whether the newer cut-off points (of 11–25)
should be used, or whether the original cut-off points of recurrence score 18–30 would be preferable.
Data relating to this are summarised in the narrative synthesis (see Report Supplementary Material 4) and
Table 8, and the general observation can be made that although use of lower cut-off points may result in
better outcomes in the low-risk group (although data are mixed on this point), it would also result in fewer
patients being classified as low risk.
Data relating to intermediate- and high-risk patients are included in the narrative synthesis (see Report
Supplementary Material 4) and appear in Table 8. It was not possible to draw any conclusions regarding
whether or not patients in intermediate- and high-risk categories had better outcomes as a result of using
oncotype DX to guide treatment, as there were no comparator (no-oncotype DX) groups.
The data on micrometastases are difficult to interpret as there is no analysis that reports all nodal statuses
in the same patient group (i.e. LN0, LNmicro, LN1–3). The analyses that have been done show that the
trend for worse outcomes with increasing risk group holds true in patients with micrometastases.66,67
The data relating to the performance of the test in patients of different races showed that BCSS survival
differed similarly in accordance with risk categories in all race categories.67
Conclusions
Without the highest level of evidence, it is not possible to conclude whether or not patient outcomes
would be affected by use of the test in a clinical setting. In LN0 patients, use of the test in clinical practice
appears to result in low rates of chemotherapy use in low-risk patients (1–12%), with acceptable outcomes
(DRFS/DRFI/IDFS 96–99.6%). Rates of chemotherapy use increased with increasing risk category, and were
generally higher in LN+ patients; only one study reported DRFS/DRFI/IDFS for LN+ patients, which was
97% (7% received chemotherapy). It was not possible to draw any conclusions regarding whether or not
patients in intermediate- and high-risk categories had better outcomes as a result of using oncotype DX
owing to the observational nature of the studies.
Results: MammaPrint
Development: MammaPrint
A description of the development of MammaPrint is provided in Report Supplementary Material 5.
Prognostic performance: MammaPrint
Here we summarise some key findings relating to DRFS/DRFI. See Report Supplementary Material 5 for a
full narrative synthesis and data relating to survival outcomes.
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Study characteristics
Several publications describe validation of the prognostic value of MammaPrint. Many include overlapping
cohorts of patients, sometimes pooled with other cohorts, sometimes focusing on patient subgroups
(e.g. ER+ or LN0/LN+), sometimes updating the data with longer follow-up and reporting a range of different
outcomes. Therefore, it should be noted that there is some overlap between patient cohorts within the
references included here. Table 9 shows both the study reference(s) (column 1) and the cohort(s) (column 2)
used for each analysis, and Report Supplementary Material 5 describes the cohorts in more detail.
There were nine main cohorts, which were small, retrospective analyses of consecutive patient series: four
were from the Netherlands,79,80,84,87,89 two were multi-European,85,88 two were from the USA90,96 and one
was from Japan95 (total n = 1805). They covered a mix of LN0 and LN+ patients, with variable proportions
receiving endocrine therapy and chemotherapy. In most studies, around 70–80% were ER+, and HER2
status was not well reported. Four analyses pooling some of the above cohorts78,83,87,93 are also included
due to their focus on specific subgroups. In addition, there was one reanalysis of a RCT [the Swedish
Stockholm Tamoxifen-3 (STO-3) trial; n = 538], of which a subgroup had endocrine monotherapy.78,91,92,94,97
Quality assessment
One study (van de Vijver et al.79) included a small proportion of patients from the derivation cohort, and
may therefore overestimate prognostic performance, although a ‘leave-one-out’ analysis was used to
mitigate this problem to some extent. Most analyses excluded some patients from the original cohort,
some because of insufficient tumour sample, which may introduce bias due to attrition of patients with
smaller tumours. Blinding of test assessors to outcomes was reported in around half of the studies.
Outcomes did not always match standardised definitions and it was not always possible to tell from the
publication whether or not all deaths and breast cancer deaths were counted as events or were censored.
Different levels of treatment use in the high- and low-risk groups may confound results by reducing
separation between the groups in recurrence rates, and selection of patients in accordance with treatment
may introduce spectrum bias because these patients may be systematically different from the whole
population. Many studies included a proportion of patients who were not in the scope of this research.
Distribution of patients by risk group
The percentage of patients categorised as low risk ranged from 20% to 71% and the percentage of those
categorised as high risk ranged from 29% to 80% across seven analyses of LN0 patients.84,86,88,89,91,95,96
In two analyses of LN+ patients,85,89 the percentages categorised as low risk were 38% and 41%, whereas
the percentages categorised as high risk were 59% and 62%.
Prognostic performance: unadjusted analyses
Prognostic data for MammaPrint is provided in Tables 10 and 11. Among LN0/LN+ studies, Mook et al.87
pooled 964 patients from seven series79–81,84–86,88 (one-third had endocrine therapy and one-quarter had
chemotherapy) and showed that MammaPrint was statistically significantly prognostic for 10-year DRFS
(HR 2.70, 95% CI 1.88 to 3.88; p < 0.0001), with 10-year DRFS of 87% in low-risk patients.87 Knauer
et al.83 pooled 541 patients (restricted to LN0–3 patients, 100% endocrine therapy, 42% chemotherapy)
from six of these series, and also reported statistically significant results. In terms of longer follow-up of the
original van de Vijver et al.79 cohort (51% LN0, 37% had chemotherapy and 14% had endocrine therapy),
MammaPrint was statistically significantly prognostic in an unadjusted analysis of DRFS over 0–25 years89
in a LN0/LN+ cohort;79 most of this difference was in the first 5 years (HR 9.6, 95% CI 4.2 to 22.1).
A separate US series (Yao et al.;90 72% LN0, 43% had chemotherapy and 87% had endocrine therapy)
also showed statistically significant prognostic ability for DRFS at 10 years (HR 2.91, 95% CI 0.97 to 8.68;
p = 0.045) (see Table 9) with DRFS rates in the low-risk group of 96% at 10 years; results were similar
(low-risk 10-year DRFS 98%) in a subset with no chemotherapy.
Among LN0 patients, in the only reanalysis of a RCT the STO-3 trial (van ‘t Veer et al.91) reported 10-year
DRFS rates (93% in low-risk patients, 85% in high-risk patients) (see Table 9) but no statistically significant
levels were reported.91 Four out of five retrospective LN0 cohorts reported statistically significant prognostic
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
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TABLE 9 Prognostic performance of MammaPrint: DRFS/DRFI
Reference
(first author
and year) Cohorts Population Nodal status ET/chemotherapy
Test or
comparator
Percentage
of patients
per group
Percentage
DRFS/DRFI
risk: 0–5 years
Percentage
DRFS/DRFI risk:
0–10 years
DRFS/DRFI: HR (95% CI)Low High Low High Low High
Pooled analyses of patient cohorts: LN status mixed
Variable ET and chemotherapy
Beumer 2016,78
n = 217
Lobular cancer
Lobular cancers, five pooled
series79–82
94% ER+, 92% HER2– LN0, 66%
LN+, 34%
59% ET, 22%
chemotherapy
MammaPrint 76 24 NR NR NR NR 0–10 years: 3.31 (1.79 to 6.12);
p < 0.001
93% ER+, 93% HER2– LN0 51% ET, 12%
chemotherapy
MammaPrint 82 18 NR NR NR NR 0–10 years: 7.81 (2.89 to 21.07);
p < 0.001
Knauer 2010,83
n = 541
Pooled six series79–81,84–86 90% ER+, 89% HER2– LN0, 49%
LN1–3, 51%
All ET, 42%
chemotherapy
MammaPrint 47 53 95 82 NR NR 0–5 years: 3.88 (1.99 to 7.58);
p < 0.01
Mook 2010,87
n = 964
Pooled seven series79–81,84–86,88
T1 only
84% ER+, 68% HER2– LN0, 72%
LN+, 27%
32% ET, 22%
chemotherapy
MammaPrint 54 46 95 80 87 72 0–10 years: 2.70 (1.88 to 3.88);
p < 0.001
n = 552 No ET, no
chemotherapy
MammaPrint 96 78 86 70 0–10 years: 2.90 (1.83 to 4.79);
p < 0.001
Retrospective studies: LN status mixed
Variable ET and chemotherapy
Drukker 2014,89
n = 295
van de Vijver 200279 77% ER+
HER2 NR
LN0, 51%, LN1–3,
36%, LN > 3, 13%
14% ET, 37%
chemotherapy
MammaPrint 39 61 94.7 58.5 82.0 50.0 0–5 years: 9.6 (4.2 to 22.1);
p =NR
5–10 years: 1.1 (0.5 to 2.5);
p =NR
10–15 years: 1.2 (0.2 to 6.0);
p =NR
15–20 years: 1.1 (0.1 to 17.9);
p =NR
20–25 years: 0.3 (0 to 2.9);
p =NR
0–25 years: 3.1 (2.02 to 4.86);
p < 0.0001
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Reference
(first author
and year) Cohorts Population Nodal status ET/chemotherapy
Test or
comparator
Percentage
of patients
per group
Percentage
DRFS/DRFI
risk: 0–5 years
Percentage
DRFS/DRFI risk:
0–10 years
DRFS/DRFI: HR (95% CI)Low High Low High Low High
Yao 2015,90
n = 238
NorthShore & Fox Chase, USA All HR+
All HER2–
LN0, 72%, LN+,
28%
87% ET, 43%
chemotherapy
MammaPrint 60 40 NR NR 96 87 0–10 years: 2.91 (0.97 to 8.68);
p = 0.045
HR+/HR– LN+/LN0 No chemotherapy MammaPrint 61 39 NR NR 98 85 NR
Reanalyses of RCTs: LN0
100% ET monotherapy
van ‘t Veer
2017,91
Esserman92
ET: n = 281
STO-3 trial: ER+ analysis All ER+
HER2 NR
LN0 All ET, no
chemotherapy
MammaPrint 71 29 NR NR 93 85 NR
No ET and chemotherapy
van ‘t Veer
2017,91
Esserman92
No ET: n = 257
STO-3 trial: ER+ analysis All ER+
HER2 NR
LN0 No ET, no
chemotherapy
MammaPrint 67 33 NR NR 83 70 NR
Pooled analyses of patient cohorts: LN0
No ET and chemotherapy
Bueno-de-
Mesquita
201193
Pooled79,84
n = 186
76% ER+
76% HER2–
LN0 No ET/
chemotherapy
MammaPrint 45 55 NR NR 88 55 NR
Retrospective studies: LN0
Variable ET and chemotherapy
Bueno-de-
Mesquita
2009,84 n = 123
Bueno-de-Mesquita 200984 76% ER+
93% HER2–
LN0 22% ET, 25%
chemotherapy
MammaPrint 52 48 98 78 NR NR 0–5 years: 5.7 (1.6 to 20); p=0.007
AOL NR NR NR NR NR NR 0–5 years: 4.6 (0.61 to 35.1);
p = 0.14
NPI NR NR NR NR NR NR 0–5 years: 2.2 (0.78 to 6.5);
p = 0.14
Buyse 200688
Company
submission94
TRANSBIG88
n = 302
70% ER+
HER2 NR
LN0 No ET/
chemotherapy
MammaPrint 37 63 NR NR 90 71 DRFI all follow-up (median
13.6 years)
2.32 (1.35 to 4.00); p = 0.002
AOL 1.68 (0.92 to 3.07); p = 0.092
NPI 1.65 (1.02 to 2.66); p = 0.043
continued
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TABLE 9 Prognostic performance of MammaPrint: DRFS/DRFI (continued )
Reference
(first author
and year) Cohorts Population Nodal status ET/chemotherapy
Test or
comparator
Percentage
of patients
per group
Percentage
DRFS/DRFI
risk: 0–5 years
Percentage
DRFS/DRFI risk:
0–10 years
DRFS/DRFI: HR (95% CI)Low High Low High Low High
Drukker 2014,89
Bueno-
de-Mesquita
2009,84 n = 151
van de Vijver 200279 72% ER+
HER2 NR
LN0 4% ET, 4%
chemotherapy
MammaPrint 40 60 94.989 52.489 8684 5084 0–10 years: 5.5 (2.5 to 12);
p < 0.00184
0–25 years: 4.57 (2.31 to 9.04);
p < 0.000189
AOL NR NR NR NR NR NR 0–10 years: 1.7 (0.84 to 3.6);
p = 0.14
NPI NR NR NR NR NR NR 0–10 years: 3.1 (1.6 to 5.9);
p < 0.001
Ishitobi 2010,95
n = 102
Osaka Medical Centre 51% ER+
HER2 NR
LN0 73% ET, 28%
chemotherapy
MammaPrint 20 80 100 94 NR NR NR
Mook 2010,86
n = 148
NKI 1984–9686 (55–71 years) 78% ER+
HER2 NR
LN0 18% ET, no
chemotherapy
MammaPrint 61 39 93 72 80 67 0–5 years: 4.6 (1.8 to 12.0);
p = 0.001
0–10 years: data per group,
but p-values NR
Wittner 2008,96
n = 100
Massachusetts, USA 80% ER+
HER2 NR
LN0 24% ET, 21%
chemotherapy
MammaPrint 27 73 NR NR NR NR DRFI:
l 0–5 years: PPV = 12%,
NPV = 100%; p = 0.192
l 0–10 years: PPV = 14%,
NPV = 100%; p = 0.330
Retrospective studies: LN+
Variable ET and chemotherapy
Drukker 2014,89
n = 144
van de Vijver 200279 ER+/ER–, HER2 NR LN1–3, 74%, LN
> 3, 26%
Some ET, some
chemotherapy
MammaPrint 38 62 94.5 64.7 78.6 54.3 0–25 years: 2.24 (1.25 to 4.00);
p = 0.01
Mook 2009,85
n = 241
NKI and Italy85 79% ER+, 84% HER2– LN1–3 73% ET, 56%
chemotherapy
MammaPrint 41 59 98 80 91 76 0–10 years: 4.13 (1.72 to 9.96);
p = 0.002
ET, endocrine therapy; NKI, Netherlands Cancer Institute; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; TRANSBIG, Translating molecular knowledge into early breast cancer management: building
on the BIG (Breast International Group) network for improved treatment tailoring.
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TABLE 10 Prognostic performance of MammaPrint for patients at high or low clinical risk
Reference (first
author and year) Cohorts Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
Percentage
of patients
per group
Percentage
risk of
outcomes:
0–5 years
Percentage
risk of
outcomes:
0–10 years HR (95% CI)
Low High Low High Low High
Low risk via AOL +NPI + St Gallen criteria (LN0)
Bueno-de-Mesquita
201193
Pooled,79,84
n = 139
ER+, low
clinical risk
LN0 No ET/chemotherapy DRFI MammaPrint 77 23 NR NR 87 70 0–10 years: HR
NR; p = 0.19
OS MammaPrint 77 23 NR NR 100 86 0–10 years: HR
NR; p = 0.016
Discordant risk via AOL +NPI + St Gallen criteria (LN0)
Bueno-de-Mesquita
201193
Pooled,79,84
n = 139
ER+,
discordant
clinical risk
LN0 No ET/chemotherapy DRFI MammaPrint 66 34 NR NR 91 63 0–10 years: HR
NR; p = 0.004
OS MammaPrint 66 34 NR NR 88 58 0–10 years: HR
NR; p = 0.06
High risk via AOL +NPI + St Gallen criteria (LN0)
Bueno-de-Mesquita
201193
Pooled,79,84
n = 139
ER+, high
clinical risk
LN0 No ET/chemotherapy DRFI MammaPrint 27 73 NR NR 77 45 0–10 years: HR
NR; p = 0.19
OS MammaPrint 27 73 NR NR 77 53 0–10 years: HR
NR; p = 0.17
High risk via AOL (LN+)
Mook 200985 NKI plus
Italy85
n = 209
High-risk AOL LN1–3 Some ET, some
chemotherapy
BCSS MammaPrint NR NR NR NR 94 76 0–10 years: 4.12
(1.45 to 11.76);
p = 0.008
ET, endocrine therapy; NKI, Netherlands Cancer Institute; NR, not reported.
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TABLE 11 Additional prognostic value for DRFS/DRFI: MammaPrint
Reference (first
author and year) Cohorts Population Nodal status ET/chemotherapy
Test or
comparator
a
C-index (AUC) (95% CI)
Increase in LR χ2 over
clinicopathological
factors
a
Multivariable model
adjuvant for
clinicopathological factors,
a
AOL
b
or NPI:
c
HR (95% CI)
Pooled analyses of patient cohorts: LN status mixed
Variable ET and chemotherapy
Beumer 2016,78
n = 217
Lobular cancer
Lobular cancers, five
pooled series79–82
94% ER+, 92% HER2– LN0, 66%; LN+, 34% 59% ET, 22%
chemotherapy
MammaPrint 10 years: 2.08 (1.05 to 4.14);
p = 0.037a
93% ER+, 93% HER2– LN0 51% ET, 12%
chemotherapy
MammaPrint 10 years: 6.40 (2.14 to 19.17);
p = 0.001a
Mook 2010,87
n = 941
Pooled seven
series79–81,84–86,88
84% ER+, 68% HER2– LN0, 72%; LN+, 27% 32% ET, 22%
chemotherapy
MammaPrint 10 years: 2.43 (1.56 to 3.77);
p < 0.001a
All ER+ (n = 788) LN+/LN0 Some ET/
chemotherapy
MammaPrint 10 years: 2.51 (1.60 to 3.95);
p < 0.001a
n= 552 LN+/LN0 No ET/
chemotherapy
MammaPrint 10 years: 2.54 (1.49 to 4.34);
p = 0.001a
Retrospective studies: LN status mixed
Variable ET and chemotherapy
van de Vijver,79
n = 295
van de Vijver79 77% ER+, HER2 NR LN0, 51%;
LN+, 49%
14% ET, 37%
chemotherapy
MammaPrint 10 years: 4.6 (2.3 to 9.2);
p < 0.001a
Yao 2015,90
n = 373
NorthShore & Fox
Chase
74% ER+, 83% HER2– LN0, 72%;
LN+, 28%
65% ET, 58%
chemotherapy
MammaPrint 10 years: 3.01 (0.88 to 10.33);
p = 0.08a
Pooled analyses of patient cohorts: LN0
No ET and chemotherapy
Bueno-de-Mesquita
2011,93 n = 186
Pooled79,84 76% ER+, 76% HER2– LN0 No ET/
chemotherapy
MammaPrint Change log-likelihood,
p < 0.001
Retrospective studies: LN0
Variable ET and chemotherapy
Bueno-de-Mesquita
2009,84 n = 123
Bueno-de-Mesquita84 76% ER+, 93% HER2– LN0 22% ET, 25%
chemotherapy
MammaPrint l Clinicopathological: 0.66
(0.50 to 0.82)
l Clinicopathological plus
MammaPrint: 0.75
(0.61 to 0.89)
l MammaPrint: 0.69
(0.56 to 0.82)
Change log-likelihood
5.5, p = 0.023
5 years: 4.8 (1.3 to 17);
p = 0.018b
5.4 (1.4 to 21); p = 0.015c
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Reference (first
author and year) Cohorts Population Nodal status ET/chemotherapy
Test or
comparator
a
C-index (AUC) (95% CI)
Increase in LR χ2 over
clinicopathological
factors
a
Multivariable model
adjuvant for
clinicopathological factors,
a
AOL
b
or NPI:
c
HR (95% CI)
van de Vijver
2002;79 Bueno-de-
Mesquita 2009;84
Buyse 2006,88
n = 151
van de Vijver79 72% ER+, HER2 NR LN0 4% ET, 4%
chemotherapy
MammaPrint l Clinicopathological: 0.70
(0.61 to 0.79)
l Clinicopathological plus
MammaPrint: 0.76
(0.68 to 0.85)
l MammaPrint: 0.68
(0.60 to 0.77)
Change log-likelihood
15.8, p < 0.01
l 10 years:84 5.3 (2.4 to 12);
p < 0.001b
l 4.3 (1.8 to 10); p = 0.001c
l All follow-up (median
6.7 years):88 6.07 (2.64 to
13.98)b
No ET and chemotherapy
Buyse 2006,88
n = 302
TRANSBIG88 70% ER+, HER2 NR LN0 No ET/
chemotherapy
MammaPrint l 5 years: 4.68 (CI NR)b
l 10 years: 3.5 (CI NR)b
l All follow-up (median
13.6 years): 2.13 (1.19 to
3.82);b 2.15 (1.19 to 3.92)c
Retrospective studies: LN+
Variable ET and chemotherapy
Mook 2009,85
n = 241
NKI plus Italy85 79% ER+, 84% HER2– LN1–3 73% ET, 56%
chemotherapy
MammaPrint 10 years: 2.99 (0.996 to 8.99);
p = 0.051a
ET, endocrine therapy; LR, likelihood ratio; NKI, Netherlands Cancer Institute; TRANSBIG, Translating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for
improved treatment tailoring.
a Adjusted for:
l van de Vijver 200279 – age, lymph node status, tumour size, grade, vascular invasion, ER status, surgery type, chemotherapy and endocrine therapy.
l Mook 2009 (LN1–3) and Mook 2010 (pooled) – age, tumour size, nodal status, grade, ER, HER2, surgery, endocrine therapy, chemotherapy.
l Bueno-de-Mesquita 2011 and 2009 – age, tumour size, grade, ER, PR, HER2.
l Yao 2015 – age, tumour size, grade, ER, HER2.
l Beumer 2016 – age, nodal status, grade, ER, HER2, chemotherapy (similar results when only adjusting for clinicopathological factors associated with MammaPrint outcome).
b Adjusted for AOL.
c Adjusted for NPI.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
3
3
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
9
V
O
L
.
2
3
N
O
.
3
0
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
9
.Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
H
arn
an
e
t
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
llrep
o
rt)m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:N
IH
R
Jo
u
rn
als
Lib
rary,N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,Evalu
atio
n
,Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
5
3
performance of MammaPrint for DRFS/DRFI at varying time points, based on unadjusted HRs between risk
groups.84,86,88,89 The 10-year DRFS/DRFI rates in low-risk patients ranged from 80% to 90% across three
analyses (with varying rates of endocrine therapy and chemotherapy use).84,86,88
Three of the LN0 cohorts84,88,89 included comparisons with AOL and NPI, which appeared to have less
prognostic value than MammaPrint, although no statistical comparisons were reported. There were no
comparisons with other risk tools such as Predict or Modified Adjuvant! Online (mAOL). Among LN+
patients, two cohorts reported statistically significant prognostic performance of MammaPrint based on
unadjusted HRs between risk groups, with 10-year DRFS rates in low-risk patients of 79% and 91%
(with varying rates of endocrine therapy and chemotherapy use).85,89
See Report Supplementary Material 5 for subgroup analyses in patients with low or high clinical risk and in
patients with lobular breast cancer, and for OS and BCSS outcomes.
Additional prognostic value
Several studies reported adjusted analyses relating to the additional prognostic value of MammaPrint over
existing clinicopathological risk scores and clinicopathological variables. A pooled analysis of LN0/LN+
patients from seven series79–81,84,85,87,88 showed that MammaPrint was statistically significantly prognostic for
10-year DRFS in a multivariable analysis adjusting for clinicopathological variables. However, in the US series
(Yao et al.90), MammaPrint was borderline non-statistically significant in a multivariable analysis (p = 0.08).
Among LN0 patients, MammaPrint was statistically significantly prognostic for DRFI when adjusted for AOL
or NPI in three cohorts reported across two publications.84,88 C-indices from two79,84 of these cohorts showed
higher values when MammaPrint was included alongside clinicopathological factors than for either alone,
although differences were not statistically compared.84 In one analysis of LN+ patients, MammaPrint was
borderline statistically significant for 10-year DRFS and statistically significantly prognostic for 10-year
BCSS,85 although in another analysis79 BCSS at 10 years was borderline non-statistically significant.
Conclusions: MammaPrint prognostic performance
The prognostic value of MammaPrint is based on nine retrospective analyses, four pooled analyses
(including six of the nine retrospective series and one prospective series) and one reanalysis of a RCT.
Studies were variable in terms of nodal status, ER status and receipt of endocrine therapy and chemotherapy.
The percentage of LN0 patients categorised as low risk ranged from 20% to 71% and the percentage of
those categorised as high risk ranged from 29% to 80%. In LN+ patients, the percentage categorised as low
risk was 38% to 41% and the percentage categorised as high risk ranged from 59% to 62%. MammaPrint
was statistically significantly prognostic for 10-year DRFS in almost all unadjusted analyses of LN0 and LN+
patients (as well as in pooled analyses). For LN0 patients, 10-year DRFS/DRFI rates for low-risk patients
ranged from 80% to 90% (with varying rates of endocrine therapy and chemotherapy use), whereas the
reanalysis of a RCT reported 10-year DRFS of 93% with endocrine monotherapy and 83% without endocrine
therapy or chemotherapy. Interestingly, although on the whole MammaPrint low-risk 10-year DRFS rates are
lower than those for the other in-scope tests, the 93% figure for patients having endocrine monotherapy is
more in line with other tests and may better reflect the population used in studies of other tests (ER+,
endocrine monotherapy). For LN+ patients, 10-year DRFS rates in low-risk patients ranged from 79% to
91% (with varying rates of endocrine therapy and chemotherapy use). In terms of additional prognostic
value, MammaPrint was statistically significantly prognostic for 10-year DRFS/DRFI in multivariable analyses
adjusted for clinicopathological risk tools (AOL and NPI) and various combinations of clinicopathological
variables in LN0/LN+ and LN0 cohorts, whereas adjusted analyses in LN+ cohorts were statistically significant
or borderline significant.
Chemotherapy benefit: MammaPrint
Study designs and patients
Two publications have reported the ability of MammaPrint to predict the benefit of chemotherapy.
Knauer et al.83 reported a pooled analysis of 541 patients (100% received endocrine therapy, 42% received
CLINICAL EVIDENCE
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chemotherapy) from six consecutive patient series (see Report Supplementary Material 5, Table 7).
Overall, 90% were ER+ and 89% were HER2–, and half were LN0 and half had one to three positive nodes
(LN1–3). In addition, the article by Mook et al.85 reported a pooled analysis of two out of the six patient
series from Knauer et al.83 (see Report Supplementary Material 5, Table 7), with an extended follow-up
(10 years), but restricted to LN1–3 patients (including micrometastases).
Quality assessment
Both studies were pooled retrospective cohorts in which patients were treated in accordance with usual
practice [in addition, one of the six cohorts in Knauer et al.83 was the prospective MicroarRAy-prognoSTics-
in-breast-cancER (RASTER) study,81 in which patients were treated in accordance with usual practice plus
MammaPrint]. For this reason, those who received chemotherapy are likely to be systematically different in
terms of known (and potentially unknown) prognostic factors to those who did not, leading to a high risk
of confounding. Both studies blinded the test assessors to clinical outcomes, and both used standard
outcome definitions. Both studies included a proportion of patients outside the scope (ER– and/or HER2+).
See Report Supplementary Material 5, Table 7.
Results
The pooled analysis of six consecutive series by Knauer et al.83 reported that at 5 years, there was a
statistically significant effect of chemotherapy in the MammaPrint high-risk group but no statistically
significant effect in the low-risk group, although HRs favoured chemotherapy in both groups (Table 12).
Unadjusted HRs for DRFS (for no chemotherapy vs. chemotherapy) were 0.26 (95% CI 0.03 to 2.02;
p = 0.20) in the low-risk group and 0.35 (95% CI 0.17 to 0.71; p < 0.01) in the high-risk group, whereas
unadjusted HRs for BCSS were 0.58 (95% CI 0.07 to 4.98; p = 0.62) in the low-risk group and 0.21 (95% CI
0.07 to 0.59; p < 0.01) in the high-risk group. Multivariable analyses of the effect of chemotherapy on 5-year
BCSS were again statistically significant in the high-risk group (HR 0.21, 95% CI 0.06 to 0.80; p = 0.02) but
not in the low-risk group (HR not estimable; p = 0.98) (see Table 12). However, the interaction test for
chemotherapy treatment and risk group was not statistically significant (p = 0.45; the interaction test appears
to relate to 5-year BCSS as opposed to DRFS but this is unclear in the publication83). This indicates that the
effect of chemotherapy versus no chemotherapy on 5-year BCSS was not statistically significantly different
between risk groups. It is unclear whether this interaction test relates to the adjusted or unadjusted analysis.
For the two pooled LNmicro–3 cohorts reported by Mook et al.85 (these were subsets of two of the six
cohorts pooled in Knauer et al.83), the only evidence relating to prediction of chemotherapy benefit was a
test of the interaction between chemotherapy treatment and risk group (within a multivariable analysis of
10-year BCSS), which was not statistically significant (p = 0.95) (see Table 12).
In the analysis of six series,83 it was unclear whether the interaction test was unadjusted or adjusted,
and, if so, for which factors. In the analysis of LN1–3 patients from two series,85 the interaction test was
conducted within a multivariable analysis adjusted for clinicopathological variables.
Conclusions: MammaPrint chemotherapy benefit
In a pooled analysis of 541 patients (half LN0, half LN1–3) in which patients were treated in accordance
with usual practice, the effect of chemotherapy versus no chemotherapy on 5-year DRFS and BCSS was
statistically significant in the MammaPrint high-risk group but not in the low-risk group in unadjusted
analyses for 5-year DRFS and BCSS and in adjusted analyses for 5-year BCSS. However, the interaction test
for chemotherapy treatment and risk group (for 5-year BCSS) was non-significant (p = 0.45). A further
pooled analysis of two of the above series, restricted to LN1–3 patients, also reported a statistically
non-significant interaction between chemotherapy treatment and risk group for 10-year BCSS (p = 0.95).
The evidence for the ability of MammaPrint to predict chemotherapy benefit is extremely limited; although
unadjusted analyses suggest a greater effect of chemotherapy in high-risk groups, adjusted analyses were
only reported for one outcome, and the non-significant interaction tests suggest that there was no
statistically significant difference in effect of chemotherapy between risk groups.
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TABLE 12 Prediction of chemotherapy responsiveness: MammaPrint
Reference
(first author
and year) Cohorts Population
Percentage
of patients
in each risk
group
Outcome
Low risk High risk
Adjusted HRs
a
Interaction testsLow High
No
chemotherapy:
% risk
Chemotherapy:
% risk HR (95% CI)
No
chemotherapy:
% risk
Chemotherapy:
% risk HR (95% CI)
Knauer 201083
Pooled cohorts
n = 541
Pooled six series:
l NKI, van de
Vijver 200279
l Bueno-de-Mesquita
200984
l Mook 200985 (LN1–3),
NKI plus EIO (Italy)
l Mook 201086
(age 55–71 years)
l Bueno-de-Mesquita
200781 (RASTER)
l Kok (personal
communication within
Knauer et al.83 study)
l 90% ER+
l 89% HER2–
l All ET
l 42%
chemotherapy
l LN0, 49%
l LN1–3, 51%
47 53 DRFS
5 years
93 99 0.26
(0.03 to 2.02);
p= 0.20
76 88 0.35
(0.17 to 0.71);
p< 0.01
NR NR
BCSS
5 years
97 99 0.58
(0.07 to 4.98);
p= 0.62
81 94 0.21
(0.07 to 0.59);
p< 0.01
No chemotherapy vs.
CT
a
(95% CI):
l Low: CI not
estimable, p = 0.98
l High: 0.21 (0.06 to
0.80); p = 0.02
Interaction
b
(risk group plus
chemotherapy):
p= 0.45
Mook 200985
(LNmicro–3)
Retrospective
n = 347
1. NKI plus EIO (Italy)85
(n = 241)
2. NKI, van de Vijver
200279 (n= 106)
l 79/82% ER+
l 84% HER2–
l 73/23% ET
l 56/70%
chemotherapy
l LNmicro–3
41 59 10-year
BCSS
NR NR NR NR NR NR Interaction
(risk group plus
chemotherapy,
series 1+ 2 pooled,
multivariable
a
):
p= 0.95
ET, endocrine therapy; NKI, Netherlands Cancer Institute; NR, not reported.
a Adjusted for:
l Knauer 2010 – age, tumour size, nodal status, grade, ER, PR, endocrine therapy, chemotherapy.
l Mook 2010 – age, tumour size, nodal status, grade, ER, HER2, surgery, endocrine therapy, chemotherapy.
b Unclear whether interaction test in Knauer 2010 relates to adjusted or unadjusted analysis.
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Clinical utility: MammaPrint
Overview
Two studies reported evidence relating to clinical utility of MammaPrint (the impact of prospective use of
the test on clinical outcomes). Microarray In Node-negative Disease may Avoid ChemoTherapy (MINDACT)
is a RCT of MammaPrint versus clinical practice.98 RASTER81,99,100 is a prospective observational study in
which patients were treated in accordance with usual practice plus MammaPrint. As these two studies are
very different in design, they are reported separately in the following sections.
This section of the report summarises the main points; a full description can be found in Report
Supplementary Material 5.
Clinical utility randomised controlled trial: MINDACT
Study design
MINDACT (Cardoso et al.98) is a partially randomised prospective study of MammaPrint versus clinical
practice. Patients with discordant risk scores (high risk/low risk or low risk/high risk) as assessed by
MammaPrint and mAOL (mAOL was calculated HER2 status as well as the usual grade, nodal status and
tumour size, and is not a tool used in clinical practice in the UK, which limits the generalisability of findings
of this trial) were randomised to chemotherapy or no chemotherapy; this also means that discordant-risk
patients were randomised to treatment determined by MammaPrint or treatment determined by mAOL.
Patients with concordant risk were not randomised, but were followed as prospective cohorts. High/high-risk
patients (via both MammaPrint and mAOL) were recommended to receive chemotherapy, whereas no
chemotherapy was recommended for low/low-risk patients.
The primary aim was to determine whether or not patients who were at high-clinical and low-MammaPrint
risk could avoid chemotherapy by comparing outcomes for patients randomised to chemotherapy or no
chemotherapy. The results were also presented for low-clinical-risk, high-MammaPrint-risk patients.
Secondary analyses included an analysis of discordant patients in accordance with treatment group
(chemotherapy vs. no chemotherapy) and for all patients when chemotherapy was recommended in
accordance with clinical risk or with MammaPrint risk. The percentage of patients assigned to
chemotherapy with each strategy was also reported.
Patients and tests
MINDACT enrolled 6693 patients from nine European countries (see Report Supplementary Material 5,
Table 9, for details of group assignments). Of these patients, 88% were hormone-receptor-positive and
90% were HER2–; 79% were LN0 and 21% were LN1–3. However, this varied by group (see Report
Supplementary Material 5, Table 9).
Quality assessment
Randomisation sequence and allocation concealment were judged as having a low risk of bias. No details
of blinding were reported (see Report Supplementary Material 5, Table 10). Intention-to-treat (ITT) and
per-protocol analyses were reported. Some patients did not adhere to their recommended chemotherapy
or no chemotherapy allocation. Other patients had a change in clinical risk group owing to initial incorrect
reporting of clinical characteristics, or a change in MammaPrint risk group owing to a change in the
RNA extraction solution that affected the calculation of risk group. For the ITT analysis, patients were
analysed in their originally allocated clinical/MammaPrint risk groups and in their randomised treatment
groups. Per-protocol analysis excluded patients who were ineligible, were non-adherent to chemotherapy
recommendations or who had a change in their clinical or MammaPrint risk group. This report uses ITT
results (when available).
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Results
High-clinical-risk, low-MammaPrint-risk group
In this group (n = 1497; 52% LN0), 5-year DMFS was 95.9% (95% CI 94.0% to 97.2%) with chemotherapy
and 94.4% (95% CI 92.3% to 95.9%) without chemotherapy; this was an absolute difference of 1.5%
favouring chemotherapy, although the HR was not statistically significant (adjusted HR 0.78, 95% CI 0.50
to 1.21; p = 0.267). Similar differences between chemotherapy and no chemotherapy were reported for
5-year DMFI, DFS and OS, as well as among both LN0 and LN1–3 patients and a LN0, HR+, HER2–
subgroup (Table 13). Statistically, this met the primary objective in that the lower bound of the 95% CI for
5-year DMFS in the no-chemotherapy group was ≥ 92%. This finding was interpreted by the authors as
showing little difference in outcomes for chemotherapy versus no chemotherapy, implying that patients
who were at high-clinical but low-MammaPrint risk could potentially avoid chemotherapy. Clinical advice to
the EAG suggests that chemotherapy would usually only be indicated when it is likely to provide an absolute
improvement in 5-year DRFS of 2–3%, which suggests that it may be reasonable to withhold chemotherapy
in patients with high-clinical, low-MammaPrint risk given the above absolute difference in 5-year DRFS of
1.5% for chemotherapy versus no chemotherapy.
Low-clinical-risk, high-MammaPrint-risk group
Among these patients (n = 690; 98% LN0) (see Table 13), 5-year DMFS was 95.8% (95% CI 92.9% to
97.6%) with chemotherapy and 95.0% (95% CI 91.8% to 97.0%) without chemotherapy, an absolute
difference of 0.8% (adjusted HR 1.17, 95% CI 0.59 to 2.28; p = 0.657). These findings could be
interpreted as showing that use of MammaPrint in low-clinical-risk patients could lead to more patients
being prescribed chemotherapy but not receiving a survival benefit from treatment.
Non-randomised concordant-risk groups
Patients with low/low-risk (recommended no chemotherapy) had a 5-year DMFS of 97.6% (95% CI 96.9%
to 98.1%). Conversely, patients with high/high-risk (recommended chemotherapy) had a 5-year DMFS of
90.6% (95% CI 89.0% to 92.0%). The results for DFS and OS followed a similar pattern (see Table 13).
Estimated outcomes in accordance with clinical and MammaPrint treatment strategies
Additional analyses assessed strategies in which chemotherapy recommendations for all patients were
determined by either clinical risk or MammaPrint risk. These included concordant (non-randomised) and
discordant (randomised) patients who had treatment that matched either their clinical risk (treatment
determined by clinical risk group) or MammaPrint risk (treatment determined by MammaPrint risk group).
Of all 6693 patients, 3356 (50%) were at high clinical risk using mAOL and 2398 (36%) were at high
MammaPrint risk (data not tabulated). Therefore 14% fewer (958/6693) patients were categorised as
being at high risk using MammaPrint than using mAOL, and of those at high clinical risk, 46% (1550/
3356) could be reclassified to low risk by MammaPrint. The 5-year DMFS rate was very similar between
the clinical strategy (5-year DMFS rate 95.0%) and the MammaPrint strategy (5-year DMFS rate 94.7%).
This was interpreted as the MammaPrint strategy leading to little difference in outcomes while sparing
many patients from chemotherapy. Given the results in the low-clinical-risk group (in which treatment in
accordance with MammaPrint risk groups would result in more patients receiving chemotherapy but with
no DMFS advantage), the most advantageous strategy may be to only test clinical high-risk patients with
MammaPrint. However, the comparator in this study was mAOL, and it is unclear whether or not the same
would be true for other clinical risk scores.
Multivariable analysis
In a multivariable analysis adjusted for chemotherapy use, clinical risk and patient and tumour
characteristics, MammaPrint low/high-risk grouping was statistically significantly associated with 5-year
DMFS (HR for high vs. low-risk 2.41, 95% CI 1.79 to 3.26; p < 0.001).
CLINICAL EVIDENCE
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TABLE 13 Clinical utility of MammaPrint (MINDACT)
Study
(first author
and year) Subgroup n Population Nodal status Outcome
Percentage risk of outcome (95% CI)
HR adjusted
a
(95% CI)
Absolute
difference
(95% CI)No chemotherapy Chemotherapy
High clinical, low MammaPrint group (randomised to chemotherapy or no chemotherapy; ITT
b
)
Node negative and node positive
Cardoso 201698 High mAOL, low
MammaPrint
1497 98% HR+, 92% HER2– LN0, 52%; LN1–3, 48% 5-year DMFS 94.4 (92.3 to 95.9) 95.9 (94.0 to 97.2) 0.78 (0.50 to 1.21);
p = 0.267
1.5%
5-year DRFI 95.3 (93.4 to 96.6) 96.6 (94.8 to 97.8) 0.76 (0.47 to 1.22);
p = 0.253
1.3%
5-year DFS 90.1 (87.5 to 92.1) 92.9 (90.5 to 94.7) 0.71 (0.50 to 1.01);
p = 0.055
2.8%
5-year OS 97.0 (95.4 to 98.1) 98.4 (97.0 to 99.1) 0.69 (0.35 to 1.35);
p = 0.278
1.4%
Node negative
Cardoso 201698 High mAOL, low
MammaPrint
787 NR LN0 5-year DMFS 93.2 (90.1 to 95.4) 95.7 (93.0 to 97.4) 0.69 (0.39 to 1.21);
p = 0.193
2.5%
699 All HR+, all HER2– LN0 5-year DMFS 93.9 (90.6 to 96.1) 95.5 (92.5 to 97.3) 0.80 (0.44 to 1.45);
p = 0.456
1.6%
Node positive
Cardoso 201698 High mAOL, low
MammaPrint
709 NR LN1–3 5-year DMFS 95.6 (92.7 to 97.4) 96.3 (93.1 to 98.1) 0.88 (0.42 to 1.82);
p = 0.724
0.7%
Low clinical, high MammaPrint group (randomised to chemotherapy or no chemotherapy; ITT
b
)
Node negative and node positive
Cardoso 201698 Low mAOL, high
MammaPrint
690 90% HR+, 88% HER2– LN0, 98%; LN1–3, 2% 5-year DMFS 95.0 (91.8 to 97.0) 95.8 (92.9 to 97.6) 1.17 (0.59 to 2.28);
p = 0.657
0.8%
5-year DRFI 95.6 (92.5 to 97.5) 98.1 (95.7 to 99.1) 0.63 (0.27 to 1.47);
p = 0.282
2.5%
5-year DFS 90.1 (86.1 to 93.0) 92.1 (88.3 to 94.6) 0.87 (0.53 to 1.45);
p = 0.603
2.0%
5-year OS 97.8 (95.5 to 99.0) 97.1 (94.5 to 98.5) 1.28 (0.54 to 3.02);
p = 0.578
–0.7%
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
3
3
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
9
V
O
L
.
2
3
N
O
.
3
0
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
9
.Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
H
arn
an
e
t
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
llrep
o
rt)m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:N
IH
R
Jo
u
rn
als
Lib
rary,N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,Evalu
atio
n
,Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
5
9
TABLE 13 Clinical utility of MammaPrint (MINDACT) (continued )
Study
(first author
and year) Subgroup n Population Nodal status Outcome
Percentage risk of outcome (95% CI)
HR adjusted
a
(95% CI)
Absolute
difference
(95% CI)No chemotherapy Chemotherapy
Node negative
Cardoso 201698 Low mAOL, high
MammaPrint
635 NR LN0 5-year DMFS 95.1 (91.9 to 97.1) 96.0 (93.1 to 97.7) 1.09 (0.54 to 2.19);
p = 0.815
0.9%
534 All HR+, all HER2– LN0 5-year DMFS 95.5 (91.6 to 97.6) 95.1 (91.5 to 97.2) 1.45 (0.68 to 3.08);
p = 0.333
–0.4%
Node positive
Cardoso 201698 Low mAOL, high
MammaPrint
NR (number too small) NR LN1–3 5-year DMFS NR NR NR NR
Outcomes for non-randomised groups
b
Low clinical, low MammaPrint (node negative and node positive)
Cardoso 201698 Low mAOL, low
MammaPrint
2745 100% HR+, 96% HER2– LN0, 94%; LN1–3, 6% 5-year DMFS 97.6 (96.9 to 98.1) N/A
5-year DFS 92.8 (91.7 to 93.7) N/A
5-year OS 98.4 (97.8 to 98.9) N/A
High clinical, high MammaPrint (node negative and node positive)
Cardoso 201698 High mAOL, high
MammaPrint
1806 62% HR+, 81% HER2– LN0, 74%; LN1–3, 26% 5-year DMFS N/A 90.6 (89.0 to 92.0)
5-year DFS N/A 85.3 (83.4 to 87.0)
5-year OS N/A 94.7 (93.4 to 95.7)
N/A, not applicable; NR, not reported.
a HRs adjusted for institution, risk group, ER, PR, nodal status, age, HER2, axillary treatment, surgery; HR below 0 favours chemotherapy.
b ITT analysis includes initially allocated risk groups and treatment assignment, irrespective of adherence to treatment.
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0
Conclusions: randomised controlled trial of clinical utility for MammaPrint (MINDACT)
MINDACT randomised patients with discordant MammaPrint and mAOL risks to chemotherapy or no
chemotherapy. For patients who were high-clinical, low-MammaPrint risk, 5-year DMFS was 95.9% with
chemotherapy and 94.4% without chemotherapy, an absolute difference of 1.5%. This raises the possibility
of avoiding chemotherapy in these patients. In patients who were low-clinical, high-MammaPrint risk, 5-year
DMFS was 95.8% with chemotherapy and 95.0% without chemotherapy, an absolute difference of 0.8%.
This could be interpreted as showing that MammaPrint may not be useful in this group as it would increase
chemotherapy rates without improving outcomes. However, the comparator was mAOL, and it is unclear
whether or not the same would be true for other clinical risk measures.
Clinical utility observational study: RASTER
Study design, patients and tests
RASTER (Drukker et al.,99 Drukker et al.,100 Bueno-de-Mesquita et al.81 and Vliek et al.101) is a prospective
observational study in which LN0 (n = 427, 80% ER+, 84% HER2–) patients in the Netherlands were
treated in accordance with MammaPrint plus usual clinical practice [2004 Dutch Institute of Healthcare
Improvement (Central Accompagnement Organization) guidelines102 and clinician and patient preference].
The aims were to assess the impact of MammaPrint on treatment decisions and to prospectively record
outcomes for patients categorised as being at high or low risk via MammaPrint, via clinical risk tools
and for various combinations of MammaPrint risk and clinical risk. An additional analysis conducted
retrospectively in LN+ patients (n = 164) was reported separately (Vliek et al.103). Frozen tumour samples
were used99 in the LN0 study and FFPE samples were used in the retrospective analysis of LN+ patients.103
MammaPrint 70-gene microarray was used, stating that cut-off points were the same as in previous
studies99 (see Report Supplementary Material 5, Table 13).
Quality assessment
Because RASTER was not a RCT, it was judged to be at a high risk of bias using standard RCT criteria
(see Report Supplementary Material 5, Table 14). Prognostic results from this study are confounded by the
differing rates of chemotherapy in different risk groups (usually more chemotherapy in the high-risk group
than in the low-risk group).
Results for lymph node-negative patients
Results for MammaPrint (in conjunction with Central Accompagnement Organization
guidelines and patient/clinician preference)
In LN0 patients (n = 427), 51% were at low risk (of whom 15% received chemotherapy) and 49% were at
high risk (of whom 81% received chemotherapy). At 5 years, DRFI was 97.0% for low-risk patients and
91.7% for high-risk patients (p = 0.03 between groups, HR not reported) (Table 14).99,100 The 10-year DRFI
was 93.7% for low-risk and 86.8% for high-risk patients (HR 1.4, 95% CI 1.0 to 1.9). Results at 10 years
were similar for the 342 ER+ patients, although not statistically significant (Vliek et al.101) (see Table 14).
The 5-year OS was not statistically significantly different between MammaPrint groups (p = 0.35, HR not
reported) (see Report Supplementary Material 5, Table 15).99,100
Results for clinical risk tools
MammaPrint results were compared with the results of the NPI and Predict Plus clinical risk tools applied
retrospectively to the data (see Tables 14 and 15). Results were similar to MammaPrint for proportions in
low- and high-risk categories and for 5-year DRFI rates. Both NPI and Predict Plus showed a significant
difference between groups (p = 0.03 and p = 0.004, respectively).99,100
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TABLE 14 Clinical utility of MammaPrint (RASTER study): DRFIa in node-negative patients
Study Subgroup
Population:
ET/chemotherapy Nodal status Outcome Test or comparator
Percentage of
patients per
group
Percentage
chemotherapy
per group
Percentage DRFI
risk: 0–5 years
Percentage
DRFI risk:
0–10 years HR (95% CI); p-value
Low High Low High Low High Low High 0–5 years 0–10 years
Node negative
RASTER99–101
LN0
All patients, n= 427 l 80% ER+
l 84% HER2–
l 43% ET
l 47% chemotherapy
LN0 DRFI MammaPrint 51 49 15 81 97.0 91.7 93.7 86.8 p = 0.03 1.4 (1.0 to 1.9)
AOL 31 69 18 60 96.7 93.4 NR NR p = 0.24 NR
NPI 58 42 21 84 96.7 91.3 NR NR p = 0.03 NR
Predict Plus (University
of Cambridge,
Cambridge, UK)
53 47 20 78 96.8 91.7 NR NR p = 0.004 NR
mAOL 57 43 NR NR NR NR 91.7 88.2 NR 1.4 (0.8 to 2.6)
ER+ patients
RASTER94,101
LN0
ER+ patients,
n= 342
l All ER+
l HER2 NR
LN0 DRFI MammaPrint 63 37 NR NR NR NR 93.6 88.8 NR 1.6 (0.8 to 3.3)
mAOL NR NR NR NR NR NR 91.6 91.9 NR NR
High clinical risk
RASTER99–101
LN0
AOL high, n= 295 l ER+/ER–
l HER2+/HER2–
LN0 DRFI MammaPrint 42 58 24 87 98.4 89.8 NR NR NR NR
NPI high, n= 179 25 75 57 93 95.5 89.9 NR NR NR NR
Predict Plus high,
n= 199
25 75 41 91 93.9 91.0 NR NR NR NR
mAOL high, n = 183 25 75 NR NR NR NR 90.9 87.3 NR NR
High clinical risk, untreated
RASTER99,100
LN0
AOL high; no
chemotherapy
(n = 117)
l ER+/ER–
l HER2+/HER2–
LN0 DRFI MammaPrint 80 20 0 0 98.9 NR NR NR NR NR
AOL high; no ET/
chemotherapy
(n = 75)
93 7 0 0 100.0 NR NR NR NR NR
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Study Subgroup
Population:
ET/chemotherapy Nodal status Outcome Test or comparator
Percentage of
patients per
group
Percentage
chemotherapy
per group
Percentage DRFI
risk: 0–5 years
Percentage
DRFI risk:
0–10 years HR (95% CI); p-value
Low High Low High Low High Low High 0–5 years 0–10 years
Low clinical risk
RASTER99–101
LN0
AOL low, n= 132 l ER+/ER–
l HER2+/HER2–
LN0 DRFI MammaPrint 72 28 3 57 95.3 100.0 NR NR NR NR
NPI low, n = 248 71 29 5 59 97.4 95.3 NR NR NR NR
Predict Plus low,
n= 228
75 25 8 57 98.0 93.9 NR NR NR NR
mAOL low, n=NR NR NR NR NR NR NR 94.4 88.5 NR NR
Low clinical risk, untreated
RASTER99,100
LN0
AOL low; no
chemotherapy
(n = 108)
l ER+/ER–
l HER2+/HER2–
LN0 DRFI MammaPrint 85 15 0 0 95.1 NR NR NR NR NR
AOL low; no ET/
chemotherapy
(n = 93)
95 5 0 0 95.0 NR NR NR NR NR
ET, endocrine therapy; NR, not reported; RASTER, MicroarRAy PrognoSTics in Breast CancER study.
a In RASTER, definition of DRFI includes DR and BC death as events, which is more similar to definitions of DRFS/DMFS in most studies in this review.
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TABLE 15 Clinical utility of MammaPrint (RASTER study): additional prognostic value in node-negative patients
Study Subgroup Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
Percentage
of patients
per group
Percentage
chemotherapy
per group
C-index
(AUC)
Increase in
C-index (AUC) over
clinicopathological
factorsLow High Low High
Node negative
RASTER99–101 All patients,
n = 427
l 80% ER+
l 84% HER2–
LN0 l 43% ET
l 47% chemotherapy
5-year DRFI MammaPrint 51 49 15 81 NR
AOL 31 69 18 60 0.532
AOL plus
MammaPrint
NR NR NR NR 0.619 p = 0.03
NPI 58 42 21 84 0.591
NPI plus
MammaPrint
NR NR NR NR 0.638 p = 0.05
Predict Plus 53 47 20 78 0.627
Predict Plus plus
MammaPrint
NR NR NR NR 0.662 p = 0.27
ET, endocrine therapy; NR, not reported; RASTER, MicroarRAy PrognoSTics in Breast CancER study.
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Conversely, AOL categorised more patients as high risk compared with MammaPrint, NPI or Predict Plus,
(69% compared with 49%, 42% and 47%, respectively). High-risk AOL patients had a lower chemotherapy
rate (60% compared with 81%, 84% and 78%, respectively), and 5-year DRFI was similar for the low-risk
group (96.7% compared with 97.0%, 96.7 and 96.8%, respectively) but was higher in the high-risk group
(93.4%, compared with 91.7%, 91.3% and 91.7%, respectively). The difference between AOL low- and
high-risk groups was p = 0.24 (see Table 14).99,100 mAOL categorised similar numbers of patients as being at
high risk and low risk as MammaPrint, NPI and Predict Plus. The 10-year DRFI for mAOL was more favourable
for the low-risk group than the high-risk group, but this was not statistically significant (HR 1.4, 95% CI
0.8 to 2.6) and any difference was lost when restricting to ER+ patients (see Table 14 and Vliek et al.101).
MammaPrint results for patients at high/low clinical risk
Results by MammaPrint risk group for patients at a high or low clinical risk in accordance with NPI, Predict
Plus and AOL are also presented. The results are presented in detail in Report Supplementary Material 5.
In summary, observed 5-year DRFI rates were lower in patients with high NPI risk/low MammaPrint risk
and in patients with high Predict Plus risk/low MammaPrint risk (5-year DRFI rates 95.5% and 93.9%,
respectively) than in the whole MammaPrint low-risk group (5-year DRFI rate 97.0%), and were similar in
the high-clinical-risk/high-MammaPrint-risk groups (5-year DRFI rates 89.9% and 91.0%, respectively)
compared with a 5-year DRFI rate of 91.7% in the MammaPrint high-risk group. AOL classified more
patients as being at high risk than NPI and Predict Plus and had a 5-year DRFI of 90.6%; a higher
proportion of these patients were reclassified by MammaPrint as being at low risk.
Additional prognostic value of MammaPrint
Table 15 shows C-indices (AUC) for clinical risk tools only and in addition to MammaPrint. The addition of
MammaPrint to AOL or NPI statistically significantly increased the C-index (AUC) (p = 0.03 and p = 0.05,
respectively), whereas the addition of MammaPrint to Predict Plus did not statistically significantly increase
the C-index (AUC) (p = 0.27) (see Table 15).100
Results for lymph node-positive patients
MammaPrint was retrospectively conducted in 164 LN+ patients (Table 16). Over 95% of patients received
chemotherapy. MammaPrint categorised 48% of LN1–3 patients as low risk. The 5-year DRFI was 98.4%
for low-risk and 86.9% for high-risk patients, whereas 10-year DRFI was 94.9% for low-risk and 80.7%
for high-risk patients, showing a statistically significant difference between groups (HR 4.7, 95% CI 1.3
to 16.2). A comparison was made with the mAOL, although this analysis included 30 additional patients
with LN > 3 who were automatically classed as high risk. The mAOL categorised only 14% of patients as
being at low risk; 10-year DRFI was 94.4% for low-risk and 85.8% for high-risk patients, which was not
statistically significantly different (HR 3.7, 95% CI 0.5 to 28.5). Within the mAOL high-risk group, 10-year
DRFI was statistically significantly better in MammaPrint low-risk (95.2%) than high-risk (79.6%) patients
(HR 4.8, 95% CI 1.1 to 21.4).101
Conclusions: observational study of clinical utility for MammaPrint (RASTER)
RASTER is a prospective observational study in which patients were treated in accordance with MammaPrint
plus usual clinical practice (LN0) or in accordance with usual clinical practice (LN+). The 5-year DRFI for LN0
patients was 97.0% for low-risk patients (15% had chemotherapy) and 91.7% for high-risk patients (81%
received chemotherapy). The 10-year DRFI for LN0 patients was 93.7% for low-risk and 86.8% for high-risk
patients. The DRFI rates in the MammaPrint low-risk group may be considered sufficiently low for these
patients to avoid chemotherapy. MammaPrint provided additional prognostic information over AOL and NPI,
but not over Predict Plus when considering C-indices. Estimates of prognostic performance between risk
groups are likely to be affected by the differing rates of chemotherapy in each group and the fact that
chemotherapy use was influenced by MammaPrint.
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TABLE 16 Clinical utility of MammaPrint (RASTER study): DRFIa in node-positive patients
Study (first
author and year) Subgroup Population: ET/chemotherapy Nodal status Outcome
Test or
comparator
Percentage of
patients per
group
Percentage
chemotherapy
per group
Percentage DRFI risk
HR (95% CI), p-value0–5 years 0–10 years
Low High Low High Low High Low High 30–5 years 0–10 years
Node positive
RASTER LN+, Vliek
2017101
LN1–3, n= 134 l ER+/ER–
l HER2NR
l 95% chemotherapy
LN1–3 DRFI MammaPrint 48 52 NR NR 98.4 86.9 94.9 80.7 NR 4.7 (1.3 to 16.2);
p= 0.008
All (three were
missing data),
n= 161
l 83% ER+
l HER2 NR
l > 95% chemotherapy
l LN1–3, 82%
l LN > 3, 18%
mAOL 14 86 NR NR 100 90.8 94.4 85.8 NR 3.7 (0.5 to 28.5);
p= 0.173
High clinical risk
RASTER LN+, Vliek
2017101
mAOL high risk,
n= 109
l ET NR
l > 95% chemotherapy
LN+ DRFI MammaPrint 40 60 NR NR 97.7 86.1 95.2 79.6 NR 4.8 (1.1 to 21.4)
ET, endocrine therapy; NR, not reported; RASTER, MicroarRAy PrognoSTics in Breast CancER study.
a In RASTER, definition of DRFI includes DR and BC death as events, which is more similar to definitions of DRFS/DMFS in most studies in this review.
Note
mAOL includes HER2.
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Results: Prosigna
A description of Prosigna and its development is given in Report Supplementary Material 6. A summary of
the key results from the review is provided in this section. A detailed narrative synthesis of all study results
is also provided in Report Supplementary Material 6.
Prosigna is based on a ROR score called ROR-PT, which incorporates the PAM50 gene signature, a
weighting for a proliferation score (P, a subset of the 50 genes) and information on tumour size (T). Nodal
status is then used when converting the score into a risk category. The results for the commercial test using
nCounter and for research-based versions using other methods (e.g. RT-qPCR) are reported here. Studies
assessing ROR-PT via whole-transcriptome microarray are summarised in Report Supplementary Material 10.
ROR-S (subtype), ROR-T/ROR-C (subtype and tumour size) and ROR-P (subtype and proliferation score) were
outside the scope of this review. Within this section, the test is referred to as ROR-PT.
Prognostic performance: Prosigna
Study designs: Prosigna prognostic performance
Eight data sets were used to assess the prognostic performance of ROR-PT (see Report Supplementary
Material 6, Table 1). These included six reanalyses of RCTs [TransATAC,38,46 Austrian Breast and Colorectal
Cancer Study Group (ABCSG) 8,104,105 Cancer and Leukemia Group B (CALGB 9741),106 National Cancer
Institute of Canada (NCIC) MA.21,107 Grupo Español de Investigación en Cáncer de Mama (GEICAM)
9906108,109 and NCIC MA.12110] and two retrospective analyses of prospective cohorts [the Danish Breast
Cancer Cooperative Group (DBCG) cohort111–114 and two analyses of the British Columbia cohort115,116].
Patients: Prosigna prognostic performance
Two of the RCTs (TransATAC38,46 and ABCSG 8;104,105 total n = 2252) and the two retrospective analyses
(total n = 3508) included patients who were all/mostly ER+ and HER2– and received endocrine monotherapy.
The other four RCTs106–110 (total n = 3358) included higher-risk patients (not restricted to ER+ and HER2–,
higher proportion LN+) and all received chemotherapy (see Report Supplementary Material 6, Table 1).
Two studies recruited only LN+ patients (CALGB 9741106 and GEICAM 9906108,109), one recruited LN0
patients (DBCG111–114) and the remainder recruited both LN0 and LN+ patients.
Tests and comparators: Prosigna prognostic performance
Four analyses of RCTs38,46,104–107 and two analyses of prospective cohorts111–115 measured ROR-PT using the
nCounter device, and two analyses of RCTs108–110 and one of a prospective cohort116 used RT-qPCR (see
Report Supplementary Material 6, Table 1). The cut-off points used to define risk groups varied across studies,
and some analyses assessed ROR-PT as a continuous score (see Report Supplementary Material 6, Table 1).
Quality assessment: Prosigna prognostic performance
See Report Supplementary Material 6, Table 1. All analyses excluded some patients recruited to the original
trial or cohort. Blinding of test assessors to outcomes was reported in five analyses. All used standardised
outcomes.
Results: Prosigna prognostic performance
Distribution of patients by risk group
For LN0 patients, the percentages categorised as low risk were reported in two analyses: 55% in TransATAC46
and 48% in ABCSG 8.104,105 Among LN+ patients, far fewer patients were categorised as low risk: 8% in
TransATAC,46 4% in ABCSG 8,104,105 19% in GEICAM 9906108,109 and 25% in DBCG.112 The percentages of
patients categorised as intermediate risk were 30%46 and 32%104,105 in LN0 patients and ranged from 27% to
56% in LN+ patients.46,104,105,108,109,112 The number of patients who are likely to be prescribed chemotherapy
on the basis of their test result will depend on how intermediate-risk patients are handled and whether or not
they would be handled in the same way in LN0 and LN+ groups.
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Prognostic performance: unadjusted analyses
For LN0 patients, ROR-PT was statistically significantly prognostic for DRFS/DFMS/DRFI in all three data
sets (TransATAC,46 ABCSG 8104,105 and DBCG112). HRs and p-values between groups are reported in many
differing formats and time points so are summarised in Table 17 rather than in the text. ROR-PT was also
statistically significantly prognostic for late (5- to 15-year) recurrence in the one study reporting this.104,105
For LN+ patients, ROR-PT was statistically significantly prognostic for 10-year DRFS/DFMS/DRFI in all four
data sets (TransATAC,46 ABCSG 8,104,105 DBCG112 and GEICAM 9906108,109). ROR-PT was also statistically
significantly prognostic for late (5- to 10-year) recurrence in the two studies reporting this.104,105,112,113
Other outcomes and subgroups (pre/post menopausal, ductal/lobular cancer) are reported in Report
Supplementary Material 6.
Additional prognostic value
In terms of additional prognostic value (Table 18), multivariable analyses of two data sets (ABCSG 8 and
DBCG)104,111,112 showed that ROR-PT was an independent prognostic parameter for 10-year DMFS/DRFS after
adjustment for clinicopathological variables across LN0/LN+ and LN+ patients. Two data sets (TransATAC46
and ABCSG 8104) reported an increase in likelihood ratio χ2 for ROR-PT plus CTS/clinical linear predictor
(CLP)/NPI over CTS/CLP/NPI only; this increase was statistically significant in LN0 and LN+ patients in
ABCSG 8,104 and in TransATAC the increase was statistically significant in LN0 patients and borderline
significant in LN+ patients.46 One study reported an increase in likelihood ratio χ2 (p < 0.0001) for ROR-PT
over clinicopathological variables in DBCG, a mixed cohort of LN+/LN0 patients.112
Conclusions: Prosigna prognostic performance
Based on six reanalyses of RCTs and two retrospective analyses of prospective cohorts, Prosigna/ROR-PT was
statistically significantly prognostic for unadjusted analyses of 10-year DRFS/DRFI in LN0 and LN+ patients.
Among LN0 patients, approximately 50% were categorised as low risk, 30% as intermediate risk and 15%
to 20% as high risk. Among LN+ patients, 4% to 25% were at low risk, 27% to 56% were at intermediate
risk and 26% to 62% were at high risk. The 10-year DRFS/DRFI rates for low-risk patients were 95% to 97%
in three studies of LN0 patients (all endocrine therapy only), and in LN+ patients these were 100% in two
studies (endocrine therapy only) and 92% in one study (all endocrine therapy and chemotherapy). ROR-PT
added prognostic information over clinicopathological variables or CTS/CLP/NPI in three studies; this was
statistically significant in LN0 patients and either significant or borderline significant in LN+ patients.
Results: EndoPredict and EndoPredict Clinical
Development: EndoPredict and EndoPredict Clinical
EndoPredict and EPClin risk scores were trained on 964 ER+, HER2– endocrine-treated samples (65% node
negative) from a range of sources (Filipits et al.117). EndoPredict generates an EndoPredict score based on
the gene signature alone. The EPClin score is calculated from the EndoPredict score plus information on
tumour size and nodal status.
Prognostic performance: EndoPredict and EndoPredict Clinical
Study characteristics
The prognostic value of EPClin was assessed in three reanalyses of RCTs,36,46,108,109,118–120 which included
four RCTs (total n = 3135): UK patients from TransATAC (n = 878), the ABCSG 6 and ABCSG 8 (total
n = 1702) and the Spanish GEICAM 9906 trial (n = 555). All recruited only, or reported a subgroup of,
patients who were ER+ and HER2–. One reported on LN0 patients (total n = 680)36,39,46 and two36,46,108,109
on LN+ patients (total n = 753; one108,109 included 36% patients with at least three positive nodes). One
reported on patients unselected by lymph node status,120 and one on both LN0 and LN1–3 together;46
additional analyses118 were provided to the EAG as commercial-in-confidence data and cannot be reported
CLINICAL EVIDENCE
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TABLE 17 Prognostic performance of Prosigna: DRFS/DRFIa
Reference (first
author and year)
Cohort,
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients per
group
Percentage DRFS/DRFI risk
DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
LN status mixed
100% ET monotherapy
Sestak 2017 (data
request)46 (reduced
data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n = 774
LN0, 76%
LN1–3, 24%
All ET, no
chemotherapy
ROR-PT,
nCounter
43 30.5 26.5 NR NR NR NR NR NR 0–10 years:
l Low vs. intermediate:
5.49 (2.63 to 11.48)
l Low vs. high: 12.40
(6.13 to 25.08)
Gnant 2014,104 Filipits
2014105
ABCSG 8,
R-RCT, Austria
ER+, HER2–
n = 1397
LN0, 71%
c
LN1–3, 26%
c
LN> 3, 3%
c
All ET, no
chemotherapy
ROR-PT,
nCounter
35 32 33 NR NR NR 96.6 91.1 79.9 5–15 years:
l Low vs. intermediate:
3.74 (NR); p = 0.002
c
l Low vs. high: 6.90
(3.08 to 15.45);
p < 0.001
d
Laenkholm 2015,112
2015113
DBCG, cohort,
Denmark
HR+, HER2 NR
n = 2722
LN0, 46%
LN1–3, 54%
All ET, no
chemotherapy
ROR-PT 27 29 44 NR NR NR 95.7 – 79.2 5–10 years:
l Low vs. intermediate:
NR, p= 0.0074
l Intermediate vs.
high: NR, p = 0.0091
LN0
100% ET monotherapy
Sestak 2017 (data
request)46 (full data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n = 663
LN0 All ET, no
chemotherapy
ROR-PT,
nCounter
55 30 15 98.6 95.9 87.9 97.4 86.6 69.0 0–5 years:
l Low vs. intermediate:
3.02 (0.99 to 9.22)
l Low vs. high: 8.87
(3.12 to 25.17)
0–10 years:
l Low vs. intermediate:
5.02 (2.32 to 10.86)
l Low vs. high: 13.42
(6.33 to 28.47)
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TABLE 17 Prognostic performance of Prosigna: DRFS/DRFIa (continued )
Reference (first
author and year)
Cohort,
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients per
group
Percentage DRFS/DRFI risk
DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Gnant 2014,104 Filipits
2014105
ABCSG 8,
R-RCT, Austria
ER+, HER2–
n = 984
LN0 All ET, no
chemotherapy
ROR-PT,
nCounter
48 32 20 NR NR NR 96.5 90.0 84.7 5–15 years:
l Low vs. intermediate:
4.03 (NR), p = 0.002
c
l Low vs. high: 4.74
(1.89 to 11.87);
p < 0.001
d
Laenkholm 2015112 DBCG, cohort,
Denmark
HR+, HER2 NR
n = 1256
LN0 All ET, no
chemotherapy
ROR-PT NR NR NR NR NR NR 95.1 92.7 81.5 0–10 years:
l Low vs. intermediate:
NR, p= 0.1543
l Intermediate vs. high:
NR, p< 0.0001
LN+
100% ET monotherapy
Sestak 2017 (data
request)46 (full data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n = 192
LN1–3 All ET, no
chemotherapy
ROR-PT,
nCounter
8 32 60 100.0 91.7 87.4 100.0 80.7 70.7 0–5 years:
l Low vs. intermediate
or low vs. high:
no events
l Intermediate vs. high:
1.30 (0.47 to 3.60)
0–10 years:
l Low vs. intermediate
or low vs. high:
no events
l Intermediate vs. high:
1.37 (0.69 to 2.72)
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Reference (first
author and year)
Cohort,
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients per
group
Percentage DRFS/DRFI risk
DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT, Austria
ER+, HER2–
n = 413
l LN1–3, 89%
c
l LN > 3, 11%
c
All ET, no
chemotherapy
ROR-PT,
nCounter
4 34 62 NR NR NR 100 93.6 76.2 5–15 years:
l Low vs. intermediate
or low vs. high:
no events
l Intermediate vs. high:
3.15 (1.20 to 8.24);
p = 0.020
d
Laenkholm 2015112 DBCG, cohort,
Denmark
HR+, HER2 NR
n = 1466
LN1–3 All ET, no
chemotherapy
ROR-PT 25 27 48 NR NR NR 95.2 78.1 0–10 years:
l Low/intermediate vs.
high: NR, p < 0.0001
100% chemotherapy and ET
Martin 2016,108
2014109
GEICAM 9906,
R-RCT, Spain
ER+, HER2–
n = 536
l LN1–3, 64%
l LN > 3, 36%
All ET, no
chemotherapy
ROR-PT
(research)
19 56 26 NR NR NR 92 74 66 0–10 years:
l Low vs. intermediate:
4.4 (NR)
l Low vs. high: 5.8
(NR), p< 0.0001
ET, endocrine therapy; NR, not reported; R-RCT, reanalysis of RCT.
a DMFS (GEICAM, ABSCG); DRFI (TransATAC).
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
c Nodal status for all patients; NR for HER2– subgroup.
d 5–15 years in ABCSG 8 analysis of Prosigna.
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TABLE 18 Additional prognostic value for DRFI/DRFS: Prosigna
Reference (first
author and year) Cohort Population Nodal status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
C-index
(AUC)
Increase in
C-index (AUC) over
clinicopathological
factors
a
Multivariable
model (adjuvant for
clinicopathological
factors
a
): HR (95% CI)
LN status mixed
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT
ER+, HER2–
n= 774
l LN0, 76%
l LN1–3, 24%
All ET, no
chemotherapy
10-year DRFI ROR-PT,
nCounter
61.47
(p< 0.0001)
Over CTS: 26.30
(p < 0.001)
Over NPI: 23.91
(p < 0.0001)
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT
ER+, HER2–
n= 1397
l LN0, 71%
c
l LN1–3, 26%
c
l LN> 3, 3%
c
All ET, no
chemotherapy
10-year DRFS ROR-PT,
nCounter
29.94 (p< 0.0001) 0.720 NR Low vs. intermediate:
2.15 (1.21 to 3.81);
p= 0.009
Low vs. high: 4.26
(2.44 to 7.43);
p< 0.0001
CLP 0.688
Laenkholm 2015112 DBCG,
cohort
HR+, HER2
NR
n= 2722
l LN0, 46%
l LN1–3, 54%
All ET, no
chemotherapy
10-year DRFS ROR-PT,
nCounter
p< 0.0001 HR (20-point change in
ROR): 1.7 (1.5 to 1.9)
LN0
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT
ER+, HER2–
n= 591
LN0 All ET, no
chemotherapy
10-year DRFI ROR-PT,
nCounter
50.77
(p< 0.0001)
Over CTS: 23.71
(p < 0.0001)
Over NPI: 25.54
(p < 0.0001)
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT
ER+, HER2–
n= 984
LN0 All ET, no
chemotherapy
10-year DRFS ROR-PT,
nCounter
Over CLP: 20.32
(p < 0.0001)
0.692 NR
CLP 0.639
Wallden 2015115 British
Columbia,
cohort
ER+, 91%;
HER2–
n= 232
LN0 All ET, no
chemotherapy
DRFS (time NR) ROR-PT,
nCounter
0.675
d
NR
AOL 0.587
d
NR
IHC-T 0.590
d
NR
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Reference (first
author and year) Cohort Population Nodal status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
C-index
(AUC)
Increase in
C-index (AUC) over
clinicopathological
factors
a
Multivariable
model (adjuvant for
clinicopathological
factors
a
): HR (95% CI)
LN+
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n= 183
LN1–3 All ET, no
chemotherapy
10-year DRFI ROR-PT,
nCounter
8.51
(p= 0.004)
Over CTS: 4.39
(p = 0.04)
Over NPI: 2.71
(p = 0.09)
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT
ER+, HER2–
n= 413
l LN1–3, 89%
d
l LN > 3, 11%
c
All ET, no
chemotherapy
10-year DRFS ROR-PT,
nCounter
Over CLP: 17.45
(p = 0.0002)
0.743 NR
CLP 0.667
Ejlertsen 2015111 DBCG,
cohort
HR+, HER2
NR
n= 1466
LN1–3 All ET, no
chemotherapy
10-year DMFS ROR-PT,
nCounter
l LN1, p < 0.0001
l LN2, p = 0.0001
l LN3, p = 0.008
100% chemotherapy and ET
Martin 2016,108
2014109
GEICAM
9906,
R-RCT
ER+, HER2–
n= 536
l LN1–3, 64%
l LN > 3, 36%
All ET, no
chemotherapy
10-year DMFS ROR-PT,
RT-qPCR
(research)
0.644 Adding ROR-PT
to EPClin plus
clinicopathological:
p = 0.567
ET, endocrine therapy; IHC-T, IHC-4 plus tumour size; NR, not reported; R-RCT, reanalysis of RCT.
a Clinicopathological factors (ABSCG) = age, grade, nodal status, tumour size and Ki-67. Clinicopathological factors (GEICAM) = age, grade, nodal status, tumour size, treatment, ER, PR and Ki-67. CTS (TransATAC) and CLP (ABCSG 8) = age,
grade, nodal status, tumour size and treatment. Clinicopathological factors (DBCG): not reported which.
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
c Nodal status for all patients, NR for HER2– subgroup.
d Estimated from graph.
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here. Patients received endocrine monotherapy in two trials36,46,120 and all patients received endocrine
therapy and chemotherapy in the GEICAM trial.108,109 All excluded some original trial participants (or this
was unclear). A detailed narrative synthesis of study characteristics is provided in Report Supplementary
Material 7. This supplement also contains relevant data in tables.
Quality assessment
The EAG’s assessment of study quality is provided in Report Supplementary Material 7, Table 2. All
analyses excluded some original trial patients (or this was unclear), sometimes owing to insufficient tumour
samples, which may introduce bias owing to attrition of patients with smaller tumours. Blinding of test
assessors to outcomes was reported in two analyses.36,108,109 All used standardised outcomes. A discussion
of how these factors might affect results is given in Results: oncotype DX.
Results
A summary of key results from the review is provided in this section. A detailed narrative synthesis of all
study results is provided in Report Supplementary Material 7.
Distribution of patients by risk group
Data are presented in Table 19. The percentage of LN0 patients categorised as low risk in accordance
with EPClin was 73%46 and the percentage categorised as high risk was 27%.46 For LN+ patients,36,46,108,109
the percentages categorised as low risk were 13%108,109 and 24%46 and the percentages categorised as
high risk were 87%108,109 and 76%.46
Prognostic performance: unadjusted analyses
Data are presented in Table 19. EPClin was a statistically significantly prognostic for DRFS/DRFI for all
unadjusted analyses at 10 years (and most analyses at 5 years) in LN0 and LN+ patients46,108,109,120 and in one
analysis of patients at high clinical risk.120 The rate of 10-year DRFS/DRFI was 94% for EPClin low-risk LN0
patients46 and 95% for LN+ patients46,118–120 in one study in which patients had endocrine monotherapy46
and 100% in one study using endocrine therapy and chemotherapy.108,109 Use of chemotherapy in the
GEICAM study108,109 could influence patient outcomes in either direction: negatively owing to the potential
selection of higher-risk patients or positively owing to the effect of chemotherapy. The HR in LN0 patients
for the low- versus high-risk groups was 3.90 (95% CI 2.33 to 6.53; p-value not reported) in TransATAC.46
HRs in LN+ patients for the low- versus high-risk groups were 6.77 (95% CI 1.63 to 28.07; p-value not
reported) in TransATAC,46 and were not estimable for GEICAM because there were no events in the low-risk
group (p < 0.0001).108,109 Report Supplementary Material 7 provides data comparing EPClin with clinical
guidelines and a subgroup analysis of patients at high clinical risk.
Additional prognostic value: adjusted analyses
Data are presented in Table 20. In terms of additional prognostic value, TransATAC reported statistically
significant increases in likelihood ratio χ2 for 10-year DRFI for EPClin plus CTS/NPI over CTS/NPI only, in
both LN0 and LN+ patients [LN0 patients 15.22 (p < 0.0001) over CTS and 17.00 (p < 0.0001) over NPI;
LN+ patients 7.36 (p = 0.007) over CTS and 5.57 (p = 0.02) over NPI].46 Two further studies reported that
the EndoPredict score added statistically significant information over clinicopathological variables in LN+
and mixed LN0/LN+ patients [based on multivariable analyses and differences in C-index (AUC) for 10-year
DMFS/DRFI]; however, neither study reported the additional prognostic value of EPClin.108,109,118–120
Conclusions: EndoPredict and EndoPredict Clinical prognostic performance
Based on three reanalyses of RCTs (total n = 3135) in ER+, HER2–, endocrine-treated patients, EPClin was
statistically significantly prognostic for unadjusted analyses of 10-year DRFS/DRFI in LN0 and LN+ patients.
The percentage of patients categorised as EPClin low risk was 73% for LN0 patients and was 13% and
24% for LN+ patients. The 10-year DRFS/DRFI rates for low-risk patients were approximately 95% in LN0
and LN+ patients receiving endocrine therapy only. EPClin added statistically significant information over
CTS/NPI in LN0 and LN+ patients in TransATAC, and in two further studies the EndoPredict score added
statistically significant information over clinicopathological variables in mixed LN0/LN+ and LN+ patients
CLINICAL EVIDENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 19 Prognostic performance of EndoPredict and EPClin: DRFS/DRFIa
Reference (first author
and year) Cohort, design, country Population Nodal status ET/chemotherapy
Test or
comparator
Percentage of
patients per
group
Percentage DRFS/DRFI risk
DMFS/DRFS/DRFI:
a
HR (95% CI)
0–5 years 0–10 years
Low High Low High Low High
Reanalyses of RCTs: LN status mixed
100% ET monotherapy
Sestak 2017 (data request)46
(reduced data set)
b
TransATAC, R-RCT, UK ER+, HER2–
n = 774
l LN0, 76%
l LN1–3, 24%
All ET, no
chemotherapy
EPClin 61 39 NR NR NR NR 0–10 years: 4.65 (2.98 to 7.24)
Dubsky 2013,120 2013119 ABCSG-6 plus ABCSG 8,
R-RCT, Austria
ER+, HER2–
n = 1702
l LN0, 68%
l LN1–3, 27%
l LN > 3, 5%
All ET, no
chemotherapy
EndoPredict 49 51 NR NR NR NR l 0–5 years: 2.80 (1.81 to 4.34); p< 0.001
l 5–10 years: 3.28 (1.48 to 7.24); p= 0.002
EPClin 63 37 NR NR 95.3 NR l 0–5 years: 4.82 (3.12 to 7.44); p< 0.001
l 0–10 years: 5.11 (3.48 to 7.51); p< 0.001
l 5–10 years: 6.25 (2.72 to 14.36); p < 0.001
Reanalyses of RCTs: LN0
100% ET monotherapy
Sestak 2017 (data request)46
(full data set)
b
TransATAC, R-RCT, UK ER+, HER2–
n = 680
LN0 All ET, no
chemotherapy
EPClin 73 27 97.9 92.2 94.1 80.0 l 0–5 years: 3.91 (1.73 to 8.79)
l 0–10 years: 3.90 (2.33 to 6.53)
Reanalyses of RCTs: LN+
100% ET monotherapy
Sestak 2017 (data request)46
(full data set)
b
TransATAC, R-RCT, UK ER+, HER2–
n = 198
LN1–3 All ET, no
chemotherapy
EPClin 24 76 97.9 87.6 95.0 71.6 l 0–5 years: 6.00 (0.80 to 44.93)
l 0–10 years: 6.77 (1.63 to 28.07)
100% chemotherapy and ET
Martin 2016,108 2014109 GEICAM 9906, R-RCT,
Spain
ER+, HER2–
n = 555
l LN1–3, 64%
l LN > 3, 36%
All ET, no
chemotherapy
EndoPredict 25 75 NR NR 93 70 0–10 years: 4.8, (2.5 to 9.6); p < 0.0001
EPClin 13 87 NR NR 100 72 0–10 years: not estimable, p< 0.0001
Premenopausal, n= 300 NR l LN1–3, 64%
l LN > 3, 36%
EndoPredict 24 76 93 67 0–10 years: 6.7 (2.4 to 18.3); p < 0.0001
Postmenopausal, n = 255 NR EndoPredict 27 73 92 74 0–10 years: 3.3 (1.3 to 8.5); p = 0.0069
Premenopausal, n= 300 NR l LN1–3, 64%
l LN > 3, 36%
EPClin 12 88 100 70 0–10 years: HR NR, p = 0.0006
Postmenopausal, n = 255 NR EPClin 13 87 100 76 0–10 years: HR NR, p = 0.0023
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TABLE 19 Prognostic performance of EndoPredict and EPClin: DRFS/DRFIa (continued )
Reference (first author
and year) Cohort, design, country Population Nodal status ET/chemotherapy
Test or
comparator
Percentage of
patients per
group
Percentage DRFS/DRFI risk
DMFS/DRFS/DRFI:
a
HR (95% CI)
0–5 years 0–10 years
Low High Low High Low High
High/intermediate risk via clinical guidelines (LN0/LN+)
Dubsky 2013120 ABCSG-6 plus ABCSG 8,
R-RCT, Austria
NCCN,
n = 1603
LN+/LN0 (% NR) All ET, no
chemotherapy
EPClin 61 39 NR NR 95 77 0–10 years: 5.09 (3.42 to 7.58); p< 0.001
St Gallen,
n = 1358
EPClin 58 42 NR NR 95 75 0–10 years: 5.18 (3.38 to 7.93); p< 0.001
S3
c
, n=1454 EPClin 58 42 NR NR 95 76 0–10 years: 5.60 (3.64 to 8.61); p< 0.001
ET, endocrine therapy; NR, not reported; R-RCT, reanalysis of RCT.
a DMFS (GEICAM, ABSCG for ROR-PT); DRFI (TransATAC); DRFI (ABSCG for EPClin).
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
c German S3 guideline 2008.
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TABLE 20 Additional prognostic value for DRFI/DMFS: EndoPredict and EPClin
Reference (first
author and year)
Cohort, design,
country Population Nodal status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
C-index
(AUC)
Increase in
C-index (AUC) over
clinicopathological
factors
a
Multivariable model
(adjuvant for
clinicopathological
factors
a
): HR (95% CI)
Reanalyses of RCTs: LN status mixed
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n= 774
l LN0, 76%
l LN1–3, 24%
All ET, no
chemotherapy
10-year DRFI EPClin 69.31
(p < 0.0001)
l Over CTS: 24.39
(p< 0.0001)
l Over NPI: 22.17
(p< 0.0001)
Dubsky 2013,120
2013119
ABCSG 6 plus
ABCSG 8,
R-RCT, Austria
ER+, HER2–
n= 1702
l LN0, 68%
l LN1–3, 27%
l LN > 3, 5%
All ET, no
chemotherapy
0- to 5-year
DMFS
EndoPredict 1.20 (1.10 to 1.31);
p< 0.001
EPClin
5- to 10-year
DMFS
EndoPredict 1.28 (1.10 to 1.48);
p= 0.001
EPClin 0.786
EndoPredict vs. AOL 0.765 p < 0.001
EndoPredict vs.
clinicopathological
a
0.716 p < 0.001
AOL 0.674
Clinicopathological
factors
a
0.644
Reanalyses of RCTs: LN0
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n= 591
LN0 All ET, no
chemotherapy
5-year DRFI EPClin 16.62
(p < 0.0001)
l Over CTS: 5.11
(p= 0.02)
l Over NPI: 5.73
(p= 0.02)
10-year DRFI 40.60
(p < 0.0001)
l Over CTS: 15.22
(p< 0.0001)
l Over NPI: 17.00
(p< 0.0001)
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TABLE 20 Additional prognostic value for DRFI/DMFS: EndoPredict and EPClin (continued )
Reference (first
author and year)
Cohort, design,
country Population Nodal status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
C-index
(AUC)
Increase in
C-index (AUC) over
clinicopathological
factors
a
Multivariable model
(adjuvant for
clinicopathological
factors
a
): HR (95% CI)
Reanalyses of RCTs: LN+
100% ET monotherapy
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT, UK
ER+, HER2–
n= 183
LN1–3 All ET, no
chemotherapy
5-year DRFI EPClin 4.24
(p < 0.039
l Over CTS: 1.86
(p= 0.20)
l Over NPI: 1.43
(p= 0.20)
10-year DRFI 12.91
(p < 0.001)
l Over CTS: 7.36
(p= 0.007)
l Over NPI: 5.57
(p= 0.02)
100% chemotherapy and ET
Martin 2016,108
2014109
GEICAM 9906,
R-RCT, Spain
ER+, HER2–
n= 536
l LN1–3, 64%
l LN > 3, 36%
All ET, all
chemotherapy
10-year
DMFS
EPClin 0.693 NR
EndoPredict vs.
clinicopathological
a
0.672 p = 0.0018
EndoPredict 0.657 1.1 (1.0 to 1.2);
p= 0.003
Clinicopathological
factors
a
0.654
ET, endocrine therapy; NR, not reported; R-RCT, reanalysis of RCT.
a Clinicopathological factors (ABSCG) = age, grade, nodal status, tumour size, Ki-67; clinicopathological factors (GEICAM) = age, grade, nodal status, tumour size, treatment, ER, PR, Ki-67.
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
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(no data for EPClin). There was no evidence relating to chemotherapy benefit or clinical utility for
EndoPredict or EPClin.
Results: IHC4
Development and analytic validity: IHC4
A narrative synthesis and data tables relating to the development of IHC4 and IHC4+C are provided in
Report Supplementary Material 8. Although derivation data sets were excluded from the review for the
other tests, for IHC4 the derivation was conducted in the TransATAC data set and is included in our tables
to facilitate comparisons between tests. It should be noted, however, that estimates from TransATAC for
IHC4 are likely to be an overestimate of true prognostic performance owing to overfitting.
Analytic validity
A rapid review of the analytic validity of IHC4 can be found in Report Supplementary Material 8.
Prognostic performance: IHC4 and IHC4+C
Eleven separate validation cohorts24,25,58,73,74,77,122–129 have reported prognostic performance data for IHC4,
with a total of 13,434 patients.
Study designs, patients and treatments: IHC4 prognostic performance
Five cohorts [Tamoxifen vs Exemestane Adjuvant Multinational (TEAM), the WSG PlanB, Intergroup
Exemestane Study (IES), GEICAM 9906 and West German Study Group epirubicine and cyclophosphamide-
Doc (WSG-AGO-Doc)]24,73,74,77,122,123,126,127,129 were reanalyses of RCT data (three LN+/LN0 studies, n = 8496; no
LN0 studies; two LN+ studies, n = 1705) and six25,58,124–126,128 were reanalyses of routinely collected data when
patients were treated in accordance with usual practice without the use of IHC4 or IHC4+C (five LN+/LN0
studies, n = 3128; one LN0 study, n = 105; no LN+ studies). All studies recruited HR+ or ER+ patients
except the IES RCT127 and the study from Taiwan.124 TransATAC,46 WSG PlanB,73,74,77 GEICAM 9906,129
WSG-AGO-Doc,123 the Kaiser Permanente cohort,125 the Institut Curie128 cohort and the Chinese58 cohort
all recruited or reported a subgroup of HER2– patients. Only one validation cohort (Stephen et al.126) treated
100% of patients with endocrine monotherapy, and the remainder treated varying proportions of patients
with endocrine therapy and chemotherapy. Two observational studies were from East Asia;58,124 clinical
advice received by the EAG suggests that these two East Asian studies may be less generalisable to the
English context because (1) patients were treated in accordance with usual clinical practice and this may
differ between these countries and England enough to affect prognostic outcomes and (2) it is possible
that people of different ethnicities have different underlying risk profiles and disease natural histories.
A detailed narrative synthesis of patient characteristics and treatments is provided in Report Supplementary
Material 8. Overall, only the derivation cohort (TransATAC)46 reported an analysis of 100% ER+, HER2–,
LN0–3 patients who had not undergone chemotherapy but had received 5 years of endocrine therapy.
For this reason, most of the evidence base has low generalisability to the decision problem.
IHC4 methodology and cut-off points: IHC4 and IHC4+C prognostic performance
The methodology for conducting IHC4 is not standardised outside the Royal Marsden Hospital. Report
Supplementary Material 8 details the methods reported in the included studies, and a judgement provided
by personal communication with the IHC4 methodologists [Andrew Dodson, National External Quality
Assessment Service (UK), personal communication, September 2017] regarding whether or not the
methods used are compatible with their own method is provided in Report Supplementary Material 8 and
Table 21. Seven data sets were analysed using IHC4 methodologies that were the same as or very similar
to the IHC4 team’s own methodology (referred to from here on in as the ‘standard IHC4 methodology’)
[TransATAC,46 TEAM,24,122,126 the Nottingham cohort,25 the Edinburgh Breast Conservation Series (BCS)
cohort,126 the Institut Curie128 cohort, GEICAM 9906129 and WSG-AGO-Doc123], whereas the remaining five
data sets were analysed using methodologies that were unclear or dissimilar to the IHC4 team’s methods
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TABLE 21 Characteristics of prognostic studies: IHC4 and IHC4+C
Reference (first author
and year) Cohorts (country)
Study
design Details of test
a
Compatibility
b
and
algorithm Population Nodal status ET/chemotherapy
Subgroup, relevant to the decision problem, of derivation cohort: LN0/LN+
TransATAC, Sestak46
n = 1005c
TransATAC (UK) R-RCT FFPE. Biomarker expression was measured by IHC.
HER2 was confirmed by FISH if ≥ IHC2+. ER used
6F11 antibody (Vector Laboratories, Burlingame,
CA, USA), PgR used diluted 1 : 40, clone 16
(Vector Laboratories) and Ki-67 used the diluted
1 : 100, or SP6 antibody (Abcam, Cambridge, MA,
USA) diluted 1 : 100. ER positive if H > 1; PR scored
as % positive cells; HER2 by manufacturer’s
instructions; Ki-67 using Ariol image system
(Genetix, San Jose, CA, USA)
Similar methods and scoring algorithms were used
for the Nottingham cohort, except that the MiB1
antibody was used on whole sections for Ki-67,
and TMAs were used for ER, PgR and HER2
l Compatible
l IHC4, IHC4+C
l Cuzick et al. 201125
l 100% ER+
l 100% HER2–
l Postmenopausal
l LN0 78.8%
l LN1–3 21.2%
100% ET monotherapy
Validation cohorts: LN0/LN+
Bartlett 201624
(n = 2919)
Christiansen 2012122
(n = 4598)
TEAM (UK/Ireland,
the Netherlands,
Belgium, Germany,
Greece)
R-RCT FFPE samples
Ariol SL50 image platform
Staining as per Bartlett et al. 2011130
Scoring as per Faratian et al. 2007131
Scores normalised
l Compatible
l IHC4
l Cuzick et al. 201125
l 100% HR+
l % HER2– NR
l 100%
postmenopausal
l % female NR
LN0/+, % NR 100% ET, some
chemotherapy,% NR130
Cuzick 201125 n = 786 Nottingham (UK) R-RD As TransATAC46 l Compatible
l As TransATAC46
l 100% HR+
l 95% HER2–
l Premenopausal/
postmenopausal
l LN0 62%
l LN+ 38%
l (% LN > 3 NR)
52% ET, %
chemotherapy NR
Nitz 2017,77 Gluz
2016,73 Gluz 201674
n = 2642
55-month follow-up
WSG PlanB
(Germany)
R-RCT Tissue microarrays (1.4-mm diameter): ER [Rabbit
(SP1)], PR (mouse monoclonal PgR636) and Ki-67
(clone 30–9 rabbit monoclonal). ER and PR
positive if ≥ 1% stained. Ki-67 scored by one
expert, > 100 cells, semi-quantitatively and
quantitatively. FISH for HER2 (unclear if
confirmatory). Instead of H-score a modified score
was used as described in Prat et al. 2013129
l Incompatible
l IHC4
l Prat et al. 2013129
l Cuzick et al. 201125
l 100% HR+
l 100% HER2–
l Premenopausal/
postmenopausal
l 100% female
l High clinical riskd
l LN0–3
l LN0 58.8%
l LN1–3 41.2%
RS < 12 ET only; RS
≥ 12, chemotherapy
plus ETe
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Reference (first author
and year) Cohorts (country)
Study
design Details of test
a
Compatibility
b
and
algorithm Population Nodal status ET/chemotherapy
Rohan, 2014125 n = 295
(147 cases; 148 controls)f
Kaiser Permanente
Northwest (USA)
CC,
R-RD
FFPE samples
ER, PR and HER2 in accordance with
ASCO-CAP.132,133 HER2 defined as ≥ 3
l Unclear/unlikely
l IHC4 – UC if +C
l Cuzick et al. 201125
l 100% ER+
l 100% HER2–
l Menopausal
status NR
l 100% female
Any LN, % NR
(for ER+/HER2–
subgroup)
Some ET and
chemotherapy, % NR
(for ER+/HER2–
subgroup)
Stephen, 2014126
a) BCS n = 831
b) TEAM n = 2513
a) BCS
b) TEAM
(UK/Ireland, the
Netherlands,
Belgium, Germany,
Greece)
a)
Cohort
b)
R-RCT
FFPE
a) 0.6-mm2 TMA cores. Dual scoring by experts134
b) As Bartlett 201624
Scores normalised. FISH for HER2– (unclear if
confirmatory)
l Similar
l IHC4 (personal
communication)
l Cuzick et al. 201125
l 100% ER+
l % HER2– NR
l a) % menopausal
status NR
l b) 100%
postmenopausal
l % female NR
l LN0/LN+,% NR
l Subgroups:
LN0, LN+
100% ET monotherapy
Viale 2013127
n = 1256
IES135 (37 countries) R-RCT FFPE samples. Biomarker expression was
measured by IHC. HER2 was confirmed by FISH if
≥ IHC2+. Tumours were deemed positive for ER/PR
if IHC ≥ 1% or Allred ≥ 3 and for HER2 if IHC3+
or if FISH amplified. Ki-67 was high if > 11% LI
(median)
l Unclear
l NR
l % ER+ NR
l % HER2– NR
l 100%
postmenopausal
l 100% female
l LN NR
l (Source study
recruited any
LN status)135
100% ET, 19%
chemotherapy
Validation cohorts: LN0
Vincent-Salomon,
2013128 n = 105
Institut Curie (France) R-RD FFPE. For each antibody, internal and external
controls were included
l Compatible
l IHC3 – UC if +C
l Cuzick et al. 201125
l Used IHC3 algorithm as
patients HER2–
l 100% ER+
l 100% HER2–
l < 3 cm
l Luminal BC
LN0 100% 9.5% ET, 0%
chemotherapy
Validation cohorts: LN+
Prat, 2013129
n = 1246
GEICAM 9906136
(Spain)
R-RCT Sections air-dried overnight. General intensity
score instead of H-score for ER expression129
l Compatible
l IHC4 – UC if +C
l Cuzick et al. 201125
l 100% ER+
l 100% HER2–
45% postmenopausal
l 100% LN+
l % LN > 3NR
(37.5% LN > 3
for unselected
cohort,
n = 1246)
ET if HER2–, 100%
chemotherapy
Gluz 2016123
n = 459
WSG-AGO-Doc137
(Germany)
R-RCT Paraffin-embedded tumour blocks, no further
details
l Similar, lacks granularity
l IHC4 – UC if +C
l Prat et al. 2013129
l Cuzick et al. 201125
l 100% HR+
l 100% HER2–
l Menopause NR
l % female NR
LN1–3 ET in accordance with
clinical guidelines,138
100% chemotherapy
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TABLE 21 Characteristics of prognostic studies: IHC4 and IHC4+C (continued )
Reference (first author
and year) Cohorts (country)
Study
design Details of test
a
Compatibility
b
and
algorithm Population Nodal status ET/chemotherapy
Retrospective studies: uncertain generalisability to UK context
Gong 201658
n = 611
SYSMH; CCSYU;
3rd HNC (China)
R-RD FFPE
Scores normalised. Other details as per Cuzick
et al. 2011.130 FISH to confirm HER2 if ≥ IHC2+
l Unclear
l IHC4
l Cuzick et al. 201125
100% HR+
100% HER2–
61% postmenopausal
% female NR
non-metastatic
l LN0 46.6%
l LN+ 53.4%
(% LN > 3 NR)
100% ET, 76.8%
chemotherapy
Lin 2015124 n= 605 National Taiwan
University Hospital
(Taiwan)
R-RD FFPE samples.
Different IHC methodologies used, used
percentiles to account for differences to Cuzick
et al. 2011.25 FISH to confirm HER2 if ≥ IHC2+
l Unclear/unlikely
l IHC4
l Cuzick et al. 201125
HR+ NR
76.2% HER2–
Menopausal status NR
Female NR
Any LN, % NR ET NR, 74.6%
chemotherapy
3rd HNC, Third Hospital of Nanchang City; CC, case–control study; ET, endocrine therapy; FFPE, formalin fixed, paraffin embedded; FISH, fluorescence in situ hybridisation; GEICAM, Grupo Espanol de Investigacion en Cancer de
Mama; NR, not reported; R-RCT, retrospective analysis of RCT; R-RD, retrospective analysis of routine data; RS, recurrence score; SYSMH, Sun Yat-sen Memorial Hospital; TEAM, Tamoxifen versus Exemestane Adjuvant Multicentre
trial.
a Full details provided in Report Supplementary Material 8.
b Compatibility of test methodology to developer’s methodology – further details in Report Supplementary Material 8.
c Data relating to the TransATAC study are also available in multiple publications, namely Sestak et al. 2016,39 Sestak et al. 2013,41 Sgroi et al. 201343 and Dowsett et al. 2013,38 all reporting slightly different analyses. The total
analysed cohort was n = 1125 patients. We have only extracted data relating to the cohorts of interest to the assessment provided by the TransATAC team (ER+, HER2–, LN0–3, n = 1048), and a further reduced data set of
patients who had undergone four of the tests relevant to the decision problem (oncotype DX, IHC4, Prosigna and EPClin), n = 774 in total, LN0 = 591, LN+ = 183.
d HER2–; pT1-T4c; LN+ [or LN0 with a risk factor (CpT2, grade 2/3, high uPA/PAI-1, < 35 years, or HR-negative)].77
e Patients were treated in accordance with oncotype DX score, with those with a RS of < 12 receiving ET only, and those with a RS of ≥ 12 receiving chemotherapy plus ET.
f Controls could be matched to more than one case.
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(WSG PlanB,73,74,77 the Kaiser Permanente cohort,125 IES,127 the Chinese cohort58 and the Taiwanese
cohort124). Results have not been excluded by IHC4 methodology, as methodologies are not currently
standardised and, for this reason, all data are of some relevance.
Data definitely stated to relate to IHC4+C were only available for the Nottingham cohort25 and TransATAC.46
For three studies, it was unclear whether the IHC4 score or the IHC4+C score was used. Other studies used
IHC4 (TEAM analyses by Barlett et al.24 and Stephen et al.,126 the Edinburgh cohort,126 WSG PlanB,73,74,77
GEICAM 9906,129 the Kaiser Permanente cohort,125 the China cohort58 and the Taiwan cohort).124 See Report
Supplementary Material 8 and Table 21 for a description of which cut-off points were used that included using
tertiles and/or quartiles, using < 10%, 10–20% and > 20% ROR or using the score as a continuous variable.
Quality assessment: IHC4 and IHC4+C prognostic performance
No study scored well on all items (see Report Supplementary Material 8, Table 4). A high number of
studies included patients who had received chemotherapy treatment and a high number were not able to
include all relevant patients owing to missing samples or insufficient tissue. Very few studies reported that
they blinded test assessors.
Results: IHC4 prognostic performance – unadjusted analyses
See Table 22 and Report Supplementary Material 8, Tables 5–7. Across the studies reporting prognostic
performance data from unadjusted analyses, none reported survival or recurrence outcomes per risk group.
In the validation cohorts, HR analyses showed statistically significant performance when high-risk groups
(defined by quartiles or tertiles) were compared with low-risk groups (when reported), whether in LN0/LN+
(n = 4),24,73,74,77,124,127 LN0-only (n = 3)58,124,125 or LN+-only (n = 1)123 patients, and regardless of patient spectrums
and treatments received. However, analyses using continuous scores were not always statistically significant or
did not report this. The use of continuous scores, quartiles and tertiles does not allow conclusions to be drawn
about which cut-off points should be used in clinical practice and how these would perform.
Additional prognostic value: IHC4
The additional prognostic value of IHC4 was analysed in six data sets24,73,74,77,123–126,129 in total. Data are presented
in Table 23. Data from the study by Stephen et al.126 in the separate cohorts (BCS and TEAM126) indicated that
IHC4 provided more prognostic information than clinicopathological variables in the LN0/LN+ mixed group,
based on D-statistics but not when considering HRs, and was more informative for years 0–5 than for years
5–10. The same study reported HRs for only LN0 and LN+ subgroups adjusted for clinicopathological factors,
and these were not statistically significant. WSG PlanB73,74,77 reported additional value over clinicopathological
factors in LN0/LN+ patients; in the Kaiser Permanente cohort,125 IHC4 did not add additional prognostic
value. Three further studies123,124,129 reported on LN+ subgroups, two of which124,129 reported statistically
significant additional prognostic value of IHC4 over clinicopathological factors.
Broadly speaking, results did not appear to be influenced by the compatibility of the IHC4 methodology
with the standard methodology, with both statistically significant and non-significant results being reported
in both compatible and non-compatible studies.
Results: IHC4+C prognostic performance – unadjusted analyses
Data relating to the prognostic performance of IHC4+C are presented in Table 24. Most information relating
to IHC4+C comes from the TransATAC trial, which was the derivation cohort, in which unadjusted HRs
between risk groups (using predefined cut-off points) for DRFI were statistically significant in LN0–3, LN0
and LN1–3 analyses, and similar results were seen for OS. Additional data from the Nottingham cohort25
and IES127 (although the description is ambiguous) are limited in nature, but support the observations in the
TransATAC derivation trial. The TransATAC results suggest that IHC4+C is prognostic for DRFI, with HRs for
high-risk versus low-risk groups (for different subgroups and time points) ranging from 4.73 (95% CI 2.79 to
8.03) to 11.39 (95% CI 4.05 to 32.01).
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TABLE 22 Prognostic performance of IHC4: DRFS and DRFI
Reference (first
author and year) Cohorts Population Nodal status ET/chemotherapy
Percentage of patients per
risk group
DRFS/DRFI: HR (95% CI) unless stated otherwise
(0–5 years)Low Intermediate High
DRFS
LN0, some ET and chemotherapy
Rohan 2014125 n= 295
(147 cases; 148 controls)
Kaiser Permanente
Northwest
100% ER+, 100% HER2– Any LN, % NR (for
ER+/HER2– subgroup)
Some ET and chemotherapy,
% NR (for ER+/HER2– subgroup)
40.7
a
51.9
a
7.5
a
OR:
l Intermediate vs. low:
a
1.76 (1.10 to 2.84)
l High vs. low:
a
2.54 (0.97 to 6.62)
l p= 0.01
Continuous OR per 10 units:
l 1.09 (1.03 to 1.15)
l AUC: 0.62
Retrospective studies: uncertain generalisability to UK context LN0/LN+, some/all ET and chemotherapy
Gong 201658
n = 611
SYSMH; CCSYU; 3rd HNC 100% HR+, 100% HER2– l LN0 46.6%
l LN+ 53.4%
(% LN >3 NR)
100% ET, 76.8% chemotherapy 25.7 48.4 25.9 l High vs. low:
b
1.454 (1.133 to 1.866); p= 0.003
l High vs. intermediate:
b
1.370 (0.931 to 2.061);
p= 0.11
l Intermediate vs. low:
b
1.508 (0.941 to 2.418);
p= 0.088
l AUC: 0.692 (0.617 to 0.767)
Lin 2015
n = 605124
National Taiwan University
Hospital
HR+ NR, 76.2% HER2– Any LN, % NR ET NR, 74.6% chemotherapy Used quartiles l High vs. low:
b
2.33 (1.41 to 3.85)
l Intermediate vs. low:
b
1.88 (1.18 to 2.99)
DRFI
LN0/LN+, some ET and chemotherapy
Cuzick 201125 n= 786 Nottingham 100% HR+, 95% HER2–,
premenopausal/
postmenopausal
l LN0 62%
l LN+ 38%
l (% LN > 3 NR)
52% ET, % chemotherapy NR 0–25th, 26th–75th, 76th–100th Below 25th vs. above 75th quartile: 4.1 (2.5 to 6.8)
LN0, some/all ET and chemotherapy
Viale 2013127 IES % ER+ NR, % HER2– NR LN0 100% ET, 19% chemotherapy Used tertiles (not further
defined)
l 2nd tertile vs. 1st tertile: 1.4 (0.7 to 2.9)
l 3rd tertile vs. 1st tertile: 2.3 (1.1 to 4.7)
l p= 0.04
3rd HNC, Third Hospital of Nanchang City; ET, endocrine therapy; SYSMH, Sun Yat-sen Memorial Hospital.
a Defined via tertiles:
l low: ≤ –7.81
l intermediate: > –7.81 to 88.32
l high: > 88.32.
Note
a DRFS definition unclear regarding whether non-cancer deaths were events or censored.
b High defined as patient above the 75th percentile; low defined as patients below the 25th percentile; intermediate defined as patients from 25th to 75th percentiles.
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TABLE 23 Additional prognostic value, all outcomes: IHC4
Reference
(author and
year) Cohorts Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
Other analyses
LN0/LN+, 100% ET, 0% chemotherapy
Stephen 2014126
a) BCS n= 831
b) TEAM n = 2513
a) BCS 100% ER+, % HER2–
NR
LN0/+,
% NR
100% ET monotherapy DRFI IHC4 vs.
clinicopathological
factors
MV model (adjuvant for clinicopathological
factors
b
):
HR (95% CI):
b
l 0–5 years: 1.79 (0.87 to 3.71)
l 5–10 years: 1.20 (0.59 to 2.44)
Full follow-up:
b
% R2 (95% CI)
l IHC4: 26.3 (17.4 to 35.1); clinicopathological
factors: 25.7 (16.7 to 34.6)
D-statistic (95% CI):
c
l IHC4: 1.22 (0.94 to 1.50); clinicopathological
factors: 1.20 (0.92 to 1.48)
5 years:
b
l % R2 (95% CI): IHC4: 39.0 (27.2 to 50.7);
clinicopathological factors: 35.3 (23.3 to 47.4)
D-statistic (95% CI):
c
l IHC4: 1.63 (1.23 to 2.04); clinicopathological
factors: 1.51 (1.12 to 1.91)
Clinicopathological plus IHC4 vs.
clinicopathological:
l Wald test: 6.4 (0.01); change R2 (%): 3.7;
change D-statistic: 0.12
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TABLE 23 Additional prognostic value, all outcomes: IHC4 (continued )
Reference
(author and
year) Cohorts Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
Other analyses
b) TEAM LN0/+,
% NR
MV model (adjuvant for clinicopathological factors
a
),
HR (95% CI):
b
l 0–5 years: 1.34 (0.85 to 2.10)
l 5–10 years: 0.89 (0.44 to 1.78)
Full follow-up:
b
l % R2 (95% CI): IHC4: 32.8 (27.0 to 38.4);
clinicopathological factors: 29.5 (23.6 to 35.3)
D-statistic (95% CI):
c
l IHC4: 1.43 (1.24 to 1.62); clinicopathological
factors: 1.33 (1.14 to 1.51)
5 years:
b
l % R2 (95% CI): IHC4: 34.9 (28.3 to 41.2);
clinicopathological factors: 30.5 (23.7 to 37.0)
D-statistic (95% CI):
c
l IHC4: 1.50 (0.29 to 1.71); clinicopathological
factors: 1.36 (1.14 to 1.57)
Clinicopathological plus IHC4 vs.
clinicopathological:
l Wald test: 34.5 (< 0.001); change R2 (%): 4.4;
change D-statistic: 0.14
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Reference
(author and
year) Cohorts Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
Other analyses
LN0/LN+, 100% ET, some chemotherapy (or chemotherapy NR)
Bartlett 2016,24
Christiansen
2012122
n = 4598122
TEAM 100% HR+, % HER2–
NR
LN0/LN+,
% NR
100% ET, some
chemotherapy, % NR130
IDFS IHC4 vs.
clinicopathological
factors
170.024 38.5 (29%)24 8 years. MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
d
1.007 (1.005 to 1.009)122
Nitz 201773,74,77
n = 2642
WSG PlanB l 100% HR+
l 100% HER2–
l High clinical risk
l 100% female
l LN0–3
l LN0
58.8%
l LN1–3
41.2%
100% ET, RS < 12 no
chemotherapy; RS ≥ 12,
chemotherapy
IDFS IHC4 vs.
clinicopathological
factors
MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI): 1.59 (95 CI 1.15 to 2.2);
p= 0.005
e
LN0/LN+, some ET and chemotherapy
Rohan 2014125
n = 295
(147 cases;
148 controls)
Kaiser
Permanente
Northwest
100% ER+,
100% HER2–
Any LN,
% NR
(for ER
+/HER2–
subgroup)
Some ET and chemotherapy,
% NR (for ER+/HER2–
subgroup)
DRFS
f
IHC4 vs.
clinicopathological
factors
Follow-up year NR
OR (95% CI):
l Intermediate vs. low:
f
1.62 (0.94 to 2.81)
l High vs. low:
f
1.61 (0.48 to 5.47)
l p= 0.12
l Continuous per 10 units: 1.06 (1.00 to 1.13)
LN0, 100% ET, 0% chemotherapy
Stephen 2014126
a) BCS n= 657
b) TEAM n = 1208
a) BCS 100% ER+, % HER2–
NR
LN0 100% ET, 0% chemotherapy DRFI IHC4 vs.
clinicopathological
factors
MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l 0–5 years: 3.16 (1.03 to 9.64)
l 5–10 years: 2.61 (0.88 to 7.75)
b) TEAM LN0 MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l 0–5 years: 1.29 (0.58 to 2.90)
l 5–10 years: 0.73 (0.23 to 2.31)
LN+, 100% ET, 0% chemotherapy
Stephen 2014126
a) BCS n= 174
b) TEAM n = 1296
a) BCS 100% ER+, % HER2–
NR
LN+ 100% ET monotherapy DRFI IHC4 vs.
clinicopathological
factors
MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l 0–5 years: 1.02 (0.33 to 3.15)
l 5–10 years: 0.53 (0.17 to 1.68)
b) TEAM LN+ MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l 0–5 years: 1.39 (0.81 to 2.40)
l 5–10 years: 0.98 (0.40 to 2.36)
continued
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TABLE 23 Additional prognostic value, all outcomes: IHC4 (continued )
Reference
(author and
year) Cohorts Population
Nodal
status ET/chemotherapy Outcome
Test or
comparator
a
Likelihood
ratio χ2
Increase in likelihood
ratio χ2 over
clinicopathological
factors
a
Other analyses
LN+,% ET NR, 100% chemotherapy
Gluz 2016123
n =NRe
WSG-AGO-Doc137 100% HR+, 100%
HER2–
LN1–3 % ET NR, 100%
chemotherapy
IDFS IHC4 vs.
clinicopathological
factors
5 year MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l IHC4 (dichotomous) not significant in
multivariable analysis (HR NR)
g
LN+, 100% ET, 100% chemotherapy
Prat 2013129
n = 580
GEICAM 9906136 100% ER+, 100%
HER2– 45%
postmenopausal
100% LN+,
% LN > 3 NR
100% ET, 100%
chemotherapy
IDFS IHC4 score vs.
clinicopathological
Follow-up year NR
13.5; p< 0.05
(estimated from graph)
Retrospective studies: uncertain generalisability to UK context
LN0/LN+, variable ET and chemotherapy
Lin 2015124
n = 605
National Taiwan
University
Hospital
HR+ NR, 76.2% HER2– Any LN,
% NR
ET NR, 74.6% chemotherapy RFS MV model (adjuvant for clinicopathological
factors
a
). HR (95% CI):
l High/intermediate vs. low:
h
1.90 (1.32 to 2.73);
p< 0.001
ET, endocrine therapy; GGI, genomic grade index; IDFS, invasive disease free survival; MV, multivariate; NR, not reported; RS, recurrence score.
a Adjusted for:
l Bartlett 201624 – grade, tumour size, age, nodal status, type of endocrine treatment (exemestane vs. exemestane plus tamoxifen), chemotherapy, radiation therapy.
l Stephen 2014126 – age, grade, tumour size, nodal status, treatment.
l Gluz 2016123 – central grade, genomic grade, Ki-67, molecular subtype, IHC4.
l Nitz 201773,74,77 – nodal status, tumour stage, local grade, central grade.
l Rohan 2014125 – nodal status, tumour size, tumour grade, hormone therapy, age at diagnosis, duration of follow-up.
l Prat 2012129 – treatment arm, histological grade, tumour stage, nodal status, age.
b High risk is > 20% risk in orignial (TransATAC) cohort; low risk is < 10% risk in original (TransATAC) cohort.
c Difference in D-statistic of ≥ 0.1 indicates improved prognostic separation.
d C-index reported in Christiansen 2012122 poster presentation, but text was illegible.
e Personal communication with Professor Gluz, WSG, 27 August 2017.
f High/intermendiate/low defined via tertiles: low, ≤ –7.81; intermediate, > –7.81 to 88.32; high, > 88.32. DRFS definition unclear regarding whether non-cancer deaths were events or censored.
g Subgroup with GGI available.
h High defined as 75th percentile; low defined as 25th percentile; intermediate 25th to 75th percentile.
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TABLE 24 Prognostic performance of IHC4+C: DRFI
Reference (first
author and year) Cohorts Population Nodal status ET/chemotherapy
Percentage of patients
per group
Percentage DRFI risk
DRFI: HR (95% CI)0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High 0–5 years 0–10 years
LN0/LN+, 100% ET, 0% chemotherapy
TransATAC,
Sestak46
n = 1005
TransATAC 100% ER+, HER2– LN0–3 (n= 774
a
) 100% ET,
0% chemotherapy
60
a
24
a
16
a
l Intermediate
vs. low: 4.73
(2.79 to 8.03)
b
l High vs. low:
7.18 (4.20 to
12.28)
b
LN0/LN+, 52% ET, NR chemotherapy
Cuzick 201125
n = 786
Nottingham l 100% HR+
l 95% HER2–
l Premenopausal/
postmenopausal
l LN0 62%
l LN+ 38%
l (% LN > 3 NR)
52% ET, %
chemotherapy NR
Tertiles Visual inspection of predicted vs. observed DRFI plot (Kaplan–Meier curves plus 95% CIs; see figure 5 in
Cuzick et al.25) showed good agreement between predicted and observed scores, although agreement
appeared to decrease over time, with lines diverging after 6 years in the high-risk group (67–100%) and
8 years in the low- (0–33%) and intermediate-risk (33–66%) groups
LN0, 100% ET, 0% chemotherapy
TransATAC46
n = 1005
TransATAC 100% ER+, HER2– LN0 100% ET,
0% chemotherapy
70
a
21
a
9
a
98.9 93.1 88.1 95.6 81.8 77.3 l Intermediate
vs. low: 6.49
(2.40 to 17.54)
b
l High vs. low:
11.39 (4.05 to
32.01)
b
l Intermediate
vs. low: 4.37
(2.48 to 7.72)
b
l High vs. low:
6.42 (3.37 to
12.24)
b
LN0, 100% ET, some chemotherapy
Viale 2013127 IES135 % ER+ NR,
% HER2– NR
LN0 100% ET,
19% chemotherapy
States ‘addition of clinical variable to IHC
made the effect more profound’
LN+, 100% ET, 0% chemotherapy
TransATAC,
Sestak46
n = 219
TransATAC 100% ER+, HER2– LN1–3 100% ET,
0% chemotherapy
28
a
34
a
38
a
98.3 90.2 85.8 96.1 75.8 67.2 l Intermediate
vs. low: 5.92
(0.7 to –48.10)
b
l High vs. low:
8.82 (1.14 to
68.30)
b
l Intermediate
vs. low: 7.32
(1.68 to 31.85)
b
l High vs. low:
10.34 (2.44 to
43.89)
b
DRFI, distant recurrence free interval; ET, endocrine therapy; NR, not reported.
a These analyses used a cut-off point of < 10% risk, 10–20% and > 20% risk to define low-, intermediate- and high-risk groups, respectively.
b These data are from the reduced data set.
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Additional prognostic value: IHC4+C
Data relating to the additional prognostic value of IHC4+C are presented in Table 25. The IHC4+C
appeared to have additional prognostic value over NPI and CTS, but this was based on the derivation
cohort (TransATAC), with increases in likelihood ratio χ2 for DRFI, ranging from 17 to 26 across LN0/LN+,
LN0 and LN1–3 groups, compared with CTS and NPI (increases were statistically significant for LN0 patients
but not for LN+ patients). In the validation cohort (Nottingham25), the HR adjusted for clinicopathological
variables remained statistically significant (HR 3.9, 95% CI 2.3 to 6.5).
Conclusions: IHC4 and IHC4+C
The IHC4 score has been validated in five reanalyses of RCTs and six retrospective cohort studies, and
provides statistically significant prognostic information consistently in unadjusted analyses in LN+/LN0,
LN0 and LN+ groups. However, most studies used quartiles or tertiles to define risk groups, which does
not allow conclusions to be drawn about which cut-off points should be used in clinical practice and how
these would perform. Many studies used laboratory methods that differed from the derivation study
methodology. Only one validation study, by Stephen et al.,126 reports using the cut-off points from the
original analysis,25 which provides a second and third validation cohort (BCS and TEAM), but only for the
IHC4 component of the test, not including the clinical factors component (i.e. IHC4+C). IHC4 was shown
to have additional prognostic value over clinicopathological factors in some studies. Test methodologies
did not appear to have an impact on the statistical significance of test results, but this does not mean
that their performance is necessarily the same, and concerns remain about the conduct of the test in
laboratories other than that used to derive the score. IHC4+C had prognostic value in unadjusted analyses
in the derivation cohort and one validation cohort. Additional prognostic value has been reported in
the derivation cohort in which IHC4+C provided statistically significantly more information than NPI in
LN0 patients but not in LN+ patients, and in one validation cohort (Nottingham25) in which statistical
significance was maintained after adjustments for clinicopathological factors.
Results: all tests compared with each other
The results of all tests compared with each other can be found in Appendix 5, which provides an overview
of three types of studies that allow some form of comparison between tests:
l Studies reporting more than one test – these are studies in which two or more of the tests were
conducted and patient outcomes were reported, such that the prognostic performance of two or more
tests in the same cohort can be compared. Very few studies conduct formal comparisons between tests.
l Microarray studies – these are studies in which the commercial versions of the tests were not used, but
rather test algorithms were applied to genetic profiles obtained using microarray techniques. Mostly,
these are publicly available in in silico (electronic database) genetic profiles, complete with patient
outcome data. As with the studies that report more than one test, the comparisons provided are not
always formal. There were also a number of microarray studies that reported data for one test only,
which are detailed in Report Supplementary Material 10.
l Concordance in risk categorisation between tests – focusing on the OPTIMA Prelim study.
Results: decision impact studies
Decision impact: study and patient characteristics
Decision impact studies assess how decisions to use or not to use chemotherapy changed pre and post
availability of the test. Report Supplementary Material 9, Tables 1–5, show the study characteristics of the
included decision impact studies, including whether studies were prospective or retrospective and whether
the data were for chemotherapy recommendations or actual treatment decisions. The ER, HER2 and nodal
statuses are also shown.
CLINICAL EVIDENCE
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TABLE 25 Additional prognostic value, all outcomes: IHC4+C
Reference (first
author and year) Cohorts Population Nodal status ET/chemotherapy Outcome Test or comparator Likelihood ratio χ2
Increase in likelihood ratio χ2
over clinicopathological factors Other analyses
LN0/LN+, 100% ET, 0% chemotherapy
TransATAC46
n = 774 (reduced
data set)
TransATAC 100% ER+, HER2– LN0–3 100% ET,
0% chemotherapy
DRFI IHC4+C (continuous)
vs. CTS
10 years: 75.30,
p< 0.0001
10 years: 20.07 (p < 0.0001)
IHC4+C (continuous)
vs. NPI
10 years: 22.84 (p < 0.0001)
Cuzick 201125
n = 786
Nottingham l 100% HR+
l 95% HER2–
l Premenopausal/
postmenopausal
l LN0 62%
l LN+ 38%
l (% LN > 3 NR)
52% ET,
% chemotherapy
NR
DRFI IHC4+C vs. clinical
score
25.89, p< 0.0001 MV model (adjuvant for
clinicopathological factors).
HR (95% CI):
l 3.9 (2.3 to 6.5)
LN0, 100% ET, 0% chemotherapy
TransATAC46
n = 591 (reduced
data set)
TransATAC 100% ER+, HER2– LN0 100% ET,
0% chemotherapy
DRFI IHC4+C (continuous)
vs. CTS
l 5 years: 30.43,
p< 0.0001
l 10 years: 48.55,
p< 0.0001
5 years: 18.03,
p < 0.0001
10 years: 17.14,
p< 0.0001
IHC4+C (continuous)
vs. NPI
5 years: 17.89,
p < 0.0001
10 years: 21.92,
p< 0.0001
LN+, 100% ET, 0% chemotherapy
TransATAC46
n = 183 (reduced
data set)
TransATAC 100% ER+, HER2– LN1–3 100% ET,
0% chemotherapy
DRFI IHC4+C (continuous)
vs. CTS
l 5 years: 7.40,
p< 0.0065
l 10 years: 12.60,
p< 0.001
5 years: 2.64,
p = 0.10
10 years: 3.08,
p= 0.08
IHC4+C (continuous)
vs. NPI
5 years: 2.65,
p = 0.10
10 years: 2.45,
p= 0.10
ET, endocrine therapy; MV, multivariate; NR, not reported.
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1
Five UK studies139–145 and 12 other European studies146–158 assessed the decision impact of oncotype DX (see
Report Supplementary Material 9, Table 1); the results of one further study were provided as commercial
in confidence and could not be presented here.62 One UK study159 and three other European studies160–162
assessed the decision impact of EndoPredict (EPClin) (see Report Supplementary Material 9, Table 2).
One UK study163 and no other European studies assessed the decision impact of IHC4+C (see Report
Supplementary Material 9, Table 3). No UK studies and three other European studies164–166 assessed the
decision impact of Prosigna (see Report Supplementary Material 9, Table 4). No UK studies and eight European
studies81,167–173 assessed the decision impact of MammaPrint (see Report Supplementary Material 9, Table 5).62
Decision impact: results
In most studies, patients were allocated pre test to either chemotherapy or no chemotherapy. This could be a
recommendation (by a physician or multidisciplinary team) or an actual treatment decision (what the patient
actually received). They were then split into four post-test groups: those whose decision/recommendation
(1) remained chemotherapy, (2) remained no chemotherapy, (3) changed from no chemotherapy to
chemotherapy or (4) changed from chemotherapy to no chemotherapy. Tables 26–30 provide these data.
These data are also summarised in terms of the proportion of patients undergoing any treatment change
(either to or from chemotherapy), the total proportion allocated to chemotherapy both pre and post test and
the net change in chemotherapy use. Within each results table subheading, studies are broadly ordered as
LN0, then mixed nodal status and then LN+.
Oncotype DX
Among four UK studies,139–144 the percentage of patients with any change in treatment recommendation
or decision (either to or from chemotherapy) ranged from 29% to 49% (Table 26). Across 11 European
(non-UK) studies,146–157 the percentage of patients with any change in treatment recommendation or
decision ranged from 5% to 70%. There was little clear difference in results in accordance with LN status.
Among UK studies, the net reduction in chemotherapy recommendations (pre test to post test) was
14% to 23% across two studies,143,144 and the net reduction in chemotherapy decisions was 8% to 14%
across two studies.141,142,144 Two further UK studies139,140,145 reported changes from pre-test chemotherapy
recommendation to the post-test decision, which may overestimate the net change: one reported a
reduction of 23% in chemotherapy use139,140 and the other assessed only patients with an initial
recommendation for chemotherapy so it is misleading to calculate the absolute change.145 Across 11
European (non-UK) studies,146–149,151–158 the net reduction in chemotherapy recommendations or decisions
ranged from 0% to 64%. Again, there was little clear difference in results in accordance with LN status.
EndoPredict
In the one UK study of EndoPredict,159 37% of patients had a change in treatment decision (either to or
from chemotherapy) (see Table 27). Across three European (non-UK) studies,160–162 the percentage of
patients with any change in treatment recommendation ranged from 38% to 41%. In the UK study, the
net increase in chemotherapy use (pre test to post test) was 1% (because treatment changes took place in
both directions).159 However, across three European (non-UK) studies,160–162 there was a net reduction in
chemotherapy recommendations, ranging from 13% to 26%. There was insufficient data to assess results
by lymph node status.
IHC4+C
In the one UK study of IHC4+C (mix of LN+/LN0),163 27% of patients had a change in treatment
recommendation (either to or from chemotherapy) (see Table 28). Pre-test decisions included either ‘recommend
chemotherapy’ or ‘discuss chemotherapy’. The net reduction in patients who were definitively recommended
chemotherapy was 2%. However, if pre-test chemotherapy recommendations were assumed to include
both ‘recommend chemotherapy’ and ‘discuss chemotherapy’, the net reduction could be up to 26%.
There were no other European studies of IHC4.
CLINICAL EVIDENCE
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TABLE 26 Decision impact results: oncotype DX
Study
(first author
and year) Country Population Nodal status Pre test Post test
Number of
patients
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
UK studies: recommendation
a
Kiernan
2016143
UK ER+, HER2–
(assumed)
LN0
(assumed)
Recommendation Recommendation 50 NR NR NR NR NR 21 (42)
a
14 (28)
a
–7 (–14)
Kuchel
2016144
UK ER+, HER2– LN0–3 Recommendation Recommendation 135 54 12 26 43 55 (41) 69 (51) 38 (28) –31 (–23)
ER+, HER2–,
NPI
intermediate
LN0–3 Recommendation Recommendation 67 17 10 17 23 33 (49) 40 (60) 27 (40) –13 (–19)
UK studies: decision
Holt 2013,141
Albanell
2016142
UK ER+, HER2–
(subgroup)
LN0 Decision Decision 94 45 9 18 22 31 (33) 40 (43) 27 (29) –13 (–14)
Kuchel
2016144
UK ER+, HER2– LN0–3 Decision Decision 131 66 13 24 28 41 (31) 52 (40) 37 (28) –15 (–11)
ER+, HER2–,
NPI
intermediate
LN0–3 Decision Decision 65 31 7 15 12 19 (29) 27 (42) 22 (34) –5 (–8)
UK studies: recommendation to decision
Hassan
2015,139
Hassan
2015140
UK ER+, HER2–
(assumed)
LN0
(assumed)
Recommendation Decision 26 9 2 7 8 10 (38) 15 (58) 9 (35) –6 (–23)
Loncaster
2017145
UK ER+, HER2– LN0 Recommendation Decision
(largely on test)
136 NR NR NR NR NR 136 (100) 54 (40) N/A
LN+ 65 NR NR NR NR NR 65 (100) 20 (31) N/A
European studies: recommendation
Albanell
2012146
(trans-
GEICAM)
Spain ER+, HER2– LN0 Recommendation Recommendation 107 56 12 17 22 34 (32) 39 (36) 29 (27) –10 (–9)
Dieci 2016149 Italy ER+, HER2– LN0 Recommendation Recommendation 123 71 5 37 10 15 (12) 47 (38) 42 (34) –5 (–4)
Eiermann
2013151
Germany ER+, HER2– LN0 Recommendation Recommendation 244 99 28 72 45 73 (30) 117 (48) 100 (41) –17 (–7)
Hejduk
2016,153
Petrakova
2016154
Czech
Republic
ER+, HER2– LN0 Recommendation Recommendation 196 43 3 27 123 126 (64) 150 (77) 30 (15) –120 (–61)
continued
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TABLE 26 Decision impact results: oncotype DX (continued )
Study
(first author
and year) Country Population Nodal status Pre test Post test
Number of
patients
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
Gligorov
2015152
(SWITCH)
France ER+, HER2– LN0micro Recommendation Recommendation 95 41 5 19 30 35 (37) 49 (52) 24 (25) –25 (–26)
Novas
2016156
Spain NR LN1micro Recommendation Recommendation 35 21 1 5 8 9 (26) 13 (37) 6 (17) –7 (–20)
Bodmer
2015147
Switzerland ER+, HER2– LN0 or LN+ Recommendation Recommendation 60 19 3 13 25 28 (47) 38 (63) 16 (27) –22 (–37)
Dreyfus
2015150
France HR+, HER2–
Indicated for
chemotherapy
l LN0, 39%
l LN1–3,
51%
Recommendation Recommendation 39 0 0 13 26 26 (67) 39 (100) 13 (33) N/A
Mouysset
2016155
France ER+, HER2– l LN0, 61%
l LN+, 39%
Recommendation Recommendation 603 NR NR NR NR 425 (70) 529 (88) 145 (24) –384 (–64)
Pestalozzi
2015157
Switzerland ER+, HER2– pN0 or pN1a Recommendation Recommendation 221 124 8 52 37 45 (20) 89 (40) 60 (27) –29 (–13)
Wassermann
2015158
France HR+, HER2– l LN0, 86%
l LNmicro or
1–3, 14
Recommendation Recommendation 72 NR NR NR NR NR 41 (57) 14 (19) –27 (–38)
Eiermann
2013151
Germany ER+, HER2– LN1–3 Recommendation Recommendation 122 18 12 58 34 46 (38) 92 (75) 70 (57) –22 (–18)
European studies: recommendation to decision
Dieci 2016149 Italy ER+, HER2– LN0 Recommendation Decision 73 3 31 16 19 (15) 47 (38) 34 (28) –13 (–11)
Eiermann
2013151
Germany ER+, HER2– LN0 Recommendation Decision 244 NR NR NR NR NR 117 (48) 83 (34) –34 (–14)
De San
Vicente
2015148
Spain HR+, HER2–
Intermediate
oncotype DX
l LN0, 73%
l LN+, 27%
Recommendation Decision 37 27 1 8 1 2 (5) 9 (24) 9 (24) 0 (0)
Eiermann
2013151
Germany ER+, HER2– LN1–3 Recommendation Decision 122 NR NR NR NR NR 92 (75) 57 (47) –35 (–29)
ET, endocrine therapy; N/A, not applicable; NR, not reported.
a Pre-/post-test chemotherapy includes ‘chemotherapy recommended’ and ‘bias towards chemotherapy recommended’, and pre-/post-test no chemotherapy includes ‘ET alone advised’ and ‘bias towards ET alone’.
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TABLE 27 Decision impact results: EndoPredict (EPClin)
Study
(first author
and year) Country Population Nodal status Pre test Post test
Number
of
patients
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
UK studies: decision
Bloomfield
2017159
UK ER+, HER2– NR Decision Decision 149 60 28 34 27 55 (37) 61 (41) 62 (42) +1 (+1)
European studies: recommendation
Penault-Llorca
2016162
(ADENDOM)
France ER+, HER2– LN0micro Recommendation Recommendation 200 85 20 40 55 75 (38) 95 (48) 60 (30) –35 (–18)
Ettl 2015160 Germany ER+, HER2– l LN0, 73%
l LN+, 27%
Recommendation Recommendation 217 NR 16 NR 73 89 (41) NR NR –57 (–26)
Muller 2013161 Germany ER+, HER2– l LN0, 62%
l LN1–3,
35.5%
l LN4+,
2.5%
Recommendation Recommendation 130 31 16 50 33 49 (38) 83 (64) 66 (51) –17 (–13)
European studies: recommendation to decision
Penault-Llorca
2016162
(ADENDOM)
France ER+, HER2– LN0micro Recommendation Decision 200 90 15 38 57 72 (36) 95 (48) 53 (27) –42 (–21)
NR, not reported.
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TABLE 28 Decision impact results: IHC4+C
Study
(first author
and year) Country Population Nodal status Pre test Post test
Number of
patients, n
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
UK studies: recommendation
a
Yeo 2015163 UK ER+ HER2– LN0, 74%;
LN1–3, 26%
Recommendation Recommendation 124 49 1 41 33 34 (27) 45 (36) to
74 (60)
a
42 (34) –3 (–2) to
–32 (–26)
European studies
None
NR, not reported.
a Pre-test chemotherapy: lower estimate includes only those classed as ‘recommend chemotherapy’ and upper estimate includes both those classed as ‘recommend chemotherapy’ and ‘discuss chemotherapy’.
TABLE 29 Decision impact results: Prosigna
Study
(first author
and year) Country Population Nodal status Pre test Post test
Number of
patients
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
UK studies
None
European studies: recommendation
Martin 2015164
(GEICAM)
Spain ER+, HER2– LN0 Recommendation Recommendation 200 122 18 38 22 40 (20) 60 (30) 56 (28) –4 (–2)
Wuerstlein
2016166
Germany ER+, HER2– LN0 Recommendation Recommendation 198 131 22 40 5 27 (14) 45 (23) 62 (31) +17 (+9)
Van Asten
2016165
Belgium ER+, HER2– NR Recommendation Recommendation 51 15 11 15 10 21 (41) 25 (49) 26 (51) +1 (+2)
NR, not reported.
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TABLE 30 Decision impact results: MammaPrint
Study (first
author and
year) Country Population Nodal status Pre test Post test
Number
of
patients
No
chemotherapy,
unchanged
No
chemotherapy,
changed to
chemotherapy
Chemotherapy,
unchanged
Chemotherapy,
changed to no
chemotherapy
Treatment
change,
n (%)
Pre-test
chemotherapy,
n (%)
Post-test
chemotherapy,
n (%)
Net change in
chemotherapy,
n (%)
UK studies
None
European studies: recommendation
a
Drukker
2014168
(RASTER)
The
Netherlands,
Germany,
France, Italy,
Portugal
ER+/ ER–,
HER2+/
HER2–
LN0 Recommendation Recommendation 37 (414)
a
202 9 144 59 68 (16) 203 (49) 153 (37) –50 (–12)
Exner
2014169
Austria ER+, HER2– LN0 Recommendation Recommendation 75 40 4 21 10 14 (19) 31 (41) 25 (33) –6 (–8)
Bueno-
de-Mesquita
200781
(RASTER)
The
Netherlands
l 80%
ER+
l 84%
HER2–
LN0micro Recommendation Recommendation 427 NR NR NR NR NR 186 (44) 219 (51) +33 (+8)
b
Cusumano
2014167
The
Netherlands,
Belgium, Italy,
Spain
ER+, HER2– l LN0
l LN1–3
Recommendation Recommendation 151
(453)
a
149 68 161 75 143 (32) 236 (52) 229 (51) –7 (–2)
c
Kuijer
2016171
The
Netherlands
ER+ (HER2
NR)
NR Recommendation Recommendation 377
c
69 38 114 156 194 (51) 270 (72) 152 (40) –118 (–31)
Wuerstlein
2016173
(WSG
PRIMe)
Germany HR+, HER2– l LN0
(72%)
l LN1–3
(28%)
Recommendation Recommendation
(unclear)
430 201 65 107 57 122 (28) 164 (38) 172 (40) +8 (+2)
European studies: recommendation to decision
Bueno-
de-Mesquita
200781
(RASTER)
The
Netherlands
l 80%
ER+
l 84%
HER2–
LN0micro Recommendation Decision 427 206 35 167 19 54 (13) 186 (44) 202 (47) +16 (+4)
Rullan
2016172
Spain HR+, HER2– 94%
LN0micro
Recommendation Decision 129 NR NR NR NR NR 119 (92) 45 (35) –74 (–57)
European studies: decision to recommendation
Hartmann
2012170
Germany HR+, HER2– l LN0
l LN1–3
Decision Recommendation 60 47 6 2 5 11 (18) 7 (12) 8 (13) +1 (+2)
NR, not reported.
a Drukker 2014168: each of the 37 patients were analysed by up to 12 physicians, giving 414 data points.
b Cusumano 2014167: each patient was analysed three times at three different hospitals (in three countries) so 151 patients but 453 data points.
c Kuijer 2016171: data presented here exclude 283 patients with pre-test chemotherapy decision recorded as ‘unsure’.
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Prosigna
There were no UK studies of Prosigna. Across three European (non-UK) studies (either LN0 or lymph node
status not reported),164–166 the percentage with any change in treatment recommendation ranged from
14% to 41% (see Table 29). The net change in chemotherapy recommendations (pre test to post test)
was a reduction of 2% in one study164 and an increase of 2% to 9% in two studies.165,166
MammaPrint
There were no UK studies of MammaPrint. Across seven European (non-UK) studies,81,167–171,173 the
percentage with any change in treatment recommendation or decision ranged from 13% to 51%
(see Table 30). The net change in chemotherapy recommendations (pre test to post test) ranged from
a reduction of 31% to an increase of 8% across six studies.81,167–169,171,173 Again there were insufficient
data to assess results by lymph node status.
Summary and discussion of decision impact studies
The percentage of patients with any change in treatment recommendation or decision (either to or from
chemotherapy) among UK studies was 29% to 49% across four oncotype DX studies,62,139–142,144 37% in
one EndoPredict study159 and 27% in one IHC4+C study.163 Ranges across European (non-UK) studies were
5% to 70% for oncotype DX,146–157 38% to 41% for EndoPredict,160–162 14% to 41% for Prosigna164–166
and 13% to 51% for MammaPrint.81,167–171,173
The net changes in the percentage of patients with a chemotherapy recommendation or decision (pre test
to post test) among UK studies were a reduction of 8% to 23% across four oncotype DX studies,141–144
an increase of 1% in one EndoPredict study159 and a reduction of between 2% and 26% in one IHC4+C
study (unclear owing to category definitions).163 Net changes across European (non-UK) studies were a
reduction of 0% to 64% for oncotype DX,146–149,151–158 a reduction of 13% to 26% for EndoPredict,160–162
a reduction of 2% to an increase of 9% for Prosigna164–166 and a reduction of 31% to an increase of 8%
for MammaPrint.81,167–169,171,173
Anxiety and health-related quality of life
Six studies (reported in seven publications)159,164,166,174–177 reported outcomes relating to anxiety (including
worry and distress) and HRQoL (Table 31). Studies reporting outcomes such as decision conflict and patient
satisfaction did not meet the inclusion criteria for the review and were excluded.
Oncotype DX
Two studies174,176 reported data for oncotype DX. Both adopted a pre–post test design, and included LN+
or LN0 patients. Evans et al.174 used the Impact of Events Scale178 and showed no difference between
pre- and post-test values (p = 0.09), and there were no differences by recurrence score risk group (interaction
tests reported as ‘not statistically significant’). Lo et al.,176 on the other hand, reported a statistically
significant improvement in overall State–Trait Anxiety Inventory (STAI) score between pre- and post-test
values (p = 0.007), but no difference in trait anxiety (p = 0.27). Results for state anxiety were not reported.
Only Lo et al.176 reported HRQoL using Functional Assessment of Cancer Therapy – Breast cancer (FACT-B)
and Functional Assessment of Cancer Therapy – General (FACT-G) and reported no statistically significant
change (p = 0.55 and p = 0.49, respectively) (Table 32).
MammaPrint
One study reported data for MammaPrint177 (see Table 31). The study recruited exclusively from patients
who had been screened for eligibility in the MINDACT trial, but included both those eligible and those
ineligible for MINDACT (due to having more than three positive lymph nodes or having a test failure).
A modified version of Lynch’s distress scale179 and one of Lerman’s Cancer Worry Scale180 were used.
Patients were separated into seven subgroups in accordance with their clinical risk, MammaPrint risk,
whether or not they were assigned to chemotherapy and whether or not the MammaPrint test result
CLINICAL EVIDENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
TABLE 31 Study and patient characteristics: anxiety and HRQoL
Reference (first
author and year) Test Cohort Country Study design Details of test
Cut-off
points
Number of
patients Population
Nodal
status Outcomes
Oncotype DX
Evans 2016174 Oncotype DX Four centres
(Washington, Maryland
and Florida)
USA Pre–post test NR NR 193 l ER+
l Stage I and II
LN+/LN0
(LN > 3 NR)
IES178
Lo 2010176 Oncotype DX NR USA Pre–post test Genomic Health NR 93 l ESBC
l HER2+ 7%
LN+/LN0
(LN > 3 NR)
STAI; FACT-B, FACT-G
MammaPrint
Retèl 2013177 MammaPrint MINDACT-enrolled and
MINDACT-ineligible
patients
The
Netherlands
Non-
randomised
clinical trial
NR NR 347 ESBC LN+/LN0 Lynch’s distress scale
(adapted); Lerman’s
Cancer Worry Scale
(adapted); FACT-B
breast cancer subscale
EPClin
Bloomfield
2017159,175
EPClin (EndoPredict
plus NS plus TS)
Eight hospitals South-east
England
Pre–post test NR NR 149 l ER+
l HER2–
l ESBC with equivocal
indications for
chemotherapy by AOL
NR STAI
Prosigna
Martin 2015164 Prosigna 15 centres Spain Pre–post test Manufacturer’s
specifications
NR 200 l ER+
l HER2–
l ESBC
l Stage I and II
LN0 STAI; FACT-G
Wuerstlein 2016166 Prosigna 11 centres Germany Pre–post test Manufacturer’s
specifications
40–60 198 l ER+
l LN0
l Postmenopausal
LN0 STAI; FACT-G
ESBC, early-stage breast cancer; FACT-B, Functional Assessment of Cancer Therapy – Breast cancer; FACT-G, Functional Assessment of Cancer Therapy – General; IES, Impact of Event Scale; NR, not reported; NS, nodal status;
STAI, State–Trait Anxiety Inventory; TS, tumour size; WSG BCIST West German Study Group Breast Cancer Intrinsic Subtype Study.
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TABLE 32 Results: anxiety and HRQoL
Reference
(first author and year) Test Country Study design Population Nodal status Anxiety HRQoL
Oncotype DX
Evans 2016174
n = 193
Oncotype DX USA PPT ER+ LN+/LN0 (LN > 3 NR) l IES
l No change pre–post test, p = 0.09.
Not different by RS group (interaction
tests not significant)
NR
Lo 2010176
n = 93
Oncotype DX USA PPT l ESBC
l HER2+ 7%
LN+/LN0 (LN > 3 NR) STAI mean score (SD)
l Pre: 39.6 (14.5)
l Immediately post: 36 (12.6)
l 12 months post: 34.0 (11.5), p = 0.007
Trait anxiety, mean (SD)
l Premenopausal: 32.2 (14.5)
l Immediately post: 31.7 (13.3)
l 12 months post: 33.2 (11.0), p = 0.27
FACT-B mean score (SD)
l Pre: 112.2 (17.4)
l 12 months post: 114.3 (18.6), p = 0.55
FACT-G mean score (SD)
l Pre: 88.7 (12.3)
l 12 months post: 87.6 (14.9), p = 0.49
MammaPrint
Retèl 2013177
n = 347
MammaPrint The
Netherlands
Non-randomised
clinical trial
ESBC LN+/LN0 Lynch’s distress scale (adapted)
Adjusted regression analysis:a
l C high/G high: p < 0.001
l C low/G high (no chemotherapy): p = 0.043
l C low/G high (chemotherapy): p < 0.001
l C high/G low (no chemotherapy): p < 0.001
l C high/G low (chemotherapy): p = 0.175
l C low/G NA: p < 0.001
l C high/G NA: p < 0.001
Lerman’s Cancer Worry Scale (adapted)
Adjusted regression analysis:a
l No risk group statistically significant
(p-values ranged from 0.081 to 0.827)
FACT-B, breast cancer subscale
Adjusted regression analysis:a
l C high/G high: p = 0.013
l C low/G high (no chemotherapy): p = 0.585
l C low/G high (chemotherapy): p = 0.254
l C high/G low (no chemotherapy): p = 0.541
l C high/G low (chemotherapy): p = 0.296
l C low/G NA: p = 0.075
l C high/G NA: p < 0.001
EPClin
Bloomfield 2017159,175
n = 149
EPClin UK PPT ER+, HER2–,
equivocal by AOL
NR l STAI
l Unchanged decision: STAI stable
l Change from chemotherapy to no
chemotherapy: STAI lower (p < 0.01)
l Change from no chemotherapy to
chemotherapy: STAI increase (p< 0.001)
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(first author and year) Test Country Study design Population Nodal status Anxiety HRQoL
Prosigna
Martin 2015164
n = 200
Prosigna Spain PPT ER+, HER2– LN0 Trait anxiety, mean (SD) (n = 180)
l Pre, all: 39.1 (11.1)
l Post: 39.2 (10.9)
l Difference: –0.1 (8.3), p = 0.858
State anxiety, mean (SD) (n = 181)
l Pre: 42.6 (12.5)
l Post: 39.8 (13.3)
l Difference: 2.8 (12.4), p= 0.003;
low p < 0.001; intermediate p = 0.2;
high p = 0.13
FACT-G
l Pre: 79.2 (15.6)
l Post: 79.6 (14.6)
l Difference: –0.4 (13.9), p = 0.713
Wuerstlein 2016166
n = 198
Prosigna Germany PPT l ER+
l LN0
l Postmenopausal
LN0 State anxiety, mean difference (SD)
l Low ROR: –4.3 (8.9), p = 0.008
l Intermediate ROR: 0.3 (8), p = 0.639
l High ROR: 0.9 (11.6), p = 0.785
l p = 0.001b
Trait anxiety
l No statistically significant difference in any
group, p = 0.431b
FACT-G
No statistically significant differences in any
group, for any subscale, except emotional and
functional well-being
l Physical well-being: p = 0.969b
l Social/family well-being: p = 0.739b
l Emotional well-being: p = 0.030b
l Functional well-being: p = 0.005b
ESBC, early-stage breast cancer; NR, not reported; NS, nodal status; PPT, pre–post test design; RS, recurrence score; SD, standard deviation; TS, tumour size.
a Adjusted for sociodemographic (age, marital status, children and education), information/knowledge levels, risk perception variables (understanding, results in first visit, knowledge, risk perception and satisfaction) and risk
groups (as listed in table).
b p-value analysis of variance of mean differences.
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was missing (see Table 32). Regression analyses adjusted for sociodemographics, understanding of
genomic results, timing of test results, perceived risk and satisfaction with the process showed statistically
significantly (the analysis plan set the significance p-value to < 0.01 to avoid type I errors) higher distress
when the genomic test failed, when the patient was categorised as high risk by both clinical scoring
and MammaPrint and in patients with discordant results when the treatment matched the MammaPrint
score (i.e. clinical low/genomic high, prescribed chemotherapy; clinical high/genomic low, not prescribed
chemotherapy). Only patients with high clinical risk and no genomic test result or high clinical risk and
high genomic risk had a statistically significant decrease in FACT-B HRQoL.
EndoPredict
One study159 reported data for EndoPredict (see Table 31). The study was a pre–post test design and reported
a statistically significant decrease in STAI for those whose treatment decision changed from chemotherapy to
no chemotherapy on the basis of EndoPredict (p < 0.01), and an increase in STAI for those whose treatment
decision changed from no chemotherapy to chemotherapy (p < 0.001) (see Table 32).
Prosigna
Two studies164,166 reported data for Prosigna (see Table 31). Both adopted a pre–post test design and
included only LN0 patients. In both studies, there was no difference in trait anxiety scores (p = 0.858164
and p = 0.431166), and in both studies state anxiety changed significantly in low-risk (by Prosigna) patients
(p < 0.001164 and p = 0.008166) but not in the intermediate- or high-risk groups (see Table 32). Both studies
reported FACT-G; Martin et al.164 reported no change in overall scores, whereas Wuerstlein et al.166
reported a statistically significant analysis of variance p-value for emotional and physical well-being
(p = 0.030, p = 0.005, respectively).
Discussion
There were no data relating to the impact of IHC4 on anxiety or HRQoL. Other available data are limited
in terms of study designs (pre–post test) and patient spectrum. The lack of a comparator makes it difficult
to tell whether or not similar changes would have occurred were patients to have received a definitive
decision based on their clinical risk factors alone. Across tests, and when reported, state anxiety decreased
post test and total FACT-G generally stayed the same. The results for one study suggest that patients had
higher distress when the genomic test failed, when the patient was deemed to be at high risk by both
clinical scoring and genomic test and in patients with discordant results when the treatment matched the
genomic score, although it was unclear if this was due to distress associated with change (in treatment
decision) or a lack of trust in the genomic score.
Conclusions
Genomic testing may reduce state anxiety in some patients in some contexts, but, generally, there was
little impact on HRQoL.
Time-to-test results
Two articles reported time to test results: Losk et al.181 and Müller et al.161 Losk et al.181 reported factors
associated with delays in chemotherapy initiation (defined as ≥ 42 days from surgery to chemotherapy) in
breast cancer patients at a US cancer centre in 2011–13. Of 263 HR+, HER2– women receiving adjuvant
chemotherapy, 82 had an oncotype DX test ordered. Of those for whom an oncotype DX test was
ordered, 31% had a delay of ≥ 42 days to chemotherapy initiation, compared with 20% of patients
for whom oncotype DX was not ordered. Müller et al.161 reports the time to test result for EndoPredict.
In this study, the median handling time was 3 working days (range 0–11 days), and 59% of tests were
conducted in ≤ 3 days.
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Chapter 3 Cost-effectiveness
This chapter presents the methods and results of a de novo model-based health economic evaluation ofeach of the tumour profiling tests compared with current practice. A systematic review of economic
analyses of tumour profiling tests for early-stage breast cancer, undertaken to inform the model structure
published since NICE DG10,20 is presented in Appendix 6. A critique of economic analyses made available
to the EAG by the manufacturers of oncotype DX62 and MammaPrint94 and by the chief investigator of the
EndoPredict decision impact study182 is presented in Appendix 7.
Independent economic evaluation
Scope of the External Assessment Group economic analysis
The EAG developed a de novo model to assess the cost-effectiveness of oncotype DX, Prosigna, IHC4+C,
EPClin and MammaPrint versus current practice only. The scope of the EAG model is summarised in Table 33.
The model assesses the health outcomes and costs associated with each strategy over a lifetime horizon from the
perspective of the UK NHS and PSS. All costs and health outcomes are discounted at a rate of 3.5% per annum.
TABLE 33 Scope of the EAG economic analysis
Element of economic
analysis Description
Population Women with ER+, HER2– and early-stage breast cancer (LN0–3)
For oncotype DX, Prosigna, IHC4+C and EPClin, analyses are presented for three discrete
patient subgroups:
1. LN0 NPI ≤ 3.4 (clinical low risk)
2. LN0 NPI > 3.4 (clinical intermediate risk)
3. LN1–3 (clinical high risk)
For the evaluation of MammaPrint, the modelled population reflects the ITT population of the
MINDACT trial.98 Additional analyses are also presented for the mAOL clinical high-risk
subgroup and the mAOL clinical low-risk subgroups separately
Interventions 1. Oncotype DXa (cut-off points: low, < 18; intermediate, 18–30; high, ≥ 31)
2. Prosigna (cut-off points for LN0: low, 0–40; intermediate, 41–60; high, 61–100)
(cut-off points for LN+: low, 0–15; intermediate, 16–40; high, 41–100)
3. IHC4+C (cut-off points: low, < 10%; intermediate, 10–20%; high, > 20%)
4. EPClin (cut-off point: 3.3)
5. MammaPrint (cut-off point as per MINDACT trial98)
Comparator The comparator for all analyses is current practice (including a mix of risk prediction tools and
diagnostic guidelines)
For MammaPrint, current practice is based on mAOL, as per the design of the MINDACT trial98
Because of evidence limitations,b the competing tests were not compared incrementally
against one another
Primary health economic
outcome
Incremental cost per QALY gained
Perspective NHS and PSS
Time horizon Lifetime
Discount rate 3.5% per annum
Price year 2015/16
a RSPC (oncotype DX including clinicopathological factors) is considered within the sensitivity analyses.
b MammaPrint data derived from a different source than the other tests; TransATAC analysis is based on non-restricted data
set with different numbers of samples available for each test.
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Unit costs are valued at 2015/16 prices. The principal sources of evidence used to inform the analyses of
oncotype DX, Prosigna, IHC4+C and EPClin are the TransATAC study46 and the NHS England Access
Scheme Database.183 As the TransATAC study does not include the MammaPrint test, the MINDACT study98
was instead used as the basis for estimating classification probabilities and conditional DMFS probabilities
for MammaPrint. Additional studies identified within the clinical evidence review (see Chapter 2), which
provide alternative relevant data on test risk classification probabilities, 10-year DMFS probabilities
conditional on risk classification and post-test chemotherapy probabilities (decision impact) are explored
within the sensitivity analyses.
Population
The population reflected in the model relates to women with ER+, HER2– early-stage breast cancer with
LN0–3. For oncotype DX, IHC4+C, Prosigna and EPClin, the economic analysis is presented for three
discrete subgroups: (1) women with node-negative disease and a NPI of ≤ 3.4 (clinical low risk), (2) women
with node-negative disease and a NPI of > 3.4 (clinical intermediate risk) and (3) node positive (one to
three nodes). The modelled population for these four tests reflects that of the TransATAC study,46 as this is
used as the source of data on risk classification for each test and the 10-year DMFS probability conditional
on each risk classification. Within the LN0 population, a NPI cut-off point of 3.4 was chosen as a means of
distinguishing between clinical low risk and clinical intermediate risk for oncotype DX, IHC4+C, Prosigna
and EPClin, as data by NPI score were available from the TransATAC trial46 and the National Cancer
Registration and Analysis Service (NCRAS) cancer registration data set.184 Predict scores were not available
in either data set, so this tool could not be used to define clinical risk.
MammaPrint was not included in the TransATAC study, hence an alternative source was required. The
economic analysis of MammaPrint was instead largely based on data reported within the original paper
and supplementary material of the MINDACT trial publication.98 As the randomisation schedule within
the MINDACT trial was conducted using a modified version of AOL (mAOL) and sufficient data were not
presented separately for patients with 1–3 lymph nodes, the population of the primary analysis largely
reflects the MINDACT ITT population.98 Additional analyses are also presented for the mAOL high-risk
subgroup and the mAOL low-risk subgroups.
Interventions
The EAG’s economic analysis includes all five tests included in the final NICE scope21 (see Table 2). The
tests are modelled in line with how their manufacturers state that they will be used in clinical practice:
IHC4 and EndoPredict are assumed to be applied together with clinicopathological factors (IHC4+C and
EPClin, respectively). RSPC (oncotype DX in conjunction with clinicopathological factors) is considered
separately within the sensitivity analyses but is not included in the EAG’s base case. The EAG’s economic
analysis also assumes that all pathology analysis is undertaken centrally; local pathology analysis is not
considered within the EAG’s base case.
Comparator
The most commonly used tools for predicting the ROR after surgery to guide the use of adjuvant chemotherapy
for breast cancer in England are Predict and NPI. At the time of writing, AOL is being updated and has been
temporarily disabled. As noted previously, a modified version of AOL was used to inform the randomisation
schedule for the discordant clinical and genomic risk groups within the MINDACT trial.98 For this reason,
the comparator for the analysis of MammaPrint is current practice using mAOL.
Owing to the use of a different evidence source for MammaPrint98 compared with the other four tumour
profiling tests, and the use of the unrestricted TransATAC trial data set,46 each test is compared only
against current practice; tests were not assessed incrementally against each other.
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Model structure
The general structure of the EAG model is based on the model previously developed by Ward et al.1
to inform NICE DG10.20 This is also broadly consistent with the majority of studies identified within the
review of published economic evaluations (see Appendix 6). The EAG model takes the form of a hybrid
decision-tree/Markov model (Figures 5 and 6). The decision tree component of the model classifies patients
in the current practice (no test) group and the tumour profiling test group into high-, intermediate- and
low-risk categories based on the results of the test. For EPClin and MammaPrint, the intermediate-risk
category is not relevant as these tests provide results in terms of high and low risk only. The treatment
group (test or no test) and the risk level predicted by the test determines the probability that the patient
will subsequently receive adjuvant chemotherapy. Within both the test group and the current practice group,
the decision tree determines the probability that a patient will be assigned to one of six groups: (1) low risk,
chemotherapy; (2) low risk, no chemotherapy; (3) intermediate risk, chemotherapy; (4) intermediate risk,
no chemotherapy; (5) high risk, chemotherapy; and (6) high risk, no chemotherapy (for the analyses of EPClin
and MammaPrint, four branches are used owing to the absence of an intermediate-risk category). Each of
the branches is then linked to a Markov model that predicts lifetime QALYs and costs in accordance with
the patient’s risk of distant recurrence and whether or not they receive chemotherapy.
Figure 6 illustrates the Markov nodes of the model. Each Markov node is evaluated over 84 6-month cycles
(42 years): patients are assumed to enter the model aged 58 years and the evaluation is continued until
the cohort has reached the age of 100 years. Each Markov node includes four health states: (1) recurrence-
free, (2) distant recurrence, (3) long-term AEs [acute myeloid leukaemia (AML)] and (4) death. Each Markov
node differs with respect to the patient’s risk of distant metastases (determined by their risk classification
and whether or not they receive adjuvant chemotherapy). For all Markov nodes, patients enter the model
in the recurrence-free health state. During any 6-month cycle, patients who are recurrence-free can remain
in their current health state, transit to the long-term AEs state, develop distant metastases or die. Patients in
the distant metastases state can remain in their current health state, transit to the long-term AEs (AML)
Markov 1
Chemotherapy
No chemotherapy
Chemotherapy
No chemotherapy
Chemotherapy
High risk
Current practice
Test
Clone of test arm
Intermediate risk
Low risk
No chemotherapy
Markov 2
Markov 3
Markov 4
Markov 5
Markov 6
FIGURE 5 The EAG model: decision tree component. For EPClin and MammaPrint, four branches are used owing to
the absence of an intermediate-risk category for these tests.
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state or die. Patients in the long-term AEs (AML) state are assumed to remain in this state until death
(if free from breast cancer recurrence, they cannot subsequently develop distant metastases owing to their
breast cancer). Patients may die because of breast cancer, AML or other causes. A HRQoL decrement is
applied during the first model cycle for patients receiving adjuvant chemotherapy to account for health
losses associated with short-term chemotherapy-related AEs. The benefit of adjuvant chemotherapy is
modelled using a RR of distant recurrence within each risk classification group. The impact of each test
is therefore captured in the model only by changing the probability that patients with each test risk
classification receive adjuvant chemotherapy. In the evaluation of oncotype DX, a sensitivity analysis is
included in which the test is assumed to provide a predictive benefit of chemotherapy, hence different RRs
of developing distant metastases (for chemotherapy vs. no chemotherapy) are applied across the low-,
intermediate- and high-risk groups.
Different health utilities are applied to each of the modelled health states. The model assumes that a proportion
of patients who experience distant recurrence will also have previously developed local recurrence: this
is assumed to be associated with additional costs and a once-only QALY loss. The model includes costs
associated with the tumour profiling test (in the intervention group only), adjuvant chemotherapy acquisition
and administration and associated toxicity, endocrine therapy (all patients), routine follow-up visits and tests,
additional therapies [zoledronic acid and granulocyte colony-stimulating factor (G-CSF)], treatments for local
recurrence and treatments for distant metastases. The costs and health outcomes for each Markov node
differ owing to the different risks of recurrence associated with each tumour profiling test and whether or
not chemotherapy is given (together with its associated benefits, AEs and costs).
Key External Assessment Group model assumptions
The EAG model makes the following structural assumptions:
l Within the base-case analysis, the proportion of patients who receive chemotherapy under current
practice (no test) is assumed to be the same for each test risk classification (low, intermediate and high risk).
However, this proportion is assumed to differ between subgroups defined in accordance with clinical
risk (LN0 NPI ≤ 3.4, LN0 NPI > 3.4, LN1–3, MINDACT ITT, MINDACT mAOL low risk and MINDACT
mAOL high risk).
Death
Distant
metastases
Local
recurrence
Long-term AEs
(AML)
Recurrence free
FIGURE 6 The EAG model: state-transition model component. AML, acute myeloid leukaemia.
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l The model assumes that clinicians interpret each of the three-level tests in the same way (e.g. an oncotype
DX high-risk score would lead to the same chemotherapy decision as a Prosigna high-risk score). The
model also assumes that clinicians interpret each of the two-level tests in the same way (a MammaPrint
high-risk score would lead to the same chemotherapy decision as an EPClin high-risk score).
l Within the base-case analysis, the relative benefit of adjuvant chemotherapy is assumed to be the same
across all risk score categories for all tests (the same RR is applied to all patients, irrespective of test risk
score). The impact of assuming a predictive benefit for oncotype DX, which is applied by assuming
different RRs between test risk score categories, is explored within the sensitivity analyses.
l The impact of the tests is modelled by changing which patients receive adjuvant chemotherapy.
l A proportion of patients who develop distant metastases are assumed to have previously developed
local recurrence. Local recurrence is not modelled as a separate event or health state. QALY losses and
costs associated with local recurrence are applied once only (on entry into the distant metastases state).
l A disutility associated with short-term AEs related to adjuvant chemotherapy is applied once during the
first model cycle only (while the patient is receiving treatment).
l Patients can enter the long-term AEs (AML) health state from either the recurrence-free state or the
distant metastases state. The prognosis of patients with AML and the costs and QALYs accrued within the
AML state are assumed to be independent of whether or not the patient has previously developed distant
metastases due to their breast cancer. Once a patient develops AML, the model assumes that this alone
determines their survival prognosis. Although congestive heart failure (CHF) is also a potentially relevant
long-term AE associated with chemotherapy, this was excluded from the model owing to a lack of
evidence on the joint survival impact of CHF and metastatic breast cancer. The importance of AEs not
included in the model on the cost-effectiveness of the tests is explored within sensitivity analyses.
l Costs associated with endocrine therapy, bisphosphonates (zoledronic acid), follow-up appointments
and mammograms are assumed to differ in accordance with time since model entry.
l Across all three analysis subgroups, patients are assumed to enter the model aged 58 years, based on the
mean age of patients in the NHS England Access Scheme Database183 (rounded down to an integer value).
l The model includes both premenopausal and postmenopausal women. However, the TransATAC study
relates only to postmenopausal women.
Evidence sources used to inform the model parameters
Table 34 summarises the evidence sources used to inform the parameters of the EAG model. The
individual parameter values are discussed in further detail in the subsequent sections; data tables relating
to these model inputs can be found in Appendix 8.
Patient age
The mean age was assumed to be 58 years, based on the NHS England Access Scheme Database183
(rounded down to an integer value).
Risk classification probabilities using each test: oncotype DX, Prosigna, IHC4+C and EPClin
Data relating to risk classification probabilities for each test were obtained from a bespoke analysis of the
TransATAC trial provided by the trial investigators46 (see Appendix 8, Table 76). As discussed in Chapter 2,
the ATAC trial evaluated the efficacy and safety of anastrozole versus tamoxifen. The TransATAC trial tested
tumour blocks from postmenopausal patients who had been included in the monotherapy arms of the
Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial198 in order to determine whether or not the tests
could provide independent information on the risk of distant recurrence. Separate data analyses were
provided by the trial investigators for ER+, HER2– patients for the three modelled subgroups [LN0 NPI ≤ 3.4,
LN0 NPI > 3.4 and LN1–3]. In order to maximise the information available for each test, data were not
restricted to only those with information on all four tests. The EAG considers that the use of this study has
particular value as (1) it includes the use of four of the five tests included in the final NICE scope (oncotype
DX, Prosigna, IHC4+C and EPClin) within the same patient population, (2) it provides a source of data on
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TABLE 34 Evidence sources used in the model
Parameter group Source
Patient age Based on the NHS England Access Scheme Database183
Risk classification probabilities for oncotype
DX, EPClin, Prosigna and IHC4+C
TransATAC bespoke data request.46 Analysed by subgroup [LN0 NPI ≤ 3.4,
LN0 NPI > 3.4 and LN1–3]
Risk classification probabilities for
MammaPrint
MINDACT.98 Analysed in accordance with ITT trial population and mAOL
low-risk and high-risk subgroups
Distant recurrence rates (10 years)
conditional on test risk classification
(oncotype DX, EPClin, Prosigna and
IHC4+C)
TransATAC bespoke data request.46 Analysed by subgroup [LN0 NPI ≤ 3.4,
LN0 NPI > 3.4 and LN1–3]
Distant recurrence rates (10 years)
conditional on test risk classification
(MammaPrint)
MINDACT.98 Analysed in accordance with ITT trial population and mAOL
low-risk and high-risk subgroups. All analyses involve extrapolation from the
5-year data
Baseline probability of receiving adjuvant
chemotherapy (current practice)
LN0 NPI ≤ 3.4 subgroup: NCRAS bespoke data request184
LN0 NPI > 3.4 subgroup: NHS England Access Scheme Database183
LN1–3 subgroup: NCRAS bespoke data request184
MINDACT population (MammaPrint only): clinical judgement (Professor
Robert Stein, UCL, 2017, estimates weighted by proportion with LN0 and
LN+ disease and mAOL low risk/high risk)
Probability of receiving chemotherapy
conditional on results of test (three-level
tests – oncotype DX, IHC4+C and Prosigna)
LN0 NPI ≤ 3.4 subgroup: UKBCG survey (see Appendix 9)
LN0 NPI > 3.4 subgroup: NHS England Access Scheme Database183
LN1–3 subgroup: Loncaster et al.145
Probability of receiving chemotherapy
conditional on results of test (two-level tests –
EPClin and MammaPrint)
Bloomfield et al.159 Applied to all analysis subgroups
10-year relative ROR for chemotherapy vs.
no chemotherapy
EBCTCG 2012 meta-analysis185
Predictive chemotherapy benefit: oncotype
DX (applied in sensitivity analysis only)
LN0 subgroups: Paik et al.50
LN1–3 subgroup: Albain et al.53
Probability of death following distant
recurrence
Thomas et al.186
Probability of local recurrence de Bock et al.187
Probability of AML Wolff et al.188
Probability of death following onset of AML Edlin et al.189
Other-cause mortality (life tables) ONS190
HRQoL Utility – recurrence-free and distant recurrence: Lidgren et al.191
Utility AML: Younis et al.192
HRQoL decrement – local recurrence and AEs related to adjuvant
chemotherapy: Campbell et al.193
Tumour profiling test costs Test manufacturers
COST-EFFECTIVENESS
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10-year DMFI probabilities conditional on test risk classification, thereby avoiding confounding due to the use
of different evidence sources for these parameters, and (3) TransATAC is a large UK study. However, two
caveats should be noted with respect to the choice of this data source. First, the non-restricted TransATAC
data set was used for the analysis – this maximises the sample size for each individual test; however, as each
additional test was analysed, more tissue was required and for some samples insufficient tissue was left.
This reduces the number of patients with available data and may introduce bias comparing across tests. In
addition, whereas the ATAC trial included only postmenopausal women, the economic analysis assumes that
the risk classification and DMFI probabilities obtained from the TransATAC analysis can be translated to a
premenopausal population; this assumption introduces an additional degree of uncertainty with respect to
the generalisability of the analysis.
Risk classification probabilities: MammaPrint
The evaluation of MammaPrint was based on the MINDACT trial.98 This study was selected for inclusion
in the analysis for three reasons: (1) the trial publication and supplementary material provide sufficient
information to estimate risk classification probabilities and DMFS probabilities conditional on risk classification
within the same patient populations, (2) it includes a large sample size and (3) the study allows for the
estimation of the benefit of chemotherapy between discordant groups.
Risk classification probabilities for MammaPrint were obtained from the trial publication of the MINDACT
trial98 and the accompanying supplementary material (see Appendix 8, Table 77).
Probability of developing distant metastases (without chemotherapy): oncotype DX,
Prosigna, IHC4+C and EPClin
The probability of developing distant metastases was based on 10-year DMFI/DMFS outcomes for each test
risk classification. For oncotype DX, Prosigna, IHC4+C and EPClin, these were obtained from a bespoke
data analysis of the TransATAC study46 (see Appendix 8, Table 78).
The 10-year DMFI probability was converted to a cumulative probability of recurrence for each test within
each risk classification category (1 – DMFI) and converted to a 6-month probability of distant recurrence
assuming a constant rate.
Probability of developing distant metastases (without chemotherapy): MammaPrint
Cardoso et al.98 report 5-year DMFS probabilities for patients who did, or did not, receive adjuvant
chemotherapy in the discordant risk groups in the MINDACT trial.98 Additional information is also provided
on chemotherapy use and 5-year DMFS in the concordant risk groups. For the economic analysis based on
TABLE 34 Evidence sources used in the model (continued )
Parameter group Source
Costs
Adjuvant chemotherapy Hall et al.30
Endocrine therapy BNF194
G-CSF BNF194 and PSSRU195
Routine follow-up NHS Reference Costs 2015/16196 and Campbell et al.193
Bisphosphonates (zoledronic acid) BNF194 and NHS Reference Costs 2015/16196
Local recurrence Karnon et al.197
Distant metastases Thomas et al.186
BNF, British National Formulary; ONS, Office for National Statistics; PSSRU, Personal Social Services Research Unit;
UCL, University College London; UKBCG, UK Breast Cancer Group.
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the MINDACT ITT population, it was necessary to estimate DMFS probabilities for all concordant and
discordant groups in accordance with clinical and genomic risk classification and whether or not patients
received chemotherapy. This was done as follows (refer to data presented in Appendix 8, Table 79):
l The 10-year DMFS outcomes were estimated for all concordant and discordant clinical and genomic risk
groups in accordance with whether or not patients received adjuvant chemotherapy (EAG group labels A–H)
based on 5-year DMFS outcomes, assuming a constant event rate. The proportions of patients who
received chemotherapy were obtained from the supplementary material of the Cardoso et al.98 trial
publication. An adjustment was made to the mAOL high-risk, MammaPrint high-risk group to estimate
counterfactual 10-year DMFS for patients not receiving chemotherapy (EAG group label H); this was
done by estimating the 10-year DMFS probability for this group (with chemotherapy) and multiplying this
value by the reciprocal of the estimated 10-year RR of distant metastases for chemotherapy versus no
chemotherapy for the overall discordant population (RR 0.77, adjusted 10-year DMFS for group 0.766).
l The 10-year DMFS outcomes for the MammaPrint low-risk group (without adjuvant chemotherapy)
were estimated by weighting the estimated 10-year DMFS probabilities for the MammaPrint low-risk
no-chemotherapy groups (EAG group labels B and D) in accordance with the number of mAOL low-risk
and high-risk patients in these groups.
l The 10-year DMFS outcomes for the MammaPrint high-risk group (without adjuvant chemotherapy)
were estimated by weighting the estimated 10-year DMFS probabilities for the genomic high-risk
no-chemotherapy groups (EAG group labels F and H, including the adjustment described above)
in accordance with the number of mAOL low-risk and high-risk patients in these groups.
Tapering of risk of recurrence over time
The EAG notes that there is uncertainty with respect to the long-term risk of distant recurrence. The EAG
model makes the same assumptions regarding long-term distant metastasis risk as the previous model
reported by Ward et al.1 The model assumes that the risk of distant metastases between 10 and 15 years is
equal to half of the risk during the preceding period (0–10 years); beyond 15-years, the risk of distant
recurrence is assumed to be zero. The EAG notes that this is a simplification. This general decrease in the
hazard of recurrence can be seen in the 10- to 15-year control arm annualised recurrence data reported in
the 2005 EBCTCG meta-analysis.199 Although there is some evidence that suggests that for some patients
with particular disease subtypes, recurrence rates remain approximately constant between 5 and 20 years,200
there is also uncertainty surrounding the duration over which the benefit of chemotherapy is sustained;
hence, constraining recurrence at 15 years reduces the likelihood of overestimating this benefit of
chemotherapy. The impact of removing this assumption of recurrence risk tapering is explored within the
sensitivity analyses.
Probability of receiving chemotherapy in the current practice group
The EAG identified two empirical sources that could be used to inform the probability that a patient
receives chemotherapy without tumour profile testing: (1) the NCRAS data set184 and (2) the NHS England
Access Scheme Database (intermediate clinical risk only).183 These alternative sources are discussed briefly
in the following sections.
National Cancer Registration and Analysis Service data set
A bespoke data request was placed with the NCRAS to obtain aggregate data relating to the use of adjuvant
chemotherapy in women with early-stage breast cancer in England (see Appendix 8, Table 80). The NCRAS
cancer registration data sets were used to estimate current levels of chemotherapy use in each of the three
model subgroups [LN0 NPI ≤ 3.4, LN0 NPI > 3.4 and LN1–3]. An age restriction of 55–75 years was applied
with the intention of only selecting those patients who were sufficiently fit to undergo chemotherapy and
therefore may benefit from tumour profile testing, and also of removing younger patients who are more
likely to receive chemotherapy and are less reflective of the populations used to estimate risk classification
probabilities and distant recurrence risk.46 An additional data analysis on chemotherapy use for the whole
population aged < 75 years was also obtained. As shown in Appendix 8, Table 80, within the 55- to 75-year
age group, the proportions of women receiving chemotherapy are 7.19%, 40.01% and 62.72% in the LN0
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NPI ≤ 3.4, LN0 NPI > 3.4 and LN1–3 subgroups, respectively. As expected, the proportion of women
receiving chemotherapy is higher in the broader aged ≤ 75 years population.
It should be noted that the NCRAS data set reflects an unselected population who are not necessarily
eligible for tumour profile testing; this may increase the size of the denominator and, hence, in reality,
the proportion of women who are eligible for testing who go on to receive adjuvant chemotherapy may
be greater than the estimates generated using this data set.
NHS England oncotype DX Access Scheme Database
The NHS England Access Scheme Database183 contains data on the pre-test chemotherapy decision for
women who received the oncotype DX test in England. It should be noted that this data set relates only
to women who were deemed to be at intermediate clinical risk, hence the data may not provide a good
reflection of pre- and post-test chemotherapy decision-making for women with LN0 disease and a NPI
score of ≤ 3.4 or for women with LN+ disease. The pre-test probability of receiving adjuvant chemotherapy
is 0.431. This estimate is only slightly higher than the estimate generated using the NCRAS data set184
(probability of 0.40).
Within the EAG base-case analysis, the following selections were made:
l For the LN0 NPI ≤ 3.4 subgroup, the NCRAS data set184 was used as these are the only data on baseline
chemotherapy use available for this patient subgroup.
l For the LN1–3 subgroup, the NCRAS data set184 was used as these are the only data on baseline
chemotherapy use available for this patient subgroup.
l For the LN0 NPI > 3.4 subgroup, the NHS England Access Scheme Database183 was used. This source
was selected on the basis of consistency: the same data set is used to inform the post-test probabilities
of receiving chemotherapy conditional on risk score. It should also be noted that the collection of these
data were requested by the NICE Diagnostics Appraisal Committee in NICE DG10.20
l For the MammaPrint analyses, the EAG is not aware of any empirical evidence source that provides
estimates of baseline chemotherapy use (without testing) for patients who are mAOL high risk or mAOL
low risk. For this reason, these parameters were informed by expert opinion (Professor Rob Stein,
University College London, 2017, personal communication). The following estimates were applied in the
model, based on the modified version of AOL applied in the MINDACT trial –
¢ LN0, mAOL high risk, baseline chemotherapy probability = 70%
¢ LN+, mAOL high risk, baseline chemotherapy probability = 90%
¢ LN0, mAOL low risk, baseline chemotherapy probability = 15%
¢ LN+, mAOL low risk, baseline chemotherapy probability = 30%.
These estimates were then weighted in accordance with the proportion of women with LN0 and LN+
disease within the overall MINDACT population and within the mAOL high-risk and low-risk subgroups.
This leads to baseline probabilities of 0.46, 0.77 and 0.16 for the MINDACT overall trial population,
the mAOL high-risk subgroup and the mAOL low-risk subgroup, respectively.
When appropriate, the source not selected for inclusion in the EAG base case was tested in the sensitivity
analyses.
Probability of receiving chemotherapy conditional on test risk classification
Based on the review of decision impact studies presented in Chapter 2, Results: decision impact studies,
five UK-based sources relating largely to the three analysis subgroups [LN0 NPI ≤ 3.4, LN0 NPI > 3.4 and
LN1–3] were identified as providing potentially usable data relating to the probability that a patient
receives adjuvant chemotherapy conditional on the risk score given by the tumour profiling test. Evidence
selection for these parameters was focused on UK-based studies as these are more likely to reflect how
clinicians will use the tests in England, although European studies were considered when the UK-based
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evidence was particularly limited (specifically for the two-level tests). The five UK-based studies identified
are (1) the NHS England Access Scheme Database,183 (2) Holt et al.,201 (3) Loncaster et al.,145 (4) Bloomfield
et al.159 and (5) the UK Breast Cancer Group (UKBCG) survey (see Appendix 9). The advantages and
disadvantages of using each of these studies are summarised in Table 35.
TABLE 35 Studies available to inform chemotherapy use conditional on test results
Study Disease type EAG comments
NHS England Access
Scheme Database183
LN0, intermediate
clinical risk
This data collection exercise was requested by the NICE Diagnostics
Appraisal Committee within the guidance for NICE DG10.20 The data
set includes only patients with intermediate clinical risk and is likely
to be relevant only to patients with LN0 disease and a NPI of > 3.4.
The data relate to the actual chemotherapy decision rather than a
recommendation
The NHS England Access Scheme data were provided as AiC and
cannot be reported here
Holt et al.201 LN0 or pN1mic
(micrometastasis)
Prospective UK clinical study of the impact of oncotype DX on
adjuvant treatment decisions and risk classification by NPI and
oncotype DX recurrence score. Results were available for 74 patients.
The data relate to the chemotherapy recommendation rather than the
final decision. The EAG notes that this study has been published only
in abstract form and few details are available regarding the methods
Bloomfield et al.159 Unclear UK study of decision impact of EndoPredict. Fourteen oncologists in
eight UK hospitals saw 149 patients judged by clinical teams to have
equivocal indications for chemotherapy. Patients and oncologists
discussed provisional treatment decisions based on conventional
prognostic factors. Initial decisions were reconsidered when
EndoPredict results were available. The data appear to relate to the
final decision rather than recommendations
The EAG notes that this is the only available UK study that relates to
decision impact with a two-level tumour profiling test. The population
relates to patients for whom there was no clear decision on whether
or not chemotherapy should be given. This study is unlikely to
accurately represent the use of chemotherapy in women with LN+
disease
Loncaster et al.145 LN0 and LN+ A prospective UK pilot study designed to evaluate the clinical value
of oncotype DX testing. Testing was carried out in 201 women
with newly diagnosed, ER+, HER2–, invasive breast cancer who
underwent breast surgery with curative intent. Separate estimates are
provided for the LN0 and LN+ subgroups. The data appear to relate
to recommendations rather than the final decision
The EAG notes that patients enrolled in this study had already been
recommended chemotherapy, therefore the use of this study may
exaggerate the proportion of women for whom the final decision was
to receive chemotherapy
UKBCG survey
(see Appendix 9)
LN0 NPI ≤ 3.4, LN0
NPI > 3.4 and LN1–3
The UKBCG network disseminated a bespoke unfunded survey
designed by the EAG to its members (see Appendix 9). Respondents
were asked ‘Based on your own subjective opinion, please estimate
the probability that a woman in each of these subgroups and with
each genomic/immunohistochemical test result would go on to receive
adjuvant chemotherapy’. Responses were requested for two-level and
three-level tests for the LN0 NPI ≤ 3.4, LN0 NPI > 3.4 and LN1–3
subgroups. Eleven usable responses were received from participating
oncologists
The results indicate considerable variation in practice. Several
respondents noted uncertainty with respect to the two-level tests as
they do not currently have access to these technologies
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Estimates of the use of adjuvant chemotherapy conditional on test risk classification based on these
alternative sources are summarised in Appendix 8, Table 81.
With respect to the EAG base case, the following study selections were made:
l For the use of the three-level tests (oncotype DX, Prosigna and IHC4+C) in the LN0 NPI ≤ 3.4 subgroup,
the UKBCG survey data were used. This selection was made owing to the absence of any published UK
evidence on the decision impact of tumour profiling tests in this patient subgroup.
l For the use of the three-level tests (oncotype DX, Prosigna and IHC4+C) in the LN0 NPI > 3.4 subgroup,
the NHS England Access Scheme Database183 was used. This selection was made for two reasons:
(1) this source is consistent with the source used to inform the baseline chemotherapy probabilities
without testing and (2) the EAG considers that this source provides the best reflection of the way in
which three-level tumour profiling tests are used in clinical practice in England.
l For the use of the three-level tests (oncotype DX, Prosigna and IHC4+C) in the LN1–3 subgroup, the
Loncaster et al.145 LN+ estimates were selected as this is the only published UK evidence on decision
impact that specifically relates to this patient subgroup.
l For the two-level tests (EPClin and MammaPrint), the Bloomfield et al.159 study was selected for use in
all three analysis subgroups as this is the only available published UK study that relates to a two-level
tumour profiling test. Given the limited UK-based evidence relating to the impact of two-level tests,
two additional European studies are explored in the sensitivity analyses.162,167
The other sources not selected for inclusion in the EAG base case were included in the sensitivity analyses.
Adjuvant chemotherapy treatment effect on distant recurrence: oncotype DX, Prosigna,
IHC4+C and EPClin
As noted in Chapter 2, Chemotherapy benefit: oncotype DX, the evidence relating to the predictive benefit of
oncotype DX is limited to two reanalyses of RCTs50,53 that do not provide consistent conclusions regarding this
aspect of the value of the test across the range of analyses reported. Within the base-case analysis, all tests
are assumed to be associated with prognostic benefit only (the relative benefit of chemotherapy is assumed to
be the same across all test risk classification groups). For the analyses of oncotype DX, Prosigna, IHC4+C and
EPClin, the RR of recurrence for chemotherapy versus no chemotherapy was derived from a meta-analysis
reported by the EBCTCG (2012).185 Based on data presented in the supplementary material (see EBCTCG
publication185 extra web material, page 12, any anthracycline-based regimen vs. no chemotherapy, distant
recurrence), the 10-year risk of distant recurrence for chemotherapy and no chemotherapy was estimated by
projecting forward the annualised risk of distant metastases (3.3% per year for chemotherapy, 4.6% per year
for no chemotherapy). The RR for chemotherapy versus no chemotherapy was then calculated based on the
difference between the projected 10-year DMFS probabilities for the two groups: this gives a 10-year RR of
0.76. The same RR was assumed to apply to the LN0 and LN+ subgroups. The impact of assuming higher and
lower RRs for distant recurrence are explored in the sensitivity analyses. Further sensitivity analyses were also
undertaken to explore the impact of assuming a predictive benefit of chemotherapy associated with oncotype
DX, based on the studies reported by Paik et al.50 (LN0) and Albain et al.53 (LN+). Within the model, this is
implemented by applying different RRs to each of the risk classification groups, based on these two studies.
Adjuvant chemotherapy treatment effect on distant recurrence: MammaPrint
Within the analysis of MammaPrint, the benefit of adjuvant chemotherapy was estimated using data
reported within the MINDACT trial publication,98 rather than from an external source. The 10-year RR of
relapse for adjuvant chemotherapy versus no adjuvant chemotherapy was estimated based only on the
discordant clinical and genomic risk group data (see Appendix 8, Table 79, EAG group labels C, D, E
and F), extrapolated beyond the study end point. RRs of chemotherapy versus no chemotherapy were
calculated for each of the two discordant groups (clinical low, genomic high, and clinical high, genomic
low) based on estimated 10-year DMFS; these were then weighted in accordance with the number of
patients in each discordant group. The weighted RR for the discordant populations was estimated to be
0.77. Within the mAOL low-risk and mAOL high-risk subgroups, the RRs of recurrence for each subgroup
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were based only on the discordant population relevant to that subgroup (mAOL low-risk RR 0.84, mAOL
high-risk RR 0.74). The impact of assuming higher and lower RRs for distant recurrence are explored in the
sensitivity analyses.
The RRs of recurrence applied in the EAG base-case analysis and sensitivity analyses are detailed in
Appendix 8, Table 78.
It should be noted that the model translates 10-year DMFS probabilities (without chemotherapy) into
6-month event probabilities assuming a constant rate. As a RR relates only to the specified time point of the
analysis, it is inappropriate to apply this directly to the 6-month probability of recurrence. Instead, the EAG
model applies a conversion by (1) estimating the 10-year DMFS probability with chemotherapy based on
the 10-year DMFS probability without chemotherapy and the 10-year RR of recurrence for chemotherapy
versus no chemotherapy; (2) estimating the HR for the DMFS outcomes at 10 years for chemotherapy versus
no chemotherapy, assuming a constant event rate; (3) applying the estimated HR to the 6-month DMFS
probability for the no-chemotherapy group; and (4) converting this HR-adjusted 6-month DMFS probability
with chemotherapy to a 6-month distant recurrence probability. This approach ensures that the relative
distance between the predicted chemotherapy group and the observed no-chemotherapy group is
maintained at 10 years.
Survival following onset of distant metastases
The survival prognosis of patients with distant metastases was based on analysis of complete hospital and
community records of 77 women randomly selected from 232 women who had relapsed breast cancer
between 2000 and 2005 (Thomas et al.186). The population included in this study had an average age of
62.3 years and included patients who had originally been diagnosed with LN+ disease (44%) and who
were LN0 (56%). Forty-five per cent of women were ER+ and 21% of women were HER2+. Median
survival was reported to be 40.1 months following distant recurrence. The 6-month probability of death
was estimated by fitting an exponential distribution with a median of 40.1 months; based this approach,
the 6-month probability of death following distant recurrence was estimated to be 0.098, assuming a
constant rate. The model assumes that the rate of death due to distant metastases is constant across the
different model subgroups and across each test risk classification group owing to a lack of population-
specific or risk-group-specific data.
Probability of local recurrence
The model assumes that 10.5% of patients entering the distant recurrence health state have previously
experienced a local recurrence. This estimate was based on a study by de Bock et al.,187 which analysed
3601 women enrolled in three EORTC (European Organisation for Research and Treatment of Cancer)
trials. The study included both LN0 and LN+ women who had been treated for early-stage breast cancer.
Of the 1224 women who developed distant metastases, 129 women (10.54%) experienced a previous
locoregional recurrence. The model does not take into account the time spent alive with local recurrence;
instead, the impact of local recurrence is applied crudely in the model as a once-only cost and QALY loss.
Probability of developing acute myeloid leukaemia
The probability of developing AML following chemotherapy was taken from an analysis of 20,063 patients
with stage I–III breast cancer treated at US academic centres between 1998 and 2007 (Wolff et al.188).
Within the cohort of 3227 patients, the estimated 10-year risk of developing AML was reported to be
0.49%. The 6-month probability of developing AML was estimated to be 0.00025, assuming a constant
event rate.
Survival following onset of acute myeloid leukaemia
Survival following the onset of AML was estimated from the NICE single technology appraisal of azacitidine
(Vidaza®, Celgene) for myelodysplastic syndromes (MDSs).202 Within this appraisal, the manufacturer
estimated mean survival following the onset of AML to be approximately 8 months; assuming a constant
event rate, this gives a 6-month probability of death following AML of 0.53.
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Health utilities associated with relapse-free and distant metastases
Systematic searches were undertaken to identify studies reporting on HRQoL associated with different
health states for women with breast cancer. Searches were undertaken in July 2017 in the following
electronic databases:
l MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations (Ovid, 1946 to present)
l EMBASE (Ovid, 1974 to 7 July 2017)
l Science Citation Index Expanded (Web of Science, 1900 to present)
l Conference Proceedings Citation Index – Science (Web of Science, 1990 to present).
The searches specifically focused on studies that reported HRQoL estimates for health states that were
measured and valued using the Euroqol 5-Dimensions (EQ-5D). The search strategy comprised sensitive
MeSH or Emtree Thesauri terms and free-text synonyms for ‘breast cancer’ combined with free-text
synonyms for ‘EQ-5D’. The search strategies are presented in Appendix 2. Studies were considered
potentially relevant if they reported EQ-5D valuations in patients both with non-metastatic disease and
with relapsed disease, thereby reflecting key health states in the model. Studies that reported disutilities
associated with AEs resulting from the use of chemotherapy were retained for separate consideration.
Studies were sifted in accordance with their titles and abstracts; full texts were retrieved for studies that
potentially met the inclusion criteria on the basis of the information provided in their title and abstract.
HRQoL estimates for other modelled health states and events were not based on new searches; instead,
these were derived through consideration of estimates that have been identified from a previous
systematic review of health utilities (Peasgood et al.203).
The EAG’s searches identified a total of 227 studies. Of these, only four studies reported EQ-5D valuations
for both non-metastatic and metastatic breast cancer states (see Appendix 8, Table 83). Three of the
identified studies were reported as full papers, and the fourth study was reported only in abstract form.
None of the identified studies were undertaken with UK patients: the studies were undertaken in Finland
(Farkkila et al.204), Sweden (Lidgren et al.191), Iran (Yousefi et al.205) and Canada (Naik et al.206).
The study reported by Lidgren et al.191 was selected for use in the EAG base-case analysis on the basis that
this population was most likely to best reflect the population of ER+ women with breast cancer who are
treated in England. This study reported values for the recurrence-free (receiving endocrine therapy) health
state and for the distant recurrence health state of 0.824 and 0.685, respectively. This same study was
used to inform the health state utility estimates within the earlier model reported by Ward et al.1 and the
Myriad model.182
Health utilities associated with other model health states and events
The disutility associated with local recurrence was taken from a published model of first-, second- and
third-generation adjuvant chemotherapy regimens for breast cancer reported by Campbell et al.193 Within
this study, the 6-month disutility associated with local recurrence was estimated to be 0.108 [standard
error (SE) 0.04]. The HRQoL impact of chemotherapy-related AEs was also taken from Campbell et al.;193
the model assumes a disutility of 0.04 (assumed SE 0.004) during the first 6-month model cycle. The
health utility associated with AML was assumed to be 0.26 based on a previous economic evaluation.192
Health utility estimates applied in the External Assessment Group model
Appendix 8, Table 84, summarises the health utilities assumed in the EAG’s base-case analysis.
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Resource use and costs
The model includes the following cost components:
l costs associated with the tumour profiling test
l costs of adjuvant chemotherapy acquisition and administration (including chemotherapy-related toxicity)
l costs associated with endocrine therapy
l costs of routine follow-up visits and tests
l costs of other therapies (zoledronic acid and G-CSF)
l costs of treating local recurrence (once-only cost)
l costs associated with treating distant metastases.
Test costs
The costs of the tumour profiling tests were sourced from information provided to NICE by the manufacturers
as part of the appraisal process. The cost of oncotype DX includes the price discount offered through the
Patient Access Scheme (PAS) for this product. The manufacturers of oncotype DX, MammaPrint and
EndoPredict submitted a cost for sample testing in each of their centralised laboratories. IHC4 and Prosigna
have no established centralised laboratory system. The manufacturers provided prices for conducting these
two tests in NHS laboratories, as outlined in Appendix 8, Table 85. NanoString Technologies submitted a
cost of £1970; this is in line with the £1596 (2013 prices) cost of the Prosigna test estimated as part of the
OPTIMA Prelim trial.207 EndoPredict can also be conducted within a NHS laboratory; the impact of assuming a
lower cost is considered within the sensitivity analyses. During the course of the appraisal, access proposals
were offered by several of the test manufacturers; the impact of these proposals is not included in this report.
Costs of adjuvant chemotherapy acquisition and administration (including toxicity)
The costs associated with adjuvant chemotherapy were obtained from a previous costing analysis
undertaken to inform the economic analysis of the OPTIMA Prelim trial (Hall et al.,30 see Appendix 8,
Table 86). The fully executable spreadsheet developed to inform the OPTIMA Prelim analysis was made
available to the EAG by the study authors (Professor Robert Stein, University College London, personal
communication). Within this analysis, standard supportive medication, procurement, laboratory, pharmacy
and administration costs were taken from the drugs and pharmaceutical electronic market information
tool,208 the British National Formulary (BNF)194 and NHS Reference Costs 2013 to 2014.209 Unit costs
associated with the management of chemotherapy-related grade 3/4 toxicity were based on NHS Reference
Costs 2013 to 2014.209 Within the original costing analysis, all costs were valued at 2013/14 prices; within
the EAG analysis, these costs were uplifted to current values using the Hospital and Community Health
Service (HCHS) indices.195 The EAG model assumes that women with ER+, HER2–, early-stage breast cancer
with zero to three nodes typically receive one of four adjuvant chemotherapy regimens:
1. fluorouracil, epirubicin, cyclophosphamide and docetaxel (FEC100-T) (three plus three cycles, assumed
to be given to 25% of patients)
2. docetaxel and cyclophosphamide (TC) (four cycles, assumed to be given to 20% of patients)
3. fluorouracil, epirubicin and cyclophosphamide (FEC75) (six cycles, assumed to be given to 45%
of patients)
4. fluorouracil, epirubicin, cyclophosphamide and weekly paclitaxel (FEC100-Pw) (three plus three cycles,
assumed to be given to 10% of patients).
The weighted mean cost of adjuvant chemotherapy acquisition, delivery and toxicity was estimated to be
£3145.19 per course. All adjuvant chemotherapy costs are applied during the first model cycle. The EAG
notes that the choice and proportionate use of alternative chemotherapy regimens may differ between
centres; for this reason, the use of alternative chemotherapy cost assumptions are explored in the
sensitivity analyses.
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Costs of endocrine therapy
The model assumes that all surviving patients receive endocrine therapy for a period of between 5 and
8 years. The costs associated with endocrine therapy were based on the assumptions employed within the
previous economic analysis reported by Ward et al.1 The model assumes that patients may receive one of
four endocrine therapy regimens: (1) tamoxifen for 5 years, (2) anastrozole for 5 years, (3) letrozole for
5 years or (4) tamoxifen for 2 years then exemestane for 3 years. The proportion of patients receiving each
regimen was taken from Ward et al.1 (tamoxifen 40% of patients, anastrozole 20% of patients, letrozole
20% of patients, tamoxifen then exemestane 20% of patients; see Appendix 8, Table 87). In line with the
previous model reported by Ward et al.,1 10% of patients are assumed to receive extended letrozole for
3 further years (years 6–8).
Costs of additional treatments (zoledronic acid)
The model assumes that 30% of women with early-stage breast cancer will receive 4 mg of bisphosphonates
(zoledronic acid) every 6 months by intravenous infusion for up to 3 years (cost per 36-month course = £58.50).
Treatment is assumed to be given in a day-case setting, based on the cost of delivering simple parenteral
chemotherapy (unit cost of £199.94, based on NHS Reference Costs 2015 to 2016,196 outpatient, currency
code SB12Z).
Follow-up costs
The model assumes that all patients receive two routine follow-up visits during the first year following
surgery, with annual visits thereafter for a period of 5 years. Patients are also assumed to undergo a
routine annual mammogram for up to 5 years. The cost of a routine follow-up visit was taken from NHS
Reference Costs 2015 to 2016196 (mean cost £162.84, SE £6.48, consultant-led, non-admitted, face-to-face
attendance, follow-up, medical oncology, service code 370). The cost of a mammogram was not available
within the NHS Reference Costs 2015 to 2016 tariff: this unit cost was instead taken from Campbell et al.193
(mean cost £46.37, SE £9.27) and uplifted to current values using the HCHS index.195
Costs of treatments for local and distant recurrence
The costs associated with treating local recurrence were taken from a UK-based patient-level costing
analysis of breast cancer recurrence reported by Karnon et al.197 This cost estimate was uplifted to current
prices using the HCHS index195 (uplifted mean cost £13,912.92, assumed SE £2010.20). This is applied as a
once-only cost on the incidence of distant recurrence.
The costs associated with treating distant metastases were derived from the study reported by Thomas et al.186
These costs included costs associated with visits, drugs, pharmacy, hospital admission and intervention,
imaging, radiotherapy, pathology and transport. Cost components specifically associated with terminal
care were excluded. The 6-monthly cost of treating metastatic breast cancer was estimated to be £4082.
This estimate was uplifted to current prices using the HCHS index195 (uplifted mean cost £4541, assumed
SE £908.13).
Methods for model evaluation
The incremental health outcomes and costs of each test versus standard care were evaluated in a pairwise
fashion; the cost-effectiveness of each test was not compared against the other tests. Central estimates of
cost-effectiveness were based on the expectation of the mean. Uncertainty was evaluated using probabilistic
sensitivity analysis (PSA) and deterministic sensitivity analyses (DSAs). PSA was undertaken using simple
Monte Carlo sampling methods (10,000 samples). The choice of distribution assumed for each group of
parameters in the model is summarised in Table 36. The results of the PSA are presented as cost-effectiveness
acceptability curves (CEACs) and in tabular form. DSAs were undertaken to explore the impact of alternative
assumptions and evidence sources regarding the probability of receiving chemotherapy with and without
the tests, risk classification probabilities, recurrence rates, the potential predictive benefit of oncotype DX,
the magnitude of chemotherapy benefit, HRQoL estimates and costs.
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The model was subjected to a number of DSAs, which are listed in Table 37.
Model verification and validation
The EAG undertook a number of measures to ensure the credibility of the model:
l peer review of the economic analysis by a modeller not involved in the assessment
l verification and scrutiny of the executable model by two model developers
l double-programming of the deterministic version of the model for all pairwise comparisons presented in
the EAG base case
l double-checking of the accuracy of all model inputs against sources
l comparison of model results using point estimates of parameters and the expectation of the mean
l comparison of mean of all probabilistic parameter samples against point estimates of parameters
l examination of all identified sources of discrepancy
l model testing using sensitivity analysis and use of extreme parameter values.
TABLE 36 Distributions used in EAG probabilistic analyses
Model parameter group Distribution EAG comments
Classification probabilities with/without test Dirichlet –
Chemotherapy use (conditional on test result) Beta –
Recurrence rates (conditional on test result) Beta Distribution parameters fitted to 95% CI
around 10-year RFS data from TransATAC46 or
based on number of patients in treatment/risk
group in MINDACT98
RR chemotherapy vs. no chemotherapy Log-normal SE assumed
Distant recurrence risk taper parameters Fixed –
OS rate following distant recurrence Beta SE estimated using 95% CI of Kaplan–Meier
curve in Thomas et al.186
Probability of local recurrence Beta –
Probability of AML Beta –
OS rate following incidence of AML Beta –
HRQoL Beta –
Chemotherapy costs Normal SE assumed to reflect uncertainty in delivery
costs only
Endocrine therapy costs Fixed –
Zoledronic acid costs Normal SE for delivery costs estimated from NHS
Reference Costs 2015 to 2016196 using
interquartile ranges and number of
submissions
Mammogram costs Normal SE taken from Campbell et al.193
Follow-up/visit costs Normal SE estimated from NHS Reference Costs 2015
to 2016196 using interquartile range and
number of submissions
Local recurrence cost Normal SE assumed to be equal to 20% of mean
Distant recurrence cost Normal SE assumed to be equal to 20% of mean
AML cost (one off) Normal SE assumed to be equal to 20% of mean
Test costs Fixed –
COST-EFFECTIVENESS
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TABLE 37 List of DSAs undertaken for each test
DSA description
DSA undertaken for test?
Oncotype
DX IHC4+C Prosigna EPClin MammaPrint
Deterministic base-case analysis Yes Yes Yes Yes Yes
Post-test chemotherapy probabilities based on NHS England
Access Scheme Database183 (clinical intermediate risk) (see
Appendix 8, Table 82)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on Holt et al.201
(see Appendix 8, Table 82)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on Loncaster et al.145
(see Appendix 8, Table 82)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on UKBCG survey
(see Appendix 8, Table 82)
Yes Yes Yes Yes Yes
Post-test chemotherapy probabilities based on NHS England
Access Scheme Database183 (see Appendix 8, Table 83); baseline
chemotherapy probabilities from NCRAS184 (see Appendix 8,
Table 81)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on Holt et al.201
(see Appendix 8, Table 83); baseline chemotherapy probabilities
from NCRAS184 (see Appendix 8, Table 81)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on Loncaster et al.145
(see Appendix 8, Table 83); baseline chemotherapy probabilities
from NCRAS184 (see Appendix 8, Table 81)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on UKBCG survey
(see Appendix 8, Table 83); baseline chemotherapy probabilities
from NCRAS184 (see Appendix 8, Table 81)
Yes Yes Yes No No
Post-test chemotherapy probabilities based on Cusumano et al.167
(see Appendix 8, Table 89)
No No No Yes Yes
Post-test chemotherapy probabilities based on Penault-Llorca
et al.162 (LN0 only, NPI > 3.4 assumed) (see Appendix 8, Table 90)
No No No Yes Yes
Baseline chemotherapy probabilities adjusted by oncotype DX
risk score (see Appendix 8, Table 91)
Yes No No No No
Chemotherapy assumptions (with and without test) based on
Ward et al.1 (LN0, NPI > 3.4 only)
Yes Yes Yes No No
Oncotype DX benefit assumed to be associated with predictive
benefit. (LN0 RRs based on Paik et al.50 – low risk 1.31,
intermediate risk 0.61, high risk 0.26; LN+ RRs based on Albain
et al.53 – low risk 1.02, intermediate risk 0.72, high risk 0.59)
Yes No No No No
Risk classification and distant metastases probabilities based on
oncotype DX RPSC46 (LN0 only) (see Appendix 8, Table 92)
Yes No No No No
Prosigna risk classification and distant metastases probabilities
derived from Gnant et al.104 (LN+ only) (see Appendix 8, Table 93)
No No Yes No No
EPClin risk classification and distant metastases probabilities derived
from Dubsky et al.120 (LN+ only) (see Appendix 8, Table 94)
No No No Yes No
MammaPrint risk classification and distant metastases
probabilities derived from van ’t Veer et al.91 (LN0 only)
(see Appendix 8, Table 95)
No No No No Yes
Subgroup analysis in ER+, HER2–, LN+ subgroup No No No No Yes
Assume MammaPrint low-risk patients receive no chemotherapy,
MammaPrint high-risk patients receive 100% chemotherapy
No No No No Yes
continued
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
Cost-effectiveness results
Oncotype DX versus current practice
Central estimates of cost-effectiveness: probabilistic
Central estimates of cost-effectiveness for oncotype DX versus current practice are presented in Table 38.
All estimates are based on the probabilistic version of the EAG model. Within the LN0 NPI ≤ 3.4 subgroup,
oncotype DX is expected to produce 0.01 additional QALYs at an additional cost of £1313 per woman
tested compared with current practice; this corresponds to an incremental cost-effectiveness ratio (ICER)
of £122,725 per QALY gained. Within the LN0 NPI > 3.4 subgroup, oncotype DX is expected to produce
0.01 fewer QALYs at an additional cost of £881 per woman tested compared with current practice; within
this subgroup, oncotype DX is expected to be dominated. Within the LN1–3 subgroup, oncotype DX is
expected to produce 0.07 fewer QALYs at an additional cost of £687 per woman tested compared with
current practice; within this subgroup, oncotype DX is, again, expected to be dominated. As shown in
Table 39, the PSA indicates that the probability that oncotype DX produces more net benefit than current
practice at willingness-to-pay (WTP) thresholds of £20,000 and £30,000 per QALY gained is ≤ 0.04 across
all three subgroups. The results for the LN0 NPI > 3.4 subgroup and the LN1–3 subgroup are primarily
driven by the lower use of chemotherapy (and the benefits forgone) with oncotype DX than with current
practice (see Appendix 10 for the impact of all tests).
TABLE 37 List of DSAs undertaken for each test (continued )
DSA description
DSA undertaken for test?
Oncotype
DX IHC4+C Prosigna EPClin MammaPrint
10% lower cost per test owing to increased efficiency (local NHS
testing)
No No Yes Yes No
10% higher cost per test owing to decreased efficiency (local
NHS testing)
No No Yes No No
Baseline chemotherapy use halved No No No No Yes
Start age based on TransATAC37 (64 years) Yes Yes Yes Yes Yes
RR of distant metastases for chemotherapy vs. no
chemotherapy = 0.70
Yes Yes Yes Yes Yes
RR of distant metastases for chemotherapy vs. no
chemotherapy = 0.80
Yes Yes Yes Yes Yes
Removal of distant metastases risk tapering Yes Yes Yes Yes Yes
Utilities derived from Farkkila et al.204 (RFS = 0.818, DM = 0.746) Yes Yes Yes Yes Yes
Distant metastases death rate doubled Yes Yes Yes Yes Yes
Distant metastases death rate halved Yes Yes Yes Yes Yes
AML removed from model Yes Yes Yes Yes Yes
Chemotherapy cost doubled Yes Yes Yes Yes Yes
Chemotherapy cost halved Yes Yes Yes Yes Yes
Endocrine therapy costs doubled Yes Yes Yes Yes Yes
Endocrine therapy costs halved Yes Yes Yes Yes Yes
Local and distant metastases costs doubled Yes Yes Yes Yes Yes
Local and distant metastases costs halved Yes Yes Yes Yes Yes
DM, distant metastasis; RFS, recurrence-free survival.
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Deterministic sensitivity analysis
The results of the DSAs for oncotype DX are presented in Table 40 (shaded cells reflect analyses that are
unchanged from the EAG’s base case). The DSAs indicate the following results across the three subgroups:
l LN0 NPI ≤ 3.4 – the ICER for oncotype DX versus current practice remains in excess of £34,000 per
QALY gained across all scenarios. The only analysis in which the ICER is < £70,000 per QALY gained
relates to the scenario in which oncotype DX is assumed to be predictive of chemotherapy benefit,
based on RRs reported by Paik et al.50
l LN0 NPI > 3.4 – oncotype DX is either dominated or has an ICER in excess of £35,000 per QALY gained
across almost all scenarios. The only exception is the scenario in which oncotype DX is assumed to be
predictive of chemotherapy benefit, based on RRs reported by Paik et al.50 Within this analysis, oncotype
DX dominates current practice.
l LN1–3 – oncotype DX remains dominated across the majority of scenarios tested. The exceptions are
(1) the scenario in which oncotype DX is assumed to be predictive of chemotherapy benefit, based on
treatment effect estimates reported by Albain et al.,53 and (2) the scenario in which the cost of adjuvant
chemotherapy is doubled.
TABLE 38 Central estimates of cost-effectiveness: oncotype DX vs. current practice – probabilistic model
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
LN0 NPI ≤ 3.4
Oncotype DX 13.89 £5474 0.01 £1313 £122,725
No test 13.88 £4161 – – –
LN0 NPI > 3.4
Oncotype DX 12.73 £11,806 –0.01 £881 Dominated
No test 12.74 £10,925 – – –
LN1–3
Oncotype DX 12.48 £13,212 –0.07 £687 Dominated
No test 12.55 £12,525 – – –
TABLE 39 Probability of optimality: oncotype DX vs. current practice
Subgroup
Probability (λ= £20,000 per QALY gained) Probability (λ= £30,000 per QALY gained)
Oncotype DX Current practice Oncotype DX Current practice
LN0 NPI ≤ 3.4 0.00 1.00 0.00 1.00
LN0 NPI > 3.4 0.01 0.99 0.04 0.96
LN1–3 0.00 1.00 0.01 0.99
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TABLE 40 Deterministic sensitivity analyses: oncotype DX vs. current practice
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Base case (deterministic) 0.01 £1317 £120,144 –0.02 £869 Dominated –0.07 £647 Dominated
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(NHSE183)
0.01 £1458 £117,326 –0.02 £869 Dominated –0.07 £647 Dominated
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.01 £1849 £173,680 –0.02 £869 Dominated –0.07 £647 Dominated
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.01 £1640 £129,527 –0.02 £869 Dominated –0.07 £647 Dominated
LN0 NPI > 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.01 £1317 £120,144 0.02 £1138 £60,831 –0.07 £647 Dominated
LN0 NPI > 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.01 £1317 £120,144 0.00 £999 £651,857 –0.07 £647 Dominated
LN0 NPI > 3.4 post-test P(chemotherapy)
(UKBCG survey)
0.01 £1317 £120,144 0.00 £978 Dominated –0.07 £647 Dominated
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Holt et al.141)
0.01 £1317 £120,144 0.03 £1207 £44,817 –0.07 £647 Dominated
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Loncaster et al.145 LN0 subgroup)
0.01 £1317 £120,144 0.01 £1069 £109,429 –0.07 £647 Dominated
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(UKBCG survey)
0.01 £1317 £120,144 0.01 £1048 £161,535 –0.07 £647 Dominated
LN+ post-test P(chemotherapy) (UKBCG
survey)
0.01 £1317 £120,144 –0.02 £869 Dominated 0.00 £1155 Dominated
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Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Baseline P(chemotherapy) adjusted by
oncotype DX RS
0.01 £1317 £120,144 –0.02 £888 Dominated –0.07 £647 Dominated
Ward et al.1 scenario: baseline
P(chemotherapy) WMCIU1, post-test
P(chemotherapy) (Holt et al.141)
0.01 £1317 £120,144 0.04 £1268 £35,782 –0.07 £647 Dominated
Oncotype DX predictive benefit 0.04 £1211 £34,245 0.27 –£364 Dominating 0.09 –£68 Dominating
Oncotype DX RSPC LN0 0.02 £1146 £70,435 –0.02 £847 Dominated –0.07 £647 Dominated
Chemotherapy disutility doubled 0.01 £1317 £121,879 –0.01 £869 Dominated –0.06 £647 Dominated
Chemotherapy disutility halved 0.01 £1317 £119,294 –0.02 £869 Dominated –0.08 £647 Dominated
Start age based on TransATAC38,46
(64 years)
0.01 £1319 £156,971 –0.01 £867 Dominated –0.05 £638 Dominated
Farkkila et al.204 utilities (RFS = 0.818,
DM = 0.746)
0.01 £1317 £125,021 –0.01 £869 Dominated –0.07 £647 Dominated
Chemotherapy RR = 0.70 0.01 £1305 £94,920 –0.02 £905 Dominated –0.10 £759 Dominated
Chemotherapy RR = 0.80 0.01 £1325 £145,102 –0.01 £845 Dominated –0.05 £573 Dominated
No risk tapering 0.01 £1292 £92,613 –0.03 £974 Dominated –0.10 £870 Dominated
Distant metastases death rate doubled 0.01 £1339 £106,090 –0.02 £803 Dominated –0.09 £443 Dominated
Distant metastases death rate halved 0.01 £1282 £154,090 –0.01 £974 Dominated –0.05 £972 Dominated
AML removed 0.01 £1318 £119,771 –0.03 £879 Dominated –0.09 £663 Dominated
Chemotherapy cost doubled 0.01 £1330 £121,322 –0.02 £374 Dominated –0.07 –£266 £3700
continued
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TABLE 40 Deterministic sensitivity analyses: oncotype DX vs. current practice (continued )
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Chemotherapy cost halved 0.01 £1311 £119,554 –0.02 £1116 Dominated –0.07 £1103 Dominated
Endocrine therapy costs doubled 0.01 £1317 £120,149 –0.02 £869 Dominated –0.07 £646 Dominated
Endocrine therapy costs halved 0.01 £1317 £120,141 –0.02 £869 Dominated –0.07 £647 Dominated
Local and distant recurrence costs doubled 0.01 £1268 £115,630 –0.02 £1017 Dominated –0.07 £1106 Dominated
Local and distant recurrence costs halved 0.01 £1342 £122,400 –0.02 £795 Dominated –0.07 £417 Dominated
DM, distant metastasis; NHSE, NHS England; P(chemotherapy), probability of receiving chemotherapy; RFS, recurrence-free survival; RS, recurrence score; WMCIU, West Midlands Cancer
Intelligence Unit.
Note
Shaded cells reflect analyses that are unchanged from the EAG’s base case.
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IHC4+C versus current practice
Central estimates of cost-effectiveness: probabilistic
Central estimates of cost-effectiveness for IHC4+C versus current practice are presented in Table 41. All
estimates are based on the probabilistic version of the EAG model. Within the LN0 NPI ≤ 3.4 subgroup,
IHC4+C is expected to produce 0.01 additional QALYs at an additional cost of £22 per woman tested
compared with current practice; this corresponds to an ICER of £2654 per QALY gained. Within the LN0
NPI > 3.4 subgroup, IHC4+C is expected to produce 0.01 additional QALYs and cost savings of £90 per
woman tested compared with current practice; within this subgroup, IHC4+C is expected to dominate
current practice. Within the LN1–3 subgroup, IHC4+C is expected to produce 0.05 additional QALYs and
cost savings of £287 per woman tested compared with current practice; within this subgroup, IHC4+C is
expected to dominate current practice. As shown in Table 42, the PSA indicates that within the LN0 NPI
≤ 3.4 subgroup, the probability that IHC4+C produces more net benefit than current practice at WTP
thresholds of £20,000 and £30,000 per QALY gained is 0.95 and 0.97, respectively. Within the LN0 NPI
> 3.4 subgroup, the probability that IHC4+C produces more net benefit than current practice at WTP
thresholds of £20,000 and £30,000 per QALY gained is 0.69 and 0.67, respectively. Within the LN1–3
subgroup, the probability that IHC4+C produces more net benefit than current practice at these WTP
thresholds is ≥ 0.94.
TABLE 42 Probability of optimality: IHC4+C vs. current practice
Subgroup
Probability (λ= £20,000 per QALY gained) Probability (λ= £30,000 per QALY gained)
IHC4+C Current practice IHC4+C Current practice
LN0 NPI ≤ 3.4 0.95 0.05 0.97 0.03
LN0 NPI > 3.4 0.69 0.31 0.67 0.33
LN1–3 0.95 0.05 0.94 0.06
TABLE 41 Central estimates of cost-effectiveness: IHC4+C vs. current practice – probabilistic model
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
LN0 NPI ≤ 3.4
IHC4+C 13.86 £4291 0.01 £22 £2654
No test 13.86 £4269 – – –
LN0 NPI > 3.4
IHC4+C 12.73 £10,941 0.01 –£90 Dominating
No test 12.72 £11,031 – – –
LN1–3
IHC4+C 12.59 £12,268 0.05 –£287 Dominating
No test 12.54 £12,554 – – –
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Deterministic sensitivity analysis
The results of the DSAs for IHC4+C are presented in Table 43 (shaded cells reflect analyses that are
unchanged from the EAG’s base case). The DSAs indicate the following:
l LN0 NPI ≤ 3.4 – the ICER for IHC4+C versus current practice remains below £16,000 per QALY gained
across all scenarios, except in the analysis in which post-test chemotherapy probabilities are derived
from Holt et al.201 IHC4+C dominates current practice in the scenario in which the cost of adjuvant
chemotherapy is doubled.
l LN0 NPI > 3.4 – IHC4+C dominates current practice or has an ICER of < £6000 per QALY gained across
all scenarios.
l LN1–3 – IHC4+C dominates current practice across all scenarios except the analysis in which the
probability of receiving chemotherapy conditional on IHC4+C risk level is based on the UKBCG survey;
within this analysis, the ICER is estimated to be £1929 per QALY gained.
Prosigna versus current practice
Central estimates of cost-effectiveness: probabilistic
Central estimates of cost-effectiveness for Prosigna versus current practice are presented in Table 44. All
estimates are based on the probabilistic version of the EAG model. Within the LN0 NPI ≤ 3.4 subgroup,
Prosigna is expected to produce 0.02 additional QALYs at an additional cost of £1884 per woman tested
compared with current practice; this corresponds to an ICER of £91,028 per QALY gained. Within the LN0
NPI > 3.4 subgroup, Prosigna is expected to produce 0.06 additional QALYs at an additional cost of £1686
per woman tested compared with current practice; the corresponding ICER is £26,058 per QALY gained.
Within the LN1–3 subgroup, Prosigna is expected to produce 0.07 additional QALYs at an additional cost
of £1936 per woman tested compared with current practice; the corresponding ICER is £28,731 per QALY
gained. As shown in Table 45, the PSA indicates that within the LN0 NPI ≤ 3.4 subgroup, the probability
that Prosigna produces more net benefit than current practice at WTP thresholds of £20,000 and £30,000
per QALY gained is approximately zero. Within the LN0 NPI > 3.4 subgroup, the probabilities that Prosigna
produces more net benefit than current practice at these WTP thresholds are 0.24 and 0.60, respectively.
Within the LN1–3 subgroup, the probabilities that Prosigna produces more net benefit than current
practice at these WTP thresholds are 0.24 and 0.55, respectively.
Deterministic sensitivity analysis
The results of the DSAs for Prosigna are presented in Table 46 (shaded cells reflect analyses that are
unchanged from the EAG’s base case). The DSAs indicate the following:
l LN0 NPI ≤ 3.4 – the ICER for Prosigna versus current practice is estimated to be > £71,000 per QALY
gained across all scenarios.
l LN0 NPI > 3.4 – the ICER for Prosigna versus current practice is estimated to be < £30,000 per QALY
gained across most scenarios. The DSAs indicate that the ICER for Prosigna versus current practice is
> £30,000 per QALY gained for scenarios in which (1) an older start age is assumed and (2) the RR of
distant metastases for chemotherapy versus no chemotherapy is set equal to 0.80.
l LN1–3 – the ICER for Prosigna versus current practice is estimated to be consistently below £38,000 per
QALY gained across all analyses. Less favourable ICERs were estimated for scenarios in which (1) the
disutility associated with chemotherapy-related AEs is doubled, (2) an older cohort age is assumed,
(3) the RR of distant metastases for chemotherapy versus no chemotherapy is set equal to 0.80, (4) the
cost of chemotherapy is doubled, (5) the costs of treating local and distant recurrence are halved,
(6) the mortality rate for distant metastases is halved and (7) the cost per test is assumed to be increased
owing to lower efficiency. The analysis in which risk classification probabilities and associated DMFS
probabilities were taken from Gnant et al.104 was not evaluable as no events occurred at 10 years within
the low-risk Prosigna category.
COST-EFFECTIVENESS
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TABLE 43 Deterministic sensitivity analyses: IHC4+C vs. current practice
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Base case (deterministic) 0.01 £22.43 £2752 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
LN0 NPI ≤ 3.4 post-test P(chemotherapy) (NHSE183) 0.01 £94.18 £9265 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.01 £390.39 £36,259 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.01 £195.20 £15,875 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
LN0 NPI > 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.01 £22.43 £2752 0.05 £194.16 £4147 0.05 –£269.39 Dominating
LN0 NPI > 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.01 £22.43 £2752 0.03 £52.99 £1864 0.05 –£269.39 Dominating
LN0 NPI > 3.4 post-test P(chemotherapy)
(UKBCG survey)
0.01 £22.43 £2752 0.02 £23.00 £1040 0.05 –£269.39 Dominating
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Holt et al.141)
0.01 £22.43 £2752 0.06 £262.95 £4760 0.05 –£269.39 Dominating
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Loncaster et al.145 LN0 subgroup)
0.01 £22.43 £2752 0.04 £121.78 £3305 0.05 –£269.39 Dominating
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(UKBCG survey)
0.01 £22.43 £2752 0.03 £91.80 £3005 0.05 –£269.39 Dominating
LN+ post-test P(chemotherapy) (UKBCG survey) 0.01 £22.43 £2752 0.01 –£89.12 Dominating 0.09 £167.12 £1929
Ward et al.1 scenario: baseline P(chemotherapy)
(WMCIU), post-test P(chemotherapy)
(Holt et al.141)
0.01 £22.43 £2752 0.06 £325.33 £5160 0.05 –£269.39 Dominating
continued
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TABLE 43 Deterministic sensitivity analyses: IHC4+C vs. current practice (continued )
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Chemotherapy disutility doubled 0.01 £22.43 £2304 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
Chemotherapy disutility halved 0.01 £22.43 £3049 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
Start age based on TransATAC38,46 (64 years) 0.01 £23.21 £3542 0.01 –£88.85 Dominating 0.04 –£264.75 Dominating
Farkkila et al.204 utilities (RFS = 0.818, DM = 0.746) 0.01 £22.43 £2802 0.01 –£89.12 Dominating 0.05 –£269.39 Dominating
Chemotherapy RR = 0.70 0.01 £19.09 £2138 0.01 –£86.90 Dominating 0.06 –£314.00 Dominating
Chemotherapy RR = 0.80 0.01 £24.62 £3223 0.01 –£90.60 Dominating 0.05 –£240.14 Dominating
No risk tapering 0.01 £19.17 £2221 0.00 –£51.24 Dominating 0.06 –£282.61 Dominating
Distant metastases death rate doubled 0.01 £28.48 £3309 0.01 –£93.23 Dominating 0.06 –£188.59 Dominating
Distant metastases death rate halved 0.01 £12.78 £1722 0.01 –£82.69 Dominating 0.04 –£398.33 Dominating
AML removed 0.00 £26.13 £5560 0.00 –£83.05 Dominating 0.04 –£260.08 Dominating
Chemotherapy cost doubled 0.01 –£108.78 Dominating 0.01 –£326.21 Dominating 0.05 –£499.21 Dominating
Chemotherapy cost halved 0.01 £88.03 £10,803 0.01 £29.42 £4056 0.05 –£154.48 Dominating
Endocrine therapy costs doubled 0.01 £22.45 £2755 0.01 –£89.10 Dominating 0.05 –£269.11 Dominating
Endocrine therapy costs halved 0.01 £22.41 £2751 0.01 –£89.14 Dominating 0.05 –£269.53 Dominating
Local and distant recurrence costs doubled 0.01 £8.80 £1079 0.01 –£79.87 Dominating 0.05 –£451.35 Dominating
Local and distant recurrence costs halved 0.01 £29.24 £3588 0.01 –£93.75 Dominating 0.05 –£178.41 Dominating
DM, distant metastasis; NHSE, NHS England; P(chemotherapy), probability of receiving chemotherapy; RFS, recurrence-free survival; WMCIU, West Midlands Cancer Intelligence Unit.
Note
Shaded cells reflect analyses that are unchanged from the EAG’s base case.
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EndoPredict Clinical versus current practice
Central estimates of cost-effectiveness: probabilistic
Central estimates of cost-effectiveness for EPClin versus current practice are presented in Table 47. All
estimates are based on the probabilistic version of the EAG model. Within the LN0 NPI ≤ 3.4 subgroup,
EPClin is expected to produce 0.01 additional QALYs at an additional cost of £1679 per woman tested
compared with current practice; this corresponds to an ICER of £147,419 per QALY gained. Within the
LN0 NPI > 3.4 subgroup, EPClin is expected to produce 0.03 additional QALYs at an additional cost of
£1388 per woman tested compared with current practice; the corresponding ICER is £46,788 per QALY
gained. Within the LN1–3 subgroup, EPClin is expected to produce 0.05 additional QALYs at an additional
cost of £1164 per woman tested compared with current practice; the corresponding ICER is £21,458 per
QALY gained. As shown in Table 48, the PSA indicates that within the LN0 NPI ≤ 3.4 subgroup, the
probability that EPClin produces more net benefit than current practice at WTP thresholds of £20,000
and £30,000 per QALY gained is zero. Within the LN0 NPI > 3.4 subgroup, the probabilities that EPClin
produces more net benefit than current practice at these WTP thresholds are 0.09 and 0.26, respectively.
Within the LN1–3 subgroup, the probabilities that EPClin produces more net benefit than current practice
at these WTP thresholds are 0.44 and 0.73, respectively.
TABLE 44 Central estimates of cost-effectiveness: Prosigna vs. current practice – probabilistic model
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
LN0 NPI ≤ 3.4
Prosigna 13.87 £6201 0.02 £1884 £91,028
No test 13.84 £4318 – – –
LN0 NPI > 3.4
Prosigna 12.65 £13,330 0.06 £1686 £26,058
No test 12.59 £11,644 – – –
LN1–3
Prosigna 12.47 £15,172 0.07 £1936 £28,731
No test 12.40 £13,236 – – –
TABLE 45 Probability of optimality: Prosigna vs. current practice
Subgroup
Probability (λ= £20,000 per QALY gained) Probability (λ= £30,000 per QALY gained)
Prosigna Current practice Prosigna Current practice
LN0 NPI ≤ 3.4 0.00 1.00 0.00 1.00
LN0 NPI > 3.4 0.24 0.76 0.60 0.40
LN1–3 0.24 0.76 0.55 0.45
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TABLE 46 Deterministic sensitivity analyses: Prosigna vs. current practice
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Base case (deterministic) 0.02 £1891.35 £89,693 0.07 £1712.67 £25,857 0.07 £1966.54 £28,666
LN0 NPI ≤ 3.4 post-test P(chemotherapy) (NHSE183) 0.02 £2025.87 £84,090 0.07 £1712.67 £25,857 0.07 £1966.54 £28,666
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.02 £2421.22 £109,620 0.07 £1712.67 £25,857 0.07 £1966.54 £28,666
LN0 NPI ≤ 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.02 £2213.71 £93,938 0.07 £1712.67 £25,857 0.07 £1966.54 £28,666
LN0 NPI > 3.4 post-test P(chemotherapy)
(Holt et al.141)
0.02 £1891.35 £89,693 0.10 £1991.89 £19,356 0.07 £1966.54 £28,666
LN0 NPI > 3.4 post-test P(chemotherapy)
(Loncaster et al.145)
0.02 £1891.35 £89,693 0.09 £1993.10 £21,216 0.07 £1966.54 £28,666
LN0 NPI > 3.4 post-test P(chemotherapy)
(UKBCG survey)
0.02 £1891.35 £89,693 0.08 £1820.85 £22,420 0.07 £1966.54 £28,666
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Holt et al.141)
0.02 £1891.35 £89,693 0.11 £2056.25 £18,288 0.07 £1966.54 £28,666
LN0 NPI > 3.4 baseline P(chemotherapy)
(NCRAS184), post-test P(chemotherapy)
(Loncaster et al.145 LN0 subgroup)
0.02 £1891.35 £89,693 0.09 £1922.48 £20,971 0.07 £1966.54 £28,666
LN0 NPI > 3.4 baseline P(chemotherapy) NCRAS184,
post-test P(chemotherapy) (UKBCG survey)
0.02 £1891.35 £89,693 0.09 £1885.20 £20,774 0.07 £1966.54 £28,666
LN+ post-test P(chemotherapy) (UKBCG survey) 0.02 £1891.35 £89,693 0.07 £1712.67 £25,857 0.11 £2227.53 £20,427
Ward et al.1 scenario: baseline P(chemotherapy)
(WMCIU), post-test P(chemotherapy) (Holt et al.141)
0.02 £1891.35 £89,693 0.13 £2109.68 £16,568 0.07 £1966.54 £28,666
Risk classification and DMFS probabilities from
Gnant et al.104 LN+ subgroup
0.02 £1891.35 £89,693 0.07 £1712.67 £25,857 Not evaluable
10% lower cost per test owing to increased
efficiency (local NHS testing)
0.02 £1694.00 £80,348 0.07 £1516 £22,882 0.07 £1769 £25,794
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Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
10% higher cost per test owing to decreased
efficiency (local NHS testing)
0.02 £2088 £99,038 0.07 £1910 £28,832 0.07 £2164 £31,539
Chemotherapy disutility doubled 0.02 £1891.35 £90,123 0.07 £1712.67 £25,935 0.07 £1966.54 £30,026
Chemotherapy disutility halved 0.02 £1891.35 £89,480 0.07 £1712.67 £25,818 0.07 £1966.54 £28,032
Start age based on TransATAC38,46 (64 years) 0.02 £1893.35 £115,741 0.05 £1718.65 £33,348 0.05 £1973.37 £37,480
Farkkila et al.204 utilities (RFS = 0.818, DM = 0.746) 0.02 £1891.35 £93,183 0.06 £1712.67 £26,854 0.07 £1966.54 £29,913
Chemotherapy RR = 0.70 0.03 £1869.14 £71,107 0.08 £1643.59 £19,926 0.09 £1884.89 £21,508
Chemotherapy RR = 0.80 0.02 £1905.92 £107,875 0.06 £1757.96 £31,645 0.06 £2020.11 £36,018
No risk tapering 0.02 £1870.73 £78,043 0.07 £1681.49 £23,298 0.08 £1874.66 £23,138
Distant metastases death rate doubled 0.02 £1931.61 £80,059 0.08 £1837.80 £24,281 0.08 £2114.58 £26,505
Distant metastases death rate halved 0.02 £1827.15 £112,523 0.05 £1513.02 £29,575 0.05 £1730.53 £34,081
AML removed 0.02 £1892.76 £91,182 0.06 £1717.28 £26,432 0.07 £1965.75 £26,851
Chemotherapy cost doubled 0.02 £1899.68 £90,088 0.07 £1729.27 £26,107 0.07 £2223.61 £32,414
Chemotherapy cost halved 0.02 £1887.19 £89,496 0.07 £1704.37 £25,731 0.07 £1838.01 £26,793
Endocrine therapy costs doubled 0.02 £1891.48 £89,699 0.07 £1713.06 £25,863 0.07 £1966.96 £28,673
Endocrine therapy costs halved 0.02 £1891.29 £89,690 0.07 £1712.47 £25,854 0.07 £1966.33 £28,663
Local and distant recurrence costs doubled 0.02 £1800.69 £85,393 0.07 £1430.87 £21,602 0.07 £1633.14 £23,806
Local and distant recurrence costs halved 0.02 £1936.69 £91,843 0.07 £1853.57 £27,984 0.07 £2133.24 £31,096
DM, distant metastasis; NHSE, NHS England; P(chemotherapy), probability of receiving chemotherapy; RFS, recurrence-free survival; WMCIU, West Midlands Cancer Intelligence Unit.
Note
Shaded cells reflect analyses that are unchanged from the EAG’s base case.
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Deterministic sensitivity analysis
The results of the DSAs for EPClin are presented in Table 49 (shaded cells reflect analyses that are
unchanged from the EAG’s base case). The DSAs indicate the following:
l LN0 NPI ≤ 3.4 – the ICER for EPClin versus current practice remains in excess of £91,000 per QALY
gained across all scenarios.
l LN0 NPI > 3.4 – the ICER for EPClin versus current practice remains in excess of £30,000 per QALY
gained across almost all of the analyses. The exceptions are the scenarios in which (1) the UKBCG
survey is used to inform the probability of receiving chemotherapy conditional on the EPClin test result
and (2) Cusumano et al.167 is used to inform the probability of receiving chemotherapy conditional on
the EPClin test result.
l LN1–3 – the ICER for EPClin versus current practice remains < £30,000 per QALY gained across
all scenarios.
MammaPrint versus current practice (Modified Adjuvant! Online)
Central estimates of cost-effectiveness: probabilistic
Central estimates of cost-effectiveness for MammaPrint versus current practice (mAOL) are presented in
Table 50. Estimates are based on the probabilistic version of the EAG model. Within the overall MINDACT
population, MammaPrint is expected to produce 0.01 additional QALYs at an additional cost of £1760 per
woman tested compared with current practice; this corresponds to an ICER of £131,482 per QALY gained.
Within the mAOL high-risk subgroup, MammaPrint is expected to produce 0.04 fewer QALYs at an
additional cost of £1413; within this subgroup, MammaPrint is expected to be dominated by current practice.
Within the mAOL low-risk subgroup, MammaPrint is expected to generate an additional 0.01 QALYs at an
TABLE 47 Central estimates of cost-effectiveness: EPClin vs. current practice – probabilistic model
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
LN0 NPI ≤ 3.4
EPClin 13.85 £6034 0.01 £1679 £147,419
No test 13.84 £4355 – – –
LN0 NPI > 3.4
EPClin 12.71 £12,612 0.03 £1388 £46,788
No test 12.68 £11,224 – – –
LN1–3
EPClin 12.52 £14,080 0.05 £1164 £21,458
No test 12.46 £12,916 – – –
TABLE 48 Probability of optimality: EPClin vs. current practice
Subgroup
Probability (λ= £20,000 per QALY gained) Probability (λ= £30,000 per QALY gained)
EPClin Current practice EPClin Current practice
LN0 NPI ≤ 3.4 0.00 1.00 0.00 1.00
LN0 NPI > 3.4 0.09 0.91 0.26 0.74
LN0 (one to three nodes) 0.44 0.56 0.73 0.27
COST-EFFECTIVENESS
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TABLE 49 Deterministic sensitivity analyses: EPClin vs. current practice
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Base case (deterministic) 0.01 £1685.68 £141,848 0.03 £1400.62 £46,482 0.06 £1184.94 £21,489
Post-test P(chemotherapy) (UKBCG survey) 0.01 £1470.85 £101,514 0.06 £1630.80 £25,250 0.12 £1632.35 £13,132
Chemotherapy disutility doubled 0.01 £1685.68 £181,242 0.03 £1400.62 £46,938 0.06 £1184.94 £21,140
Chemotherapy disutility halved 0.01 £1685.68 £127,943 0.03 £1400.62 £46,257 0.05 £1184.94 £21,667
Risk classification and DMFS (Dubsky et al.119
LN+ subgroup)
0.01 £1685.68 £141,848 0.03 £1400.62 £46,482 0.05 £1179.22 £21,450
Post-test P(chemotherapy) (Penault-Llorca et al.56
LN0 subgroup)
0.02 £1515.12 £91,800 0.04 £1425.80 £33,212 0.06 £1184.94 £21,489
Post-test P(chemotherapy) (Cusumano et al.167) 0.02 £1673.61 £109,964 0.06 £1532.67 £26,689 0.14 £1668.00 £12,205
10% lower cost per test owing to increased
efficiency (local NHS testing)
0.01 £1536 £129,225 0.03 £1251 £41,504 0.06 £1035 £18,768
Start age based on TransATAC38,46 (64 years) 0.01 £1687.17 £194,520 0.02 £1403.45 £60,061 0.04 £1190.15 £27,705
Farkkila et al.204 utilities (RFS = 0.818,
DM = 0.746)
0.01 £1685.68 £150,858 0.03 £1400.62 £48,314 0.05 £1184.94 £22,275
Chemotherapy RR = 0.70 0.02 £1664.55 £99,445 0.04 £1368.43 £36,317 0.07 £1130.67 £16,663
Chemotherapy RR = 0.80 0.01 £1699.55 £195,508 0.03 £1421.74 £56,485 0.05 £1220.54 £26,089
No risk tapering 0.02 £1638.80 £94,376 0.03 £1380.99 £41,242 0.06 £1146.32 £18,707
Distant metastases death rate doubled 0.01 £1724.04 £116,644 0.03 £1458.96 £42,242 0.06 £1283.29 £20,510
Distant metastases death rate halved 0.01 £1624.61 £223,409 0.02 £1307.57 £56,592 0.04 £1028.09 £23,745
AML removed 0.02 £1681.60 £99,734 0.03 £1402.34 £46,797 0.05 £1190.90 £22,954
continued
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TABLE 49 Deterministic sensitivity analyses: EPClin vs. current practice (continued )
Scenario
Subgroup
LN0 NPI ≤ 3.4 LN0 NPI > 3.4 LN1–3
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Chemotherapy cost doubled 0.01 £1899.47 £159,838 0.03 £1424.85 £47,286 0.06 £1109.61 £20,122
Chemotherapy cost halved 0.01 £1578.79 £132,853 0.03 £1388.51 £46,080 0.06 £1222.61 £22,172
Endocrine therapy costs doubled 0.01 £1685.77 £141,855 0.03 £1400.80 £46,488 0.06 £1185.25 £21,494
Endocrine therapy costs halved 0.01 £1685.64 £141,844 0.03 £1400.53 £46,479 0.06 £1184.79 £21,486
Local and distant recurrence costs doubled 0.01 £1599.30 £134,579 0.03 £1269.24 £42,122 0.06 £963.46 £17,472
Local and distant recurrence costs halved 0.01 £1728.87 £145,482 0.03 £1466.31 £48,662 0.06 £1295.69 £23,497
DM, distant metastasis; P(chemotherapy), probability of receiving chemotherapy; RFS, recurrence-free survival.
Note
Shaded cells reflect analyses that are unchanged from the EAG’s base case.
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additional cost of £2410; this corresponds to an expected ICER of £414,202 per QALY gained. The PSA
indicates that within the overall MINDACT population and both subgroups, the probability that MammaPrint
produces more net benefit than current practice at WTP thresholds of £20,000 and £30,000 per QALY
gained is approximately zero (Table 51).
Deterministic sensitivity analysis
The results of the DSAs for MammaPrint are presented in Table 52 (shaded cells reflect analyses that are
unchanged from the EAG’s base case). The DSAs indicate the following:
l Within the overall MINDACT population, the ICER for MammaPrint versus current practice is estimated
to be > £76,000 per QALY gained across all scenarios.
l Within the mAOL high-risk subgroup, MammaPrint is dominated by current practice across almost
all scenarios. The most favourable ICER relates to the scenario in which the probability of receiving
chemotherapy under current practice is halved.
l Within the mAOL low-risk subgroup, the ICER for MammaPrint versus current practice is > £161,000
per QALY gained across all analyses.
TABLE 50 Central estimates of cost-effectiveness: MammaPrint vs. current practice (mAOL) – probabilistic model
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
MINDACT ITT population
MammaPrint 13.51 £9151 0.01 £1760 £131,482
No test 13.49 £7391 – – –
MINDACT mAOL high-risk subgroup
MammaPrint 12.86 £12,727 –0.04 £1413 Dominated
No test 12.90 £11,313 – – –
MINDACT mAOL low-risk subgroup
MammaPrint 13.70 £7777 0.01 £2410 £414,202
No test 13.69 £5366 – – –
TABLE 51 Probability of optimality: MammaPrint vs. current practice (mAOL)
Subgroup
Probability (λ= £20,000 per QALY gained) Probability (λ= £30,000 per QALY gained)
MammaPrint Current practice MammaPrint Current practice
MINDACT overall population 0.00 1.00 0.00 1.00
mAOL high-risk subgroup 0.00 1.00 0.00 1.00
mAOL low-risk subgroup 0.00 1.00 0.00 1.00
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TABLE 52 Deterministic sensitivity analyses: MammaPrint vs. current practice (mAOL)
Scenario
Subgroup
MINDACT ITT population MINDACT mAOL high-risk subgroup MINDACT mAOL low-risk subgroup
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Base case (deterministic) 0.01 £1756.58 £134,059 –0.04 £1380.11 Dominated 0.01 £2415.05 £399,182
Risk classification and DMFS probabilities
(van ‘t Veer et al.91)
0.01 £1609.52 £169,183 –0.04 £1380.11 Dominated 0.01 £2415.05 £399,182
ER+, HER2–, LN0 subgroup 0.01 £1756.58 £134,059 –0.04 £1400.94 Dominated 0.01 £2415.05 £399,182
Post-test P(chemotherapy) (Penault-Llorca
et al.56 LN0 subgroup)
0.02 £1724.59 £97,939 –0.03 £1386.99 Dominated 0.01 £2291.88 £257,484
Post-test P(chemotherapy) (Cusumano
et al.167)
0.02 £1874.42 £91,453 –0.01 £1492.18 Dominated 0.01 £2454.55 £336,904
Post-test P(chemotherapy) (UKBCG) 0.01 £1610 £130,970 –0.01 £1601 Dominated –0.01 £3421 Dominated
MammaPrint low-risk patients receive no
chemotherapy; MammaPrint high-risk
patients all receive chemotherapy
0.02 £1846.54 £76,201 0.00 £1497.09 £375,444 0.01 £2350.50 £242,895
Baseline chemotherapy probabilities halved 0.03 £2512.88 £96,782 0.07 £2243.31 £32,800 0.00 £2704.26 £903,528
Chemotherapy disutility doubled 0.02 £1756.58 £93,877 –0.03 £1380.11 Dominated 0.00 £2415.05 £503,351
Chemotherapy disutility halved 0.01 £1756.58 £170,560 –0.05 £1380.11 Dominated 0.01 £2415.05 £361,750
Start age based on TransATAC38,46
(64 years)
0.01 £1757.57 £158,110 –0.03 £1374.22 Dominated 0.00 £2415.84 £547,979
Farkkila et al.204 utilities (RFS = 0.818,
DM = 0.746)
0.01 £1756.58 £133,215 –0.04 £1380.11 Dominated 0.01 £2415.05 £423,893
Chemotherapy RR = 0.70 0.01 £1762.13 £148,424 –0.06 £1431.22 Dominated 0.01 £2377.25 £161,338
Chemotherapy RR = 0.80 0.01 £1753.86 £127,971 –0.03 £1296.55 Dominated 0.01 £2403.58 £276,670
No risk tapering 0.01 £1784.24 £173,280 –0.07 £1591.64 Dominated 0.01 £2391.23 £270,639
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Scenario
Subgroup
MINDACT ITT population MINDACT mAOL high-risk subgroup MINDACT mAOL low-risk subgroup
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Incremental
QALYs
Incremental
costs ICER
Distant metastases death rate doubled 0.01 £1747.73 £140,551 –0.06 £1218.99 Dominated 0.01 £2434.08 £325,055
Distant metastases death rate halved 0.01 £1770.62 £125,010 –0.03 £1636.40 Dominated 0.00 £2384.61 £636,029
AML removed 0.00 £1768.44 £1,353,592 –0.07 £1401.41 Dominated 0.01 £2413.62 £291,353
Chemotherapy cost doubled 0.01 £1292.39 £98,632 –0.04 £351.31 Dominated 0.01 £2518.68 £416,311
Chemotherapy cost halved 0.01 £1988.67 £151,772 –0.04 £1894.51 Dominated 0.01 £2363.24 £390,617
Endocrine therapy costs doubled 0.01 £1756.59 £134,060 –0.04 £1379.77 Dominated 0.01 £2415.09 £399,189
Endocrine therapy costs halved 0.01 £1756.57 £134,058 –0.04 £1380.28 Dominated 0.01 £2415.03 £399,178
Local and distant recurrence costs doubled 0.01 £1776.51 £135,580 –0.04 £1743.07 Dominated 0.01 £2372.26 £392,109
Local and distant recurrence costs halved 0.01 £1746.61 £133,298 –0.04 £1198.63 Dominated 0.01 £2436.45 £402,719
DM, distant metastasis; P(chemotherapy), probability of receiving chemotherapy; RFS, recurrence-free survival.
Note
Shaded cells reflect analyses that are unchanged from the EAG’s base case.
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Comparison between the Genomic Health model, the current External Assessment
Group model and the previous External Assessment Group model (lymph node
negative, clinical intermediate-risk subgroup)
There are notable differences between the cost-effectiveness estimates for oncotype DX versus current
practice generated using the current EAG model and those produced using the Genomic Health model62
(see Appendix 7) and the earlier EAG model reported by Ward et al.:1
l The current EAG model indicates that within the ER+ LN0 NPI > 3.4 subgroup, oncotype DX is expected
to be dominated by current practice. This finding sharply contrasts with the findings of the Genomic
Health model and the previous EAG model.
l The Genomic Health model62 produces a base-case ICER of (confidential information has been removed)
per QALY gained, assuming that the test is used for women with ER+, LN0 early-stage breast cancer
who are deemed to be at clinical intermediate risk.
l The previous EAG model (Ward et al.1) produced a base-case ICER for oncotype DX versus current
practice of £22,572 per QALY gained, assuming that the test is given to women with ER+, LN0
early-stage breast cancer with NPI > 3.4 (deemed to be at clinical intermediate risk).
In order to understand the differences between these results, it is important to consider the differences
between the key parameters and structural assumptions between the three models (Table 53):
l The general modelling approach is very similar between the three models, although the Ward et al.1
model defined test risk classification in accordance with both oncotype DX Breast Recurrence Score and
IHC4, rather than oncotype DX Breast Recurrence Score only.
l Within the original and current EAG models, data on risk reclassification (the proportion of patients
with a low, intermediate and high recurrence score) were taken from analyses of the TransATAC trial46
(albeit using different data sets). Conversely, the Genomic Health model derives these proportions from
the NHS England Access Scheme Database.183
l Data on the risk of distant recurrence in the absence of chemotherapy were taken from the ATAC trial
in all three models.198 The updated EAG model uses newer data from the ATAC trial.46
l The proportions of women who are assumed to receive chemotherapy conditional on the oncotype DX
risk score were taken from the NHS England Access Scheme Database183 in both the updated EAG
model and the Genomic Health model. Ward et al.1 used unpublished data (Holt et al.141) to estimate
the probability of receiving chemotherapy conditional on oncotype DX Breast Recurrence Score.
l The proportion of patients receiving chemotherapy in the standard care arm was taken from the NHS
England Access Scheme Database183 in both the updated EAG model and the Genomic Health model.
Conversely, Ward et al.1 derived estimates of these proportions from English cancer registry data sets.
l Within both the current and earlier EAG models, the benefit of chemotherapy was assumed to be
constant across all oncotype DX Breast Recurrence Score classifications (non-predictive); the RR of
distant recurrence was taken from EBCTCG meta-analyses. The current EAG model uses a different
mathematical approach to apply this RR, which ensures that modelled treatment effect at 10 years is
maintained within the Markov trace.
l The Genomic Health model assumes a predictive benefit and uses different treatment effects across the
low, intermediate and high recurrence score classifications, based on Paik et al.50 These differential
effects are applied only to the oncotype DX testing group; a constant treatment effect is applied in the
current practice group.
l The current and earlier EAG models both apply a HRQoL decrement associated with short-term
chemotherapy-related AEs in the first model cycle. In contrast, the Genomic Health model applies a
decrement during every model cycle; the implicit assumption is that patients who receive adjuvant
chemotherapy remain less well, relative to those do not receive adjuvant chemotherapy, for the
remainder of their lives.
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As described in Appendix 7, the EAG identified several errors within the Genomic Health model. Three key
errors are corrected here:
1. The application of risk reclassification in the model. Although Genomic Health use data from the NHS
England Access Scheme Database for the risk reclassification, this is applied incorrectly in the model.
This can be seen by examining the proportion of women receiving chemotherapy predicted by the
model. The NHS England Access Scheme data were provided as AiC and cannot be reported here.62
2. The application of the HRQoL decrement associated with chemotherapy-related AEs. The Genomic
Health dossier62 stated that the utilities in their model were the same as those used by Ward et al.
(2013)1 (page 159), and Table 6-4 (page 159) of the dossier states that the disutility associated with
chemotherapy is –0.038. However, the Genomic Health model applies this decrement for women
receiving chemotherapy during every model cycle, including for decades after the adjuvant treatment
has been discontinued. This overestimates the health losses associated with chemotherapy and is
therefore favourable to oncotype DX, as the test is estimated to reduce the proportion of women
receiving chemotherapy.
3. Predictive chemotherapy benefit. The Genomic Health model assumes that women with a low, intermediate
and high oncotype DX Breast Recurrence Score experience different benefits of chemotherapy in the
modelled oncotype DX group compared with the same patients across these recurrence score classifications
in the modelled current practice group. Irrespective of whether oncotype DX is predictive of chemotherapy
benefit, the modelling approach adopted by the company is illogical, as the benefits of chemotherapy
for women within these recurrence score classifications will be identical irrespective of whether the test
is used to classify that level of risk or not (they are exactly the same patients).
In order to understand the differences between the results of the three models, the errors identified above
were corrected by the EAG. In addition, the Genomic Health model was modified to assume a prognostic
benefit only, thereby making it consistent with the current EAG base-case model. The earlier EAG model
(Ward et al.1) was also modified to include the chemotherapy probabilities (with and without the test) from
TABLE 53 Summary of structural assumptions and evidence sources
Assumption/evidence
source Current EAG model Genomic Health model62
Original EAG model
(Ward et al.1)
Approach Risk classification based on
oncotype DX RS
Risk classification based on
oncotype DX RS
Risk classification
based on oncotype
DX RS and IHC4
Data on risk classification TransATAC46 NHS England Access Scheme
Database183
TransATAC46
Data on ROR TransATAC46 (updated) TransATAC46 TransATAC46
Proportion of people receiving
chemotherapy in the oncotype
DX arm
NHS England Access Scheme
Database183
NHS England Access Scheme
Database183
Holt et al.141
Proportion of people receiving
chemotherapy in the standard
care arm
NHS England Access Scheme
Database183
NHS England Access Scheme
Database183
Registry data
Benefit of adjuvant
chemotherapy
No predictive effect (based
on EBCTCG meta-analysis)
Predictive effect only in the
oncotype DX group. No
predictive effect assumed in
people with same risk score in
current practice group
No predictive effect
(based on EBCTCG
meta-analysis)
HRQoL decrement associated
with chemotherapy
Applied to the first cycle only Applied to all model cycles over
patients’ remaining lifetimes
Applied to the first
cycle only
RS, recurrence score.
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the NHS England Access Scheme Database. Although there are other differences between the models,
these are more difficult to align across the models and/or are expected to have only a negligible impact on
results. The results of the current EAG model, the amended Ward et al.1 model and the corrected Genomic
Health model are presented in Table 54.
In the scenario in which all three models use pre- and post-test chemotherapy probabilities from the NHS
England Access Scheme Database and no predictive benefit is assumed, all three models produce the
same economic conclusion: oncotype DX is dominated by current practice. When a predictive effect is
incorporated into these versions of the models, these three models consistently suggest that oncotype DX
has an ICER that is < £7000 per QALY gained.
Discussion
The EAG undertook a systematic review of existing economic evaluations of tumour profiling tests to guide
treatment decisions in people with early-stage breast cancer (see Appendix 6). Only those studies that
were published since the previous appraisal of tumour profiling tests (NICE DG1020) were included in the
review. The review suggests a high level of consistency in terms of the general modelling approach and
structure: the majority of published models adopted a decision tree–Markov approach based on test risk
classification and DMFS outcomes conditional on test risk classification probabilities. None of the published
analyses included all relevant tumour profiling tests listed in the final NICE scope.
Two manufacturers provided economic evidence to inform the appraisal (Agendia94 and Genomic Health62)
(see Appendix 7). The models developed to inform these two analyses were made available to the EAG for
scrutiny. In addition, the chief investigator of the EndoPredict UK decision impact study provided a draft
cost-effectiveness paper that compares EPClin with AOL.182 The model supporting this analysis was not
made available to the EAG.
Agenda submitted a model, which was critiqued by the EAG as part of the assessment process, but it
cannot be reported here as Agendia withdrew permission to reproduce the model.
Genomic Health provided a model that compares oncotype DX with current practice in patients with LN0
early-stage breast cancer. The EAG notes that the model includes a number of errors. Based on the
uncorrected model, the Genomic Health submission presents a base-case ICER for oncotype DX versus
current practice of (confidential information has been removed) per QALY gained. Three errors were
corrected by the EAG [see Comparison between the Genomic Health model, the current External
Assessment Group model and the previous External Assessment Group model (lymph node-negative,
clinical intermediate-risk subgroup)]; these relate to (1) the incorrect application of risk classifications,
(2) the application of health losses associated with short-term chemotherapy-related AEs during every model
cycle and (3) the inconsistent handling of predictive benefits of chemotherapy between the test and no-test
groups. The EAG’s corrected version of the model suggests that under the assumption of no predictive
benefit of chemotherapy, oncotype DX is dominated by current practice. When the test is assumed to be
predictive of chemotherapy benefit, the ICER for oncotype DX versus current practice is estimated to be
(confidential information has been removed) per QALY gained. The EAG notes that other errors may remain
within the company’s model.
The draft cost-effectiveness paper assessing EPClin versus AOL suggests that the expected ICER for EPClin
versus AOL is £26,836 per QALY gained. The EAG has some concerns regarding this analysis, in particular
the use of separate evidence sources to estimate test risk classification probabilities and DMFS probabilities
conditional on test risk classification.
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TABLE 54 Comparison of ICERs generated using the current EAG model, the previous EAG model and the Genomic Health model (LN0 NPI > 3.4 subgroup)
Model
QALYs Costs
Incremental
QALYs Incremental costs ICER
Oncotype
DX
No
test Oncotype DX No test
Assuming no predictive effect
Current EAG model (no predictive effect) 12.68 12.70 £11,249 £10,380 –0.02 £869 Dominated
Uncorrected Genomic Health model62
(with predictive effect)
10.50 10.43 Confidential information
has been removed
Confidential information
has been removed
0.07 Confidential information
has been removed
Confidential information
has been removed
Corrected Genomic Health model
(no predictive effect)
10.59 10.62 Confidential information
has been removed
Confidential information
has been removed
–0.03 Confidential information
has been removed
Confidential information
has been removed
Ward et al.1 model (no predictive effect) 12.85 12.80 £10,172 £8897 0.06 £1275 £22,572
Ward et al.1 model, including NHS England
Access Scheme Database for proportion
of people who receive chemotherapy
(no predictive effect)
12.83 12.83 £9861 £9253 –0.00 £608 Dominated
Assuming predictive effect
Current EAG model (predictive effect) 12.87 12.60 £10,457 £10,822 0.27 –£364 Dominating
Uncorrected Genomic Health model62
(predictive effect)
10.50 10.43 Confidential information
has been removed
Confidential information
has been removed
0.07 Confidential information
has been removed
Confidential information
has been removed
Corrected Genomic Health model
(predictive effect)
10.74 10.69 Confidential information
has been removed
Confidential information
has been removed
0.05 Confidential information
has been removed
Confidential information
has been removed
Ward et al.1 model (predictive effect) 13.06 12.83 £9681 £8816 0.23 £865 £3720
Ward et al.1 model, including NHS England
Access Scheme Database for proportion
of people who receive chemotherapy
(including predictive effect)
13.02 12.91 £9412 £9078 0.11 £334 £2917
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The EAG developed a de novo health economic model to assess the cost-effectiveness of oncotype DX,
MammaPrint, Prosigna, EPClin and IHC4+C, each versus current practice. The health economic analysis
was undertaken from the perspective of the NHS and PSS and was largely based on the model developed
to inform NICE DG10.1 The EAG model adopts a hybrid decision tree–Markov structure. The model
parameters were informed by a number of sources including a bespoke analysis of the TransATAC trial,46
the MINDACT trial,98 a bespoke analysis of the NCRAS data set,184 a bespoke survey disseminated by the
UKBCG, the NHS England Access Scheme Database,183 standard costing sources and other literature.
The EAG’s base-case model suggests the following results.
l Oncotype DX – within the LN0 NPI ≤ 3.4 subgroup, the ICER for oncotype DX versus current practice is
expected to be £122,725 per QALY gained (£34,245 per QALY gained assuming a predictive benefit).
Within the LN0 NPI > 3.4 and LN1–3 subgroups, oncotype DX is expected to be dominated by current
practice (conversely, oncotype DX dominates current practice if a predictive benefit is assumed). The
results generated using the EAG model are primarily driven by the modelled reduction in the use of
adjuvant chemotherapy using the oncotype DX test.
l IHC4+C – within the LN0 NPI ≤ 3.4 subgroup, the ICER for IHC4+C versus current practice is expected
to be £2654 per QALY gained. Within the LN0 NPI > 3.4 and LN1–3 subgroups, IHC4+C is expected to
dominate current practice.
l Prosigna – within the LN0 NPI ≤ 3.4 subgroup, the ICER for Prosigna versus current practice is expected
to be £91,028 per QALY gained. Within the LN0 NPI > 3.4 and LN1–3 subgroups, the ICERs for
Prosigna versus current practice are £26,058 and £28,731 per QALY gained, respectively.
l EPClin – within the LN0 NPI ≤ 3.4 subgroup, the ICER for EPClin versus current practice is expected to
be £147,419 per QALY gained. Within the LN0 NPI > 3.4 subgroup, the ICER for EPClin versus current
practice is expected to be £46,788 per QALY gained. Within the LN1–3 subgroup, the ICER for EPClin
versus current practice is expected to be £21,458 per QALY gained.
l MammaPrint – within the overall MINDACT population, the ICER for MammaPrint versus current practice
is expected to be £131,482 per QALY gained. Within the mAOL high-risk subgroup, MammaPrint is
expected to be dominated by current practice. Within the mAOL low-risk subgroup, the ICER for
MammaPrint versus current practice is expected to be £414,202 per QALY gained.
The EAG model is subject to the following strengths:
l The model structure is consistent with the general approach used in a number of previous economic
analyses of tumour profiling tests for early-stage breast cancer (see Appendix 6, Tables 69 and 70).
l For all tests, test risk classification probabilities and DMFS probabilities are derived from the same source –
this maintains correlation between these parameters and avoids the potential for spectrum bias to
produce spurious results.
l Within the LN0 intermediate-risk subgroup (NPI > 3.4, analysis of three-level tests), the probability of
receiving chemotherapy with and without the test is based on the same source – the NHS England
Access Scheme Database.183 The EAG takes the view that this source is likely to best reflect how the
three-level tumour profiling tests would be used in clinical practice in England. However, this evidence
source relates only to the clinical intermediate-risk group; the UK-specific evidence surrounding decision
impact within the LN0 NPI ≤ 3.4 and LN+ subgroups is considerably weaker.
l When based on the same test risk classification probabilities, recurrence rates and the same estimates
of pre- and post-test chemotherapy use, the EAG model produces similar results to the previous model
reported by Ward et al.1 and the Genomic Health model.62
l A large number of scenarios have been considered to explore the impact of alternative evidence choices
and assumptions on the cost-effectiveness of the alternative tests.
The EAG model is also subject to a number of limitations and uncertainties:
l Test risk classification probabilities and DMFS probabilities for oncotype DX, Prosigna, IHC4+C and
EPClin are based on a postmenopausal population only (TransATAC). It is expected that the tumour
profiling tests may also be used in premenopausal women.
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l The subgroups employed within the analysis are defined in accordance with NPI. In practice, other tools
may be used to define risk (e.g. Predict). The EAG explored the possibility of framing the analyses around
Predict; however, this was not possible as Predict scores were not available within either the TransATAC
data set or the NCRAS data set, nor was an analysis presented by Predict within the publication of the
MINDACT trial.98 It may be possible to calculate Predict scores within these data sets in the future;
however this would require access to the individual patient-level data.
l The analysis of MammaPrint using the MINDACT trial compares the test only against mAOL and may
therefore not reflect current practice in England. This issue is particularly relevant to determining the
baseline level of chemotherapy use for the current practice group within this population.
l Within the current practice group of the EAG model, the probability of receiving chemotherapy is assumed
to be the same irrespective of test risk score. This is unlikely to be realistic, as those with higher test risk
scores may already be more likely to receive adjuvant chemotherapy, and those with lower test risk scores
may already be less likely to receive adjuvant chemotherapy. It was possible to explore this assumption for
the evaluation of oncotype DX within the sensitivity analyses (and the conclusions were unchanged);
however, there were insufficient data available to undertake similar analyses for the other four tests.
l The TransATAC trial was the derivation study for IHC4+C. This means that there is potential for the
overestimation of prognostic performance; this leads to additional uncertainty around the likely
cost-effectiveness profile of this test.
l The MINDACT trial used to inform the analyses of MammaPrint is limited as this study does not provide
information regarding predictive benefit. In addition, the follow-up period for this study was limited to a
duration of 5 years.
l Across all analyses, it is clear that the model results are dependent on assumptions about pre- and
post-test chemotherapy use. This aspect of the evidence base is subject to considerable uncertainty. In
particular, there is only one UK-based decision impact study relating to a two-level tumour profiling test
(Bloomfield et al.159); the characteristics of patients enrolled into this study, and their relevance to the
modelled subgroups, are unclear. As shown in the DSAs, the use of alternative European studies162,167
and the UKBCG survey appear to lead to generally more favourable cost-effectiveness estimates for
EPClin and MammaPrint. In addition, the use of the Loncaster et al.145 study to estimate chemotherapy
use in the LN+ population may be biased as this study included a preselected population for whom
chemotherapy had already been recommended.
l As NanoString Technologies does not offer a centralised testing service for Prosigna, the cost per test
will depend on the efficiency of local testing centres and the number of tests undertaken within each
centre. This may affect the cost-effectiveness estimates presented here.
l The model does not include CHF as a long-term AE associated with adjuvant chemotherapy; this was
excluded from the model owing to a lack of evidence on the joint survival impact of CHF and metastatic
breast cancer. Although CHF is a more common event than AML, the development of cancer is likely to
have more serious consequences and is expected to be associated with a greater impact on health-care
resources.
l There is uncertainty surrounding whether or not oncotype DX is predictive of chemotherapy benefit;
based on the current EAG model, the inclusion of this potential test characteristic has a marked impact
on the conclusions drawn from the analysis. Although the ongoing TAILORx study may generate
additional evidence to inform this, the cut-off points used within this trial differ from those employed
within the TransATAC analysis.
l Overall, there remains uncertainty regarding the cost-effectiveness of all tests. It is noteworthy that the
inclusion of additional data collected through the NHS England Access Scheme Database has a
significant impact on the conclusions drawn from the oncotype DX analysis within NICE DG1020
(moving from an ICER of £22,572 per QALY gained to a situation in which oncotype DX is dominated
in the LN0 NPI > 3.4 subgroup). The EAG considers that additional UK-based data collection relating to
pre- and post-test chemotherapy use for EPClin, IHC4+C, Prosigna and MammaPrint may be important
in reducing existing uncertainty surrounding the cost-effectiveness of these tests.
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Chapter 4 Discussion and conclusions
Statement of principal findings
Clinical effectiveness: principal findings
The review included 153 studies across all five tests and across all outcomes listed in the NICE scope.
Among studies of LN0 patients receiving endocrine monotherapy, percentages categorised as high risk
ranged from 9% to 33% across all five tests. In LN+ patients, three tests (Prosigna/ROR-PT, EPClin and
IHC4+C) categorised far more (38% to 76%) LN+ patients than LN0 patients as being at high risk among
studies of endocrine monotherapy, whereas oncotype DX categorised a similar number as high risk in LN0
and LN+ groups. However, oncotype DX categorised more patients in the LN+ group as being at low risk
than other tests (57% for oncotype DX vs. 4–28% for other tests), but with worse 10-year DRFS/DRFI
outcomes (82% for oncotype DX vs. 95–100% for other tests).
In terms of prognostic performance, all tests had statistically significant prognostic power in unadjusted
analyses in LN0 and LN+ populations. However, RSPC was only validated in LN0 patients, and unadjusted
analyses using clinical cut-off points were not reported in the validation sets for IHC4 or IHC4+C. All tests
provided additional prognostic information over most commonly used clinicopathological factors and over
CTS and NPI in LN0 patients. Results were more varied in LN+ patients.
There was some evidence of differential chemotherapy benefit between risk groups for oncotype DX, as
shown by significant interaction tests between risk group and chemotherapy treatment in unadjusted analyses,
but interaction tests sometimes became non-significant when clinicopathological factors were adjusted for
and key LN0 data came from the derivation cohort (NSABP B-20) for oncotype DX, putting it at high risk of
bias. Oncotype DX RSPC (oncotype DX plus age, tumour size and grade) was prognostic but not statistically
significantly predictive for chemotherapy benefit, indicating that the incorporation of clinicopathological
factors (formally or informally in a clinical setting) in oncotype DX may reduce prediction of chemotherapy
benefit; this study also used NSABP B-20 and is at risk of bias as a consequence. Considering the limitations of
the available data, the EAG concludes that there remains uncertainty surrounding whether or not oncotype DX
is associated with a predictive benefit of chemotherapy (i.e. a difference in relative effect by genomic risk
group) and, if so, that there is uncertainty in the likely magnitude of this predictive effect in clinical practice.
Evidence relating to the ability of MammaPrint to predict benefit from chemotherapy was extremely limited.
Although the effect of chemotherapy was significant in high-risk groups and not in low-risk groups, interaction
tests between risk groups and chemotherapy treatment were not significant, suggesting that there was no
statistically significant difference in the effect of chemotherapy between risk groups.
For oncotype DX and MammaPrint, evidence from observational, non-comparative studies assessing the
impact of the test used prospectively in clinical practice suggested that recurrence/survival outcomes in
low-risk groups were acceptable even with low rates of chemotherapy. There was no similar evidence
relating to the other tests.
The MINDACT RCT for MammaPrint98 was the only RCT to have reported in full. It reported that for
patients who were high mAOL, low MammaPrint risk, chemotherapy gave a non-significant absolute
benefit of 1.5% in 5-year DMFS (p = 0.267). This met the primary objective in that the lower bound of the
95% CI for 5-year DMFS in the no-chemotherapy group was ≥ 92%. This finding was interpreted by the
authors as implying that patients who were high clinical risk but low MammaPrint risk could potentially
avoid chemotherapy. In patients who were low mAOL risk, high MammaPrint risk, chemotherapy gave an
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absolute benefit of 0.8%. This could be interpreted to mean that MammaPrint would not be a useful test
in mAOL-low-risk patients, as it would not alter treatment decisions.
Decision impact studies from the UK and Europe reported that the percentage of patients with any change
in chemotherapy recommendation or decision pre/post test ranged from 27% to 49% across UK studies
(included oncotype DX, EndoPredict and IHC4+C) and from 5% to 70% across European studies (included
all tests except IHC4). The net change in the percentage of patients with a chemotherapy recommendation
or decision pre/post test ranged from an increase of 1% to a decrease of 23% among UK studies and
from a decrease of 0% to a decrease of 64% across European studies.
Concordance between tests was not fully reviewed, but one UK study (OPTIMA Prelim30), which compared
oncotype DX, MammaPrint, Prosigna and IHC4, concluded that although tests assigned similar proportions
of patients to low/intermediate- and high-risk categories, test results for an individual patient could differ
markedly depending on which test was used.
Data relating to anxiety and HRQoL were limited as most studies did not include a comparator, instead adopting
a pre–post test design. Anxiety generally reduced post test, but it is unclear to what extent this would happen
after a definitive treatment decision made in accordance with clinical factors. HRQoL improved in some analyses.
Microarray studies support conclusions from studies using the commercial versions of the assays in
suggesting that oncotype DX, MammaPrint and EndoPredict can discriminate between high- and low-risk
patients regardless of LN status (there were no relevant microarray studies for Prosigna or IHC4).
Cost-effectiveness: principal findings
The EAG developed a de novo health economic model to assess the cost-effectiveness of oncotype DX,
MammaPrint, Prosigna, EPClin and IHC4+C, each versus current practice. The health economic analysis
was undertaken from the perspective of the NHS and PSS and was largely based on the model developed
to inform NICE DG10.20 The EAG model adopts a hybrid decision tree–Markov structure. The model
parameters were informed by a number of sources including a bespoke analysis of the TransATAC trial,
the MINDACT trial, a bespoke analysis of the NCRAS data set, a bespoke survey disseminated by the
UKBCG, the NHS England Access Scheme Database, standard costing sources and other literature.
The EAG’s base-case model suggests the following results:
l Oncotype DX – within the LN0 NPI ≤ 3.4 subgroup, the ICER for oncotype DX versus current practice
is expected to be £122,725 per QALY gained (£34,245 per QALY gained assuming a predictive
chemotherapy benefit). Within the LN0 NPI > 3.4 and LN1–3 subgroups, oncotype DX is expected to
be dominated by current practice (conversely, oncotype DX dominates current practice if a predictive
chemotherapy benefit is assumed). The results generated using the EAG model are primarily driven by
the modelled reduction in the use of adjuvant chemotherapy using the oncotype DX test.
l IHC4+C – within the LN0 NPI ≤ 3.4 subgroup, the ICER for IHC4+C versus current practice is expected
to be £2654 per QALY gained. Within the LN0 NPI > 3.4 and LN1–3 subgroups, IHC4+C is expected to
dominate current practice.
l Prosigna – within the LN0 NPI ≤ 3.4 subgroup, the ICER for Prosigna versus current practice is expected
to be £91,028 per QALY gained. Within the LN0 NPI > 3.4 and LN1–3 subgroups, the ICERs for
Prosigna versus current practice are £26,058 and £28,731 per QALY gained, respectively.
l EPClin – within the LN0 NPI ≤ 3.4 subgroup, the ICER for EPClin versus current practice is expected to
be £147,419 per QALY gained. Within the LN0 NPI > 3.4 subgroup, the ICER for EPClin versus current
practice is expected to be £46,788 per QALY gained. Within the LN1–3 subgroup, the ICER for EPClin
versus current practice is expected to be £21,458 per QALY gained.
l MammaPrint – within the overall MINDACT population, the ICER for MammaPrint versus current
practice is expected to be £131,482 per QALY gained. Within the mAOL high-risk subgroup,
MammaPrint is expected to be dominated by current practice. Within the mAOL low-risk subgroup,
the ICER for MammaPrint versus current practice is expected to be £414,202 per QALY gained.
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Strengths and limitations of the assessment
Strengths and limitations in the clinical evidence base
The clinical review benefited from a comprehensive search strategy and a high-quality, prospectively
designed systematic review methodology.
The evidence base was large, but included only one RCT of a test being used in clinical practice versus
usual clinical practice that had reported in full (MINDACT, for MammaPrint).98 A number of reanalyses of
RCTs, which are generally considered to be a high-quality source of data, were also included in the reviews
of prognosis and prediction of chemotherapy benefit. However, nearly all studies excluded patients who
did not have enough tissue sample (although this is unavoidable in retrospective analyses), which leaves
the evidence base at potential risk of spectrum bias, as patients with smaller tumours (who may be
systematically different from those with large tumours) will likely be under-represented.
Although, due to time constraints, we did not record every instance of industry funding for included
studies, a large number of key studies were funded by industry, and the risk of bias from this should be
borne in mind when interpreting the evidence base.
Many prognostic studies were observational in nature, and these are subject to confounding, whereby
exclusion of patients who received chemotherapy is likely to introduce bias as these patients are likely to
be systematically different in terms of known (and potentially unknown) prognostic variables. Equally,
studies that included patients who received chemotherapy may underestimate prognostic effect and/or
have more higher-risk patients included.
There were some key gaps in the literature for IHC4+C and RSPC. Notably, the IHC4+C algorithm has
been validated only in one cohort (in an adjusted analysis), and RSPC has also been validated in only one
cohort (in an unadjusted analysis, and for chemotherapy benefit). In both cases, the validation study was
conducted as part of the derivation study. The IHC4/IHC4+C evidence base was also limited in that most
of the data related to the IHC4 score alone, without the clinical score, and most studies used tertiles and
quartiles to define low-, intermediate- and high-risk patients, which may not be useful in a clinical setting.
In addition, there are known problems with conducting the analyses required for IHC4, and although a
number of studies report methodologies that are largely compliant with the original methodology, it is
unclear whether or not the absolute IHC4 values obtained would be similar across centres.
Much of the evidence base relates to unadjusted analyses, which do not assess the crucial question of
whether or not a test has additional value over clinicopathological factors. When adjusted analyses were
conducted, the clinicopathological variables included were not always consistent, and it is unclear if all
important factors (including stratification factors from the original RCT studies, when applicable) were
included in all analyses.
There were limited data relating to the ability of oncotype DX and MammaPrint to predict benefit from
chemotherapy, and some of the analyses conducted were also subject to criticisms relating to adjustment
for all relevant variables. It may be difficult to conduct further such studies as there are few studies in
which patients were randomised to chemotherapy versus no chemotherapy, and tissue samples may not
be available.
Data relating to the ability of the test to affect patient outcomes (such as recurrence and survival) through
the prospective use of the test to guide treatment decisions were also limited. Most studies were
observational in nature, and the selection of patients on the basis of them having received a test may have
introduced spectrum bias, and, for this reason, these studies may not match the decision problem. They
also do not, by their nature, include a comparator arm, and it is difficult to draw any firm conclusions
about the effect of the test in real clinical practice. Similarly, such studies that reported data relating to
chemotherapy effects in different risk groups are subject to the same limitations in terms of spectrum bias,
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but are also at risk of bias from confounding whereby patients who received chemotherapy are likely to be
systematically different in terms of known (and potentially unknown) prognostic variables (e.g. age) and
treatment effect modifiers from those who did not, which may have an impact on observed recurrence
rates and estimates of chemotherapy benefit.
Retrospective observational studies (in which patients were treated in accordance with usual practice
without the tests) reporting data relating to prognostic performance are also at risk of confounding in
that chemotherapy rates per risk group may differ (and thus affect estimates of prognostic performance).
Observational studies that excluded patients who received chemotherapy, in order to obtain a group of
patients unaffected by treatment, are likely to be subject to spectrum bias, as patients who receive
chemotherapy are likely to be systematically different from those who do not, and this may also affect
estimates of prognostic performance. These problems were particularly relevant to the MammaPrint
evidence base, in which most studies were observational in nature rather than reanalyses of RCTs.
MammaPrint was also unusual, in that many of the included studies pooled multiple cohorts, and, for this
reason, it was not possible to gauge the degree of double-counting of patients. The overall sample size
was also low (total n = 1805) compared with the evidence base for most other tests.
The evidence base relating to the impact of tests on treatment decisions (decision impact studies) was
limited in that use of chemotherapy differs across countries and there were no UK studies for two tests
(MammaPrint and Prosigna) and only one UK study for another two tests (EndoPredict and IHC4+C).
Strengths and limitations relating to the health economic analysis
The EAG model has a number of strengths; in particular:
l For all tests, risk classification and DMFS probabilities are derived from the same source (TransATAC
or MINDACT).
l Within the LN0 intermediate-risk subgroup (NPI > 3.4, analysis of three-level tests), the probability of
receiving chemotherapy with and without the test is based on the NHS England Access Scheme
Database – this is likely to best reflect how the three-level tumour profiling tests would be used in
clinical practice in England.
l The model structure is consistent with that of other published models of tumour profiling tests – when
similar data inputs are used, the EAG model produces similar results to the previous EAG model and the
Genomic Health model.
l Extensive DSAs have been conducted to explore the impact of uncertainty on the model results.
However, the model is also subject to several limitations, most of which stem from uncertainties in the
evidence base. The main limitations and uncertainties relating to the cost-effectiveness analysis are:
l With the exception of oncotype DX in the LN0 NPI > 3.4 group (clinical intermediate risk), the evidence
surrounding the pre- and post-test chemotherapy probabilities is subject to considerable uncertainty –
this has the propensity to influence the conclusions regarding the cost-effectiveness of all tests.
l There is uncertainty regarding whether or not oncotype DX and MammaPrint are predictive of chemotherapy
benefit – the inclusion of such effects are likely to strongly influence economic conclusions drawn from
the analysis.
l The analysis of MammaPrint is based on a different data source than the other four tests.
l The TransATAC study used to estimate test risk classification and DMFS probabilities was the derivation
study for IHC4 – for this reason, there is potential for the overestimation of prognostic performance for
this test.
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Uncertainties
Because of time and data constraints, it was not possible to conduct a thorough analysis of how the
baseline clinicopathological characteristics of patients (e.g. tumour grade, stage and age) affect prognostic
performance.
The evidence relating to the impact on patient outcomes when the test is used in clinical practice remains
largely unanswered, and is impeded by the long-term follow-up required, the large sample sizes required
and ethical problems with withholding chemotherapy from clinically high-risk patients.
Evidence relating to key subgroups defined in the scope were largely lacking. Data relating specifically to
micrometastases were rarely reported, there were no data at all in male-only subgroups or cohorts and
data relating to people of different ethnicities were difficult to interpret due to differences in treatment
practices in different countries. A more detailed consideration of the available evidence base may have
allowed some observations to be drawn regarding premenopausal and postmenopausal patients, but time
constraints prevented this.
The IHC4 test is known to have implementation issues in terms of conducting the test in other
laboratories, especially local laboratories. The precise details are beyond the expertise of the EAG. It is
uncertain if these could be overcome. Furthermore, it is somewhat unclear what cut-off values should be
used for IHC4 and IHC4+C.
Generalisability
The EAG notes that there may be issues relating to the generalisability of the evidence contained within
this report. In particular, issues with spectrum bias (loss of patients with small tumours with insufficient
tissue to test) were evident throughout the clinical evidence base. Furthermore, the classification of risk by
NPI will not reflect current practice across all centres. In addition, the TransATAC study that was used to
inform test risk classification and DMFS probabilities for oncotype DX, Prosigna, IHC4+C and EPClin relates
only to a postmenopausal population only; it is expected that the tumour profile testing may also be used
in premenopausal women.
Implications for service provision
The per-test costs for Prosigna provided by NanoString Technologies (used in the EAG economic analyses)
are based on an efficient level of throughput. This may not hold if centres do not undertake the
anticipated number of tests (e.g. in smaller centres, or if multiple tumour profiling tests are available).
Furthermore, as NanoString Technologies does not offer a centralised testing service, local testing services
will need to be established.
The IHC4 test is not currently commercially available. Standardisation of IHC4 and quality-assurance
programmes are required before this test may be used routinely within the NHS.
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Suggested research priorities
l There is uncertainty regarding whether or not oncotype DX and MammaPrint are predictive of chemotherapy
benefit. Further studies that adjust for all relevant clinicopathological factors in validation cohorts
are required.
l There is limited evidence demonstrating long-term impacts resulting from the use of the five tumour
profiling tests. Future studies assessing the comparative long-term impact of the tests compared with
risk prediction tools commonly used in clinical practice would be valuable.
l There is uncertainty regarding the cost-effectiveness of all five tests included in the NICE scope.
It is noteworthy that under the assumption of no predictive chemotherapy benefit, the inclusion of
additional data collected through the NHS England Access Scheme Database has a significant impact
on the conclusions previously drawn from the oncotype DX analysis within NICE DG1020 (moving from
an ICER of £22,572 per QALY gained to a situation in which oncotype DX is dominated in the LN0
NPI > 3.4 subgroup). Additional UK-based data collection relating to pre- and post-test chemotherapy
use for EPClin, IHC4+C, Prosigna and MammaPrint may be important in reducing existing uncertainty
surrounding the cost-effectiveness of these tests.
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Appendix 1 Additional tables for Chapter 1
TABLE 55 Incidence of breast cancer per 100,000 people in England, by age group and sex (2014)
Age (years)
Sex (n)
Male Female
All 319 45,764
0–24 0 21
25–29 0 191
30–34 4 593
35–39 3 1071
40–44 7 2299
45–49 11 4369
50–54 17 5386
55–59 23 4589
60–64 30 5072
65–69 57 6502
70–74 45 4436
75–79 52 3889
80–84 42 3419
≥ 85 28 3927
TABLE 56 Breast cancer risk prediction tools
Characteristic
Tool
NPI AOL Predict
Factors included in prediction
algorithm
l Tumour size
l Nodal status
l Tumour grade
l Age at diagnosis
l Comorbidity factors
l ER status
l Tumour size
l Tumour grade
l Nodal status
l Age at diagnosis
l Mode of detection
l Tumour size
l Tumour grade
l Number of positive nodes
l ER status
l HER2 status
l Ki-67 statusa
l Generation of chemotherapy regimen
Outcome(s) predicted Mortality Mortality or relapse Mortality
a Predict can also be used without Ki-67 status.
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Appendix 2 Literature search strategies
Clinical effectiveness
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R)
Date range searched: 1946 to search date.
Search date: 27 February 2017.
Search strategy
# Searches
1 exp Breast Neoplasms/
2 exp mammary neoplasms/
3 exp “Neoplasms, Ductal, Lobular, and Medullary”/
4 exp breast/
5 exp neoplasms/
6 4 and 5
7 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).mp.
8 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).mp.
9 1 or 2 or 3 or 6 or 7 or 8
10 EndoPredict.mp.
11 myriad genetics.mp.
12 sividon diagnostics.mp.
13 ep score.mp.
14 epclin score.mp.
15 MammaPrint.mp.
16 70-gene.mp.
17 gene70.mp.
18 gene?seventy.mp.
19 seventy?gene.mp.
20 amsterdam profile.mp.
21 oncotype.mp.
22 oncotype dx.mp.
23 21-gene.mp.
24 gene21.mp.
25 gene?twentyone.mp.
26 twentyone?gene.mp.
27 ghi recurrence score.mp.
28 ghi-rs.mp.
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29 92-gene.mp.
30 gene92.mp.
31 gene?ninetytwo.mp.
32 ninetytwo?gene.mp.
33 (rct-pcr adj5 “21”).mp.
34 prosigna.mp.
35 pam50.mp.
36 50-gene.mp.
37 gene50.mp.
38 gene?fifty.mp.
39 fifty?gene.mp.
40 breast bioclassifier.mp.
41 ihc4.mp.
42 or/10–14
43 or/15–41
44 9 and 42
45 9 and 43
46 limit 45 to yr=“2011 -Current”
47 44 or 46
EMBASE
Date range searched: 1974 to 24 February 2017.
Search date: 27 February 2017.
Search strategy
# Searches
1 exp breast tumor/
2 exp breast/
3 exp neoplasm/
4 2 and 3
5 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).mp.
6 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).mp.
7 1 or 4 or 5 or 6
8 EndoPredict.mp.
9 myriad genetics.mp.
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10 sividon diagnostics.mp.
11 ep score.mp.
12 epclin score.mp.
13 MammaPrint.mp.
14 70-gene.mp.
15 gene70.mp.
16 gene?seventy.mp.
17 seventy?gene.mp.
18 amsterdam profile.mp.
19 oncotype.mp.
20 oncotype dx.mp.
21 21-gene.mp.
22 gene21.mp.
23 gene?twentyone.mp.
24 twentyone?gene.mp.
25 ghi recurrence score.mp.
26 ghi-rs.mp.
27 92-gene.mp.
28 gene92.mp.
29 gene?ninetytwo.mp.
30 ninetytwo?gene.mp.
31 (rct-pcr adj5 “21”).mp.
32 prosigna.mp.
33 pam50.mp.
34 50-gene.mp.
35 gene50.mp.
36 gene?fifty.mp.
37 fifty?gene.mp.
38 breast bioclassifier.mp.
39 ihc4.mp.
40 or/8-12
41 or/13-39
42 7 and 40
43 7 and 41
44 limit 43 to yr=“2011 -Current”
45 42 or 44
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Web of Science Core Collection databases
Date range searched: 1900–search date.
Search date: 27 February 2017.
Science Citation Index Expanded
Date range searched: 1900–search date.
Search date: 27 February 2017.
Conference Proceedings Citation Index – Science
Date range searched: 1900–search date.
Search date: 27 February 2017.
Search strategy
# Searches
# 1 TOPIC: ((breast* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullary)))
# 2 TOPIC: ((mammar* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma*
or dcis or ductal or infiltrat* or intraductal* or lobular or medullar)))
# 3 #2 OR #1
# 4 TOPIC: (EndoPredict) OR TOPIC: (myriad genetics) OR TOPIC: (sividon diagnostics) OR TOPIC: (ep score) OR TOPIC:
(epclin score)
# 5 TS=(MammaPrint) OR TS=(70-gene) OR TS=(gene70) OR TS=(gene?seventy) OR TS=(seventy?gene) OR TS=
(amsterdam profile)
# 6 TS=(oncotype) OR TS=(oncotype dx) OR TS=(21-gene) OR TS=(gene21) OR TS=(gene?twentyone) OR TS=
(twentyone?gene) OR TS=(ghi recurrence score) OR TS=(ghi-rs) OR TS=(92-gene) OR TS=(gene92) OR TS=(gene?
ninetytwo) OR TS=(ninetytwo?gene) OR TS=((rct-pcr NEAR/5 ‘21’))
# 7 TOPIC: (prosigna) OR TOPIC: (pam50) OR TOPIC: (50-gene) OR TOPIC: (gene50) OR TOPIC: (gene?fifty) OR TOPIC:
(fifty?gene) OR TOPIC: (breast bioclassifier)
# 8 TOPIC: (ihc4)
# 9 #8 OR #7 OR #6 OR #5
# 10 #9 AND #3 Indexes=SCI-EXPANDED, CPCI-S Timespan=2011–2017
# 11 #4 AND #3
# 12 #11 OR #10
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Wiley Interscience databases
Cochrane Database of Systematic Reviews: Wiley Interscience
Date range searched: 1996–search date.
Search date: 28 February 2017.
Database of Abstracts of Reviews of Effects: Wiley Interscience
Date range searched: 1995–2015.
Search date: 28 February 2017.
Cochrane Central Register of Controlled Trials: Wiley Interscience
Date range searched: 1995–search date.
Search date: 28 February 2017.
Health Technology Assessment Database: Wiley Interscience
Date range searched: 1995–2016.
Search date: 28 February 2017.
NHS Economic Evaluation Database: Wiley Interscience
Date range searched: 1995–2015.
Search date: 28 February 2017.
Search strategy
# Searches
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 MeSH descriptor: [Neoplasms, Ductal, Lobular, and Medullary] explode all trees
#3 MeSH descriptor: [Breast] explode all trees
#4 MeSH descriptor: [Neoplasms] explode all trees
#5 #3 and #4
#6 (breast* near/5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullary))
#7 (mammar* near/5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullar))
#8 #1 or #2 or #5 or #6 or #7
#9 EndoPredict
#10 myriad genetics
#11 sividon diagnostics
#12 ep score
#13 epclin score
#14 MammaPrint
#15 70-gene
#16 gene70
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#17 gene*seventy
#18 seventy*gene
#19 amsterdam profile
#20 oncotype
#21 oncotype dx
#22 21-gene
#23 gene21
#24 gene*twentyone
#25 twentyone*gene
#26 ghi recurrence score
#27 ghi-rs
#28 92-gene
#29 gene92
#30 gene*ninetytwo
#31 ninetytwo*gene
#32 (rct-pcr near/5 ‘21’)
#33 prosigna
#34 pam50
#35 50-gene
#36 gene50
#37 gene*fifty
#38 fifty*gene
#39 breast bioclassifier
#40 ihc4
#41 (or #9-#13)
#42 28–#40–#40
#43 #8 and #41
#44 #8 and #42 Publication Year from 2011
#45 #43 or #44
World Health Organization International Clinical Trials Registry Platform
Search date: 19 January 2017.
Search strategy
# Searches
1 EndoPredict or MammaPrint or oncotype or IHC4 or Prosigna
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Cost-effectiveness studies of tumour profiling tests
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Search date: 6 March 2017.
Search strategy
# Searches
1 exp Breast Neoplasms/
2 exp mammary neoplasms/
3 exp “Neoplasms, Ductal, Lobular, and Medullary”/
4 exp breast/
5 exp neoplasms/
6 4 and 5
7 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).mp.
8 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).mp.
9 1 or 2 or 3 or 6 or 7 or 8
10 EndoPredict.mp.
11 myriad genetics.mp.
12 sividon diagnostics.mp.
13 ep score.mp.
14 epclin score.mp.
15 MammaPrint.mp.
16 70-gene.mp.
17 gene70.mp.
18 gene?seventy.mp.
19 seventy?gene.mp.
20 amsterdam profile.mp.
21 oncotype.mp.
22 oncotype dx.mp.
23 21-gene.mp.
24 gene21.mp.
25 gene?twentyone.mp.
26 twentyone?gene.mp.
27 ghi recurrence score.mp.
28 ghi-rs.mp.
29 92-gene.mp.
30 gene92.mp.
31 gene?ninetytwo.mp.
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32 ninetytwo?gene.mp.
33 (rct-pcr adj5 ‘21’).mp.
34 prosigna.mp.
35 pam50.mp.
36 50-gene.mp.
37 gene50.mp.
38 gene?fifty.mp.
39 fifty?gene.mp.
40 breast bioclassifier.mp.
41 ihc4.mp.
42 or/10-14
43 or/15-41
44 9 and 42
45 9 and 43
46 limit 45 to yr=“2011 -Current”
47 44 or 46
48 exp “Costs and Cost Analysis”/
49 Economics/
50 exp Economics, Hospital/
51 exp Economics, Medical/
52 Economics, Nursing/
53 exp models, economic/
54 Economics, Pharmaceutical/
55 exp “Fees and Charges”/
56 exp Budgets/
57 budget$.tw.
58 ec.fs.
59 cost$.ti.
60 (cost$adj2 (effective$or utilit$or benefit$or minimi$)).ab.
61 (economic$or pharmacoeconomic$or pharmaco-economic$).ti.
62 (price$or pricing$).tw.
63 (financial or finance or finances or financed).tw.
64 (fee or fees).tw.
65 (value adj2 (money or monetary)).tw.
66 quality-adjusted life years/
67 (qaly or qalys).af.
68 (quality adjusted life year or quality adjusted life years).af.
69 or/48-68
70 47 and 69
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EMBASE
Date range searched: 1974 to 3 March 2017.
Search date: 6 March 2017.
Search strategy
# Searches
1 exp breast tumor/
2 exp breast/
3 exp neoplasm/
4 2 and 3
5 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).mp.
6 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).mp.
7 1 or 4 or 5 or 6
8 EndoPredict.mp.
9 myriad genetics.mp.
10 sividon diagnostics.mp.
11 ep score.mp.
12 epclin score.mp.
13 MammaPrint.mp.
14 70-gene.mp.
15 gene70.mp.
16 gene?seventy.mp.
17 seventy?gene.mp.
18 amsterdam profile.mp.
19 oncotype.mp.
20 oncotype dx.mp.
21 21-gene.mp.
22 gene21.mp.
23 gene?twentyone.mp.
24 twentyone?gene.mp.
25 ghi recurrence score.mp.
26 ghi-rs.mp.
27 92-gene.mp.
28 gene92.mp.
29 gene?ninetytwo.mp.
30 ninetytwo?gene.mp.
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31 (rct-pcr adj5 ‘21’).mp.
32 prosigna.mp.
33 pam50.mp.
34 50-gene.mp.
35 gene50.mp.
36 gene?fifty.mp.
37 fifty?gene.mp.
38 breast bioclassifier.mp.
39 ihc4.mp.
40 or/8-12
41 or/13-39
42 7 and 40
43 7 and 41
44 limit 43 to yr=“2011 -Current”
45 42 or 44
46 Socioeconomics/
47 Cost benefit analysis/
48 Cost effectiveness analysis/
49 Cost of illness/
50 Cost control/
51 Economic aspect/
52 Financial management/
53 Health care cost/
54 Health care financing/
55 Health economics/
56 Hospital cost/
57 (fiscal or financial or finance or funding).tw.
58 Cost minimization analysis/
59 (cost adj estimate$).mp.
60 (cost adj variable$).mp.
61 (unit adj cost$).mp.
62 or/46-61
63 45 and 62
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Web of Science Core Collection databases
Date range searched: 1900–search date.
Search date: 6 March 2017.
Science Citation Index Expanded
Date range searched: 1900–search date.
Search date: 6 March 2017.
Conference Proceedings Citation Index – Science
Date range searched: 1900–search date.
Search date: 6 March 2017.
Search strategy
# Searches
# 1 TOPIC: ((breast* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullary)))
# 2 TOPIC: ((mammar* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullar)))
# 3 #2 OR #1
# 4 TOPIC: (EndoPredict) OR TOPIC: (myriad genetics) OR TOPIC: (sividon diagnostics) OR TOPIC: (ep score) OR TOPIC:
(epclin score)
# 5 TS=(MammaPrint) OR TS=(70-gene) OR TS=(gene70) OR TS=(gene?seventy) OR TS=(seventy?gene) OR TS=
(amsterdam profile)
# 6 TS=(oncotype) OR TS=(oncotype dx) OR TS=(21-gene) OR TS=(gene21) OR TS=(gene?twentyone) OR TS=
(twentyone?gene) OR TS=(ghi recurrence score) OR TS=(ghi-rs) OR TS=(92-gene) OR TS=(gene92) OR TS=(gene?
ninetytwo) OR TS=(ninetytwo?gene) OR TS=((rct-pcr NEAR/5 ‘21’))
# 7 TOPIC: (prosigna) OR TOPIC: (pam50) OR TOPIC: (50-gene) OR TOPIC: (gene50) OR TOPIC: (gene?fifty) OR TOPIC:
(fifty?gene) OR TOPIC: (breast bioclassifier)
# 8 TOPIC: (ihc4)
# 9 #8 OR #7 OR #6 OR #5
# 10 #9 AND #3 Indexes=SCI-EXPANDED, CPCI-S Timespan=2011-2017
# 11 #4 AND #3
# 12 #11 OR #10
# 13 TS=(cost* and (effective* or utilit* or benefit* or minimi*)) OR TS=(cost*) OR TI=(economic* or
pharmacoeconomic* or pharmaco-economic*) OR TS=(price* or pricing*) OR TS=(financial or finance or finances
or financed) OR TS=(fee or fees) OR TS=(value and (money or monetary)) OR TS=(economic*) OR TS=(economic*
and (hospital or medical or nursing or pharmaceutical)) OR TS=(“quality adjusted life year” or “quality adjusted life
years”) OR TS=(qaly or qalys) OR TS=(budget*)
# 14 #13 AND #12
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Health Technology Assessment Database: Wiley Interscience
Date range searched: 1995–2016.
Search date: 7 March 2017.
NHS Economic Evaluation Database: Wiley Interscience
Date range searched: 1995–2015.
Search date: 7 March 2017.
Search strategy
# Searches
1 MeSH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES
2 MeSH DESCRIPTOR Neoplasms, Ductal, Lobular, and Medullary EXPLODE ALL TREES
3 MeSH DESCRIPTOR Breast EXPLODE ALL TREES
4 MeSH DESCRIPTOR Neoplasms EXPLODE ALL TREES
5 #3 AND #4
6 ((breast* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or dcis
or ductal or infiltrat* or intraductal* or lobular or medullary)))
7 ((mammar* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullar)))
8 #1 OR #2 OR #5 OR #6 OR #7
9 (EndoPredict or myriad genetics or sividon diagnostics or ep score or epclin score)
10 (MammaPrint or 70-gene or gene70 or gene*seventy or seventy*gene or amsterdam profile)
11 (oncotype or oncotype dx or 21-gene or gene21 or gene*twentyone or twentyone*gene or ghi recurrence score or
ghi-rs or 92-gene or gene92 or gene*ninetytwo or ninetytwo*gene or (rct-pcr ADJ5 ‘21’))
12 (prosigna or pam50 or 50-gene or gene50 or gene*fifty or fifty*gene or breast bioclassifier)
13 (ihc4)
14 #8 AND #9
15 #10 OR #11 OR #12 OR #13
16 (#8 AND #15) FROM 2011 TO 2017
17 (#8 AND #15) IN HTA FROM 2011 TO 2017
18 (#8 AND #15) IN NHSEED FROM 2011 TO 2017
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Cost-effectiveness reviews for breast cancer
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Search date: 7 March 2017.
Search strategy
# Searches
1 exp Breast Neoplasms/
2 exp mammary neoplasms/
3 exp “Neoplasms, Ductal, Lobular, and Medullary”/
4 exp breast/
5 exp neoplasms/
6 4 and 5
7 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
8 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
9 1 or 2 or 3 or 6 or 7 or 8
10 exp “Costs and Cost Analysis”/
11 Economics/
12 exp Economics, Hospital/
13 exp Economics, Medical/
14 Economics, Nursing/
15 exp models, economic/
16 Economics, Pharmaceutical/
17 exp “Fees and Charges”/
18 exp Budgets/
19 budget$.tw.
20 ec.fs.
21 cost$.ti.
22 (cost$adj2 (effective$or utilit$or benefit$or minimi$)).ab.
23 (economic$or pharmacoeconomic$or pharmaco-economic$).ti.
24 (price$or pricing$).tw.
25 (financial or finance or finances or financed).tw.
26 (fee or fees).tw.
27 (value adj2 (money or monetary)).tw.
28 quality-adjusted life years/
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29 (qaly or qalys).af.
30 (quality adjusted life year or quality adjusted life years).af.
31 or/10-30
32 9 and 31
33 meta-analysis/
34 meta-analysis as topic/
35 (meta analy* or metanaly* or metaanaly*).ti,ab.
36 ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
37 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
38 (search strategy or search criteria or systematic search or study selection or data extraction).ab.
39 (search* adj4 literature).ab.
40 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or scie nce citation
index or bids or cancerlit).ab.
41 cochrane.jw.
42 ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
43 or/33-42
44 32 and 43
45 limit 44 to yr=“2011 -Current”
EMBASE
Date range searched: 1974 to 6 March 2017.
Search date: 7 March 2017.
Search strategy
# Searches
1 exp breast tumor/
2 exp breast/
3 exp neoplasm/
4 2 and 3
5 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
6 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
7 1 or 4 or 5 or 6
8 Socioeconomics/
9 Cost benefit analysis/
10 Cost effectiveness analysis/
11 Cost of illness/
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12 Cost control/
13 Economic aspect/
14 Financial management/
15 Health care cost/
16 Health care financing/
17 Health economics/
18 Hospital cost/
19 (fiscal or financial or finance or funding).tw.
20 Cost minimization analysis/
21 (cost adj estimate$).mp.
22 (cost adj variable$).mp.
23 (unit adj cost$).mp.
24 or/8-23
25 7 and 24
26 systematic review/
27 meta-analysis/
28 (meta analy* or metanaly* or metaanaly*).ti,ab.
29 ((systematic or evidence) adj3 (review* or overview*)).ti,ab.
30 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
31 (search strategy or search criteria or systematic search or study selection or data extraction).ab.
32 (search* adj4 literature).ab.
33 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation
index or bids or cancerlit).ab.
34 cochrane.jw.
35 ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
36 or/26-35
37 25 and 36
38 limit 37 to yr=“2011 -Current”
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Web of Science Core Collection databases
Date range searched: 1900–search date.
Search date: 7 March 2017.
Science Citation Index Expanded
Date range searched: 1900–search date.
Search date: 7 March 2017.
Conference Proceedings Citation Index – Science
Date range searched: 1900–search date.
Search date: 7 March 2017.
Search strategy
# Searches
# 1 TI=((breast* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or
ductal or infiltrat* or intraductal* or lobular or medullary)))
# 2 TI=((mammar* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis
or ductal or infiltrat* or intraductal* or lobular or medullar)))
# 3 #2 OR #1
# 4 TS=(cost* and (effective* or utilit* or benefit* or minimi*)) OR TS=(cost*) OR TI=(economic* or
pharmacoeconomic* or pharmaco-economic*) OR TS=(price* or pricing*) OR TS=(financial or finance or finances or
financed) OR TS=(fee or fees) OR TS=(value and (money or monetary)) OR TS=(economic*) OR TS=(economic* and
(hospital or medical or nursing or pharmaceutical)) OR TS=(“quality adjusted life year” or “quality adjusted life
years”) OR TS=(qaly or qalys) OR TS=(budget*)
# 5 #4 AND #3
# 6 TS=(meta-analysis or meta analy* or metaanaly*) OR TS=(“review literature” or “literature review”) OR TS=
(“systematic review*” or “systematic overview*”) OR TS=(cochrane or embase or psychlit or psyclit or psychinfo or
psycinfo or cinahl or cinhal or science citation index or bids or cancerlit) OR TS=(“reference list*” or bibliograph* or
hand-search* or “relevant journals” or “manual search*”) OR TS=((“selection criteria” or “data extraction”) and
review)
# 7 #6 AND #5 Indexes=SCI-EXPANDED, CPCI-S Timespan=2011-2017
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Health Technology Assessment Database: Centre for Reviews and Dissemination
Date range searched: 1995–2016.
Search date: 7 March 2017.
NHS Economic Evaluation Database: Centre for Reviews and Dissemination
Date range searched: 1995–2015.
Search date: 7 March 2017.
Search strategy
# Searches
1 MeSH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES
2 MeSH DESCRIPTOR Neoplasms, Ductal, Lobular, and Medullary EXPLODE ALL TREES
3 MeSH DESCRIPTOR Breast EXPLODE ALL TREES
4 MeSH DESCRIPTOR Neoplasms EXPLODE ALL TREES
5 #3 AND #4
6 ((breast* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or dcis
or ductal or infiltrat* or intraductal* or lobular or medullary)))
7 ((mammar* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullar)))
8 #1 OR #2 OR #5 OR #6 OR #7
9 (EndoPredict or myriad genetics or sividon diagnostics or ep score or epclin score)
10 (MammaPrint or 70-gene or gene70 or gene*seventy or seventy*gene or amsterdam profile)
11 (oncotype or oncotype dx or 21-gene or gene21 or gene*twentyone or twentyone*gene or ghi recurrence score or
ghi-rs or 92-gene or gene92 or gene*ninetytwo or ninetytwo*gene or (rct-pcr ADJ5 ‘21’))
12 (prosigna or pam50 or 50-gene or gene50 or gene*fifty or fifty*gene or breast bioclassifier)
13 (ihc4)
14 #8 AND #9
15 #10 OR #11 OR #12 OR #13
16 (#8 AND #15) FROM 2011 TO 2017
17 (#8 AND #15) IN HTA FROM 2011 TO 2017
18 (#8 AND #15) IN NHSEED FROM 2011 TO 2017
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Quality-of-life reviews for breast cancer
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Search date: 7 March 2017.
Search strategy
# Searches
1 exp Breast Neoplasms/
2 exp mammary neoplasms/
3 exp “Neoplasms, Ductal, Lobular, and Medullary”/
4 exp breast/
5 exp neoplasms/
6 4 and 5
7 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
8 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
9 1 or 2 or 3 or 6 or 7 or 8
10 “Quality of Life”/
11 (qol or (quality adj2 life)).ab,ti.
12 (value adj2 (money or monetary)).tw.
13 value of life/
14 quality adjusted life year/
15 quality adjusted life.tw.
16 (qaly$or qald$or qale$or qtime$).tw.
17 disability adjusted life.tw.
18 daly$.tw.
19 health status indicators/
20 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform thirtysix or shortform thirty six
or short form thirtysix or short form thirty six).tw.
21 (sf 6 or sf6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
22 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
23 (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form six D).tw.
24 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty).tw.
25 (euroqol or euro qol or eq5d or eq 5d).tw.
26 (hql or hqol or h qol or hrqol or hr qol).tw.
27 (hye or hyes).tw.
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28 health$year$equivalent$.tw.
29 health utilit$.tw.
30 (hui or hui1 or hui2 or hui3).tw.
31 disutilit$.tw.
32 rosser.tw.
33 (quality adj2 wellbeing).tw.
34 qwb.tw.
35 (willingness adj2 pay).tw.
36 standard gamble$.tw.
37 time trade off.tw.
38 time tradeoff.tw.
39 tto.tw.
40 letter.pt.
41 editorial.pt.
42 comment.pt.
43 40 or 41 or 42
44 or/10-39
45 44 not 43
46 9 and 45
47 meta-analysis/
48 meta-analysis as topic/
49 (meta analy* or metanaly* or metaanaly*).ti,ab.
50 ((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.
51 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
52 (search strategy or search criteria or systematic search or study selection or data extraction).ab.
53 (search* adj4 literature).ab.
54 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or scie nce citation
index or bids or cancerlit).ab.
55 cochrane.jw.
56 ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
57 or/47-56
58 46 and 57
59 limit 58 to yr=“2011 -Current”
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EMBASE
Date range searched: 1974 to 6 March 2017.
Search date: 7 March 2017.
Search strategy
# Searches
1 exp breast tumor/
2 exp breast/
3 exp neoplasm/
4 2 and 3
5 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
6 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
7 1 or 4 or 5 or 6
8 socioeconomics/
9 quality adjusted life year/
10 quality adjusted life.tw.
11 (qaly$or qald$or qale$or qtime$).tw.
12 disability adjusted life.tw.
13 daly$.tw.
14 health survey/
15 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty
six or short form thirtysix or short form thirty six).tw.
16 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
17 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
18 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form
sixteen).tw.
19 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form
twenty).tw.
20 (euroqol or euro qol or eq5d or eq 5d).tw.
21 (hql or hqol or h qol or hrqol or hr qol).tw.
22 (hye or hyes).tw.
23 health$year$equivalent$.tw.
24 health utilit$.tw.
25 (hui or hui1 or hui2 or hui3).tw.
26 disutili$.tw.
27 rosser.tw.
28 quality of wellbeing.tw.
29 qwb.tw.
30 willingness to pay.tw.
31 standard gamble$.tw.
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
220
32 time trade off.tw.
33 time tradeoff.tw.
34 tto.tw.
35 or/8-34
36 7 and 35
37 systematic review/
38 meta-analysis/
39 (meta analy* or metanaly* or metaanaly*).ti,ab.
40 ((systematic or evidence) adj3 (review* or overview*)).ti,ab.
41 (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.
42 (search strategy or search criteria or systematic search or study selection or data extraction).ab.
43 (search* adj4 literature).ab.
44 (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation
index or bids or cancerlit).ab.
45 cochrane.jw.
46 ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.
47 or/37-46
48 36 and 47
49 limit 48 to yr=“2011 -Current”
Web of Science Core Collection databases
Date range searched: 1900–search date.
Search date: 7 March 2017.
Science Citation Index Expanded
Date range searched: 1900–search date.
Search date: 7 March 2017.
Conference Proceedings Citation Index – Science
Date range searched: 1900–search date.
Search date: 7 March 2017.
Search strategy
# Searches
# 1 TI=((breast* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or
ductal or infiltrat* or intraductal* or lobular or medullary)))
# 2 TI=((mammar* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis
or ductal or infiltrat* or intraductal* or lobular or medullar)))
# 3 #2 OR #1
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
221
# 4 TS=(qol or “quality of life” or “quality adjusted life” or qaly* or qald* or qale* or qtime* or “disability adjusted
life” or daly*)OR TS=(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shorform
thirtysix or shortform thirty six or short form thirtysix or short form thirty six) OR TS=(sf 6 or sf6 or short form 6 or
shortform 6 or sf six or sfsix or shortform six or short form six) OR TS=(sf12 or sf 12 or short form 12 or shortform
12 or sf twelve or sftwelve or shortform twelve or short form twelve) OR TS=(sf16 or sf 16 or short form 16 or
shortform 16 or sf sixteen or sfsixteen or shortfrom sixteen or short form sixteen) OR TS=(sf20 or sf 20 or short form
20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty) OR TS=(euroqol or euro qol
or eq5d or eq 5d or hql or hqol or h qol or hrqol or hr qol or disutilit* or rosser “quality of wellbeing” or qwb or
“willingness to pay” or “standard gamble*” or “time trade off” or “time tradeoff” or tto)
# 5 #4 AND #3
# 6 TS=(meta-analysis or meta analy* or metaanaly*) OR TS=(“review literature” or “literature review”) OR TS=
(“systematic review*” or “systematic overview*”) OR TS=(cochrane or embase or psychlit or psyclit or psychinfo or
psycinfo or cinahl or cinhal or science citation index or bids or cancerlit) OR TS=(“reference list*” or bibliograph* or
hand-search* or “relevant journals” or “manual search*”) OR TS=((“selection criteria” or “data extraction”) and
review)
# 7 #6 AND #5
Indexes=SCI-EXPANDED, CPCI-S Timespan=2011-2017
Health Technology Assessment Database: Centre for Reviews and Dissemination
Date range searched: 1995–2016.
Search date: 7 March 2017.
NHS Economic Evaluation Database: Centre for Reviews and Dissemination
Date range searched: 1995–2015.
Search date: 7 March 2017.
Search strategy
# Searches
1 MeSH DESCRIPTOR Breast Neoplasms EXPLODE ALL TREES
2 MeSH DESCRIPTOR Neoplasms, Ductal, Lobular, and Medullary EXPLODE ALL TREES
3 MeSH DESCRIPTOR Breast EXPLODE ALL TREES
4 MeSH DESCRIPTOR Neoplasms EXPLODE ALL TREES
5 #3 AND #4
6 (((breast* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullary)))):TI
7 (((mammar* ADJ5 (neoplasm* or cancer* or tumor* or tumour* or carcinoma* or adenocarcinoma* or sarcoma* or
dcis or ductal or infiltrat* or intraductal* or lobular or medullar)))):TI
8 #1 OR #2 OR #5 OR #6 OR #7
9 (#8) IN HTA FROM 2011 TO 2017
10 (#8) IN NHSEED FROM 2011 TO 2017
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EuroQol 5-Dimensions and breast cancer
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily
and Ovid MEDLINE(R)
Date range searched: 1946 to present.
Search date: 10 July 2017.
Search strategy
# Searches
1 exp Breast Neoplasms/
2 exp mammary neoplasms/
3 exp “Neoplasms, Ductal, Lobular, and Medullary”/
4 exp breast/
5 exp neoplasms/
6 4 and 5
7 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
8 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
9 1 or 2 or 3 or 6 or 7 or 8
10 (euroqol or euro qol or eq5d or eq 5d).tw.
11 9 and 10
EMBASE
Date range searched: 1974 to 7 July 2017.
Search date: 10 July 2017.
Search strategy
# Searches
1 exp breast tumor/
2 exp breast/
3 exp neoplasm/
4 2 and 3
5 (breast* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or
infiltrat* or intraductal* or lobular or medullary)).ti.
6 (mammar* adj5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal
or infiltrat* or intraductal* or lobular or medullar)).ti.
7 1 or 4 or 5 or 6
8 (euroqol or euro qol or eq5d or eq 5d).tw.
9 7 and 8
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Web of Science Core Collection databases
Date range searched: 1900–search date.
Search date: 10 July 2017.
Science Citation Index Expanded
Date range searched: 1900–search date.
Search date: 10 July 2017.
Conference Proceedings Citation Index – Science
Date range searched: 1900–search date.
Search date: 10 July 2017.
Search strategy
# Searches
# 1 TI=((breast* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis or
ductal or infiltrat* or intraductal* or lobular or medullary)))
# 2 TI=((mammar* NEAR/5 (neoplasm* or cancer* or tumo?r* or carcinoma* or adenocarcinoma* or sarcoma* or dcis
or ductal or infiltrat* or intraductal* or lobular or medullar)))
# 3 #2 OR #1
# 4 TOPIC: (euroqol or euro qol or eq5d or eq 5d)
# 5 #4 AND #5
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Appendix 3 Table of excluded studies with
rationale
Type of exclusion Reason for exclusion References
Population exclusions l More than three lymph nodes
l Advanced breast cancer
l Neoadjuvant setting
l Not breast cancer
l Non-European (for decision impact studies)
40176,210–248
Intervention exclusions l Not in-scope test 27249–275
Comparator exclusions l Not in-scope comparator 3276–278
Outcome exclusions l No outcomes of interest
l Follow-up of < 5 years
l Insufficient data
l Pooled analysis (where individual studies are included)
l Correlation only
l Analytic validity only
146279–424
Study type exclusions l Not in English language
l Editorial or comment
l Systematic review
l Modelling
l Review
l Retrospective use of test
34121,425–457
Other reasons for exclusions l Could not obtain full text 2458,459
l No novel data (secondary reference to other study) 128460–586
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Appendix 4 Summary of the clinical review
This appendix provides a summary of results for all included tests, ordered by type of evidence.For the sake of clarity, this section focuses on LN0 and LN+ subgroups only, DRFI/DRFS outcomes
and key points. Full descriptions and discussions of the evidence base are reported in Chapter 2, Report
Supplementary Material 1–10, and Appendix 5, and should be read in conjunction with this summary to
obtain a full understanding. The derivation cohorts are excluded from the summary (i.e. three US cohorts
for oncotype DX,49 TransATAC46 for IHC4 and IHC4+C, TransATAC and NSABP B-14 pooled44 for RSPC,
van ‘t Veer et al.587 for MammaPrint, van de Vijver et al.79 for Prosigna and Filipits et al.117 for EndoPredict),
except in the case of IHC4+C, as only the derivation data reported numerical values.
Risk classification
Lymph node negative
Among studies of LN0 patients receiving endocrine monotherapy, percentages categorised as high risk
ranged from 9% to 33% across all five tests (Table 57): 9–33% for oncotype DX (three studies46,49,50,52,60,61),
29% for MammaPrint (one study91), 15–20% for Prosigna/ROR-PT (three studies46,104,105,112), 27% for EPClin
(one study46,118–120), 9% for IHC4+C (derivation cohort46) and not reported for IHC4. Within studies with
variable endocrine therapy and chemotherapy use, percentages categorised as high risk were similar to the
above for oncotype DX (25–28%), but higher for MammaPrint (33–73%); this may reflect the selection of
higher-risk patients for MammaPrint studies (some not ER+, some required chemotherapy).
Lymph node positive
Three tests (Prosigna/ROR-PT, EPClin and IHC4+C) categorised far more LN+ than LN0 patients as high risk
among studies of endocrine monotherapy (see Table 57): 48–62% for Prosigna/ROR-PT (three studies46,104,105,112),
76% for EPClin (one study46,118–120) and 38% for IHC4+C (one study46). Conversely, oncotype DX categorised
similar percentages of LN+ and LN0 patients as high risk (11% for LN+; one study46). For MammaPrint, there
were no LN+ endocrine monotherapy studies, but in studies with variable endocrine therapy and chemotherapy
use, 59–62% were high risk (two studies85,89); this was similar to LN0 studies.
For tests with three categories, how many patients would be prescribed chemotherapy would depend on
how intermediate patients are handled (see Table 57).
Prognostic performance and additional prognostic value
Oncotype DX
Seven reanalyses of RCTs37,46,49–56 and four retrospective cohort studies57–60 were included (total n = 4929).
The 10-year DRFI rates for LN0 low-risk patients were 93–97% (with endocrine monotherapy); for
intermediate-risk patients they were somewhat higher (86–100%). LN+ patients were generally at higher
risk of recurrence than LN0 patients in both low and intermediate categories (10-year DRFI for LN+ was
< 85% for low-risk patients and ≤ 75% for intermediate-risk patients). Unadjusted analyses indicated that
oncotype DX was prognostic (statistically significant differences between low-risk and high-risk groups)
across various recurrence outcomes regardless of lymph node status, although HRs between intermediate-
risk and high- or low-risk groups were not always statistically significant. Oncotype DX provided additional
prognostic information over most commonly used clinicopathological variables (age, grade, size and nodal
status) regardless of lymph node status, and over CTS and NPI in LN0 (but not LN+) patients, but analyses
used a 50-point or 1-point difference rather than categories defined by the 18–30 cut-off points.
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TABLE 57 Summary of risk categorisation and prognostic and predictive (of chemotherapy benefit) ability across tests
Test
Number of
studies with
DRFS/DRFI Population
Nodal
status ET/chemotherapy
Percentage of patients per group
Percentage with 10-year
DRFS/DRFI risk
Significantly
prognostic for
DRFS/DRFI?
Additional value over
clinicopathological
factors or tests?
a
Chemotherapy
benefit?Low risk
Intermediate
risk High risk Low risk
Intermediate
risk High risk
LN0, all ET, no chemotherapy
Oncotype DX 346,49,52,60,61 ER+; HER2+/– LN0 All ET; no
chemotherapy
48–64 20–27 9–33 93–97 86–100 70–77 Yes (3 of 4 studies,
NR in 1)
Yes (3 studies) Weak
b
MammaPrint 191 ER+; HER2 NR LN0 All ET; no
chemotherapy
71 – 29 93 85 NR NR
Prosigna/ROR-PT 346,104,105,112 Most ER+; HER2– LN0 All ET; no
chemotherapy
48–55 30–32 15–20 95–97 87–93 69–85 Yes (3 of 3 studies) Yes vs. CTS and NPI
(2 studies)
N/A
EPClin 146,118–120 ER+; HER2– LN0 All ET; no
chemotherapy
73 – 27 94 80 Yes (1 study) Yes vs. CTS and NPI
(1 study)
N/A
IHC4 2 cohorts126 ER+; HER2– NR LN0 All ET; no
chemotherapy
NR NR NR NR NR NR NR Yes (2 cohorts) N/A
IHC4+C 146 (derivation) ER+; 95% HER2– LN0 All ET; no
chemotherapy
70 21 9 96 82 77 Yes (1 study) Yes vs. CTS and NPI
(1 study)
N/A
LN0, variable ET/chemotherapy
Oncotype DX 250,58 ER+; HER2+/– LN0 75–100% ET;
79–100%
chemotherapy
49–51 21–26 25–28 9650 8950 8850 Yes (1 of 1 study) NR NR
Oncotype DX
RSPC
144 ER+; HER2– NR LN0 All ET; 64%
chemotherapy
NR NR NR NR NR NR Yes (1 analysis) Yes (derivation set) No (1 study)
MammaPrint
c
779,84,86,88,91,95,96 70–100% ER+;
HER2 NR
LN0 0–25% ET/
chemotherapy
27–67 – 33–73 80–90 50–71 Yes (4 of 7 studies,
1 not significant,
NR in 2)
Yes (pooled study,
2 cohorts, others NR)
Not statistically
significant
(pooled LN0/LN+)
b
IHC4 2125,127 ER/HER2 varies Some ET/
chemotherapy
Clinical cut-off points not used NR NR NR Yes (some analyses
non-significant)
NR N/A
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Test
Number of
studies with
DRFS/DRFI Population
Nodal
status ET/chemotherapy
Percentage of patients per group
Percentage with 10-year
DRFS/DRFI risk
Significantly
prognostic for
DRFS/DRFI?
Additional value over
clinicopathological
factors or tests?
a
Chemotherapy
benefit?Low risk
Intermediate
risk High risk Low risk
Intermediate
risk High risk
LN+, all ET, no chemotherapy
Oncotype DX 146 ER+; HER2– LN1–3 All ET; no
chemotherapy
57 32 11 82 75 67 Yes (1 study) No vs. CTS and NPI Weak
b
Prosigna/ROR-PT 346,104,105,112 Most ER+; HER2– LN1–3 (most) All ET; no
chemotherapy
4–25 27–34 48–62 100–100 81–94 71–78 Yes or borderline
(3 studies)
Yes vs. CTS, no vs. NPI NR
EPClin 146,118–120 ER+; HER2– LN1–3 All ET; no
chemotherapy
24 – 76 95 – 72 Yes (1 study) Yes vs. CTS and NPI at
10 years (not 5 years)
NR
IHC4 2 cohorts126 ER+; HER2– NR LN+ All ET; no
chemotherapy
NR NR NR Mixed (1 yes, 1 no) NR
IHC4+C
d
146 ER+; HER2– LN1–3 All ET; no
chemotherapy
28 34 38 96 75 67 Yes (1 study) No vs. CTS and NPI NR
LN+, variable ET/chemotherapy
Oncotype DX 351,52,56,59 ER+; HER2+/– LN+ 74–100% ET/
chemotherapy
36–39 30–34 30–31 81
e
65
e
59
e
Yes Yes N/A
MammaPrint 285,89 80% ER+; 84%
HER2 or NR
LN1–3; LN
> 3, 26%
Some ET/
chemotherapy
38–41 – 59–62 79–91 54–76 Yes (2 of 2 studies) Borderline (1 study) Not statistically
significant
(pooled LN0/LN+)
b
Prosigna/ROR-PT 1108,109 ER+; HER2– LN > 3, 36% All ET; all
chemotherapy
19 56 26 92 74 66 Yes (1 study) NR NR
EPClin 1108,109 ER+; HER2– LN > 3, 36% All ET; all
chemotherapy
13 – 87 100 72 Yes (1 study) NR NR
IHC4 2123,136 HR+; HER2– LN+ ET varies; 100%
chemotherapy
Clinical cut-off points not used No clinical groups NR Mixed (1 yes, 1 no) NR
ET, endocrine therapy; N/A, not applicable; NR, not reported.
a Judged via multivariate analyses adjusted for clinicopathological factors, change in likelihood ratios, C-index or D-statistics.
b Judged via p values and non-significant interaction tests after adjustments for clinicopathological factors.
c Where an outlier, Ishitobi et al.95 (Japan) omitted owing to unknown generalisability.
d For IHC alone, there were few data by LN status.
e Sun et al.59 (China) omitted, as much lower DRFS than other studies.
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Oncotype DX RSPC
One study44 derived the RSPC score in a meta-analysis of two RCT data sets (LN0/LN+; n = 1735) and
validated it in another (LN0; n = 625), which included 233 patients used to derive the oncotype DX Breast
Recurrence Score. Based on the derivation analysis set, the oncotype DX RSPC algorithm (oncotype DX plus
age, tumour size and grade) appeared to provide additional prognostic information over oncotype DX and
over clinicopathological variables, and was able to classify more patients into a low-risk category than
oncotype DX while maintaining a roughly equivalent rate of distant recurrence in the low-risk group. In the
validation cohort, RSPC had prognostic value in univariate analyses (no adjusted analysis was reported).
However, RSPC has only been validated in one independent cohort that included patients who were used
to derive one of its constituent parts (oncotype DX Breast Recurrence Score), and has not been tested in
premenopausal or LN+ patients.
MammaPrint
The prognostic value of MammaPrint is based on nine retrospective analyses (total n = 1805), four pooled
analyses (n = 964; including six of the nine series above) and one reanalysis of a RCT (n = 538). Studies
were variable in terms of nodal status, ER status and receipt of endocrine therapy and chemotherapy.
MammaPrint was statistically significantly prognostic for 10-year DRFS in almost all unadjusted analyses of
LN0 and LN+ patients. For LN0 patients, 10-year DRFS/DRFI rates for low-risk patients ranged from 80%
to 90% (with varying rates of endocrine therapy and chemotherapy use), while the reanalysis of a RCT
reported 10-year DRFS of 93% with endocrine monotherapy and 83% without endocrine therapy or
chemotherapy. For LN+ patients, 10-year DRFS rates in low-risk patients ranged from 79% to 91%
(with varying rates of endocrine therapy and chemotherapy use). In terms of additional prognostic value,
MammaPrint was statistically significantly prognostic for 10-year DRFS/DRFI in multivariable analyses
adjusted for clinicopathological risk tools (AOL and NPI) and various combinations of clinicopathological
variables in LN0/LN+ and LN0 cohorts, while adjusted analyses in LN+ cohorts were statistically significant
or borderline significant.
Prosigna/risk of recurrence based on Prediction Analysis of Microarray 50 subtype
information plus proliferation score plus tumour size
Based on six reanalyses of RCTs and two retrospective analyses of prospective cohorts (total n = 9118),
Prosigna/ROR-PT was statistically significantly prognostic for unadjusted analyses of 10-year DRFS/DRFI in
LN0 and LN+ patients. The 10-year DRFS/DRFI rates for low-risk patients were 95% to 97% in three studies
of LN0 patients (endocrine monotherapy), and in LN+ patients these were 100% in two studies (endocrine
monotherapy) and 92% in one study (all endocrine therapy and chemotherapy). For intermediate-risk patients,
10-year DRFS/DRFI rates were 87% to 93% for LN0 and 81% to 94% for LN+ (endocrine monotherapy).
Prosigna/ROR-PT added prognostic information over clinicopathological variables or CTS/CLP/NPI in three
studies; this was statistically significant in LN0 patients and either significant or borderline significant in LN+
patients.
EndoPredict and EndoPredict Clinical
Based on three reanalyses of RCTs (total n = 3135) in ER+ HER2– endocrine-treated patients, EPClin was
statistically significantly prognostic for unadjusted analyses of 10-year DRFS/DRFI in LN0 and LN+ patients.
The 10-year DRFS/DRFI rates for low-risk patients were approximately 95% in LN0 and LN+ patients receiving
endocrine therapy only. EPClin added statistically significant information over CTS/NPI in LN0 and LN+
patients in TransATAC, while in two further studies, the EndoPredict score added statistically significant
information over clinicopathological variables in mixed LN0/LN+ and LN+ patients (no data for EPClin).
IHC4
The IHC4 has been validated in five reanalyses of RCTs and six retrospective cohort studies (total n = 13,434)
and provides statistically significant prognostic information consistently in unadjusted analyses in LN+/LN0,
LN0 and LN+ groups. However, most studies used quartiles or tertiles to define risk groups, which are
specific to each cohort and do not allow conclusions to be drawn about which cut-off points should be used
in clinical practice and how these would perform. Many used laboratory methods that differed from the
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derivation study methodology. Only one validation study126 used the cut-off points from the original analysis,25
and provides second and third validation cohorts (BCS and TEAM). IHC4 had additional prognostic value over
clinicopathological factors in some studies. Test methodologies did not appear to have an impact on the
statistical significance of results, but concerns remain about the conduct of the test in laboratories other
than that used to derive the score.
IHC4+C
The IHC4+C had prognostic value in one validation cohort (Nottingham) in which statistical significance
was maintained after adjustments for clinicopathological factors.
Microarray studies
Microarray studies are defined here as those that applied a test algorithm to either in silico data
(microarray gene expression data held on a database) or a de novo microarray assessment. These studies
support conclusions from studies using the commercial versions of the assays in suggesting that oncotype
DX, MammaPrint and EndoPredict can discriminate between high- and low-risk patients regardless of LN
status.
Outcomes in low-risk and intermediate-risk groups
Lymph node negative
Among studies of LN0 patients receiving endocrine monotherapy, the 10-year DRFS/DRFI rates in low-risk
groups were similar across all five tests (see Table 57): 93% to 97% for oncotype DX (four studies46,49,50,52,60,61),
93% for MammaPrint (one study91), 95% to 97% for Prosigna/ROR-PT (three studies46,104,105,112), 94% for
EPClin (one study46,118–120) and 96% for IHC4+C (one study46). Intermediate-risk groups for oncotype DX,
Prosigna/ROR-PT and IHC4+C had worse DRFS/DRFI rates than low-risk groups (EPClin and MammaPrint do
not have intermediate-risk groups). Many studies of MammaPrint included some ER– patients, did not treat all
patients with endocrine therapy, and treated some with chemotherapy; for these studies, 10-year DRFS/DRFI
rates in low-risk groups were 80% to 90% (seven studies79,84,86,88,91,96).
Lymph node positive
Among studies of LN+ patients receiving endocrine monotherapy (see Table 57), 10-year DRFS/DRFI rates in
low-risk groups were less favourable for oncotype DX (82%; one study46) than for Prosigna/ROR-PT (100%;
two studies46,104,105), EPClin (95%; one study46,118–120) or IHC4+C (96%; one study46). There were no studies
of MammaPrint in this population. Intermediate-risk patients had lower DRFS/DRFI than low-risk patients for
oncotype DX (75%, one study46), Prosigna/ROR-PT (81% to 94%, two studies46,104,105) and IHC4+C (75%,
one study46). For MammaPrint, the only LN+ data were in populations that included some ER– patients, did
not treat all patients with endocrine therapy, and treated some with chemotherapy; 10-year DRFS/DRFI rates
in low-risk groups were 79% to 91% (two studies85,89).
Chemotherapy benefit
Evidence of chemotherapy benefit was only assessed for oncotype DX, oncotype DX RSPC and
MammaPrint. There was no chemotherapy benefit evidence for EndoPredict or EPClin, Prosigna/ROR-PT,
IHC4 or IHC4+C.
Oncotype DX and oncotype DX RSPC
Analyses were reported in five studies.50,53,61,64–67,70 Two were reanalyses of RCTs (one LN0,50,61 one LN+,53
total n = 1018) in which patients were randomised to endocrine monotherapy, or endocrine therapy plus
chemotherapy. Three were observational studies64–67,70 (total approximately 44,000 with some double-
counting, two LN0,64,65,67,70 one LN+/LN066) in which patients were treated in accordance with usual
practice and their oncotype DX score. The two reanalyses of RCTs suggest that benefit from chemotherapy
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is highest in oncotype DX high-risk patients. Unadjusted interaction tests between oncotype DX risk group
and chemotherapy benefit were mainly statistically significant. Adjusted interaction tests were borderline
significant in the NSABP-B20 cohort (significant in HER2– patients), whereas in SWOG-8814 they were
significant when adjusted for some clinicopathological variables individually, but not when adjusting for
ER determined by Allred status. However, part of the NSABP-B20 cohort was the derivation cohort for
oncotype DX and this may bias results in favour of observing an interaction. The RSPC algorithm (oncotype
DX plus age, tumour size and grade) showed a non-significant interaction test between chemotherapy
benefit and RSPC risk group,44 indicating that the incorporation of clinicopathological factors may reduce
prediction of chemotherapy benefit, and therefore if chemotherapy decisions are based on an informal
consideration of clinicopathological factors alongside the oncotype DX score, this may reduce the
predictive ability of oncotype DX in clinical practice. Three observational cohort studies were at high risk
of confounding; one reported a statistically significant interaction test adjusted for limited clinical factors.
If predictive ability were assumed, it is unclear below which exact cut-off point patients could avoid
chemotherapy (although one study suggests that this is a recurrence score of 20), as chemotherapy benefit
is uncertain in the intermediate-risk group. Although the ongoing RCT TAILORx will address the issue of
whether or not low-risk and intermediate-risk patients can avoid chemotherapy, it is unclear to what
extent it will address the question of whether or not the test can predict chemotherapy benefit. The EAG
considers that there remains uncertainty surrounding whether or not oncotype DX is associated with a
predictive benefit of chemotherapy (i.e. a difference in relative effect by genomic risk group) and, if so,
that there is uncertainty in the likely magnitude of this predictive effect within the clinical subgroups
considered in this appraisal.
MammaPrint
Prediction of chemotherapy benefit for MammaPrint was reported in a pooled analysis of six non-randomised
series (n = 541; half LN0, half LN1–3) in which patients were treated in accordance with usual practice.
The effect of chemotherapy versus no chemotherapy was statistically significant in the MammaPrint high-risk
group but not in the low-risk group in unadjusted analyses for 5-year DRFS and BCSS and in adjusted
analyses for 5-year BCSS. However, the interaction test between chemotherapy treatment and risk group
(for 5-year BCSS) was non-significant (p = 0.45). A further pooled analysis of two of the above series,
restricted to LN1–3 patients, also reported a statistically non-significant interaction between chemotherapy
treatment and risk group for 10-year BCSS (p = 0.95). The evidence for the ability of MammaPrint to predict
chemotherapy benefit is therefore extremely limited; although unadjusted analyses suggest a greater effect
of chemotherapy in high-risk groups, adjusted analyses were only reported for one outcome, and the
non-significant interaction tests suggest no statistically significant difference in effect of chemotherapy
between risk groups.
Clinical utility
Clinical utility is defined in this assessment as the impact of tests used prospectively in clinical practice on
recurrence/survival outcomes. Studies assessing prospective use of tests were only available for oncotype
DX and MammaPrint, and only one RCT had reported in full (MINDACT for MammaPrint). There was no
clinical utility evidence for EndoPredict or EPClin, Prosigna/ROR-PT, IHC4, IHC4+C or oncotype DX RSPC.
Oncotype DX
Without the highest level of evidence (RCT of treatment guided by a test vs. treatment guided by usual
practice), it is not possible to conclude whether or not patient outcomes would be affected by the use of
the test in a clinical setting. In LN0 patients, the use of the test in clinical practice appears to result in low
rates of chemotherapy use in low-risk patients (2% to 12%), with acceptable outcomes (5-year DRFS/DRFI/
IDFS of 96% to 99.6%). Rates of chemotherapy use increased with increasing risk category, and were
generally higher in LN+ patients; only one study reported 5-year DRFS/DRFI/IDFS for LN+ patients, which
was 97% (7% received chemotherapy). It was not possible to determine whether or not patients in
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intermediate- and high-risk categories had better outcomes than low-risk patients as a result of using
oncotype DX, owing to the observational nature of the studies.
MammaPrint
Two studies reported evidence relating to the clinical utility of MammaPrint. MINDACT is a RCT of
MammaPrint versus clinical practice. This study randomised patients with discordant MammaPrint and mAOL
risks to chemotherapy or no chemotherapy. For patients who were high-clinical, low-MammaPrint risk,
5-year DMFS was 95.9% with chemotherapy and 94.4% without chemotherapy, a non-significant absolute
difference of 1.5% (p = 0.267). This raises the possibility of avoiding chemotherapy in these patients. In
patients who were low-clinical, high-MammaPrint risk, 5-year DMFS was 95.8% with chemotherapy and
95.0% without chemotherapy, an absolute difference of 0.8%. This could be interpreted as showing that
MammaPrint may not be useful in this group as it would increase chemotherapy rates without improving
outcomes. However, the comparator was mAOL, and it is unclear whether or not the same would be true
for other clinical risk scores.
RASTER is a prospective observational study in which patients were treated in accordance with MammaPrint
plus usual clinical practice (LN0) or in accordance with usual clinical practice (LN+). The 5-year DRFI for LN0
patients was 97.0% for low-risk patients (15% had chemotherapy) and 91.7% for high-risk patients (81%
received chemotherapy). The 10-year DRFI for LN0 patients was 93.7% for low-risk patients and 86.8% for
high-risk patients. The DRFI rates in the MammaPrint low-risk group may be considered sufficiently low for
these patients to avoid chemotherapy.
Decision impact
Decision impact studies assess how decisions to use or not to use chemotherapy change pre and post use of
the test. Only decision impact studies from the UK and Europe were included, because other countries may
have very different rates of chemotherapy use. The percentage of patients with any change in treatment
recommendation or decision (either to or from chemotherapy) among UK studies was 29% to 49% across
four oncotype DX studies, 37% in one EndoPredict study and 27% in one IHC4+C study. Ranges across
European (non-UK) studies were 5% to 70% for oncotype DX, 38% to 41% for EndoPredict, 14% to 41%
for Prosigna and 13% to 51% for MammaPrint. The net change in the percentage of patients with a
chemotherapy recommendation or decision (patients changing to chemotherapy minus those changing to
no chemotherapy) among UK studies was a reduction of 8% to 23% across four oncotype DX studies, an
increase of 1% in one EndoPredict study and a reduction of between 2% and 26% in one IHC4+C study
(unclear owing to category definitions). Net changes across European (non-UK) studies were a reduction of
0% to 64% for oncotype DX, a reduction of 13% to 26% for EndoPredict, a reduction of 2% to an increase
of 9% for Prosigna and a reduction of 31% to an increase of 8% for MammaPrint.
Concordance
Concordance is defined in this review as the degree to which tests assign the same patients to the same
risk groups. Concordance analyses do not report long-term outcomes. A full review of these data was
beyond the scope of this review and, instead, the OPTIMA Prelim study588 was included as a key example
of concordance between tests and included oncotype DX, MammaPrint, Prosigna and IHC4. The authors
concluded, that although tests assigned similar proportions of patients to low/intermediate- and high-risk
categories, test results for an individual patient could differ markedly depending on which test was used.
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Anxiety and health-related quality of life
Six studies (seven publications)159,164,166,174–177 reported outcomes relating to anxiety (including worry and
distress) and HRQoL. For oncotype DX (two studies, n = 286),174,176 EndoPredict (one study, n = 149)159
and Prosigna (two studies, n = 398),163,166 all studies had a pre–post test design, whereas MammaPrint
compared patients subgrouped in accordance with their clinical risk, MammaPrint risk, whether or not they
were assigned to chemotherapy and whether or not the MammaPrint test result was missing.177 Across
tests, and when reported, state anxiety decreased post test and total FACT-G scores generally stayed the
same. However, without a comparator group it is not possible to tell if anxiety would have reduced post
treatment decision regardless of how the decision was made. Emotional and functional well-being in
FACT-G improved in one study,166 and FACT-B scores improved for some subgroups in one study.177
Time-to-test results
One study181 of 263 US patients reported that the percentage having a delay of ≥ 42 days from surgery
to chemotherapy initiation was 31% for patients for whom an oncotype DX test was ordered, compared
with 20% for other patients. In another study, the median handling time was 3 working days (range
0–11 days), and 59% of tests were conducted within 3 days.161
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Appendix 5 Results: all tests compared with each
other
This appendix provides an overview of three types of studies that allow some form of comparisonbetween tests:
1. Studies reporting more than one test – these are studies in which two or more of the tests were
conducted and patient outcomes were reported, such that the prognostic performance of two or more
tests in the same cohort can be compared. Very few studies conduct formal comparisons between tests.
2. Microarray studies – these are studies in which the commercial version of the tests was not conducted;
rather, test algorithms were applied to genetic profiles obtained using microarray techniques. Mostly,
these are publicly available in silico (electronic database) genetic profiles, complete with patient outcome
data. As with the studies that report more than one test, the comparisons provided are not always formal.
3. Concordance in risk categorisation between tests – focusing on the OPTIMA Prelim study.
Studies reporting more than one test
Prognostic performance: studies assessing multiple tests
Few studies assessed multiple tests in the same cohort. This section of the report focuses on how the
tests compare with each other in terms of prognostic performance. Evidence is often limited and formal
statistical comparisons are often lacking.
Study designs: studies assessing multiple tests
Data were reported for six cohorts (Table 58). Four studies were reanalyses of RCTs (TransATAC;46 ABCSG 6
and ABCSG 8118–120 and ABCSG 8 only;104,105 GEICAM 9906;108,109 and WSG PlanB73,74,77). The most
comprehensive analysis in terms of the number of tests compared was the translational research analysis of
UK-based patients from the ATAC589 trial (TransATAC; see Report Supplementary Material 1), which assessed
four tests: EndoPredict, Prosigna, oncotype DX and IHC4+C. Analyses were reported across 10 publications,25,36–44
but none reported only ER+, HER2–, LN0–3 patients. In this section of the report, we use the reduced
TransATAC data set (only including patients with a result for all four tests), whereas we have used the data
from the full analysis set (where all patients with the relevant test were included) in the sections relating to
each of the tests individually (see Chapter 2). A pooled analysis of 1702 patients from the ABCSG 6 and
ABCSG 8 trials assessing EndoPredict (EndoPredict and EPClin) was reported by Dubsky et al.119,120 plus subgroup
analyses submitted to NICE by Myriad Genetics,117,118 and an analysis of 1397 patients from ABCSG 8 only
assessed Prosigna (Gnant et al.104 and Filipits et al.105). Because these two analyses have a large overlap
(the majority of patients are from ABCSG 8), they are used here to compare EndoPredict and Prosigna.
Finally, 555 patients from the Spanish GEICAM 9906 trial were analysed for EndoPredict (EndoPredict and
EPClin) and Prosigna by Martin et al.108,109 WSG PlanB73,74,77 was a reanalysis of RCT data from Germany,
but has limitations in its use for assessing prognostic performance (discussed in the next paragraph).
The three remaining studies (Russell et al.,57 WSG PlanB73,74,77 and Gong et al.;58 see Table 58) all had
limitations. Russell et al.57 was an observational study of oncotype DX and MammaPrint in which patients
were treated in accordance with MammaPrint results, and is therefore confounded as a prognostic study
as chemotherapy treatment is likely to have differed across risk groups. However, as there were no other
data that compared MammaPrint with other tests, except from microarray studies (see Appendix 5 and
Report Supplementary Material 10), it has been included as the next available level of evidence. Two studies
(WSG PlanB73,74,77 and Gong et al.58) that both have limitations were included because they compared
oncotype DX with IHC4, and the only other data (apart from microarray studies) that compare oncotype
DX with IHC4 are from the IHC4 derivation cohort (TransATAC). WSG PlanB73,74,77 was a reanalysis of
RCT data from Germany and was included as a clinical utility study for oncotype DX (see Chapter 2,
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TABLE 58 Characteristics of prognostic studies: multiple tests
Study (first
author and year) Cohort(s)
Number
of
patients Country Study design Test Details of test Cut-off points Population
Nodal
status ET/chemotherapy
Sestak 2017 (data
requested)46
TransATAC 774 UK R-RCT EPClin FFPE
RT-qPCR
3.3 ER+ HER2–
Postmenopausal
100% female
LN0, 76%
LN1–3, 24%
ET 5 years
No chemotherapy
Onoctype DX FFPE
Genomic Health
18–30
Onoctype DX
RSPC
FFPE
Genomic Health
10 year DR risk < 10%,
10–20%, > 20%
Prosigna FFPE
NanoString
Technologies
nCounter
LN0: 41–60
LN+: 16–40
IHC4+C FFPE
Cuzick et al. 201125
10–20
Dubsky 2013,119,120
Myriad Genetics118
ABCSG 6 and ABCSG 8 1702 (all) Austria R-RCT EndoPredict
EPClin
FFPE
RT-qPCR
5
3.3
ER+ HER2–
Postmenopausal
Stage I–II
100% female
LN0, 68%
LN1–3, 27%
LN > 3, 5%
ET 5 years
No chemotherapy
Gnant 2014,104
Filipits 2014105
ABCSG 8 1397 Prosigna FFPE
nCounter
LN0: 40–60
LN1–3: 15–40
LN > 3: all high
ER+ HER2–
Postmenopausal
100% female
LN0, 71%a
LN1–3, 26%a
LN > 3, 3%a
Martin 2016,108
Martin 2014109
GEICAM 9906 555 Spain R-RCT EndoPredict
EPClin
FFPE
RT-qPCR
5
3.3
ER+ HER2–
46%
postmenopausal
Stage II–III
100% female
All LN+
LN1–3, 64%
LN > 3, 36%
Adjuvant
chemotherapy
(FEC/FEC-P)
ET 5 yearsProsigna RT-qPCR, then
microarray
18–65
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Study (first
author and year) Cohort(s)
Number
of
patients Country Study design Test Details of test Cut-off points Population
Nodal
status ET/chemotherapy
Russell 201657 University of South
Florida; Morton Plan
Hospital
135 USA Observational,
RPWT
Onoctype DX NR NR 100% ER+
HER2– NR
Menopausal NR
Female NR
NR NR – RPWT
MammaPrint NR
Nitz 2017,77
Gluz 201673,74
WSG PlanB 2642 Germany R-RCT Onoctype DX NR
Genomic Health
25th–75th percentile HR+ HER2–
Premenopausal/
postmenopausal
100% female
High clinical riskb
LN0–3
LN0 58.8%
LN1–3
41.2%
RS < 12,
ET monotherapy;
RS ≥ 12,
chemotherapy plus
ETcIHC4 PE
IHC4
Prat et al. 2013590
Cuzick et al. 201125
25th–75th percentile
Gong 201658 SYSMH; CCSYU;
3rd HNC
153 China Observational,
RPWOT
Onoctype DX FFPE
Multiplex branched-
DNA liquid chip
technology (SurExam,
Guangzhou, China)
NR 100% HR+
100% HER2–
61%
postmenopausal
% female NR
Non-metastatic
LN0 100% ET
79% chemotherapy
IHC4 IHC4
Cuzick et al. 201125
25th–75th percentile
3rd HNC, Third Hospital of Nanchang City; ET, endocrine therapy; FEC, 5-fluorouracil, epirubicin and cyclophosphamide; FEC-P, FEC+ paclitaxel; N+, node positive; N0, node negative; R-RCT, reanalysis of RCT; RPWT, routine
practice with MammaPrint test results; RS, recurrence score; SYSMH, Sun Yat-sen Memorial Hospital.
a Nodal status for all 1478 patients; NR for 1397 who were HER2–.
b HER2– negativity; pT1–T4c; LN+ [or LN0 with a risk factor (CpT2, grade 2/3, high uPA/PAI-1, < 35 years or HR-negative)].
c Patients were treated in accordance with oncotype DX score, with those with RS < 12 receiving ET only, and those with RS ≥ 12 receiving chemotherapy plus ET.
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Clinical utility: oncotype DX) as patients were not treated with chemotherapy when the recurrence score
was < 12, and as a prognostic study for IHC4 (see Section 2.7.2). Gong et al.58 is an observational study in
which patients were treated in accordance with usual practice and it was not clear if this included the test
result, and the assay used was not the commercial version of oncotype DX.
As the TransATAC analysis is key to this assessment and compares the most in-scope tests (n = 4), to
simplify the write-up we have structured this section of the report around the TransATAC data and
compared other data with these, or used other data to provide comparative data when TransATAC data
are lacking. The section contents are:
l TransATAC46 comparing oncotype DX, EPClin, Prosigna and IHC4+C.
l EndoPredict compared with EPClin (n = 2 studies, ABCSG 6 plus ABCSG 8; and GEICAM 9906).108,109,118–120
l EPClin compared with Prosigna (n = 3 studies, TransATAC; GEICAM 9906; ABCSG 6 plus ABCSG 8 or
ABCSG 8).42,104,105,108,109,118–120
l Oncotype DX compared with MammaPrint (n = 1 study57). The limitations of Russell et al.57 are discussed
in the following section.
l Oncotype DX compared with IHC4 or IHC4+C (n = 3 studies46,58,73,74,77). The limitations of WSG PlanB73,74,77
and Gong et al.58 are discussed in the following section.
Patients and treatments: studies assessing multiple tests
Patient characteristics and details of the treatments received are presented in Table 58. Six of the seven
data sets consisted of, or had analyses available for, ER+, HER2– patients,46,58,73,74,77,104,105,108,109,118–120
whereas Russell et al.57 consisted of all ER+ patients, but did not report the proportion who were HER2–.57
In terms of nodal status, one study was in LN0 patients only,58 one study was in LN+ patients only108,109
and one did not report nodal status.57 Three data sets included node-negative and node-positive patients
(TransATAC, ABCSG 6 plus ABCSG 8 and WSG PlanB104,105,118–120). In GEICAM 9906,108,109 36% of
participants had more than three positive nodes; in ABCSG 6 plus ABCSG 8,118–120 5% had more than
three positive nodes. In WSG PlanB, patients were at clinically high risk, defined as LN+ or LN0 with a
risk factor (CpT2, grade 2/3, high uPA/PAI-1, < 35 years).73,74,77 Patients in all analyses received 5 years of
endocrine therapy, apart from those in the study by Russell et al.,57 in which this was not reported, and
Gong et al.,58 in which 100% of participants received endocrine therapy, but the duration was not
reported. Patients in the GEICAM 9906 analysis108,109 also received adjuvant chemotherapy; Russell et al.57
did not report how many patients received chemotherapy; WSG PlanB73,74,77 patients with a recurrence
score of ≥ 12 received chemotherapy; and 79% of patients in Gong et al.58 received chemotherapy.
Tests and comparators: studies assessing multiple tests
Details of the tests conducted and the cut-off points applied are presented in Table 58. All data sets that
included EndoPredict and Prosigna assessed EndoPredict as marketed, using RT-qPCR and standard cut-off
points for risk groups (5 for EndoPredict and 3.3 for EPClin). In two analyses (TransATAC and ABCSG 6 plus
ABCSG 8104,105), Prosigna was assessed using the nCounter device and cut-off points of 40 and 60 (LN0) or
15 and 40 (LN1–3), while GEICAM 9906108,109 used a ‘research-based non-standardised’ PAM50 ROR-PT
assay, using RT-qPCR then microarray rather than nCounter, with cut-off points of 18 and 65 (LN+). Russell
et al.57 did not report how oncotype DX and MammaPrint were obtained. WSG PlanB73,74,77 ordered oncotype
DX from Genomic Health and conducted IHC4 tests according to Prat et al.590 and Cuzick et al.,25 and used
25th to 75th percentiles as cut-off points for oncotype DX and IHC4. Gong et al.58 conducted oncotype DX
assays using SurExam (Guangzhou, China) and IHC4 according to Cuzick et al.,25 also using 25th to 75th
percentiles as cut-off points.
Comparators in TransATAC39,46 included the CTS score and NPI. ABCSG 6 plus ABCSG 8118–120 compared
AOL with EndoPredict.
Quality assessment: studies assessing multiple tests
A summary of the quality of the studies is presented in Table 59. Two data sets (TransATAC and ABCSG 8
or 6 + 8)41,46,104,105,118–120 were reanalyses of RCTs in which no patients received chemotherapy and all
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TABLE 59 Quality assessment of prognostic studies: multiple tests
Study (first author
and year) Cohort(s)
Derivation or
validation?
Study design
appropriate?
All eligible
patients included?
Blinding
(of test
assessors to
outcomes)?
Outcome
definition
standardised
or a priori?
Applicability:
patient
spectrum
Applicability: test
as per decision
problem?
Sestak 2017 (data
request)46
TransATAC V Yes, R-RCT,
no chemotherapy
No; InT, FT Yes Yes Yes Yes
Dubsky 2013,119,120
Myriad Genetics118
ABCSG 6 plus
ABCSG 8
V Yes, R-RCT,
no chemotherapy
UC UC Yes N, includes 5%
LN > 3
Yes
Gnant 2014,104
Filipits 2014105
ABCSG 8 V Yes, R-RCT,
no chemotherapy
No; InT, MS, TF Yes Yes Yes (for subgroup
analysis)
Yes
Martin 2016,108
2014109
GEICAM 9906 V No, R-RCT, adjuvant
chemotherapy
No (reason NR) Yes Yes N (36% LN > 3) No, Prosigna via
RT-qPCR then
microarray
Nitz 2017,77
Gluz 2016,73,74
WSG PlanB V No, some
chemotherapy
No, MS Yes Yes Yes, but high risk Yes
Russell 201657 University of
South Florida;
Morton Plan
Hospital
V No, cohort study,
usual practice
(some chemotherapy)
No; InT, sent for test UC Yes N; InT Yes
Gong 201658
(n = 611)
SYSMH; CCSYU;
3rd HNC
V No, some
chemotherapy
No; InT; MD UC Yes N, InT, MD,
chemotherapy
No – oncotype DX
algorithm, but used
SurExam assay
3rd HNC, Third Hospital of Nanchang City; D, Development; FT, failed test; InT, insufficient tissue; MS, missing samples; N, number of positive nodes; R-RCT, reanalysis of RCT; SYSMH, Sun
Yat-sen Memorial Hospital; TF, test failure; UC, unclear; V, validation.
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received adjuvant endocrine therapy. Two (GEICAM and WSG PlanB)73,74,77,108,109 were reanalyses of RCTs
in which some patients received chemotherapy, and two57,58 were observational studies in which patients
were either treated in accordance with routine practice but it was not clear if the test results were known,58
or were treated in accordance with routine practice including a test result (MammaPrint).57 None of the
studies reported including all relevant patients, meaning that there is a risk of bias and the generalisability
of the cohort to the decision problem is uncertain. Test assessors were blind to patient outcomes in four
studies.46,73,74,77,104,105,108,109 All used standardised outcomes. Two studies58,108,109 used assays that were not
the same as the commercially marketed version of the test: Prosigna not using nCounter in one study;108,109
oncotype DX performed by SurExam and the IHC4 process was not clear in one study.58
Results: studies assessing multiple tests
Tables 60–63 present the data for all patients (node positive or node negative) and separate data for
node-positive and node-negative patients.
Prognostic performance
Distribution of patients by risk group, event rates (distant recurrence/relapse-free
interval/distant metastasis-free survival/distant recurrence/relapse-free survival) and
hazard ratios (unadjusted analyses)
This section reports unadjusted analyses. Adjusted analyses, which show whether or not the test has
prognostic value over clinicopathological variables, are reported in Additional prognostic value.
TransATAC data
In the TransATAC cohort (see Table 60),42,46 the proportion of patients categorised as low risk was similar
for oncotype DX, EPClin and IHC4+C (62%, 61% and 57%, respectively), and Prosigna placed the fewest
patients in this group (43%). In the LN0 subgroup, the proportion in the low-risk group was generally
higher (63% for oncotype DX, 73% for EPClin, 66% for IHC4+C, 54% for Prosigna and 73% for
oncotype DX RSPC) than in the LN+ group (57%, 23%, 27% and 8%, respectively; oncotype DX RSPC
not assessed in LN+). Notably, oncotype DX categorised a high proportion as low risk in both subgroups
(63% and 57%, respectively), and Prosigna always reported the smallest proportion (54% and 8%,
respectively). The 5-year event rates in low-risk LN0 patients were largely similar across tests, ranging from
97.6% (EPClin) to 98.8% (oncotype DX), but at 10 years Prosigna low-risk patients had the best DRFI
rates (97.0%) with the other four tests having similar rates (93.4% to 94.7%). In LN+ patients, event rates
in low-risk patients were more variable, with DRFI rates ranging from 95.1% (oncotype DX) to 100%
(Prosigna) at 5 years, and 80.6% (oncotype DX) to 100% (Prosigna) at 10 years. Notably, oncotype DX
consistently had the worst survival rates in low-risk patients at both time points, whereas Prosigna had
the best. However, only 8% of patients were assigned low-risk status by Prosigna, whereas 57% were
assigned low-risk status by oncotype DX. IHC4+C and EPClin assigned fewer patients (27% and 23%,
respectively) to the low-risk group than oncotype DX, but more than Prosigna, and had event rates of
95.2% and 94.4%, respectively.46
In LN0–3 patients, the HRs for 10-year DRFI between risk groups were all statistically significant, with HRs
for low vs. high risk ranging from 4.41 (oncotype DX) to 12.40 (Prosigna). In LN0 patients, there was
not a consistent pattern regarding whether HRs were greater at 0–5 years than at 0–10 years. All were
statistically significant except the analysis comparing low- with high-risk patients for Prosigna at 5 years
[2.91 (95% CI 0.95 to 8.89)]. The greatest HR was for the analysis of low- versus high-risk patients for
oncotype DX [13.07 (95% CI 3.93 to 43.41)], and the lowest was for Prosigna at 5 years [2.91 (95% CI
0.95 to 8.89)]. When comparing LN0 with LN+ HRs, both EPClin and IHC4+C tests reported lower HRs in
the LN0 subgroup than in the LN+ subgroup at 10 years, whereas oncotype DX reported higher HRs in the
LN0 subgroup than in the LN+ subgroup.46
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TABLE 60 Prognostic performance of multiple tests: DRFI/DMFS/DRFSa
Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group
Percentage risk
DRFI/DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Node negative and node positive
Sestak 2017 (data
request)46 (reduced
data set)
b
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 774)
l LN0, 76%
l LN1–3, 24%
l All ET
l No chemotherapy
EPClin 61 – 39 – – – – – – 0–10 years: 4.65 (2.98 to 7.24)
Oncotype
DX
62 28 10 – – – – – – 0–10 years:
l Low vs. intermediate: 2.72
(1.74 to 4.27)
l Low vs. high: 4.41
(2.60 to 7.51)
Prosigna 43 30.5 26.5 – – – – – – 0–10 years:
l Low vs. intermediate: 5.49
(2.63 to 11.48)
l Low vs. high: 12.40
(6.13 to 25.08)
IHC4+C 57 26 17 – – – – – – 0–10 years:
l Low vs. intermediate: 4.73
(2.79 to 8.03)
l Low vs. high: 7.18
(4.20 to 12.28)
Dubsky 2013,119,120
Myriad Genetics118
ABCSG 6 plus
ABCSG 8,
R-RCT, Austria
ER+ HER2–,
(n= 1702)
l LN0, 68%
l LN1–3, 27%
l LN > 3, 5%
l All ET
l No chemotherapy
EndoPredict 49 – 51 NR – NR 0–5 years: 2.80 (1.81 to 4.34);
p< 0.001
5–10 years: 3.28 (1.48 to 7.24);
p=0.002
EPClin 63 – 37 95.3 – NR 0–5 years: 4.82 (3.12 to 7.44);
p< 0.001
0–10 years: 5.11 (3.48 to
7.51); p < 0.001
5–10 years: 6.25 (2.72 to
14.36); p < 0.001
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT, Spain
ER+ HER2–,
(n= 1397)
l LN0, 71%
c
l LN1–3, 26%
c
l LN > 3, 3%
c
l All ET
l No chemotherapy
Prosigna 35 32 33 96.6 91.1 79.9 5–15 years:
l Intermediate vs. low: 3.74
(NR); p= 0.002
f
l High vs. low: 6.90 (3.08 to
15.45); p < 0.001
f
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TABLE 60 Prognostic performance of multiple tests: DRFI/DMFS/DRFSa (continued )
Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group
Percentage risk
DRFI/DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Nitz 2017,77
Gluz 201673,74
WSG PlanB,
Germany
HR+ HER2–,
(n= 2642)
l LN0–3
l LN0 58.8%
l LN1–3
41.2%
RS < 12 ET; RS ≥ 12,
chemotherapy and ET
d
Oncotype
DX
17
e
58
e
21
e
93.6
d
94.3
d
84.2
d
0–5 years: 2.33 (1.73 to 3.14);
p< 0.001
IHC4 NR NR NR NR NR NR 0–5 years: 2.04 (1.47 to 2.83);
p< 0.001
Russell 201657 University of
South Florida,
Morton Plan
Hospital, USA
ER+, NR
HER2–,
(n= 135)
NR NR Oncotype
DX
53 26 21 Log-rank 0–5 years:
l Intermediate vs. low:
p = 0.760
l High vs. low: p= 0.036
MammaPrint 63 72 Log-rank, 0–5 years: p= 0.032
Node negative
Sestak 2017 (data
request)46 (reduced
data set)
b
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 591)
LN0 l All ET
l No chemotherapy
EPClin 73 – 27 97.6 – 91.2 93.4 – 77.9 0–5 years: 3.76 (1.67 to 8.46)
0–10 years: 3.88 (2.31 to 6.52)
Oncotype
DX
63 26 10 98.8 92.1 86.8 94.1 83.3 72.8 0–5 years:
l Low vs. intermediate: 7.40
(2.39 to 22.93)
l Low vs. high: 13.07
(3.93 to 43.41)
0–10 years:
l Low vs. intermediate: 3.28
(1.79 to 5.98)
l Low vs. high: 5.83
(2.96 to 11.48)
Oncotype
DX RSPC
73 19 9 98.3 91.4 86.2 93.8 80.2 70.5 0–5 years:
l Low vs. intermediate: 5.42
(1.88 to 15.63)
l Low vs. high: 8.74
(2.82 to 27.11)
0–10 years:
l Low vs. intermediate: 3.67
(1.92 to 7.01)
l Low vs. high: 6.07
(2.96 to 14.43)
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Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group
Percentage risk
DRFI/DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Prosigna 54 30 16 98.4 95.4 88.1 97.0 85.9 67.6 0–5 years:
l Low vs. intermediate: 2.91
(0.95 to 8.89)
l Low vs. high: 7.62 (2.65 to
21.92)
0–10 years:
l Low vs. intermediate: 4.60
(2.12 to 9.99)
l Low vs. high: 12.19
(5.73 to 25.95)
IHC4+C 66 23 11 98.4 93.2 85.7 94.7 79.8 74.6 0–5 years:
l Low vs. intermediate: 4.51
(1.60 to 12.66)
l Low vs. high: 9.78 (3.48 to
27.49)
0–10 years:
l Low vs. intermediate: 3.98
(2.18 to 7.28)
l Low vs. high: 6.06
(3.07 to 11.94)
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT, Austria
ER+ HER2–,
(n= 984)
LN0 l All ET
l No chemotherapy
Prosigna 48 32 20 96.5 90.0 84.7 5–15 years:
l Intermediate vs. low: 4.03
(NR); p= 0.002
f
l High vs. low: 4.74 (1.89 to
11.87); p < 0.001
f
Gong 201658 SYSMH,
CCSYU,
3rd HNC,
China
ER+ HER2–,
(n= 153)
LN0 l 100% ET
l 79% chemotherapy
Oncotype DX 49 26 25 0–10 years C-index (AUC):
0.685 (0.540 to 0.830)
IHC4 29 48 23 0–10 years C-index (AUC):
0.602 (0.436 to 0.767)
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
3
3
0
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
9
V
O
L
.
2
3
N
O
.
3
0
©
Q
u
een
’s
Prin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
1
9
.Th
is
w
o
rk
w
as
p
ro
d
u
ced
b
y
H
arn
an
e
t
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cialC
are.
Th
is
issu
e
m
ay
b
e
freely
rep
ro
d
u
ced
fo
r
th
e
p
u
rp
o
ses
o
f
p
rivate
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
llrep
o
rt)m
ay
b
e
in
clu
d
ed
in
p
ro
fessio
n
aljo
u
rn
als
p
ro
vid
ed
th
at
su
itab
le
ackn
o
w
led
g
em
en
t
is
m
ad
e
an
d
th
e
rep
ro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g
.
A
p
p
licatio
n
s
fo
r
co
m
m
ercialrep
ro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:N
IH
R
Jo
u
rn
als
Lib
rary,N
atio
n
alIn
stitu
te
fo
r
H
ealth
R
esearch
,Evalu
atio
n
,Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,A
lp
h
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
p
to
n
Scien
ce
Park,So
u
th
am
p
to
n
SO
1
6
7
N
S,U
K
.
2
4
3
TABLE 60 Prognostic performance of multiple tests: DRFI/DMFS/DRFSa (continued )
Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group
Percentage risk
DRFI/DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Node positive
Sestak 2017
(data request)46
(reduced data set)
b
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 183)
LN1–3 l All ET
l No chemotherapy
EPClin 23 – 77 97.7 – 86.7 94.4 – 69.7 0–5 years: 5.89 (0.79 to 44.15)
0–10 years: 6.58 (1.59 to 27.27)
Oncotype DX 57 32 11 95.1 82.0 79.7 80.6 70.9 62.0 0–5 years:
l Low vs. intermediate: 3.83
(1.31 to 11.20)
l Low vs. high: 4.69
(1.26 to 17.47)
0–10 years:
l Low vs. intermediate: 1.89
(0.96 to 3.74)
l Low vs. high: 2.77
(1.15 to 6.68)
Prosigna 8 32 60 100.0 91.1 86.8 100.0 79.3 69.3 0–5 years:
l Low vs. intermediate or low
vs. high: no events
l Intermediate vs. high: 1.59
(0.57 to 4.41)
0–10 years:
l Low vs. intermediate or
low vs. high: no events
l Intermediate vs. high: 1.59
(0.80 to 3.19)
IHC4+C 27 34 39 98.0 88.5 83.8 95.2 71.6 64.3 0–5 years:
l Low vs. intermediate: 5.88
(0.73 to 47.81)
l Low vs. high: 8.57
(1.11 to 66.41)
0–10 years:
l Low vs. intermediate: 7.31
(1.68 to 31.78)
l Low vs. high: 9.57
(2.25 to 40.71)
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Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group
Percentage risk
DRFI/DMFS/DRFS:
a
HR
(95% CI)
0–5 years 0–10 years
Low Intermediate High Low Intermediate High Low Intermediate High
Gnant 2014,104
Filipits 2014105
ABCSG 8,
R-RCT, Austria
ER+ HER2–,
(n= 413)
l LN1–3, 89%
c
l LN > 3, 11%
c
l All ET
l No chemotherapy
Prosigna 4 34 62 100 93.6 76.2 5–15 years:
l Intermediate vs. low: no
events; high vs. low:
no events
l High vs. intermediate: 3.15
(1.20 to 8.24); p = 0.020
f
Martin 2016,108
2014109
GEICAM 9906,
R-RCT, Spain
ER+ HER2–,
(n= 536)
l LN1–3, 64%
l LN > 3, 36%
l All ET
l All chemotherapy
EndoPredict 25 – 75 93 – 69 0–10 years: 4.7 (CI NR),
p< 0.0001
EPClin 13 – 87 100 – 71 0–10 years: not estimable;
p< 0.0001
ROR-PT
(research)
19 56% 26 92 74 66 0–10 years:
l 4.4 (low vs. intermediate)
l 5.8 (low vs. high) (CI NR);
p< 0.0001
ET, endocrine therapy; N+, node positive; N0, node negative; NR, not reported; RS, recurrence score.
a DMFS (GEICAM, ABSCG); DRFI (TransATAC); DFS (Nitz et al.77).
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
c Nodal status for all patients; NR for HER2– subgroup.
d Patients treated in accordance with RS: RS < 12 no chemotherapy, RS ≥ 12 chemotherapy.
e For cut-off points of < 12, 12–25 and > 25.
f 5–15 years in ABCSG-8 analysis of Prosigna.
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TABLE 61 Prognostic performance of multiple tests: OS
Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group OS at 5 years OS at 10 years
HR, low vs. high (95% CI)Low Intermediate High Low Intermediate High Low Intermediate High
Node negative and node positive
Sestak 201746
(reduced data set)
a
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 774)
LN0, 76%
LN1–3, 24%
l All ET
l No
chemotherapy
EPClin 61 – 39 – – – – – – 0–10 years: 2.15 (1.65 to 2.80)
Oncotype DX 62 28 10 – – – – – – 0–10 years:
l Low vs. intermediate: 1.68
(1.25 to 2.26)
l Low vs. high: 2.59 (1.79 to 3.74)
Prosigna 43 30.5 26.5 – – – – – – 0–10 years:
l Low vs. intermediate: 1.84
(1.29 to 2.61).
l Low vs. high: 3.42 (2.46 to 4.75)
IHC4+C 57 26 17 – – – – – – 0–10 years:
l Low vs. intermediate: 2.19
(1.60 to 2.99)
l Low vs. high: 3.05 (2.20 to 4.22)
Node negative
Sestak 201746
(reduced data set)
a
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 591)
LN0 l All ET
l No
chemotherapy
EPClin 73 – 27 92.8 – 88.9 79.6 – 63.3 0–5 years: 1.56 (0.87 to 2.79)
0–10 years: 2.06 (1.46 to 2.89)
Oncotype DX 63 26 10 94.4 87.7 85.2 80.7 69.2 55.8 0–5 years:
l Low vs. intermediate: 2.24
(1.20 to 4.16)
l Low vs. high: 2.81 (1.28 to 6.13)
0–10 years:
l Low vs. intermediate: 1.75
(1.20 to 2.56)
l Low vs. high: 2.79 (1.76 to 4.42)
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Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group OS at 5 years OS at 10 years
HR, low vs. high (95% CI)Low Intermediate High Low Intermediate High Low Intermediate High
Oncotype DX
RSPC
73 19 9 94.5 87.3 84.1 80.7 69.4 50.5 0–5 years:
l Low vs. intermediate: 2.44
(1.19 to 4.99)
l Low vs. high: 3.08 (1.30 to 7.28)
0–10 years:
l Low vs. intermediate: 1.87
(1.22 to 2.96)
l Low vs. high: 3.33 (2.03 to 5.45)
Prosigna 54 30 16 93.4 92.7 84.1 83.6 72.7 51.7 0–5 years:
l Low vs. intermediate: 1.12
(0.56 to 2.24)
l Low vs. high: 2.48 (1.28 to 4.82)
0–10 years:
l Low vs. intermediate: 1.75
(1.17 to 2.62)
l Low vs. high: 3.64 (2.41 to 5.48)
IHC4+C 66 23 11 94.9 85.3 85.7 82.2 63.1 57.3 0–5 years:
l Low vs. intermediate: 3.00
(1.62 to 5.58)
l Low vs. high: 2.94 (1.34 to 6.47)
0–10 years:
l Low vs. intermediate: 2.31
(1.59 to 3.37)
l Low vs. high: 3.01 (1.90 to 4.78)
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TABLE 61 Prognostic performance of multiple tests: OS (continued )
Study (first author
and year)
Cohort(s),
design,
country Population Nodal status ET/chemotherapy Test
Percentage of patients
per group OS at 5 years OS at 10 years
HR, low vs. high (95% CI)Low Intermediate High Low Intermediate High Low Intermediate High
Node positive
Sestak 201746
(reduced data set)
a
TransATAC,
R-RCT, UK
ER+ HER2–,
(n= 183)
LN1–3 l All ET
l No
chemotherapy
EPClin 23 – 77 95.3 – 81.4 72.9 – 57.8 0–5 years: 4.28 (1.02 to 18.03)
0–10 years: 1.99 (1.02 to 3.91)
Oncotype DX 57 32 11 90.4 77.6 75.0 66.8 58.1 44.4 0–5 years:
l Low vs. intermediate: 2.50
(1.10 to 5.70)
l Low vs. high: 2.95 (1.01 to 8.64)
0–10 years:
l Low vs. intermediate: 1.52
(0.90 to 2.59)
l Low vs. high: 2.31 (1.16 to 4.59)
Prosigna 8 32 60 100.0 87.9 80.8 90.0 70.1 52.9 0–5 years:
l Low vs. intermediate or low vs.
high: no events
l Intermediate vs. high: 1.70
(0.72 to 4.01)
0–10 years:
l Low vs. intermediate: 5.15
(0.68 to 38.63)
l Low vs. high: 9.02 (1.25 to 65.36)
IHC4+C 27 34 39 94.0 85.3 77.5 77.4 62.9 49.1 0–5 years:
l Low vs. intermediate: 2.52
(0.68 to 9.32)
l Low vs. high: 4.17 (1.22 to 14.32)
0–10 years:
l Low vs. intermediate: 2.03
(0.96 to 4.28)
l Low vs. high: 3.08 (1.52 to 6.22)
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TABLE 62 Additional prognostic value (likelihood ratio χ2 values): multiple tests
Study (first author and year)
Cohort(s),
design, country Population Nodal status Outcome
Test or
comparatora
Likelihood
ratio χ2
Increase in likelihood ratio
χ2 over CTS/CLPa
Node negative and node positive
Sestak 2017 (data request)46
(reduced data set)b
TransATAC,
R-RCT, UK
l ER+ HER2–
l ET, no chemotherapy
l n = 774
l LN0, 76%
l LN1–3, 24%
DRFI at 10 years EPClin 69.31
(p < 0.0001)
Over CTS: 24.39 (p < 0.0001)
Over NPI: 22.17 (p < 0.0001)
Oncotype DX 26.94
(p < 0.0001)
Over CTS: 15.22 (p = 0.0001)
Over NPI: 11.89 (p = 0.0006)
Prosigna 61.47
(p < 0.0001)
Over CTS: 26.30 (p < 0.0001)
Over NPI: 23.91 (p < 0.0001)
IHC4+C 75.30
(p < 0.0001)
Over CTS: 20.07 (p < 0.0001)
Over NPI: 22.84 (p < 0.0001)
Gnant 2014,104 Filipits 2014105 ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l ET, no chemotherapy
l n = 1397
l LN0, 71%
l LN1–3, 26%
l LN > 3, 3%
DRFS at 10 years Prosigna Over CLP: 29.94 (p < 0.0001)
Node negative
Sestak 2017 (data request)46
(reduced data set)b
TransATAC,
R-RCT, UK
l ER+ HER2–
l ET, no chemotherapy
l n = 591
LN0 DRFI at 10 years EPClin 40.60
(p < 0.0001)
Over CTS: 15.22 (p = 0.0001)
Over NPI: 17.00 (p < 0.0001)
Oncotype DX 22.78
(p < 0.0001)
Over CTS: 10.64 (p = 0.001)
Over NPI: 8.82 (p = 0.003)
Oncotype DX
RSPC
24.30
(p < 0.0001)
Over CTS: 5.10 (p = 0.02)
Over NPI: 8.71 (p = 0.003)
Prosigna 50.77
(p < 0.0001)
Over CTS: 23.71 (p < 0.0001)
Over NPI: 25.54 (p < 0.0001)
IHC4+C 48.55
(p < 0.0001)
Over CTS: 17.14 (p < 0.0001)
Over NPI: 21.92 (p < 0.0001)
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Study (first author and year)
Cohort(s),
design, country Population Nodal status Outcome
Test or
comparatora
Likelihood
ratio χ2
Increase in likelihood ratio
χ2 over CTS/CLPa
Gnant 2014,104 Filipits 2014105 ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l ET, no chemotherapy
l n = 984
LN0 DRFS at 10 years Prosigna Over CLP: 20.32 (p < 0.0001)
Node positive
Sestak 2017 (data request)46
(reduced data set)b
TransATAC,
R-RCT, UK
l ER+ HER2–
l ET, no chemotherapy
l n = 183
LN1–3 DRFI at 10 years EPClin 12.91
(p < 0.001)
Over CTS: 7.36 (p = 0.007)
Over NPI: 5.57 (p = 0.02)
Oncotype DX 4.75
(p = 0.023)
Over CTS: 3.56 (p = 0.06)
Over NPI: 2.14 (p = 0.10)
Prosigna 8.51
(p = 0.004)
Over CTS: 4.39 (p = 0.04)
Over NPI: 2.71 (p = 0.09)
IHC4+C 12.60
(p < 0.001)
Over CTS: 3.08 (p = 0.08)
Over NPI: 2.45 (p = 0.10)
Gnant 2014,104 Filipits 2014105 ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l ET, no chemotherapy
l n = 413
l LN1–3, 89%c
l LN > 3, 11%c
DRFS at 10 years Prosigna Over CLP: 17.45 (p = 0.0002)
ET, endocrine therapy; N+, node positive; N0, node negative.
a Clinicopathological factors (ABSCG) = age, grade, nodal status, tumour size, Ki-67. Clinicopathological factors (GEICAM) = age, grade, nodal status, tumour size, treatment, ER, PR, Ki-67.
CTS (TransATAC) and CLP (ABCSG 8) = age, grade, nodal status, tumour size, treatment. Clinicopathological factors (WSG PlanB) = nodal status, tumour stage, local grade, central grade,
Ki-67, ER, PR, IHC4, oncotype DX recurrence score.
b Full data set = all patients with EndoPredict data available; reduced data set = patients with data for all four in-scope tests analysed in TransATAC.
c Nodal status for all patients; NR for HER2– subgroup.
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TABLE 63 Additional prognostic value (C-indices and multivariable analyses): multiple tests
Study (first
author and
year)
Cohort(s), design,
country Population Nodal status Outcome Test or comparator
a
C-index
(AUC)
Increase in C-index (AUC) over
clinicopathological factors
a
Multivariable Cox proportional
hazards model (adjusted for
clinicopathological factors
a
):
HR (95% CI)
Node negative and node positive
Dubsky
2013,119,120
ABCSG 6 plus
ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l Endocrine therapy,
no chemotherapy
l n = 1702
l LN0, 68%
l LN+, 32%
DMFS at 0–5 years EndoPredict 1.20 (1.10 to 1.31); p< 0.001
DMFS at 5–10 years EndoPredict 1.28 (1.10 to 1.48); p= 0.001
EPClin 0.786
EndoPredict plus AOL 0.765 EndoPredict plus AOL vs. AOL:
p < 0.001
EndoPredict plus
clinicopathological
factors
0.716 EndoPredict plus clinicopathological
factors vs. clinicopathological
factors: p < 0.001
AOL 0.674
Clinicopathological
factors
0.644
Gnant 2014,104
Filipits 2014105
ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l Endocrine therapy,
no chemotherapy
l n = 1397
l LN0, 71%
l LN1–3, 26%
l LN > 3, 3%
DRFS at 10 years Prosigna 0.720 NR HR (intermediate vs. low) 2.15
(1.21 to 3.81); p= 0.009
HR (high vs. low) 4.26 (2.44 to 7.43);
p<0.0001
CLP 0.688
Nitz 201773,74,77
(n = 2642)
WSG PlanB l 100% HR+
l 100% HER2–
l High clinical risk
l n = 2642
l LN0, 58.8%
l LN1–3, 41.2%
IDFSc Oncotype DX HR (25th to 75th percentile) 1.73
(1.21 to 2.47); p= 0.001
IHC4 HR (25th to 75th percentile) NS
Node negative
Gnant 2014,104
Filipits 2014105
ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l Endocrine therapy,
no chemotherapy
l n = 984
l LN0 DRFS at 10 years Prosigna 0.692 NR
CLP 0.639
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Study (first
author and
year)
Cohort(s), design,
country Population Nodal status Outcome Test or comparator
a
C-index
(AUC)
Increase in C-index (AUC) over
clinicopathological factors
a
Multivariable Cox proportional
hazards model (adjusted for
clinicopathological factors
a
):
HR (95% CI)
Node positive
Gnant 2014,104
Filipits 2014105
ABCSG 8, R-RCT,
Austria
l ER+ HER2–
l Endocrine therapy,
no chemotherapy
l n = 413
l LN1–3, 89%b
l LN > 3, 11%b
DRFS at 10 years Prosigna 0.743 NR
CLP 0.667
Martin 2016,108
2014109
GEICAM 9906,
R-RCT, Spain
l ER+ HER2–
l Chemotherapy-
treated
l n = 536
l LN1–3, 64%
l LN > 3, 36%
DMFS at 10 years EPClin 0.693 Adding EPClin to ROR-PT plus
clinicopathological factors: p < 0.001
EndoPredict plus
clinicopathological
factorsa
0.672 EndoPredict plus clinicopathological
factors vs. clinicopathological
factors: p = 0.0018
EndoPredict 0.657 1.1 (1.0 to 1.2); p = 0.003
Clinicopathological
factorsa
0.654
ROR-PT (research-based) 0.644 Adding ROR-PT to EPClin plus
clinicopathological factors: p = 0.567
ET, endocrine therapy; IDFS, invasive disease free survival; N+, node positive; N0, node negative; RS, recurrence score.
a Clinicopathological factors (ABSCG) = age, grade, nodal status, tumour size, Ki-67. Clinicopathological factors (GEICAM) = age, grade, nodal status, tumour size, treatment, ER, PR, Ki-67. CTS (TransATAC) and CLP
(ABCSG 8) = age, grade, nodal status, tumour size, treatment. Clinicopathological factors (WSG PlanB) = nodal status, tumour stage, local grade, central grade, Ki-67, ER, PR, IHC4, oncotype DX RS.
b Nodal status for all patients; NR for HER2– subgroup.
c Patients treated in accordance with RS: RS < 12, no chemotherapy; RS ≥ 12, chemotherapy.
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EndoPredict versus EndoPredict Clinical
Results are presented in Table 60. Similar proportions of low-risk patients as seen in the TransATAC cohort
were reported for EPClin in ABCSG 6 plus ABCSG 8 [63% LN0–3 (additional analyses were provided in
confidence by the company but cannot be reported here)]. When comparing EndoPredict with EPClin in
the ABCSG 6 plus ABCSG 8 cohort, EndoPredict placed fewer patients in the low-risk category [49% for
LN0–3 (additional analyses were provided in confidence by the company but cannot be reported here)]
than EPClin (63%).118–120 Only DRFS rates for EPClin were reported, which for low-risk patients at 5 years
were 95.3%. In contrast, in the LN+ study GEICAM 9906, EndoPredict placed more patients in the
low-risk category (25%) than EPClin (13%), but event rates were lower in EPClin low-risk groups (100%)
than in EndoPredict (93%). HRs for EPClin were higher than for EndoPredict [e.g. 0- to 5-year HR for low
vs. high 4.82 (EPClin) and 2.80 (EndoPredict)].108,109
Prosigna versus EndoPredict Clinical
Results are presented in Table 60. For LN0–3 cohorts, data from ABCSG 6 plus ABCSG 8118–120 were
consistent with TransATAC:46 Prosigna/ROR-PT placed a smaller proportion of patients in the low-risk group
than EPClin in both cohorts (TransATAC and ABCSG 6 plus ABCSG 8/ABCSG 8),104,105,118–120 with 43%
versus 61% (TransATAC) and 35% versus 63% (ABCSG trials), respectively. Additional analyses were
provided in confidence by the company but cannot be reported here. This was also true in LN0 subgroups
[54% vs. 73% (TransATAC)]. In LN+ subgroups, there were 8% versus 23% in TransATAC, although in
the GEICAM 9906 data set,108,109 the direction was reversed, with 18% versus 13%, respectively. In LN0,
patients were better in Prosigna/ROR-PT than EPClin (97%46 and 93.4%) in TransATAC.105 In GEICAM
9906 (LN+), the direction of the event rates were reversed, at 92% and 100% at 10 years, respectively.
Oncotype DX versus MammaPrint
Results are presented in Table 60. Only one study reported data for both tests.57 MammaPrint assigned a
larger proportion of patients (63%) to the low-risk category than oncotype DX (53%) in the observational
study by Russell et al.57 Event rates were not reported, and only p-values for log-rank tests given, where
both tests showed a statistically significant difference in DRFS at the p < 0.05 level for high- versus low-risk
group comparisons.
Oncotype DX versus IHC4 and IHC4+C
Results are presented in Table 60. Two studies reported oncotype DX and IHC4 analyses [WSG PlanB73,74,77
(LN0–3 only) and Gong et al.58 (LN0 only)], and both used quartiles to define boundaries for risk categories,
making the comparisons of proportions in risk categories and event rates in risk categories of little relevance
to the decision problem. For IHC4 only, Gong et al. reported C-indices (AUC; which analyse IHC4 and
oncotype DX as continuous variables) in LN0 patients, which indicate that the two tests have similar
prognostic performance [oncotype DX 0.685 (95% CI 0.540 to 0.830) and IHC4 0.602 (95% CI 0.436 to
0.767)].
TransATAC46 (LN0–3, LN0, LN+; see Table 60) reported oncotype DX and IHC+C (rather than IHC4 only),
and reported similar proportions of patients in the low-risk group in LN0–3 patients (62% and 57%,
respectively) and LN0 patients (63% and 66%, respectively) but not in LN+ patients (57% and 27%,
respectively). In LN0 patients, 10-year DRFI was similar between the two tests in low-risk patients (94.1%
and 94.7%, respectively).46 HRs for low- versus high-risk patients were very similar at 5.83 compared with
6.06, respectively.46 In LN+ patients, 10-year DRFI was better for IHC4+C (95.2%) than for oncotype DX
(80.6%).46
Impact of menopausal status
Patients were subgrouped in accordance with menopausal status (premenopausal or postmenopausal),
in GEICAM 9906.108,109 For EndoPredict, event rates in the low-risk groups were similar in premenopausal
and postmenopausal patients (93% and 92%, respectively), although HRs were somewhat different,
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at 6.7 (p < 0.0001) and 3.3 (p = 0.069), respectively. For EPClin, DRFS rates in the low-risk groups were
identical (100%). HRs between groups were not reported, but between-group differences were statistically
significant.
Overall survival
Data relating to OS are reported in Table 61. Only TransATAC46 and GEICAM 9906108,109 report OS.
For 0–10 years in LN0–3 groups,46 HRs are all statistically significant and for low-risk versus high-risk
group comparisons range from 2.15 (EPClin) to 3.42 (Prosigna). In LN0 patients, HRs comparing low- with
high-risk groups range from 2.06 (EPClin) to 3.64 (Prosigna). In LN+ groups, however, the low- to high-risk
groups show more variation, ranging from 1.99 (EPClin) to 9.02 (Prosigna) in TransATAC, and 19.38 for
EPClin in GEICAM 9906.
Additional prognostic value
This section reports adjusted analyses, which indicate the additional prognostic value of IHC4 over
clinicopathological factors. The clinicopathological factors adjusted for vary from study to study, and are
detailed in the footnotes to the tables.
Likelihood ratios
In TransATAC,46 additional prognostic value was assessed via increases in likelihood ratio χ2 for 10-year
DRFI, for each test plus NPI or CTS, over NPI or CTS only (see Table 62). In LN0 patients, increases in
likelihood ratio χ2 over CTS and NPI were statistically significant for all tests (p-values range from p = 0.02
to p < 0.0001). Prosigna, EPClin and IHC4+C all showed greater increases (range 15.22 to 25.54) than
oncotype DX Breast Recurrence Score or oncotype DX RSPC (range 5.10 to 10.64; see Table 62). However,
for LN+ patients, increases in likelihood ratio χ2 were much more modest (range 2.14 to 7.36 across all
tests; greatest increase for EPClin), and were borderline statistically significant for all tests (p-values range
from 0.10 to 0.007).
In ABCSG-8,104 likelihood ratios also showed a statistically significant increase for Prosigna over the CLP
(same variables as CTS) in node-negative patients (p < 0.0001) and node-positive patients (p = 0.0002).
C-indices (area under the curve)
In node-positive patients in GEICAM 9906,108,109 the C-index was higher for EPClin (0.693) and EndoPredict
(0.657) than for the research-based ROR-PT (0.644) (see Table 63), although the lack of p-values and/or
CIs mean that it is unclear whether or not the difference in C-indices were statistically significant. Adding
EPClin to ROR-PT plus clinical variables increased the statistical significance of the test of the C-index
(C-indices not reported; p < 0.001). Conversely, adding ROR-PT to EPClin plus clinical variables did not
increase the statistical significance of the test of the C-index (p = 0.567) (see Table 63), although this
finding should be interpreted with caution owing to the non-standard ROR-PT assay.
In ABCSG 6 plus ABCSG 8, a C-index for EPClin was only reported for a mixed node-negative and node-
positive population (including 5% with more than three positive nodes) and for years 5–10 (no data for
years 0–5).119 In this period, the C-index statistically significantly increased when adding EndoPredict to a
combination of clinical variables or to AOL (both p < 0.001; see Table 63). In the ABCSG 8 analysis of
Prosigna,104 C-indices were numerically higher for Prosigna (0.720) than for the CLP (0.688), but any
statistical significance of the difference was not reported.
Multivariable Cox proportional hazards models
Both ABCSG 6 plus ABCSG 8118–120 and GEICAM 9906108,109 used multivariable analyses and showed that
EndoPredict was an independent prognostic parameter for 10-year DMFS/DRFS after adjustment for clinical
variables (see Table 63), and ABCSG 8104 showed a similar finding for Prosigna.
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Discussion: studies assessing multiple tests
Few studies reported data from multiple tests and no study reported all comparisons of interest to the
decision problem. Of most relevance to the decision problem was the TransATAC analysis,46 as this includes
patients from the UK, analyses four of the five tests, reports ER+, HER2–, LN0–3 patients only, and provides
change in likelihood ratios, which allows comparisons between tests to be made. However, the TransATAC
data also has limitations: it is the derivation set for IHC4 and is therefore likely to be subject to some
overfitting and overestimation of prognostic performance, only menopausal patients were recruited and
MammaPrint was not tested. It is also only a single cohort and ideally all comparisons would be available in
multiple independent cohorts. Data from other cohorts also have limitations: ABCSG 6 plus ABCSG 8118–120
only evaluated Prosigna for a proportion of patients (ABCSG 8);104,105 WSG PlanB recruited only high-risk
patients, and patients were treated with chemotherapy in accordance with oncotype DX score;73,74,77 Russell
et al.57 was an observational study and reported only very limited study characteristics and analyses, Gong
et al.58 used non-standard test methods for oncotype DX and IHC4, and was conducted in a population of a
different ethnic composition to the decision problem population; and GEICAM 9906108,109 included a high
proportion of LN > 4 patients (36%) and used a non-standard ROR-PT assay.
As the data comparing the tests with each other are limited, so are the conclusions that can be drawn.
Broad observations include that, generally speaking, the more patients who are placed in a low-risk category,
the poorer the event-free survival for that group. For example, in LN0 patients in TransATAC,46 EPClin
categorised 73% as low risk and these patients had a 10-year DRFI of 93.4%, and Prosigna categorised 54%
as low risk and these patients had a 10-year DRFI of 97%. This effect was more pronounced in LN+ patients
in TransATAC, among whom oncotype DX categorised 57% as low risk and these patients had a 10-year
DRFI of 80.6%, and Prosigna categorised 8% as low risk and these patients had a 10-year DRFI of 100%.
Another broad observation is that the tests generally perform differently in LN+ and LN0 patients. In
TransATAC, both EPClin and IHC4+C tests reported lower HRs in the LN0 subgroup than in the LN+
subgroup at 10 years (EPClin LN0 HR 3.88 vs. LN+ HR 6.58; IHC4+C LN0 6.06 vs. LN+ 9.57), whereas
oncotype DX reported higher HRs in the LN0 subgroup than the LN+ subgroup (oncotype DX LN0 HR 5.83
vs. LN+ HR 2.77). Data from other cohorts generally supported these broad observations.
In terms of how much additional prognostic information the tests provide over clinicopathological variables
or algorithms (e.g. NPI, AOL, CTS), most data came from TransATAC,46 in which increases in likelihood
ratio χ2 over CTS or NPI were statistically significant in LN0 patients across all tests (with Prosigna showing
the greatest increase) and borderline significant for all tests in LN+ (with EPClin showing the greatest
increase). One analysis108 suggested that EPClin could provide additional information over ROR-PT (plus
clinicopathological variables), whereas ROR-PT could not provide additional information over EPClin (plus
clinicopathological variables), but this was limited by the use of a non-standard version of ROR-PT.108,109
Microarray studies
Microarray studies are defined, for the purposes of this review, as any study that applied a test algorithm
(e.g. oncotype DX, MammaPrint) to either in silico data [microarray gene expression data held electronically,
usually accessed from the National Centre for Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO)]68 or to a de novo microarray assessment conducted for the purpose of the study. These studies differ
from studies that used the commercially offered assays in that the agreement between microarray and
commercial assays is unknown, and, for this reason, the generalisability of the findings to the decision
problem is also unknown.
It should be noted that some of the early MammaPrint studies were conducted using a 25,000-gene
microarray platform, until the mini-array specific to the 70 MammaPrint genes was developed (see Chapter 2,
Development: MammaPrint). To minimise heterogeneity between studies, MammaPrint studies conducted
after the development of the mini-array that used wider microarray data are included here as ‘microarray
studies’ rather than alongside studies using the mini-array (see Chapter 2, Results: MammaPrint).
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Given the limitations of these studies in terms of analytic validity and owing to time constraints, we have
conducted a rapid review rather than a full systematic review. This section of the report differs from other
sections in that:
l No quality assessment of studies has been conducted.
l Data were not checked by a second reviewer.
It should also be noted that, owing to time and expertise constraints, the EAG was not able to fully
consider the following factors:
l The degree to which the same cohorts of patients are included in multiple studies. There is likely to be
considerable overlap.
l The quality of the methodology used to conduct the microarray analyses.
l The cut-off points used across the studies.
l The proportion of ER+ and HER2– patients in each cohort.
l The proportion receiving endocrine therapy or chemotherapy in each cohort.
l The ethnic composition of the cohorts used.
Further general limitations of the studies as a whole include:
l A lack of clarity as to the characteristics of the patients.
l A lack of clarity as to whether patients were treated with endocrine therapy or chemotherapy.
l A lack of clarity as to whether patients were treated in accordance with a protocol or in accordance
with routine practice, and whether or not the exclusion of patients who were treated would therefore
lead to spectrum bias.
Some of this information may have been obtainable by reference to the GEO, or to the primary
publications relating to each cohort, but due to time constraints these data were not sought.
Although acknowledging the considerable limitations of these studies and the review methodology,
microarray studies hold some value as they report data on more than one test. This is important as there
are very few studies using the commercial versions of the assays that report data for more than one test
(see Appendix 5; Studies reporting more than one test). Specifically, there are few studies that report data
for MammaPrint compared with any other test, meaning that it is difficult to assess the relative merits of
this test compared with others.
For this reason, the review of these studies will focus on the information provided relating to the prognostic
performance and additional prognostic value of the tests in comparison with each other, rather than on
absolute values provided for individual tests, which may not be generalisable. It is of course entirely possible
that such comparisons between tests are not generalisable, but given the lack of data comparing the
commercial tests, the information provided has some value to the decision problem.
Microarray studies
A total of 18 studies591–608 reported data from microarray analyses (Table 64). Of these, five reported
only data for one test (three reported oncotype DX593,599,600 and two reported MammaPrint592,607); the
results of these studies are presented in Report Supplementary Material 10 but are not considered further.
Of the remaining 13 studies, six591,594,596–598,602 reported seven cohorts of data from single institutions,
five595,596,601,604,608 reported pooled in silico data from multiple cohorts, three603,605,608 reported data from
METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) (a UK–Canada data set), one606
analysed TRANSBIG [Translating molecular knowledge into early breast cancer management: building on
the BIG (Breast International Group) network for improved treatment tailoring] data (an international
collaboration of 22 countries) and one analysed four previously reported cohorts605 in addition to METABRIC.
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TABLE 64 Characteristics of microarray studies
First author, year,
number of patients Cohorts Country
Tests
Population Nodal Status ET/chemotherapy
Oncotype
DX EndoPredict MammaPrint Prosigna
Other
tests
Oncotype DX vs. MammaPrint vs. EndoPredict
Finetti 2014,595
n = 1229
33 publicly available gene
expression data sets from NCBI
GEO database
NR Yes Yes Yes l ER+, HER2– NR (n = 1299)
l 95% ER+, 92% HER2– (n = 3,074)
l All luminal (A or B)
NR (n = 1,299)
58% LN0 (% LN > 3 NR)
(n= 3,074)
NR
Zhao 2014608
a) n = 912
a-i) n = 692
b) n = 996
a) GSE6532, GSE3494, GSE1456,
GSE7390, GSE2603, E-TABM-158
b) METABRIC cohort
Yes Yes Yes Excluded
a
a) ER+ 76%, HER2– 85%
l Subgroup:
a-i) ER+ 100%, HER2– NR
b) ER+ NR, HER2– NR
a) LN0 67% (LN > 3 NR)
a-i) NR
b) NR
NR
Oncotype DX vs. MammaPrint studies
Ahn 2013591
a) n = 186
b) n = 82
Gananam Severance Hospital
(1997–2007)
Korea Yes Yes 100% ER+ 12% HER2+
a) all patients
b) subset with RS 19–30
a) 47.8% LN+ (% LN > 3 NR)
b) 43.9% LN+ (LN > 3 NR)
a) 84% ET,
13% chemotherapy
b) 94% ET,
82% chemotherapy
Fan 2006594
Microarray:
a) n = 295
b) Subgroup n= 225
NKI (derivation cohort for
MammaPrint)
The
Netherlands
Yes Yes a) 77% ER+
l HER2 NR
l Age ≤ 52 years
l 100% female
b)100% ER+
a) LN0, 51%
LN1–3, 36%
LN >3, 13%
b) NR
a) 14% ET,
37% chemotherapy
b) NR
Jonsdottir, 2014,597
n = 94
NR Norway Yes Yes a) ER+ NR
l 85% HER2–
a-i) 100% ER+, HER2– NR
LN0 100% (% LN >3 NR) a) 14% ET,
11% chemotherapy
a-i) NR
Li 2009,598 n = 27 Fudan University Cancer Hospital China Yes Yes HR+ NR, 70% HER2– LN0 56% (% LN >3 NR) ET NR,
100% chemotherapy
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First author, year,
number of patients Cohorts Country
Tests
Population Nodal Status ET/chemotherapy
Oncotype
DX EndoPredict MammaPrint Prosigna
Other
tests
Gyo˝rffy 2015596
a) n = 3534
b) n = 325
a) 25 data sets from GEO
b
b) University Hospitals (Frankfurt
and Hamburg)
a) NR
b) Germany
Yes Yes a) 83.1% ER+, 84.4% HER2+ NR
Subgroup: 100% ER+, HER2– b) 81.1%
ER+, HER2– NR
Subgroup: i) 100% ER+; HER2– NR
a) LN+ 30.8%
b) LN+ 39.4% (LN > 3 NR)
Subgroup: ER+, LN0
a) ET NR,
19% chemotherapy
Subgroups:
i) ER+, HER2–,
untreated
ii) ER+, HER2–
treated
b) ET and
chemotherapy NR
Subgroup:
i) NR
Prat 2012,601
n = 594/1380
a) n = 339
b) n = 171
GSE17705, GSE6532, GSE12093,
GSE1456, MDACC133
NR Yes Yes Excluded
a
ER+, HER2– NR (n = 549)
100% ER+
HER2– NR (n= 1380)
NR (n = 549)
LN0 47% (% LN >3 NR)
(n= 1380)
a) LN0 100%
b) LN+ 100%
ET 100%,
chemotherapy 0%
Tobin 2014602
a) n = 253
b) n = 159
a) Uppsala cohort
b) Stockholm cohort (Karolinska
Hospital)
Sweden Yes Yes HR+ NR
HER2– NR
Subgroup:
a-i) ER+ 100%
a) LN0 63%
b) LN0 59%
a) ET 58%,
chemotherapy 11%
b) ET 72%,
chemotherapy 19%
Vollan 2015,603
n = 1412
METABRIC International Yes Yes ER+ 100%, HER2– NR NR NR
Xu 2017604
a) n = 917
a) METABRIC/Bioconductor data
sets: GSE11121, GSE7390,
GSE3494, GSE2990, Breast
Cancer NKI
International Yes Yes Excluded
a
NPI ER+ 100%, HER2– NR LN0 100% NR
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TABLE 64 Characteristics of microarray studies (continued )
First author, year,
number of patients Cohorts Country
Tests
Population Nodal Status ET/chemotherapy
Oncotype
DX EndoPredict MammaPrint Prosigna
Other
tests
Ou Yang 2014605
i) LN0 subgroup
ii) ER+ subgroup
a) n = 1981
(1037;1526)
b) n = 216 (125; 134)
c) n= 393 (250; 348)
d) n = 115 (64; 66)
e) n = 236 (158; 201)
a) METABRIC
b) Loi (GSE6532)
c) Buffa (GSE22219)
d) Wang (GSE19615)
e) Miller (GSE3494)
International;
NR
Yes Yes Excluded
a
ER+:
a) 77%
b) 62%
c) 89%
d) 57%
e) 85%
Subgroup:
i) ER+ NR ii) ER+ 100%
HER2– NR
LN0:
a) 52%
b) 58%
c) 64%
d) 56%
e) 67%
Subgroup:
i) LN0 100%, ii) LN0 NR
NR
Yin, 2014,606 n= 198 TRANSBIG GSE7390 France,
Sweden, UK
Yes Yes AOL
NPI
ER+ NR, HER2– NR LN0 100% ET 0%,
chemotherapy 0%
ET, endocrine therapy; LN, lymph node; NKI, Netherlands Cancer Institute; NR, not reported; RS, recurrence score.
a Cockburn 2016:609 data were reported in this study for a simulation of Prosigna. However, only 45 of the 50 Prosigna genes were available for analysis and the data are excluded as they does not conform to algorithm used in the commercially
offered test; Prat 2012:601 ROR-P, not ROR-PT; Xu 2017:604 ROR-S not ROR-PT; Ou Yang 2014605 used ROR-T and ROR-S not ROR-PT; Zhao 2014:608 ROR-S only, not ROR-PT.
b GSE1456, GSE4922, GSE5327, GSE6532, GSE7390, GSE9195, GSE11121, GSE12093, GSE12276, GSE2034, GSE16391, GSE16446, GSE17705, GSE17907, GSE19615, GSE2603, GSE20685, GSE20711, GSE21653, GSE25066, GSE2990,
GSE31519 and GSE3494.
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All studies reported data on oncotype DX and MammaPrint, and two595,608 also reported data on
EndoPredict. For the most part, only HRs for recurrence/survival rates between test risk groups were
reported, which give an indication of the test’s association with an outcome, but these do not allow
conclusions to be drawn about the prognostic ability of one test versus another. These data are presented
in Table 65, and C-index (AUC) data are presented in Table 66, and data that provide direct comparisons
of the prognostic performance of one test compared with another are presented in Table 67.
Prognostic performance in microarray studies
Categorisation
Only four studies594,597,601,602 reported the numbers of patients in each risk category, and these only included
oncotype DX and MammaPrint (see Table 65). In LN+/LN0 cohorts for oncotype DX, the proportions were
24%, 31% and 37% low-risk patients, 11%, 16% and 19% intermediate-risk patients and 44%, 53% and
65% high-risk patients. In LN0 groups, the proportions were 14% and 19% low-risk patients, 19% and
45% intermediate-risk patients and 67% and 36% high-risk patients. For MammaPrint, the proportions
were 39%, 48% and 51% low-risk patients, 61%, 52% and 49% high-risk patients in LN+/LN0 patients,
and similar proportions in LN0 patients (40% and 48% low risk and 60% and 52% high risk).
Hazard ratios
Nine studies594–597,601–604,608 reported HR data (see Table 65). Data for oncotype DX and MammaPrint were
reported in four studies594,596,602,603 with a mix of LN+/LN0 patients, LN0 only patients were reported in four
studies596,597,601,604 and LN+ patients in one study.601 Two studies595,608 reported HRs for oncotype DX,
MammaPrint and EndoPredict.
Oncotype DX versus MammaPrint: LN+/LN0
Six studies594–596,602,603,608 reported data for both oncotype DX and MammaPrint in a mixed LN+/LN0 cohort
(see Table 65; seven cohorts/pooled cohorts analysed, including the two that also report EndoPredict HRs).
Across various outcome measures, including DRFS, RFS, OS and BCSS, all reported statistically significant
HRs between test risk groups for both tests, apart from Vollan et al.,603 in which the HR for BCSS for
MammaPrint was not significant [HR 1.25 (95% CI 0.95 to 1.64; p = 0.11)], and Zhao et al.,608 which
reported HRs at 5 and 10 years, and the 10-year HRs were not statistically significant. As both Zhao et al.
and Vollan et al. used the METABRIC cohort, and Vollan et al. did not report the length of follow-up,
it is possible the statistically non-significant result was for 10 or more years of follow-up. Oncotype DX
had higher HRs in three studies (HR 2.65 vs. 1.91, 2.57 vs. 1.96 and 2.05 vs. 1.5 for oncotype DX vs.
MammaPrint, respectively)595,596,602 and MammaPrint HRs were higher in two studies (3.40 vs. 2.82
and 4.61 vs. 2.87, for MammaPrint vs. oncotype DX, respectively).596,602 Whether the HR was higher in
oncotype DX or MammaPrint did not appear to depend on whether the tests were analysed categorically
or as continuous variables.
Oncotype DX versus MammaPrint: lymph node negative
Three studies597,601,604 reported data for oncotype DX and MammaPrint in LN0 patients (see Table 65).
Neither test was statistically significant in Jonsdottir et al.,597 (oncotype DX, p = 0.522; MammaPrint,
p = 0.287) when DMFS was measured at 14 years. HRs were statistically significant [HR 2.7 (95% CI not
reported; p < 0.001) and HR 2.5 (95% CI not reported; p < 0.001), respectively] in Xu et al.604 when RFS
was measured at 15 years and in Prat et al.601 (HR 1.97, p < 0.0001, and 1.42, p < 0.005, respectively;
95% CIs not reported), when outcomes were censored at 8.5 years. NPI was also measured in Xu et al.,604
with a HR a little higher than MammaPrint and a little lower than oncotype DX, at 2.6 (p < 0.001).
Oncotype DX versus MammaPrint: lymph node positive
Only one study601 reported results in a subgroup of LN+ patients (see Table 65). Both oncotype DX and
MammaPrint had statistically significant HRs [4.67 (95% CI not reported; p = 0.01) and 2.12 (95% CI not
reported; p = 0.03), respectively].
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TABLE 65 Microarray results: HRs
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of
patients per
group
Outcome Test
Outcomes, HR (95% CI) unless stated otherwise
Low Inter High 0–5 years 0–10 years 5–10 years
Oncotype DX and MammaPrint
LN0/LN+
Fan 2006594
a) n = 295
NKI (derivation cohort
for MammaPrint)
a) 77% ER+, HER2 NR a) LN0, 51%, LN1–3,
36%, LN > 3, 13%
a) 14% ET,
37% chemotherapy
24 11 65 RFS Oncotype DX – NR, p< 0.001 –
39 – 61 RFS MammaPrint – NR, p< 0.001 –
24 11 65 OS Oncotype DX – NR, p< 0.001 –
39 – 61 OS MammaPrint – NR, p< 0.001 –
Gyo˝rffy 2015596
a) n = 3534
a) 25 data sets from
GEO
a) 83.1% ER+, 84.4%
HER2+ NR
a) LN+/LN0, LN+ 30.8% a) ET NR,
19% chemotherapy
– – – RFS Oncotype DX 2.55 (2.21 to 2.94;
p< 0.001)
– – – MammaPrint 3.40 (2.47 to 4.68;
p< 0.001)
Gyo˝rffy 2015596
a-i) n = 672
Subgroups a-i and ii:
100% ER+, HER2–
a-i) Untreated – – – Oncotype DX 2.82 (2.04 to 3.90;
p< 0.001)
– – – MammaPrint 3.07 (1.87 to 5.04;
p< 0.001)
Gyo˝rffy 2015596
a-ii) n = 1316
a-ii) Treated – – – Oncotype DX 2.47 (2.14 to 3.49;
p< 0.001)
– – – MammaPrint 3.01 (1.85 to 4.90;
p< 0.001
Gyo˝rffy 2015596
b) n = 325
b) University Hospitals
(Frankfurt and
Hamburg)
b) ER+, HER2– NR b) LN+/LN0 (LN > 3 NR) b) ET and chemotherapy
NR
– – – Oncotype DX 2.65 (1.73 to 4.07;
p< 0.001)
– – – MammaPrint 1.91 (1.05 to 3.50;
p= 0.0322)
Tobin, 2014602
a) n = 253
a) Uppsala cohort HR+ NR, HER2– NR a) LN0 63% a) ET 58%,
chemotherapy 11%
37 19 44 BCSS Oncotype DX 21-year follow-up: HR continuous NR; p= 0.004
Intermediate vs. low: HR NR; p= 0.018
High vs. low: HR NR; p = 0.001
High/intermediate vs. low: 2.57 (1.43 to 4.62)
51 – 49 MammaPrint 21-year follow-up: HR continuous NR; p= 0.005
High vs. low: 1.96 (1.21 to 3.17)
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First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of
patients per
group
Outcome Test
Outcomes, HR (95% CI) unless stated otherwise
Low Inter High 0–5 years 0–10 years 5–10 years
Tobin, 2014602
b) n = 159
b) Stockholm cohort
(Karolinska Hospital)
HR+ NR, HER2– NR b) LN0 59% b) ET 72%,
chemotherapy 19%
31 16 53 Oncotype DX Follow-up NR: HR NR; p = 0.006
High/intermediate vs. low: 2.87 (1.43 to 5.75)
48 – 52 MammaPrint Follow-up NR: HR NR; p < 0.001
High vs. low: 4.61 (2.12 to 10.03)
Vollan, 2015603
n = 1412
METABRIC ER+ 100%, HER2– NR NR NR – – – BCSS Oncotype DX Follow-up NR
Intermediate vs. low: 1.23 (0.91 to 1.68; p = 0.179)
High vs. low: 2.35 (1.64 to 3.36; p < 0.001)
– – – MammaPrint Follow-up NR
High vs. low: 1.25 (0.95 to 1.64; p = 0.11)
LN0
Jonsdottir, 2014597
n = 94
NR – Norway a) ER+ NR, 85%
HER2–
LN0 100% a) 14% ET,
11% chemotherapy
19 45 36 DRFS Oncotype DX 14-year HR
Intermediate vs. low: 1.2 (0.3 to 4.4)
High vs. low: 1.8 (0.5 to 6.5), p = 0.522
Rates: low, 83%; intermediate, 79%; high, 68%
48 – 52 MammaPrint 14-year HR 1.6 (0.7 to 3.6; p= 0.287)
Rates: low, 80%; high, 71%
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TABLE 65 Microarray results: HRs (continued )
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of
patients per
group
Outcome Test
Outcomes, HR (95% CI) unless stated otherwise
Low Inter High 0–5 years 0–10 years 5–10 years
Gyo˝rffy 2015596
b-i) n = 113
b) University Hospitals
(Frankfurt and
Hamburg)
Subgroup b-i:
100% ER+; HER2– NR
Subgroup b-i: ER+, LN0 NR – – – RFS Oncotype DX Oncotype DX
Sensitivity 0.80
(0.76 to 0.82)
Specificity 0.55
(0.53 to 0.58)
Accuracy: 0.64
(0.62 to 0.65)
MammaPrint
Sensitivity 0.98
(0.96 to 0.98)
Specificity 0.14
(0.12 to 0.16)
Accuracy: 0.47
(0.46 to 0.47)
Prat 2012601
a) n = 339
GSE17705, GSE6532,
GSE12093, GSE1456,
MDACC133
100% ER+, HER2– NR a) LN0 100% ET 100%,
chemotherapy 0%
14 19 67 DRFS Oncotype DX Rates:
l Low: 98%
l Intermediate: 95%
l High: 86%
l p= 0.004
DRFS censored at 8.5 years
Continuous: 1.97, p< 0.0001
High vs. Low: 3.79, p< 0.0023
40 – 60 MammaPrint Rates:
1. Low: 95%
2. High: 84%
3. p= 0.004
DRFS censored at 8.5 years
Continuous: 1.42, p< 0.005
High vs. Low: 2.6, p = 0.0054
Xu 2017604
a) n = 917
METABRIC/
Bioconductor data sets:
GSE11121, GSE7390,
GSE3494, GSE2990,
breastCancerNKI
ER+ 100%, HER2– NR LN0 100% NR – – – RFS Oncotype DX 15 years: 2.7 (95% CI NR; p< 0.001)
– – – MammaPrint 15 years: 2.5 (95% CI NR; p< 0.001)
– – – NPI 15 years: 2.6 (95% CI NR; p< 0.001)
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First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of
patients per
group
Outcome Test
Outcomes, HR (95% CI) unless stated otherwise
Low Inter High 0–5 years 0–10 years 5–10 years
LN+
Prat 2012601
b) n = 171
GSE17705, GSE6532,
GSE12093, GSE1456,
MDACC133
100% ER+, HER2– NR b) LN+ 100%
(% LN >3 NR)
ET 100%,
chemotherapy 0%
8 12 80 DRFS Oncotype DX Rates:
l Low: 91%
l Intermediate: 95%
l High: 72%
l p = 0.015
DRFS censored at
8.5 years
Continuous: 1.51,
p= 0.01
High vs. Low: 4.67,
p= 0.01
31 – 69 MammaPrint Rates:
l Low: 85%
l High: 72%
l p = 0.03
DRFS censored at
8.5 years
Continuous: 1.26,
p= 0.06
High vs. Low: 2.12,
p= 0.03
Oncotype DX and MammaPrint and EndoPredict
Finetti 2014595
n = 1229
33 publicly available
gene expression data
sets from NCBI GEO
database
NR LN+/LN0 NR – – – DRFS Oncotype DX Median follow-up: 7.8 years
Intermediate vs. low: 1.82 (1.44 to 2.3; p < 0.001)
High vs. low: 2.05 (1.59 to 2.63; p < 0.001)
– – – MammaPrint Median follow-up: 7.8 years
1.5 (1.21 to 1.85; p = 0.0002)
– – – EndoPredict Median follow-up: 7.8 years
1.88 (1.52 to 2.32; p< 0.001)
Zhao 2014608
a-i) n = 692
a) GSE6532, GSE3494,
GSE1456, GSE7390,
GSE2603, E-TABM-158
a-i) ER+ 100%,
HER2– NR
a) LN0 67% (LN > 3 NR)
a-i) NR
– – – Oncotype DX 1.79 (1.55 to 2.07;
p< 0.0001)
0.65 (0.26 to 1.61;
p= 0.3535)
1.06 (0.78 to 1.43;
p= 0.7311)
– – – MammaPrint 1.70 (1.43 to 2.03;
p< 0.0001)
1.06 (0.57 to 1.96;
p= 0.8468)
1.16 (0.87 to 1.55;
p= 0.3054)
– – – EndoPredict 1.97 (1.66 to 2.33;
p< 0.0001)
1.02 (0.55 to 1.91;
p= 0.9462)
1.13 (0.83 to 1.53;
p= 0.4393)
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TABLE 65 Microarray results: HRs (continued )
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of
patients per
group
Outcome Test
Outcomes, HR (95% CI) unless stated otherwise
Low Inter High 0–5 years 0–10 years 5–10 years
Zhao 2014608
b) n = 996
b) METABRIC cohort b) ER+ NR, HER2– NR b) NR – – – Oncotype DX 1.94 (1.69 to 2.24;
p< 0.0001)
1.19 (0.86 to 1.65;
p= 0.2856)
1.11 (0.89 to 1.38;
p= 0.3481)
– – – MammaPrint 1.99 (1.63 to 2.41;
p< 0.0001)
1.21 (0.87 to 1.68;
p= 0.2545)
1.11 (0.89 to 1.38;
p= 0.3514)
– – – EndoPredict 1.96 (1.64 to 2.33;
p< 0.0001)
1.13 (0.82 to 1.55;
p= 0.4593)
1.29 (1.04 to 1.59;
p= 0.0183
ET, endocrine therapy; LN, lymph node; NKI, Netherlands Cancer Institute; NR, not reported.
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TABLE 66 Microarray results: C-index (AUC) data
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of patients per group
Outcome Test OutcomesLow Intermediate High
Unique cohorts
Oncotype DX vs. MammaPrint
LN0/LN+
Li 2009,598
n = 27
Fudan University Cancer
Hospital
HR+ NR, 70% HER2– LN0 56% ET NR, 100%
chemotherapy
– – – DFS Oncotype DX 5-year C-index (AUC): 0.59;
sensitivity 68%; specificity
50.0%
– – – MammaPrint 5-year C-index (AUC):
0.691; sensitivity 72%;
specificity 66.2%
Studies drawing from more than one data source, with multiple overlaps between studies
Oncotype DX vs. MammaPrint studies
LN0/LN+
Ahn 2013591
b) n = 82
Gananam Severance
Hospital
100% ER+ 12% HER2+
b) subset with RS 19–30
b) 43.9% LN+ (LN > 3 NR) b) 94% ET, 82%
chemotherapy
OS MammaPrint vs.
Oncotype DX
10 years
Oncotype DX intermediate-
risk (RS 19–30) group
K–M curve: MammaPrint
low vs. high: HR NR,
p = 0.013
C-index (AUC) MammaPrint:
0.844
Prat 2012601
n = 1380
GSE17705, GSE6532,
GSE12093, GSE1456,
MDACC133
100% ER+, HER2– NR LN0 47% (% LN > 3 NR) ET 100%,
chemotherapy 0%
DRFS Oncotype DX
vs. MammaPrint
8.5 years
Increase in LR χ2 of oncotype
DX over MammaPrint: 14.4,
p < 0.001
Increase in LR χ2 of
MammaPrint over oncotype
DX: 9.2, p = 0.002
Tobin 2014602
a) n = 253
a) Uppsala cohort a-i) ER+ 100% NR NR BCSS Oncotype DX 13 years
C-index (AUC): 0.68
MammaPrint 13 years
C-index (AUC): 0.81
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TABLE 66 Microarray results: C-index (AUC) data (continued )
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of patients per group
Outcome Test OutcomesLow Intermediate High
Tobin 2014602
b) n = 159
b) Stockholm cohort
(Karolinska Hospital)
HR+ NR, HER2– NR b) LN0 59% b) ET 72%,
chemotherapy 19%
31 16 53 BCSS Oncotype DX 14.5 years C-index (AUC):
0.72, p=NR
48 – 52 MammaPrint 14.5 years C-index (AUC):
0.76, p=NR
Ou Yang 2014605
n = 1981
a-ii) n = 1526
a) METABRIC ER+ 100%, HER2– NR NR – – – BCSS Oncotype DX 0- to 10-year C-index (AUC):
0.657, p=NR
– – – MammaPrint 0- to 10-year C-index (AUC):
0.612, p=NR
Ou Yang 2014605
b-ii) n = 134
b) Loi (GSE6532) ER+ 100%, HER2– NR NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.640, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.606, p< 0.05
Ou Yang 2014605
c-ii) n = 348
c) Buffa (GSE22219) ER+ 100%, HER2– NR NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.727, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.647, p< 0.05
Ou Yang 2014605
d-ii) n = 66
d) Wang (GSE19615) ER+ 100%, HER2– NR NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.435, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.372, p< 0.05
Ou Yang 2014605
e-ii) n = 201
e) Miller (GSE3494) ER+ 100%, HER2– NR NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.645, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.650, p< 0.05
LN0
Tobin, 2014602
a) n = 253
a) Uppsala cohort HR+ NR, HER2– NR a) LN0 63% a) ET 58%,
chemotherapy 11%
37 19 44 BCSS Oncotype DX 13-year C-index (AUC): 0.73
51 – 49 MammaPrint 13-year C-index (AUC): 0.84
Prat 2012601
a) n = 610
GSE17705, GSE6532,
GSE12093, GSE1456,
MDACC133
100% ER+, HER2– NR a) LN0 100% ET 100%,
chemotherapy 0%
DRFS Oncotype DX
vs. MammaPrint
8.5-year C-index (AUC):
l Oncotype DX: 0.71
l MammaPrint: 0.64
A
P
P
E
N
D
IX
5
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
2
6
8
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of patients per group
Outcome Test OutcomesLow Intermediate High
Xu 2017604
a) n = 917
METABRIC/bioconductor
data sets: GSE11121,
GSE7390, GSE3494,
GSE2990, breastCancer
NKI
ER+ 100%, HER2– NR LN0 100% NR – – – RFS Oncotype DX 15-year C-index (AUC): 0.68
(estimate off graph)
– – – MammaPrint 15-year C-index (AUC): 0.71
(estimate off graph)
– – – NPI 15-year C-index (AUC): 0.68
(estimate off graph)
Ou Yang 2014605
n = 1981
a-i) n = 1037
a) METABRIC NR LN0 100% NR – – – BCSS Oncotype DX 0- to 10-year C-index (AUC):
0.650, p=NR
– – – MammaPrint 0- to 10-year C-index (AUC):
0.641, p=NR
Ou Yang 2014605
b-i) n = 125
b) Loi (GSE6532) NR LN0 100% NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.635, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.604, p< 0.05
Ou Yang 2014605
c-i) n = 250
c) Buffa (GSE22219) NR LN0 100% NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.681, p=NS
– – – MammaPrint 0- to 10-year C-index (AUC):
0.628, p< 0.05
Ou Yang 2014605
d-i) n = 64
d) Wang (GSE19615) NR LN0 100% NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.665, p< 0.05
– – – MammaPrint 0- to 10-year C-index (AUC):
0.674, p=NS
Ou Yang 2014605
e-i) n = 158
e) Miller (GSE3494) NR LN0 100% NR – – – Oncotype DX 0- to 10-year C-index (AUC):
0.608, p=NS
– – – MammaPrint 0- to 10-year C-index:
0.604, p=NS
LN+
Prat 2012601
b) n = 699
GSE17705, GSE6532,
GSE12093, GSE1456,
MDACC133
100% ER+, HER2– NR b) LN+ 100%
(% LN > 3 NR)
ET 100%,
chemotherapy 0%
DRFS Oncotype DX
vs. MammaPrint
0- to 10-year C-index (AUC):
l Oncotype DX: 0.64
l MammaPrint: 0.61
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TABLE 66 Microarray results: C-index (AUC) data (continued )
First author, year,
number of patients Cohorts Population Nodal status ET/chemotherapy
Percentage of patients per group
Outcome Test OutcomesLow Intermediate High
Oncotype DX vs. MammaPrint vs. EndoPredict
Zhao 2014608
a) n = 912
a) GSE6532, GSE3494,
GSE1456, GSE7390,
GSE2603, E-TABM-158
a) ER+ 76%, HER2–
85%
NR – – DRFS Oncotype DX Follow-up year NR for
C-index analysis
C-index (AUC): 0.648
(95% CI 0.63 to 0.67)
PVE: 4.05
– – – MammaPrint C-index (AUC): 0.612
(95% CI 0.60 to 0.63)
PVE: 4.76
– – – EndoPredict C-index (AUC): 0.648
(95% CI 0.63 to 0.67)
PVE: 4.78
ET, endocrine therapy; K–M, Kaplan–Meier; LN, lymph node; LR, likelihood ratio; RS, recurrence score.
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TABLE 67 Microarray results: additional prognostic value
Study first author
and year Cohorts Population Nodal status ET/chemotherapy Outcome
Test or
comparison
Likelihood
ratio χ2
Increase in likelihood ratio χ2
over clinicopathological factors
a
Other analyses
LN+/LN0 or NR
Ahn 2013591
b) n = 82
Gananam Severance
Hospital
100% ER+, 12% HER2+
b) Subset with RS 19–30
b) 43.9% LN+ (LN > 3 NR) b) 94% ET, 82%
chemotherapy
OS MammaPrint vs.
oncotype DX
Oncotype DX intermediate
(RS 19–30) risk group
Adjusted HR
a
of MammaPrint:
10.19 (95% CI 1.05 to 99.01;
p= 0.045)
Fan 2006594
a) n = 295
NKI (derivation
cohort for
MammaPrint)
a) 77% ER+, HER2 NR a) LN0, 51%
LN1–3, 36%
LN > 3, 13%
a) 14% ET, 37%
chemotherapy
RFS Oncotype DX Adjusted HR
a
Intermediate vs. low: 1.81
(95% CI 0.70 to 4.68, p= 0.22)
High vs. low: 4.27 (95% CI
2.05 to 8.92; p = 0.001)
MammaPrint Adjusted HR:
a
3.44 (95% CI
1.98 to 5.99; p < 0.001)
OS Oncotype DX Adjusted HR
a
Intermediate vs. low: 1.81
(95% CI 0.39 to 8.27; p= 0.45)
High vs. low: 6.14 (95% CI
1.84 to 20.4; p = 0.003)
MammaPrint Adjusted HR:
a
4.71 95% CI
(2.02 to 11.00; p< 0.001)
Fan 2006594
b) Subgroup
n = 225
b) 100% ER+ b) NR b) NR RFS Oncotype DX Adjusted HR
a
Intermediate vs. low: 0.82
(95% CI 0.27 to 2.46; p= 0.72)
High vs. low: 2.59 (95% CI
1.44 to 4.65; p = 0.001)
MammaPrint Adjusted HR:
a
3.88 (95% CI
2.15 to 7.02; p < 0.001)
OS Oncotype DX Adjusted HR
a
Intermediate vs. low: 1.42
(95% CI 0.27 to 7.50; p= 0.68)
High vs. low: 4.95 (95% CI
1.82 to 13.4; p = 0.002)
MammaPrint Adjusted HR:
a
5.47 (95% CI
2.13 to 14.1, p < 0.001)
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TABLE 67 Microarray results: additional prognostic value (continued )
Study first author
and year Cohorts Population Nodal status ET/chemotherapy Outcome
Test or
comparison
Likelihood
ratio χ2
Increase in likelihood ratio χ2
over clinicopathological factors
a
Other analyses
Zhao 2014608
a-i) n = 692
a) GSE6532,
GSE3494, GSE1456,
GSE7390, GSE2603,
E-TABM-158
a-i) ER+ 100%, HER2–
NR
a) LN0 67% (LN > 3 NR)
a-i) NR
NR DRFS Oncotype DX 43.6,
p < 0.0001
23.1, p < 0.0001
a
MammaPrint 36.0,
p < 0.0001
21.5, p < 0.0001
a
EndoPredict 53.6,
p < 0.0001
31.4, p < 0.0001
a
LN0
Yin 2014606
n = 198
TRANSBIG GSE7390 ER+ NR, HER2– NR LN0 100% ‘Systemically
untreated patients’
b
DRFS Oncotype DX 13.734, p= 0.004
MammaPrint 3.038, p = 0.986
AOL 3.325, p = 0.601
NPI 6.823, p = 0.131
OS Oncotype DX 13.286, p= 0.002
MammaPrint 0.221, p = 0.647
AOL 0.377, p = 0.551
NPI 3.658, p = 0.16
ET, endocrine therapy; LN, lymph node; NKI, Netherlands Cancer Institute; RFS, relapse free survival; RS, recurrence score.
a Multivariable analysis covariates. Ahn 2013: tumour size; nodal status; PR; chemotherapy treatment. Fan 2006 data set a): ER status, tumour grade, nodal status, age, tumour size, treatment (ET, chemotherapy or both). Fan 2006 data set b): as
a) but omitting ER status. Zhao 2014: nodal status, grade, tumour size. Yin 2014, not adjusted, but gives values for AOL and NPI on same cohort for comparison.
b From www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE7390. (accessed 11 April 2019).
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Oncotype DX versus MammaPrint versus EndoPredict: lymph node positive/negative
Two studies595,608 reported two pooled analyses of 33 cohorts595 and six cohorts,608 and one analysis using
METABRIC data (see Table 65).608 These cohorts are likely to contain some of the same patients. All three
tests reported statistically significant HRs for DRFS at time points of < 10 years, but an analysis of 0- to
5-year, 5- to 10-year and 0- to 10-year HRs in Zhao et al.608 only reported statistically significant HRs in the
period 0–5 years, for all three tests. Oncotype DX high versus low HR was the highest in the Finetti et al.595
analysis [HR 2.05 (95% CI 1.59 to 2.63; p < 0.001)] compared with a HR for MammaPrint of 1.5 (95% CI
1.21 to 1.85; p = 0.0002) and a HR for EndoPredict of 1.88 (95% CI 1.52 to 2.32; p < 0.001), although
when all tests were analysed as continuous variables in Zhao et al.,608 the HR was highest for EndoPredict
[1.97 (95% CI 1.66 to 2.33; p < 0.0001)] compared with MammaPrint [1.70 (95% CI 1.43 to 2.03;
p < 0.0001)] and oncotype DX [1.79 (95% CI 1.55 to 2.07; p < 0.0001)].
C-index (area under the curve) and other comparative data
Data relating to C-indices and other outcomes are presented in Table 66.
Oncotype DX and MammaPrint: lymph node positive/negative
Pairs of C-indices (AUC) for oncotype DX and MammaPrint were reported in three studies598,602,605 in LN+/LN0
patients (for eight cohorts). Outcomes included DRFS, DFS, OS and BCSS. The C-index ranged from 0.372605
to 0.84,591,602 indicating a wide range of fit. Notably, the worst fit was reported for an analysis in Ou Yang
et al.605 of cohort GSE19615, when oncotype DX had a C-index of 0.435 (p < 0.05) and MammaPrint had
a C-index of 0.372 (p < 0.05), both indicating that the test was worse than chance alone at categorising
patients into risk groups. Apart from these data, C-indices for oncotype DX ranged from 0.59598 to 0.73602
and for MammaPrint from 0.606 to 0.84. Oncotype DX had a higher C-index in four cohorts (METABRIC,
GSE6532, GSE22219 and GSE19615),605 whereas MammaPrint had a higher C-index in three (Fundan
University, the Uppsala cohort and the Stockholm cohort).598,602 p-values were only reported in one study605
(four out of five cohorts) and were all statistically significant. 95% CIs were not reported in any analyses,
meaning that it was not possible to determine if the C-indices were substantially different from each other.
One further study591 reported data (see Table 66) that explored the prognostic value of MammaPrint in a
group of patients with intermediate risk oncotype DX. MammaPrint still had prognostic value in this group,
with a statistically significant difference between risk groups (HR not reported, p = 0.013) and a C-index of
0.844, indicating that MammaPrint was able to further discriminate between patients with and without OS
events.
A further study601 reported increases in likelihood ratio χ2 for oncotype DX (low-/intermediate-risk group vs.
high-risk group) over MammaPrint and vice versa (see Table 66). This showed that the likelihood ratio χ2
increased by 14.4 units (p < 0.001) when oncotype was added to MammaPrint, and by 9.2 (p = 0.002)
when MammaPrint was added to oncotype DX, indicating that both tests had added prognostic value over
the other, but oncotype DX added a little more.
Oncotype DX and MammaPrint: lymph node negative
Pairs of C-indices (AUC) for oncotype DX and MammaPrint were reported in four studies601,602,604,605
(for eight cohorts, two of which were pooled analyses). C-indices for oncotype DX ranged from 0.608 to
0.71 and for MammaPrint from 0.604 to 0.81. p-values were only reported in one study605 (five cohorts) and
were not always statistically significant, possibly due to smaller sample sizes in these subgroup analyses than
in the full LN+/LN0 cohorts. Oncotype DX had a higher C-index in five cohorts (Prat et al.601 and four of the
cohorts reported in Ou Yang et al.605), and MammaPrint had a higher C-index in three (Tobin et al., Xu and
GSE19615 from Ou Yang et al.).602,604,605
Oncotype DX and MammaPrint: lymph node positive
One study601 reported the C-index for LN+ patients. This was 0.64 for oncotype DX and 0.61 for MammaPrint.
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Additional prognostic value in microarray studies
Oncotype DX, MammaPrint and EndoPredict in lymph node-positive/-negative patients
One study594 reported a multivariable analysis including oncotype DX and MammaPrint separately
alongside ER status, tumour grade, nodal status, age, tumour size and treatment (endocrine therapy,
chemotherapy or both) in patients with mixed nodal status (see Table 67). The cohort used was the
derivation cohort for MammaPrint (and there may therefore be some overfitting of the model, resulting
in overestimation of the prognostic performance for MammaPrint) and a subgroup of ER+-only patients.
Tests were analysed as categorical rather than as continuous variables. All high versus low HRs were
statistically significant, although the intermediate versus low analyses (oncotype DX only) were not.
High versus low HRs were higher for oncotype DX than for MammaPrint, although this is perhaps to be
expected as oncotype DX high versus low comparisons do not account for the intermediate patients,
and MammaPrint has only two categories; the analyses are therefore not comparable.
One study reported a multivariable analysis in oncotype DX intermediate patients (see Table 67), and
MammaPrint was shown to have additional prognostic value in this subgroup of patients (adjusted for
tumour size, nodal status, PR and chemotherapy treatment) with a HR of 10.19 (95% CI 1.05 to 99.01;
p = 0.045).591
One study608 reported likelihood ratio χ2 and differences in likelihood ratio χ2 for oncotype DX, MammaPrint
and EndoPredict (see Table 67). EndoPredict had the highest likelihood ratio χ2, at 53.6 (p < 0.0001),
compared with 43.6 (oncotype DX) and 36.0 (MammaPrint) (both p < 0.0001). In an analysis that adjusted
for nodal status, grade and tumour size, the difference in likelihood ratio χ2 over these clinicopathological
variables was also highest for EndoPredict (31.4 vs. 23.1 and 21.5, respectively, all p < 0.0001), indicating
that all these tests have prognostic value over these clinical factors, and EndoPredict appears to perform best.
Oncotype DX and MammaPrint versus Nottingham Prognostic Index and Adjuvant!
Online in lymph node negative patients
One study reported data for LN0 patients (see Table 67). The increase in likelihood ratio χ2 over
clinicopathological variables was reported for oncotype DX, MammaPrint, NPI and AOL. For DMFS, oncotype
DX had the highest increase, at 13.734 (p = 0.004), compared with MammaPrint (3.038, p = 0.986), AOL
(3.325, p = 0.601) and NPI (6.823, p = 0.131), and was the only test to report a statistically significant
change. Results were similar for OS.
Discussion: microarray studies
Data from microarray studies have been included in this report to provide additional information relating
to the comparative prognostic value of the tests, as comparative data from studies using the commercial
versions of the tests are limited in number (see Appendix 5, Studies reporting more than one test). In
particular, comparisons between MammaPrint and other tests (specifically oncotype DX and EndoPredict)
were made in microarray studies but rarely in the studies using the commercial tests. However, these data
should be interpreted with caution because of the unknown comparability of microarray studies and the
commercial versions.
Data relating to HRs for outcomes between test risk groups support the data from studies using the
commercial assays that show a statistically significant difference between test risk categories for outcomes
such as DRFS, DFS, OS and BCSS for oncotype DX, MammaPrint and EndoPredict (no microarray studies
were identified assessing Prosigna or IHC4). One study did not report statistically significant HRs at
≥ 10 years. However, conversely, three studies reported statistically significant HRs at ≥ 10 years,594,602,604
suggesting that the assumption of proportional hazards may not hold in all cohorts, and the tests are likely
to be more often accurate at 0–5 years than at time points beyond that. HRs were generally statistically
significant in LN+/LN0 cohorts, LN0 cohorts and LN+ cohorts, although the evidence base for the LN0
cohorts and LN+ cohorts was limited and one study did not report a statistically significant HR in a LN0
cohort, which may have been due to a small sample size (n = 94) or follow-up duration (14 years).597
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No study reported HRs in LN+/LN0, LN0 and LN+ patients separately, so it is difficult to draw any
conclusions about whether HRs differ in accordance with lymph node status.
C-indices (AUC) were generally good for all tests, and did not appear to differ in accordance with lymph
node status. Conclusions that can be drawn from the data reporting C-indices were limited by the
non-reporting of 95% CIs, meaning that it was not possible to tell whether the tests were substantially
better or worse than each other. One further problem with determining the superiority of tests was that
oncotype DX has three risk categories (high, intermediate and low) whereas MammaPrint and EndoPredict
have only two (high and low); C-index analyses represent the prognostic potential of the test, but do not
indicate which cut-off points should be used, what clinical decisions should be made for intermediate-risk
patients or what the long-term clinical outcomes would be for patients treated in accordance with the test
as commercially marketed. One study showed that MammaPrint could further categorise oncotype DX
intermediate-risk patients into high- and low-risk patients, with an excellent C-index of 0.844. However,
without seeing the overall performance of MammaPrint in this cohort, it is not possible to conclude that
MammaPrint outperforms oncotype DX. For this reason, it is difficult to draw any conclusions about
superiority given these differences in categories and the clinical significance in terms of treatment options.
As in previous sections of this report, it can be argued that the true value of the test lies in how much
additional prognostic information is provided over and above clincial factors. The one study608 to report such
data across three tests (oncotype DX, MammaPrint, EndoPredict) reported likelihood ratio χ2 and change
in likelihood ratio χ2 in analyses adjusted for clinicopathological variables suggesting that EndoPredict had
the greatest additional value, followed by oncotype DX, then MammaPrint, which agrees with the analyses
reported in TransATAC. One study606 (not adjusted for clinicopathologial variables) in LN0 patients reported
that only oncotype DX had a statistically significant change in likelihood ratio χ2 whereas AOL, NPI and
MammaPrint did not, which supports the order of prognostic performance reported in TransATAC.
Conclusions: microarray studies
Microarray studies support conclusions from studies using the commercial versions of the assays in
suggesting that oncotype DX, MammaPrint and EndoPredict can discriminate between high- and low-risk
patients regardless of LN status (data limited to mixed LN+/LN0 patients for EndoPredict); the utility of the
intermediate-risk group in oncotype DX is uncertain; the additional prognostic performance of the tests
over clinicopathological variable is less certain for MammaPrint, although the order of superiority appears
similar to that reported by TransATAC, namely EndoPredict, then oncotype DX, then MammaPrint,
although the evidence base is limited.
OPTIMA Prelim: a study of concordance between tests
Concordance between tests
Concordance is defined in this review as the degree to which tests assign the same patients to the same
risk groups. They do not report long-term outcomes. They are distinct from decision impact studies, in
which patients are actually assigned to treatment or not based on the test result and clinician and patient
preference.
In accordance with the scope21 and the protocol,610 we did not conduct a systematic review of concordance.
Instead, we present a summary of one high-quality, highly relevant study [the Optimal Personalised
Treatment of early breast cancer usIng Multi-parameter Analysis preliminary (OPTIMA Prelim) study]588
conducted in the UK.
OPTIMA Prelim: methods
The OPTIMA Prelim study (ISRCTN42400492) was a feasibility phase of Optimal Personalised Treatment of
early breast cancer usIng Multi-parameter Analysis (OPTIMA).611 OPTIMA is an ongoing trial that aims to
test the effectiveness of multiparameter testing in identifying a subgroup of patients (among those who
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would ordinarily be offered chemotherapy) who will not respond to chemotherapy and can therefore
avoid it and move more quickly to more appropriate treatments (i.e. endocrine therapy and radiotherapy).
OPTIMA Prelim was designed to help select which of six available tests [oncotype DX, MammaPrint,
Prosigna, IHC4, MammaTyper (BioNTech Diagnostics GmbH, Mainz, Germany), and NexCourse Breast by
Aqua (IHC4 automated quantitative immunofluorescence-AQUA)(NexCourse BreastTM, Genoptix Inc.
Carlsbad, CA, USA)] to use in the trial. Here, we only report data for the four in-scope tests (oncotype DX,
MammaPrint, Prosigna and IHC4). Three clinical prognostic scores were also used, namely AOL, NPI and
Predict, but these were only compared with each other.
The OPTIMA Prelim study selected women who would routinely be offered chemotherapy, specifically
women aged ≥ 40 years with ER+, HER2– early-stage breast cancer with either 1–9 positive lymph nodes
or a tumour of ≥ 30 mm if node negative. Women were randomised to test-directed therapy or standard
treatment (chemotherapy followed by endocrine therapy). Patients in the test-directed arm received
oncotype DX testing and those with a recurrence score of ≤ 25 received endocrine monotherapy.
OPTIMA Prelim: results
Results are presented in Table 68. A total of 313 patients from 35 UK hospitals were recruited and
randomised; 302 patients received multiple tests. Eleven patients were excluded: four withdrew consent,
one was ineligible and six had insufficient tissue for all tests to be conducted.
Nottingham Prognostic Index, Predict and Adjuvant! Online
With NPI, patients were at high (21%), intermediate (75%) and low (4%) risk. All patients with an NPI of
≤ 3.4 had tumours of ≥ 30 mm. Predict and AOL predict a risk for patients depending on whether they
take only endocrine monotherapy or take chemotherapy and endocrine therapy; the difference between
the Predict and AOL median predicted 10-year OS within each treatment type ranged from 6.2% to 8.4%.
Oncotype DX, MammaPrint, Prosigna and IHC4, MammaTyper, NexCourse Breast by Aqua
Results for all tests were available from 236 patients (78%). IHC4 could not be determined for 45 patients
(15%); one patient did not have enough tissue for oncotype DX testing, and three Prosigna and seven
MammaPrint tests were unobtainable.
Out of the four in-scope tests, MammaPrint assigned the most patients to the low-risk category (61%),
although when low and intermediate categories were treated as one category for the three tests that
have three risk groups (oncotype DX, Prosigna and IHC4), oncotype DX assigned the most to the low/
intermediate category (82%) and MammaPrint assigned the least (61%) (see Table 68).
Kappa statistics indicated modest agreement between tests, ranging from 0.33 (95% CI 0.3 to 0.5)
between MammaPrint and IHC4 and 0.53 (95% CI 0.4 to 0.7) between MammaPrint and Prosigna, and
0.53 (95% CI 0.4 to 0.7) between oncotype DX and IHC4 (see Table 68). Data are not reported for the
four in-scope tests alone, but across all five tests (that have risk groups rather than intrinsic subtypes,
TABLE 68 Percentage in each risk category and kappa statistics between tests
Test
Percentage
tested
Percentage in risk category Kappa statistic (95% CI)
Low Intermediate High MammaPrint Prosigna (L/I) IHC4 (L/I)
Oncotype
DX
99.7 54 28 18 0.40 (0.30 to 0.5) 0.44 (0.3 to 0.5) 0.53 (0.4 to 0.7)
MammaPrint 98.9 61 39 – 0.53 (0.4 to 0.6) 0.33 (0.2 to 0.4)
Prosigna (L/I) 99.0 36 29 35 – – 0.39 (0.3 to 0.5)
IHC4 (L/I) 85.1 24 48 28 – – –
I, intermediate; L, low.
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i.e. oncotype DX, MammaPrint, Prosigna, IHC4 and IHC4-AQUA), 61% of tumours gave no consensus,
and only 119 tumours (39%) were uniformly classified as either low/intermediate or high by all five tests.
Of these, 93 (31%) were low/intermediate risk by all tests and 26 (8%) were high risk by all tests.
An exploratory analysis using high/intermediate- versus low-risk patients also showed only moderate
agreement.
The authors report a number of further analyses that demonstrate that no tests appeared to be more in
agreement than others, and that there were no statistically significant differences in clinicopathological
variables between concordant and discordant patients. Disagreement spanning two categories (i.e. between
low and high risk) was not infrequent. Agreement was not better at the extremes of the ranges of the tests
(i.e. the very low- and very high-risk tumours).
Conclusions
The authors concluded that, although tests assigned similar proportions of patients to low/intermediate-
and high-risk categories, test results for an individual patient could differ markedly depending on which
test was used.
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Appendix 6 Review of existing economic analyses
published since National Institute for Health and Care
Excellence Diagnostics Guidance 10
Cost-effectiveness review: methods
Systematic searches were undertaken to identify existing economic evaluations of tumour profiling tests to
guide treatment decisions in people with early-stage breast cancer. Only those studies that were published
since the previous appraisal of tumour profiling tests (NICE DG1020) were considered to be potentially
relevant for inclusion in the review; a review and a critical appraisal of economic analyses published prior
to this date is available in Ward et al.1 The review was undertaken solely with the purpose of exploring
methodological choices and their potential relevance to the current decision problem, rather than to assess
the results of published economic evaluations or the potential sources of bias that might affect these.
A comprehensive search was undertaken to systematically identify economic evaluations of the five tumour
profiling tests (EndoPredict, oncotype DX, MammaPrint, IHC4 and Prosigna) and reviews of economic
evaluations of tumour profiling tests for breast cancer.
Literature searching for economic evaluation studies was undertaken in March 2017 in the following
electronic databases:
l MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations: via Ovid, 1946 to present
l EMBASE: via Ovid, 1974 to present
l Health Technology Assessment Database: CRD, 1995 to 2016
l NHS Economic Evaluation Database: CRD, 1995 to March 2015
l Science Citation Index Expanded: Web of Science, 1900 to present
l Conference Proceedings Citation Index – Science: Web of Science, 1990 to present.
The search strategies comprised MeSH or Emtree Thesauri terms and free-text synonyms for (1) ‘tumour
profiling tests’ and ‘breast cancer’ and (2) ‘breast cancer’ only. Searches for oncotype DX, MammaPrint,
IHC4 and Prosigna were limited by publication date from 2011 (the cut-off date for the previous appraisal),
whereas no date limits were applied to EndoPredict. Searches were translated across databases and were
not limited by language. The search strategies are presented in Appendix 2. Search filters designed to
identify economic evaluations and reviews were used in MEDLINE and other databases, where appropriate.
Reference and citation searching of included papers was undertaken.
In order to be considered potentially relevant for inclusion in the review, studies were required to meet all
of the following criteria:
l full economic evaluations comparing tumour profiling for breast cancer tests against other tests and/or
current practice
l published in English
l available in full-text format (studies that were available in abstract form only were excluded from
the review)
l relevant to the populations included within the final NICE scope.21
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Cost-effectiveness review results: summary of studies identified
A total of 294 potentially includable studies (including potential duplicates) were identified by the searches.
Of these, 59 studies were deemed to be potentially eligible for inclusion in the review and full texts were
obtained, when available. A total of 26 unique studies met the inclusion criteria and were included in the
review. The scope and methodological approaches adopted within the included studies are summarised in
Tables 69 and 70, respectively.
The models reported within the included studies were developed to assess the cost-effectiveness of tumour
profiling tests across a variety of different countries including the UK, the USA, Canada, Mexico, Japan,
Austria, Germany, France and the Netherlands. Most studies compared oncotype DX (18 studies) or
MammaPrint (eight studies) against comparators such as AOL, the St Gallen guidelines, standard practice or
other conventional diagnostic tools. One included study (Blank et al.433) compared EndoPredict against a
comparator that comprised a combination of three different guidelines. There was variation between the
analyses with respect to the patient populations evaluated, their disease type and other patient characteristics.
The models included populations with initial ages (when reported) ranging from 45 years to 64 years.
Across the breadth of included studies, there was a high level of consistency in terms of the general
modelling approach and structure, and several studies were based on a previously published model.
The majority of the included models adopted a Markov or hybrid decision tree–Markov approach, with
discrete nodes applied to estimate long-term costs and outcomes for patients assigned to different test
risk classification categories. Two studies adopted a partitioned survival approach. One further study used
a discrete event simulation approach. The structure of the model used in one study was not reported.
The time horizons used in the economic models ranged from 10 years to the patient’s remaining lifetime,
with cycle lengths (when reported) ranging from 1 month to 1 year. Most of the models that evaluated
oncotype DX against current practice assumed that the test was associated with a predictive benefit of
chemotherapy.
Most of the included studies that adopted a Markov structure included a common set of three health
states: (1) alive and recurrence-free, (2) alive with distant recurrence and (3) dead. However, several models
also included other health states, such as local recurrence, disease-free after local recurrence, distant
recurrence with response to treatment, distant recurrence with no response to treatment, progression of
disease after distant recurrence, CHF, chronic myeloid leukaemia, AML/MDS, and febrile neutropenia and
chemotherapy-induced nausea and vomiting. One model, which was reported across two studies,499,500
used different health states for patients receiving endocrine therapy only (remission, local recurrence,
distant recurrence and dead) and for patients receiving chemotherapy plus endocrine therapy (remission
with chemotherapy, remission without chemotherapy, local recurrence, distant recurrence and dead).
Although many of the models identified by the review adopted a similar modelling approach, none
included all of the relevant tests listed in the final NICE scope.21 For this reason, none of the existing
models included in the review was considered to be suitable for the current appraisal.
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TABLE 69 Existing economic evaluations: analytic scope
First author and
year Population Age Intervention Comparator Country Perspective Time horizon Discount rate
Bargalló-Rochaa
(2015)430
HR+, LN0 or LN1–3 early-stage
breast cancer
Baseline age
55.5 years
Oncotype DX Current standard of care Mexico Instituto Mexicano del
Seguro Social perspective
40 years 5%
Holta (2013)141 LN0 or pNImi, ER+ breast cancer
in the UK
Mean age
60.55 years
Oncotype DX Conventional diagnostic
procedures (including AOL
and NPI)
UK NHS 30 years 3.5%
Davidsona
(2013)478
ER+ LN0 breast cancer Mean age 53 years Oncotype DX Conventional diagnostic
procedures
Canada Canadian health-care
system
Lifetime (up to maximum
age of 100 years)
5%
Jahn (2015)618 ER+ and/or PR+, HER2/neu
negative, and LN0 breast cancer
Baseline age 50 years Oncotype DX AOL score Austria Societal perspective in line
with the Austrian health-
care system
Lifetime 5%
Kondo (2011)440 ER+ early-stage breast cancer Baseline age 45 years Oncotype DX St Gallen criteria Japan Societal Lifetime (with assumptions
about maximum survival
after 10 1-year cycles)
3%
Lamond (2012)362 Early-stage, endocrine-sensitive
breast cancer undergoing adjuvant
chemotherapy or no
chemotherapy
Median age 50 years Oncotype DX Current practice
(population-based study)
Canada Canadian health-care
system perspective
25 years 3%
Paulden (2013)619 LN0, ER+ and/or PR+ (HER2–/neu)
early-stage breast cancer patients
who are candidates for adjuvant
chemotherapy
Baseline age 50 years Oncotype DX AOL Canada Ontario Ministry of Health
and Long-Term Care
Lifetime 5%
Reeda (2013)620 LN0, ER+ breast cancer Baseline age 55 years Oncotype DX No RS-guided strategy USA US health-system
perspective and societal
perspective
Lifetime 3%
Blanka (2015)433 ER+, HER2–breast cancer Median age appears
to be 64 years
EndoPredict (EPClin)± three
guidelines
Three guidelines (German
S3, St Gallen, NCCN)
Germany German health-care
system
Lifetime (50 years) 3%
Bonastre
(2014)434
LN0 early-stage breast cancer.
Subgroup analysis of ER+ patients
Patients aged
< 61 years
MammaPrint AOL, chemotherapy for all France French National Insurance
Scheme
10 years 4%
Retèla (2012)621 Early, operable, LN0, ER+ breast
cancer
Baseline age 50 years MammaPrint Clinical-pathological
guidelines (such as AOL)
The
Netherlands
Dutch health-care
perspective
20 years 4% costs, 1.5%
health outcomes
Retèla (2012)622 Early, LN0 breast cancer Not reported MammaPrint; oncotype DX AOL The
Netherlands
Dutch health-care
perspective
20 years 4% costs, 1.5%
health outcomes
Retèla (2013)623 Early LN0 ER+ breast cancer after
local therapy
Baseline age 50 years MammaPrint 70G-FFT;
MammaPrint 70G-PAR
AOL The
Netherlands
Societal perspective 20 years 4% costs, 1.5%
health outcomes
Retèla (2013)624 Reflective of RASTER population Mean age 48 years MammaPrint AOL The
Netherlands
Dutch health-care
perspective
20 years 4% costs, 1.5%
health outcomes
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TABLE 69 Existing economic evaluations: analytic scope (continued )
First author and
year Population Age Intervention Comparator Country Perspective Time horizon Discount rate
Hall (2012)438 LN+, ER+ early-stage breast
cancer
Baseline age 60 years Oncotype DX Standard care
(chemotherapy for all)
UK NHS Lifetime (up to maximum
age of 100 years)
3.5%
Hannouf
(2012)499
Early-stage ER+/PR+ axilliary LN0
breast cancer
Starting age unclear Oncotype DX Current practice
(population-based study)
Canada Canadian public
health-care system
Lifetime 5%
Hannouf
(2014)500
Postmenopausal women with
early-stage ER+/PR+ axillary LN+
breast cancer
Mean age 61 years Oncotype DX Current practice Canada Canadian public
health-care system
Lifetime 5%
Kondo (2012)625 HR+, LN0, HER2– early-stage
breast cancer
Baseline age 55 years MammaPrint St Gallen criteria Japan Societal 10 years 3%
Mislicka (2014)626 Early-stage, LN0, ER+ breast
cancer
Not reported Mammostrat Oncotype DX USA Third-party payer
perspective
10 years 3%
Stein (2016)207 ER+, HER2– early-stage breast
cancer patients
Median age 58 years Oncotype DX; MammaPrint/
Bluetest; Prosigna
Chemotherapy for all UK NHS Lifetime (up to maximum
age of 100 years)
3.5%
Tiwana (2013)627 Women who are LN0, ER+
and/or PR+, HER2/neu-negative
early-stage breast cancer, who
are candidates for adjuvant
chemotherapy
50 years Oncotype DX AOL Canada Not reported – appears to
be payer perspective
Lifetime 5%
Vanderlaana
(2011)628
Minimally LN+, early-stage breast
cancer
Mean age 62 years Oncotype DX Current care (US NCCN
guidelines)
USA US payer (managed care)
perspective
30 years 3%
Wong (2012)629 Women with LN+ HR+ breast
cancer (one to three nodes)
Reflective of
RxPONDER630
Oncotype DX Current care (US NCCN
guidelines)
USA Payer Lifetime (40 years) 3%
Ward (2013)1 Women with ER+ LN0, and HER2–
early-stage breast cancer
Mean age 58.3 years Oncotype DX, IHC4,
MammaPrint and
Mammostrat (Mammostrat,
Clarient Diagnostic Services,
Inc, Aliso Viejo, CA, USA)
Current clinical practice UK NHS and PSS Lifetime (up to age of
100 years)
3.5%
Yanga (2012)631 LN0, ER+ breast cancer Not reported Oncotype DX MammaPrint USA Third party payer 10 years 3%
Yamauchia
(2014)247
Women with ER+, LN0 (including
micrometastases) ESBC who
were eligible for treatment with
adjuvant chemotherapy after
having undergone surgery for
primary tumour removal and
lymph node dissection
Mean age 49.8 years Oncotype DX No RS guided strategy Japan Societal Lifetime 3%
ESBC, early-stage breast cancer; FFT, fresh frozen tissue; RS, recurrence score; RxPONDER, Rx for Positive Node, Endocrine Responsive breast cancer.
a Known or potential conflict of interest declared.
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TABLE 70 Existing economic evaluations: modelling approach and assumptions regarding predictive benefit and chemotherapy
First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Bargalló-Rocha
(2015)430
Markov 1 year Classification to LR, IR, HR Yes – RRR only in the
high-risk group, based
on Paik50
Proportion of all groups
receive chemotherapy
3 states:
1. recurrence-free
2. recurrence
3. dead
Holt (2013)141 Markov 1 year Classification to LR, IR, HR Yes – RRRs in
intermediate and high
risk based on Paik50
Change in chemotherapy
use informed by decision
conflict analysis (changes
applied to all three risk
groups)
3 states:
1. recurrence-free
2. recurrence
3. dead
Davidson
(2013)218
Markov 1 year Classification to LR, IR, HR Yes – different RRRs
between risk groups
Proportion of all groups
receive chemotherapy
5 states:
1. RFS no chemotherapy
2. RFS chemotherapy
3. distant recurrence no chemotherapy
4. distant recurrence post chemotherapy
5. dead
Jahn (2015)618 DES N/A Sequential use of AOL and
oncotype DX – eight test
strategies considered
Yes Chemotherapy provided to
proportion of patients in all
groups except AOL low risk
and oncotype DX low risk
DES includes:
1. recurrence-free
2. distant recurrence
3. death
Kondo
(2011)440
Markov Unclear – appears
to be 1 year
Reclassification based on
use of assay
Yes Half of cases with no
definitive indication
undergo adjuvant
chemotherapy and only
cases with high RS
undergo chemotherapy
after the use of the assay
based on the results of
Japanese validation study
5 states:
1. ER+, ESBC after adjuvant therapy
2. distant recurrence with response
to treatment
3. distant recurrence with no response
to treatment
4. progression of disease after distant
recurrence
5. death
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TABLE 70 Existing economic evaluations: modelling approach and assumptions regarding predictive benefit and chemotherapy (continued )
First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Lamond
(2012)362
Markov 1 month Classification to LR, IR, HR Yes – only in low risk
and high risk
For no test, based on
Canadian population-based
study; for test, based on
RS. Usage in intermediate
group assumed to be the
same in both groups
10 states:
1. chemotherapy
2. CINV
3. FN
4. disease-free
5. local relapse
6. distant relapse
7. treated local relapse
8. AML/MDS
9. CHF
10. dead
Paulden
(2013)619
Markov Appears to be
monthly
Reclassification based on
use of assay
Yes Different regimens assumed
for different risk groups.
Different proportions of
patients assumed to receive
chemotherapy in accordance
with risk group (estimated by
linear regression)
5 states:
1. risk classification
2. adjuvant chemotherapy
3. no distant recurrence
4. distant recurrence
5. dead
Reed (2013)620 Markov 6 months Classification based on RS Yes – different RRR
assumed in each risk
group
No low risk get
chemotherapy, all
intermediate risk and high
risk get chemotherapy
3 states:
1. disease-free
2. distant recurrence
3. dead
Blank (2015)433 Markov 1 year Based on sensitivity and
specificity of test/guideline
No – same treatment
effect applied to all
groups irrespective of
risk
No chemotherapy for
low-risk patients
3 states:
1. disease-free
2. distant recurrence
3. dead
LR modelled implicitly
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First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Bonastre
(2014)434
EEACT with
partitioned
survival
Unclear Unclear No – authors state that
there is no evidence
to support predictive
benefit for MammaPrint
For MammaPrint and AOL,
only high-risk patients
were assumed to receive
chemotherapy. For the all
chemotherapy comparator,
all patients receive
chemotherapy irrespective
of risk
4 states:
1. post surgery with chemotherapy
(disease-free)
2. first year post surgery without
chemotherapy (disease-free)
3. DRFS
4. dead
Retèl (2012)621 Markov 1 year Based on sensitivity and
specificity of test/guideline
Unclear Chemotherapy used only
in high-risk patients in
accordance with treatment
guidelines
4 health states:
1. DFS
2. relapse (including local and regional
recurrences, secondary primary and
contralateral breast cancer)
3. metastasis
4. dead
Retèl (2012)622 Markov 1 year Based on sensitivity and
specificity of test/guideline
Unclear High and intermediate
groups combined – both
assumed to receive ET plus
chemotherapy
4 health states:
1. DFS
2. relapse (including local and regional
recurrences, secondary primary and
contralateral breast cancer)
3. metastasis
4. dead
Retèl (2013)623 Markov 1 year Based on sensitivity and
specificity of test/guideline
Unclear Chemotherapy used only
in high-risk patients in
accordance with treatment
guidelines
Not reported but based on previous
4-state model reported by Retèl et al.621
(see above)
Retèl (2013)624 Markov Not reported, but
likely to be 1 year
Based on sensitivity and
specificity of test/guideline
Unclear Not reported but likely to
be same as other Retèl
studies
4 health states:
1. DFS
2. relapse (including local and regional
recurrences, secondary primary and
contralateral breast cancer)
3. metastasis
4. dead
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TABLE 70 Existing economic evaluations: modelling approach and assumptions regarding predictive benefit and chemotherapy (continued )
First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Hall (2012)438 Decision tree
and modified
Markov model
Not reported Classification to LR or HR Unclear – data
contained within the
appendices appear to
suggest that predictive
benefit is modelled
All high-risk patients
receive chemotherapy
6 health states:
1. disease-free
2. distant recurrence
3. local recurrence
4. disease-free after local recurrence
5. CHF
6. dead
Hannouf
(2012)499
Markov 1 month Classification to LR, IR,
HR with separate Markov
nodes for chemotherapy plus
ET vs. ET only (accounting for
chemotherapy-related AEs)
Unclear – appears to
assume predictive
benefit
Model assumes that 50%
of intermediate-risk
patients receive
chemotherapy
ET-only model – 4 states:
1. remission
2. local recurrence
3. distant recurrence
4. dead
Chemotherapy plus ET model – 5 states:
1. remission with chemotherapy SAEs
2. remission without chemotherapy SAEs
3. local recurrence
4. distant recurrence
5. dead
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First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Hannouf
(2014)500
Markov 1 month Classification to LR, IR, HR
with separate Markov
nodes for chemotherapy
plus ET vs. ET alone
(accounting for
chemotherapy-related AEs)
Unclear – appears to
assume predictive
benefit
Model assumes that 50%
of intermediate-risk
patients receive
chemotherapy
ET-only model – 5 states:
1. remission
2. local recurrence
3. distant recurrence
4. dead
Chemotherapy plus ET model – 5 states:
1. remission with chemotherapy SAEs
2. remission without chemotherapy SAEs
3. local recurrence
4. distant recurrence
5. dead
Kondo
(2012)625
Markov 1 year Classification to LR, HR No Chemotherapy applied to
HR, ET only for low-risk
patients
5 states:
1. ER+, LN0, HER2– early-state breast
cancer after adjuvant chemotherapy
2. distant recurrence responded
to treatment
3. distant recurrence not responded
to treatment
4. progression of disease after distant
recurrence
5. dead
Mislick
(2014)626
Markov 1 year Classification to LR, IR, HR Yes – for both
Mammostrat and
oncotype DX
80% HR assumed to
receive chemotherapy;
10% low risk assumed to
receive chemotherapy;
50% intermediate risk
assumed to receive
chemotherapy
3 states:
1. no recurrence
2. recurrence
3. dead
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TABLE 70 Existing economic evaluations: modelling approach and assumptions regarding predictive benefit and chemotherapy (continued )
First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Stein (2016)207 Decision tree
and modified
Markov model
1 year Classification to LR or HR Separate analyses
undertaken including
predictive benefit and
assuming constant
benefit across risk
groups
All high-risk patients
receive chemotherapy
7 health states:
1. disease-free
2. distant recurrence
3. local recurrence
4. disease-free after local recurrence
5. CHF
6. chronic myeloid leukaemia
7. dead
Tiwana
(2013)627
Not reported –
appears to be
Markov
Not reported Classification to low–low
risk, low–intermediate risk,
low–high risk, low–none
risk, intermediate–low risk,
intermediate–intermediate
risk intermediate–high
risk, intermediate–none
risk, high–low risk,
high–intermediate
risk, high–high risk or
high–none risk. Based on a
model constructed for the
Ontario Heath Technology
Assessment Committee
Yes – different
recurrence rates
modelled between
groups and tests
Based on usage reported in
Asad et al.632
Not reported – appears to include
3 states:
relapse-free
distant metastases
dead
Vanderlaan
(2011)628
Appears to be
Markov
Not reported Classification to LR or HR.
Original source model
provided by Cedar
Associates based in
California, USA
No – same recurrence
rates for all HR patients
71% of women in usual
care assumed to receive
chemotherapy treatment
3 states:
1. non-progressed disease
2. progressed disease
3. death
Wong
(2012)629
Decision tree
with partitioned
survival
approach to
determine
sojourn time
Not reported For patients whose
treatment decision was
based on US NCCN criteria
classification to LR or HR.
For patients whose
treatment was based on the
oncotype DX test results
classification to LR, IR or HR
Yes – different
treatment effects
applied for each risk
category
≈55% of women assumed
to receive chemotherapy
Not clearly reported – appears to be
3 states:
1. disease-free
2. relapsed
3. dead
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First author
and year
Model
approach Cycle length Model type
Does model claim
predictive benefit for
test?
Assumptions on
chemotherapy use Long-term health states
Ward (2013)1 Markov 6 months Classification to risk/
prognosis group
No Baseline chemotherapy use
(without test) based on
English cancer registry
data. Use of chemotherapy
conditional on test based
on unpublished data
4 states:
1. recurrence-free
2. distant recurrence
3. long-term AEs (AML)
4. dead
Local recurrence included as event
Yang (2012)631 Markov 1 year Classification to LR or HR
using AOL and
reclassification probabilities
from the literature
Yes – different risk
reductions applied
between HR and LR
90% of patients who were
high risk in accordance
with both AOL and
oncotype DX/MammaPrint
received chemotherapy,
90% of patients who were
at low risk in accordance
with both AOL and
oncotype DX/MammaPrint
did not receive
chemotherapy. For patients
who experienced a
conflicting result between
AOL and oncotype DX/
MammaPrint, 50% of the
subpopulation received
chemotherapy
3 states:
1. no recurrence
2. recurrence
3. dead
Yamauchi
(2014)247
Markov Unclear – appears
to be 1 year
Classification to LR, IR, HR Yes – different risk
reductions applied
between risk groups
Based on empirical study
(Yamauchi et al.247)
3 states:
1. no recurrence
2. recurrence
3. dead
CINV, chemotherapy-induced nausea and vomiting; DES, discrete event simulation; EEACT, Economic evaluation alongside a clinical trial; ESBC, early-stage breast cancer; ET, endocrine
therapy; FN, febrile neutropaenia; HR, high risk; IR, intermediate risk; LR, low risk; RFS, recurrence-free survival; N/A, not applicable; RRR, relative risk reduction; RS, recurrence score;
SAE, serious adverse event.
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Appendix 7 Review and critical appraisal of
economic analyses provided by test manufacturers
Economic analyses were provided by the manufacturers of oncotype DX (Genomic Health) andMammaPrint (Agendia) and the chief investigator of the EndoPredict (Myriad Genetics) decision impact
study.62,94,159,182 The fully executable health economic models developed for the analyses of oncotype
DX and MammaPrint were made available to the EAG; the model referred to in the draft EndoPredict
cost-effectiveness paper was not provided to the EAG. These three analyses are detailed and critically
appraised in the following sections.
Agendia cost-effectiveness report: MammaPrint versus current practice
Agendia submitted a model, which was critiqued by the EAG as part of the assessment process, but it
cannot be reported here as Agendia withdrew permission to reproduce the model.
Genomic Health dossier: oncotype DX versus current practice
The Genomic Health dossier made available to NICE and the EAG includes a cost-effectiveness report
detailing the methods and results of a de novo health economic evaluation of oncotype DX versus current
practice for early-stage breast cancer in the UK.62 The fully executable economic model was also made
available to the EAG for scrutiny.
Genomic Health model scope
According to the Genomic Health dossier,62 the model was based on the previous analysis reported by
Ward et al.1 The company’s base-case model evaluates the cost-effectiveness of oncotype DX versus current
practice in ER+ LN0 patients. The model also allows for the evaluation of oncotype DX versus MammaPrint,
EndoPredict and Prosigna as secondary analyses. The base case includes ER+, LN0 early-stage breast cancer
patients, with the option to evaluate LN+ patients as a secondary analysis. Cost-effectiveness results are
expressed in terms of the incremental cost per QALY gained. Health outcomes and costs are discounted at a
rate of 3.5% per annum. Costs are valued at 2016 prices and reflect a NHS and PSS perspective.
Genomic Health model structure
The company’s model is referred to as a Markov model in the Genomic Health dossier, but is more
accurately described as a hybrid decision tree–Markov model. The decision tree portion of the model
incorporates the decision to give adjuvant chemotherapy or not. Within the oncotype DX group, this
probability is driven by the oncotype DX Breast Recurrence Score, and in the comparator group, this
probability is driven by current clinical practice as recorded in the pre-oncotype DX chemotherapy decision
in the NHS England oncotype DX Access Scheme Data set.183
The Markov component of the model includes three health states: (1) recurrence free, (2) distant recurrence
and (3) dead. The model adopts a 30-year time horizon and a 6-month cycle length. The age of patients on
entry into the model is 58.9 years, based on the mean age of patients in the NHS England Access Scheme
Database.183 Patients can die from breast cancer or from other causes. The model assumes that oncotype
DX is predictive of chemotherapy benefit, hence different treatment effects are applied in accordance
with the low, intermediate and high recurrence score groups (applied to the oncotype DX group only).
Health utilities are assigned to the recurrence-free and distant recurrence states. A chemotherapy-related
disutility is applied during each cycle for those who receive chemotherapy in either the test or no-test group.
A further QALY loss is applied for women who experience local recurrence. Separate health utility values are
DOI: 10.3310/hta23300 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 30
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harnan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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applied for patients who develop AML and for those in the final 3 months of life prior to death due to
breast cancer. As the model does not contain separate health states for these two states, the health utility
values for patients in the recurrence-free and distant recurrence health states are adjusted to account for
the lower health utility values for patients with AML and for those dying from breast cancer.
The costs used in the Genomic Health model were based on Ward et al.;1 these were uplifted to current
values using the HCHS pay and prices inflation index.195 According to the Genomic Health dossier,
all patients are assumed to receive endocrine therapy, based on the following assumptions:
l tamoxifen for 5 years (40% of patients)
l anastrozole for 5 years (20% of patients)
l letrozole for 5 years (20% of patients)
l tamoxifen for 2 years plus exemestane for 3 years (20% of patients)
l tamoxifen for 5 years followed by letrozole for a further 3 years (half of patients completing tamoxifen
for 5 years received an additional 3 years of letrozole) (10% of patients).
The model assumes that adjuvant chemotherapy consists of six cycles of FEC75 (5 fluorouracil, epirubicin
and cyclophosphamide). The cost of chemotherapy is included as a once-only cost and includes the costs
of drug acquisition, administration, monitoring and an echocardiogram for 25% of patients undergoing
chemotherapy (total chemotherapy cost = £4678). The model includes costs associated with the following
short-term AEs: anaemia (1.4%), thrombocytopenia (0.3%), neutropenic infection (1.6%), nausea/vomiting
(24.2%) and stomatitis (4%). This cost is applied as a once-only cost of £315 for women receiving
adjuvant chemotherapy. A proportion of women receiving chemotherapy (0.46%) are assumed to
subsequently develop AML; this is included as a once-only cost of £13,123. Half of the annual cost of
distant recurrence (half of £9316) is applied to patients in the distant recurrence health state during each
cycle. A once-only cost (£16,127) of treating local recurrence is applied to 10.5% of patients entering the
distant recurrence state. The model also includes a cost of £4608 to reflect end-of-life costs for women
who die as a consequence of their breast cancer.
The Genomic Health model makes the following structural assumptions:
l The results of the oncotype DX test are assumed to be predictive of the benefit deriving from
subsequent chemotherapy use. Conversely, a common relative ROR is applied to all patients in the
current practice group.
l Survival following distant recurrence is assumed to be 3.3 years (based on Thomas et al.186).
l A HRQoL decrement associated with AEs is applied during every model cycle for the remaining lifetime
of patients who receive adjuvant chemotherapy.
l The costs of short-term AEs are included only in the first model cycle.
l AML is included as a long-term complication of chemotherapy.
l All patients are assumed to receive endocrine therapy.
Evidence sources used to inform the Genomic Health model
Table 71 summarises the evidence sources used to inform the Genomic Health model.
Probability of receiving chemotherapy under current practice and with oncotype DX
Data from the NHS England Access Scheme on the use of oncotype DX from 2015/16183 were used to
model the levels of chemotherapy use resulting from the use of oncotype DX and from the use of standard
practice. These data were provided as AiC and cannot be reported here.
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Risk of distant recurrence
The 10-year risk of distant recurrence in accordance with oncotype DX Breast Recurrence Score was taken
from Dowsett et al.;37 the proportion of patients in each recurrence score category is common to both
modelled groups (Table 72). Based on the assumptions employed in the model reported by Ward et al.,1
the ROR is tapered to be 50% of the estimated risk during years 11–15 and 0% thereafter. The RR of
distant recurrence for chemotherapy versus no chemotherapy is taken from Paik et al.50 Within the
oncotype DX group, it is assumed that the oncotype DX test is predictive of chemotherapy benefit. As
shown in Table 72, the RR applied is dependent on the oncotype DX risk group, with the largest treatment
effect applied in the high recurrence score group. In contrast, within the standard care group, the model
assumes that the RR associated with chemotherapy is constant across all patients.
TABLE 71 Evidence sources used in the Genomic Health model
Parameter Source EAG comments
10-year risk of distant recurrence
on endocrine therapy
Dowsett et al.37 Estimates presented in the Genomic Health dossier and model
do not match the estimates in the Dowsett et al.37 paper
Oncotype DX recurrence score
classification
NHS England Access
Scheme Database183
Risk classification probabilities and risk of distant recurrence
are not derived from the same source. This may produce a
bias due to differences in the distribution of prognostic
variables for patients within each recurrence score category
between the two sources. Risk reclassification is applied
incorrectly in the model
Relative risk reduction associated
with chemotherapy
Paik et al.50 This is applied incorrectly within the standard care group in a
way that suggests that the same patient receiving the same
treatment accrues a different level of benefit if they are tested
with oncotype DX
Probability patient receives
chemotherapy
NHS England Access
Scheme Database183
This source reflects the LN0 ‘intermediate-risk’ group only
Health utilities Ward et al.1 Health losses due to chemotherapy-related AEs are applied
incorrectly
Probability of short-term AEs
during the first 6 months
Ward et al.1 –
Probability of local recurrence Ward et al.1 –
Probability of AML Ward et al.1 –
Other-cause mortality rates ONS190 –
Oncotype DX cost Genomic Health62 –
All other costs Ward et al.1 –
ONS, Office for National Statistics.
TABLE 72 Risk of distant recurrence and the benefit (RR) of chemotherapy
Oncotype DX recurrence score risk groups
Risk of distant recurrence
(no chemotherapy)
(Dowsett et al. 201037) (%)
RR with chemotherapy
Standard care Oncotype DX
Low RS 9 82.7 1.00a
Intermediate RS 16 82.7 0.61
High RS 23 82.7 0.26
RS, recurrence score.
a Assumed value.
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Node-positive patients
The Genomic Health dossier includes a secondary analysis that explores the use of oncotype DX in ER+ LN+
patients. The main differences between this analysis and the base-case LN0 analysis are summarised in
Table 73. The proportion of patients receiving chemotherapy in the oncotype DX group was based on
Loncaster et al.,145 which resulted in a 69.2% reduction in chemotherapy following the use of the test.
It should be noted that unlike the base case, the analysis in the LN+ population did not use DRFS to
estimate chemotherapy benefit; instead, DFS rates were derived from Albain et al.53 (this same approach is
used within the EAG’s sensitivity analyses). The dossier states that only RRs for chemotherapy that were
statistically significant were used; if this statement was accurate, this would result in a RR of 1.0 for the low
recurrence score and intermediate recurrence score group and 0.59 in the high recurrence score group.
However, the Genomic Health model inputs do not reflect this: all reported RRs were used, irrespective of
whether or not they were associated with a statistically significant difference (see Table 73).
Comparison of oncotype DX and other tests (MammaPrint, EndoPredict score,
EndoPredict Clinical and Prosigna)
In order to estimate the proportion of patients receiving chemotherapy in the comparator group, data on
concordance between oncotype DX and the comparator tests were used to recategorise patients in the
NHS England Access Scheme Database.183 The proportions of patients receiving chemotherapy in each
oncotype DX Breast Recurrence Score group are shown in Table 74. For MammaPrint, concordance data
from Shivers et al.,401 a US study with 135 patients, were used. For EndoPredict, data from Varga et al.,410
a small study of 24 patients in Germany and Switzerland, were used. For Prosigna, a US study of 52
patients was used.462 For MammaPrint, EndoPredict and Prosigna, it was assumed that 100% of high-risk
and 0% of low-risk patients in the comparator group would receive chemotherapy, and, for Prosigna,
50% of the intermediate-risk group were assumed to receive chemotherapy. With the exception of the
comparator test cost, all other parameters were held at the base-case values.
TABLE 73 Parameter values in the LN+ analysis
Population
Percentage receiving
chemotherapy 10-year cumulative
probability of
distant recurrence
(no chemotherapy) (%)
RR with chemotherapy
Current practice
group
Oncotype DX
group Current practice Oncotype DX
Low RS 100 7.5 40 0.72 1.02
Intermediate RS 100 63.2 51 0.72 0.72
High RS 100 83.3 57 0.72 0.59
RS, recurrence score.
TABLE 74 Parameter values for MammaPrint, EndoPredict score, EPClin and Prosigna
Oncotype DX
RS group Proportion of patients
Proportion of patients receiving chemotherapy by
test (%)
MammaPrint
EndoPredict
score EPClin Prosigna
Low RS Confidential information has been removed 29 40 27 26
Intermediate RS Confidential information has been removed 51 80 50 38
High RS Confidential information has been removed 86 100 67 50
RS, recurrence score.
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Results of the Genomic Health model
The Genomic Health deterministic base-case analysis indicates that oncotype DX produces positive health
gains [0.03 life-years gained (LYGs) and 0.07 QALYs] at an additional cost of (confidential information has
been removed); this corresponds to an ICER of (confidential information has been removed) per QALY
gained. The results are driven by an overall reduction in chemotherapy levels in women with a low or
intermediate oncotype DX Breast Recurrence Score (who benefit less from chemotherapy) and an increase
in chemotherapy levels in those with a high oncotype DX Breast Recurrence Score (who benefit more from
chemotherapy). The company’s probabilistic results indicate that the modelled estimates of incremental
QALYs and costs are associated with considerable uncertainty. The cost-effectiveness plane generated
using the Genomic Health model shows a wide dispersion of results, with a substantial number of samples
being in the north-west quadrant (dominated) and the south-east quadrant (dominating). It should be
noted that the cost-effectiveness plane presented in Figure 6 of the Genomic Health62 dossier appears very
different from that generated by the EAG using the model; the reasons for this are unclear. The CEAC
generated using the model suggests that the probability that oncotype DX produces more net benefit than
current practice at WTP thresholds of £20,000 and £30,000 per QALY gained is approximately 0.51 and
0.52, respectively. The EAG has concerns regarding the robustness of the company’s probabilistic ICER
as different model runs produced very different results, ranging from < £10,000 per QALY gained to
> £170,000 per QALY gained.
The results for the LN+ population and for the LN0 population comparing oncotype DX with the other
four tests are presented in Table 75. These analyses consistently indicate that, using mean values, oncotype
DX dominates the comparators. As with the LN+ analysis, the cost-effectiveness plane presented in the
Genomic Health62 dossier (Figure 6) shows a wide dispersion of results, with a large proportion of samples
in the north-west (dominated) and south-east (dominating) quadrants.
The company’s one-way sensitivity analyses (not shown) indicate that the model results are sensitive to
changes in several parameter values including the time horizon, the discount rate, the disutility associated
with chemotherapy and current levels of chemotherapy use.
The EAG notes that given that most of the probabilistic samples suggest that oncotype DX either dominates
or is dominated by current practice, it is surprising that none of the DSAs indicate this result.
Critical appraisal of the Genomic Health model
The EAG has several concerns regarding the Genomic Health model (Box 1). In particular, the EAG identified
a number of programming errors within the model. As a consequence, the EAG does not consider the
results of the Genomic Health model to be robust. The EAG’s concerns are discussed in more detail in the
following sections.
Use of inappropriate structural assumptions that bias in favour of oncotype DX
The Genomic Health model assumes that the oncotype DX test is predictive of chemotherapy benefit.
As shown in Table 72, this results in the RR for distant recurrence being dependent on the oncotype DX
Breast Recurrence Score category, with the greatest chemotherapy benefit being applied to the high
recurrence score group. In the model, the standard care arm mirrors the oncotype DX arm in that patients
are also split into the three oncotype DX Breast Recurrence Score categories. The difference between
the arms is the proportion of patients in each risk group who go on to receive adjuvant chemotherapy.
However, as shown in Table 72, the RR used in the standard care arm is constant across all three risk
groups and is based on the crude average of the three RRs reported in the Paik et al.50 study. The
distribution of patients between the three recurrence score groups differs between the NHS England
Access Scheme Database183 used in the Genomic Health model and the Paik et al.50 study and, therefore,
the crude mean RR from Paik et al. does not represent the average RR for the population in the Genomic
Health model. Furthermore, as oncotype DX only identifies patients who may benefit from chemotherapy,
the same RR of distant recurrence by recurrence score category should be applied to both the modelled
oncotype DX and current practice groups (by recurrence score score), as each group has exactly the same
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TABLE 75 Results of the Genomic Health model: oncotype DX vs. standard care and other comparator tests
Option LYGs QALYs Costs Incremental LYGs Incremental QALYs Incremental costs ICER (per QALY gained)
Analysis 1: LN0 – comparison vs. standard care
Oncotype DX 12.82 10.50 Confidential information
has been removed
0.03 0.07 Confidential information
has been removed
Confidential information
has been removed
Standard care 12.80 10.43 Confidential information
has been removed
– – – –
Analysis 2: LN+ comparison vs. standard care
Oncotype DX 12.95 10.60 Confidential information
has been removed
–0.05 0.15 Confidential information
has been removed
Dominating
Standard care 13.00 10.44 Confidential information
has been removed
– – – –
Analysis 3: LN0 – comparison with MammaPrint
Oncotype DX 12.82 10.50 £6319 0.02 0.07 –£1272 Dominating
MammaPrint 12.80 10.43 £7590 – – – –
Analysis 4: LN0 – comparison vs. EndoPredict score alone
Oncotype DX 12.82 10.50 £6139 0.01 0.08 –£762 Dominating
EndoPredict 12.82 10.41 £7081 – – – –
Analysis 5: LN0 – comparison vs. EPClin score
Oncotype DX 12.82 10.50 £6319 0.03 0.06 –£532 Dominating
EndoPredict 12.80 10.44 £6850 – – – –
Analysis 6: LN0 – comparison vs. Prosigna
Oncotype DX 12.82 10.50 £6319 0.03 0.06 –£655 Dominating
Prosigna 12.79 10.44 £6974 – – – –
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patient distribution across recurrence score scores. If a patient is identified by oncotype DX as being high
risk, the benefit they accrue from adjuvant chemotherapy should be identical to that accrued by the same
patient who receives chemotherapy without the test.
Inappropriate application of chemotherapy-related disutility over remaining patient
lifetime
The QALY decrement resulting from the use of chemotherapy is applied during every cycle for the
remainder of the modelled patients’ lifetimes. The EAG considers it unlikely that patients would suffer the
adverse effects of adjuvant chemotherapy years after they have completed their treatment. This represents
a very pessimistic assumption that increases the overall reduction in QALYs associated with chemotherapy
and overestimates the benefits associated with reducing overall chemotherapy use.
Risk classification probabilities and distant recurrence rates derived from separate sources
The risk of distant recurrence and the proportion of patients in each oncotype DX Breast Recurrence Score
category were taken from two separate studies (Dowsett et al.37 and the NHS England Access Scheme
Database183). The use of separate sources for these inputs may produce confounding due to differences in
the characteristics of patients within each recurrence score category between the two sources. In addition,
the EAG notes that the risk of distant recurrence in the Genomic Health model does not match the 9-year
risk of distant recurrence for LN0 patients presented in Dowsett et al.37 or the Genomic Health62 dossier.
Application of NHS England Access Scheme Database to all lymph node-negative patients
The NHS England Access Scheme Database183 is only applicable to women who are at clinical intermediate-
risk based on the NPI or other clinical indicators. However, it is unclear from the Genomic Health dossier
whether the model applies only to this population or whether the model is intended to reflect costs and
outcomes of the oncotype DX test across the whole LN0 population.
Model errors
The EAG identified an error in the company’s calculations relating to the proportion of patients in the
low-, intermediate- and high-risk groups who receive chemotherapy. The correct proportions are presented
in the model; however, these are not applied directly but are instead incorrectly adjusted when used to
calculate the traces for the Markov nodes (confidential information has been removed).183 This error leads
to a substantial underestimate of the number of patients receiving chemotherapy in both the intermediate-
and high-risk groups and has a significant impact on the model results.
In addition, the results reported for the node-positive patients in the Genomic Health model could not
be replicated by the EAG using the data described in the Genomic Health dossier. In order to replicate
the results, two different sets of data were required. For the risk of distant recurrence, the Dowsett et al.37
used in the base-case analysis had to be selected (rather than the appropriate Albain et al.53 study).
In addition, the results in the dossier use Paik et al.50 (rather than the appropriate Albain et al.53 study).
BOX 1 Main issues relating to the Genomic Health model identified by the EAG
l Use of inappropriate structural assumptions that bias in favour of oncotype DX.
l Inappropriate application of chemotherapy-related disutility over remaining patient lifetime.
l Risk classification probabilities and distant recurrence rates derived from separate sources.
l Application of NHS England Access Scheme Database to all LN0 patients.
l Model errors.
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The impact of correcting the major errors in the Genomic Health model is explored further through comparison
with the EAG model in Chapter 3, Comparison between the Genomic Health model, the current External
Assessment Group model and the previous External Assessment Group model (lymph node negative, clinical
intermediate-risk subgroup).
EndoPredict draft cost-effectiveness paper (Myriad Genetics)182
Model scope
The chief investigator of the EndoPredict decision impact study159 made available a draft manuscript that
outlines the methods and results of an economic analysis comparing of EPClin plus AOL versus AOL only
in women with ER+, HER2– early-stage breast cancer, having had an intermediate-risk score using AOL.
The EAG notes that the AOL risk interval is not explicitly defined. The executable model was not made
available, hence the EAG was unable to verify whether it has been implemented appropriately.
The manuscript presents two sets of analyses: (1) a short-term cost-minimisation analysis of EPClin versus
usual practice (including only chemotherapy acquisition costs and the costs of providing the EPClin test),
and (2) a cost-effectiveness analysis of EndoPredict plus AOL versus AOL only from the perspective of the
NHS over a lifetime horizon. Most of the details of the Myriad model182 were provided in confidence and
cannot be reported here.
Results of the Myriad model
The cost-minimisation analysis suggests that EndoPredict led to a small but non-statistically significant
increase in the mean per-patient cost of acquisition and provision of chemotherapy to the NHS of £149.
The cost-effectiveness analysis suggests that the ICER for EndoPredict plus AOL versus AOL is £26,836 per
QALY gained.182
The critical appraisal of the Myriad model was held as confidential and cannot be reported here.
Summary of economic evidence made available to the External Assessment Group
The EAG has concerns regarding the economic evidence for oncotype DX and EndoPredict that was made
available to it. In particular, the Genomic Health model for oncotype DX includes a number of errors and,
in the opinion of the EAG, unreasonable assumptions. The EAG did not receive a model for EndoPredict
and, therefore, cannot comment fully on the reliability of the results presented. No economic evidence
was provided by the manufacturers of Prosigna or IHC4. Agendia submitted a model, which was critiqued
by the EAG as part of the assessment process, but it cannot be reported here as Agendia withdrew
permission to reproduce the model.
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Appendix 8 External Assessment Group model
input parameter tables
TABLE 76 Risk classification probabilities using oncotype DX, Prosigna, IHC4+C and EPClin (TransATAC)
Test (number of samples)
Proportion of patients with risk classificationa
Low Intermediate High
LN0 NPI ≤ 3.4
Oncotype DX (541) 0.72 0.24 0.04
Prosigna (410) 0.72 0.24 0.03
IHC4+C (510) 0.88 0.11 0.01
EPClin (423) 0.90 – 0.10
LN0 NPI > 3.4
Oncotype DX (284) 0.50 0.31 0.19
Prosigna (253) 0.27 0.38 0.35
IHC4+C (279) 0.36 0.38 0.25
EPClin (254) 0.47 – 0.53
LN1–3
Oncotype DX (219) 0.57 0.32 0.11
Prosigna (192) 0.08 0.32 0.60
IHC4+C (213) 0.28 0.34 0.38
EPClin (198) 0.24 – 0.76
a Values may not sum to 1.0 due to rounding errors.
TABLE 77 Risk classification probabilities using MammaPrint (MINDACT)
Population
Proportion of patients with risk classification
MammaPrint low risk MammaPrint high risk
MINDACT ITT population (n = 6693) 0.64 0.36
MINDACT mAOL clinical high-risk subgroup (n = 3370) 0.46 0.54
MINDACT mAOL clinical high-risk subgroup (n = 3324) 0.82 0.18
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TABLE 78 The 10-year distant recurrence rates by risk classification for oncotype DX, Prosigna, IHC4+C and EPClin
Population
10-year DMFI (95% CI)
Oncotype DXa Prosigna IHC4+C EPClin
LN0, NPI ≤ 3.4, low risk 0.983
(0.963 to 0.992)
0.986
(0.962 to 0.995)
0.975
(0.954 to 0.987)
0.971
(0.947 to 0.984)
LN0, NPI ≤ 3.4, intermediate risk 0.931
(0.867 to 0.965)
0.933
(0.857 to 0.969)
0.878
(0.747 to 0.943)
N/A
LN0, NPI ≤ 3.4, high risk 0.838
(0.577 to 0.945)
0.636
(0.297 to 0.845)
0.800
(0.204 to 0.969)
0.870
(0.714 to 0.944)
LN0, NPI > 3.4, low risk 0.854
(0.776 to 0.907)
0.923
(0.825 to 0.967)
0.873
(0.787 to 0.926)
0.848
(0.761 to 0.905)
LN0, NPI > 3.4, intermediate risk 0.798
(0.694 to 0.869)
0.796
(0.687 to 0.870)
0.788
(0.688 to 0.859)
N/A
LN0, NPI > 3.4, high risk 0.749
(0.598 to 0.851)
0.699
(0.584 to 0.788)
0.769
(0.645 to 0.855)
0.774
(0.688 to 0.838)
LN1–3, low risk 0.818
(0.727 to 0.880)
1 (N/A) 0.961
(0.851 to 0.990)
0.95
(0.811 to 0.988)
LN1–3, intermediate risk 0.754
(0.630 to 0.842)
0.807
(0.679 to 0.889)
0.758
(0.635 to 0.845)
N/A
LN1–3, high risk 0.686
(0.447 to 0.839)
0.707
(0.604 to 0.788)
0.672
(0.546 to 0.771)
0.716
(0.629 to 0.785)
N/A, not applicable.
a Equivalent data relating to RPSC (oncotype DX plus clinicopathological factors) were also provided by the study
investigators. The cost-effectiveness of this option is explored within the sensitivity analyses.
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TABLE 79 Calculation of 5-year DMFS probabilities by clinical/genomic risk group and chemotherapy use
Randomised
group Treatment
EAG group
labelc
Number
randomised
before genomic
correction
Number
randomised
after genomic
correction
Number
in groupa
Percentage
of overall
trial
population
5-year
DMFS (%)
5-year
cumulative DMFS
probability (%)
Distant
metastases
event rate
(year)
10-year
DMFS
probability
for group
6-month
recurrence
probability
for group
mAOL low risk,
MammaPrint
low risk
Chemotherapy A 2634 2745 37 0.55 97.60 2.40 0.005 0.953 0.002
No
chemotherapy
B 2708 40.46 97.60 2.40 0.005 0.953 0.002
mAOL high risk,
MammaPrint
low risk
Chemotherapy C 1497 1550 793 11.85 95.90 4.10 0.008 0.920 0.004
No
chemotherapy
D 757 11.31 94.40 5.60 0.012 0.891 0.006
mAOL low risk,
MammaPrint
high risk
Chemotherapy E 690 592 296 4.42 95.80 4.20 0.009 0.918 0.004
No
chemotherapy
F 296 4.42 95.00 5.00 0.010 0.903 0.005
mAOL high risk,
MammaPrint
high risk
Chemotherapy G 1873 1806 1735 25.92 90.60 9.40 0.020 0.821 0.010
No
chemotherapy
H 71 1.06 90.60 9.40 0.020 0.821b 0.010
a Based on Cardoso et al.98 supplementary material, Table S11.
b Adjusted 10-year DMFS without chemotherapy estimated to be 0.766.
c EAG group labels are described on p.113 of the EAG report.
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TABLE 81 Summary of post-test chemotherapy probabilities conditional on risk classification
Source Population
Proportion of patients receiving adjuvant
chemotherapy conditional on test risk
classification
Low risk Intermediate risk High risk
NHS England Access Database183 LN0, intermediate clinical risk 0.01 0.33 0.89
Holt et al.201 LN0 or pN1mic 0.07 0.59 0.91
Bloomfield et al.159 Unclear 0.07 N/A 0.77
Loncaster et al.145 LN0 0.02 0.51 0.85
LN+ 0.08 0.63 0.83
UKBCG survey (three-level tests) LN0, NPI ≤ 3.4 0.00 0.17 0.74
LN0, NPI > 3.4 0.04 0.41 0.92
LN1–3 0.46 0.76 0.95
UKBCG survey (two-level tests) LN0, NPI ≤ 3.4 0.01 N/A 0.71
LN0, NPI > 3.4 0.15 N/A 0.92
LN1–3 0.40 N/A 0.97
N/A, not applicable.
TABLE 80 Baseline chemotherapy probabilities by risk group [provided by NCRAS (Dr Kwok Wong, Senior Cancer
Analyst, National Cancer Registration and Analysis Service, 28 June 2017)]
Group
Age (years)
55–75 ≤ 75
ACT No ACT Percentage ACT No ACT Percentage
LN0, NPI ≤ 3.4 329 4248 7.19 964 6008 13.83
LN0, NPI > 3.4 1388 2081 40.01 3265 2897 52.99
LN1–3 1849 1099 62.72 4557 1526 74.91
ACT, adjuvant chemotherapy.
TABLE 82 Estimates of adjuvant chemotherapy benefit applied in the EAG model
Test risk group
10-year RR of distant recurrence: chemotherapy vs. no chemotherapy
EAG base case: oncotype DX,
Prosigna, EPClin, IHC4+C,
non-predictive (EBCTCG199)
EAG sensitivity analysis:
oncotype DX, predictive
benefit (Paik et al.50 and
Albain et al.53)
EAG base case:
MammaPrint MINDACT
population, non-predictive
(Cardoso et al.98)
LN0 subgroups (NPI ≤ 3.4 and NPI > 3.4)
Low risk 0.76 1.31a –
Intermediate risk 0.76 0.61a –
High risk 0.76 0.26a –
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TABLE 82 Estimates of adjuvant chemotherapy benefit applied in the EAG model (continued )
Test risk group
10-year RR of distant recurrence: chemotherapy vs. no chemotherapy
EAG base case: oncotype DX,
Prosigna, EPClin, IHC4+C,
non-predictive (EBCTCG199)
EAG sensitivity analysis:
oncotype DX, predictive
benefit (Paik et al.50 and
Albain et al.53)
EAG base case:
MammaPrint MINDACT
population, non-predictive
(Cardoso et al.98)
LN1–3 subgroup
Low risk 0.76 1.02a,b –
Intermediate risk 0.76 0.72a,b –
High risk 0.76 0.59a,b –
MINDACT ITT population
MammaPrint low risk – – 0.77
MammaPrint high risk – – 0.77
MINDACT mAOL low risk
MammaPrint low risk – – 0.84
MammaPrint high risk – – 0.84
MINDACT mAOL high risk
MammaPrint low risk – – 0.74
MammaPrint high risk – – 0.74
a Deterministic values applied in the sensitivity analyses are also adjusted by half of the variance, derived from reported
95% CIs.
b HRs treated as RRs.
TABLE 83 Summary of EQ-5D health state valuations in identified studies
Author
Publication
type Country Population
Health state
description
EQ-5D
valuation for
health state
Farkkila et al.204 Abstract Finland 778 breast cancer patients aged
31–90 years in the Hospital
District of Helsinki and Uusimaa
Baseline 0.818 (SD 0.228)
First year of remission 0.860 (SD 0.178)
Following years after
remission
0.843 (SD 0.189)
Metastatic disease 0.746 (SD 0.251)
Palliative patients 0.514 (SD 0.300)
Lidgren et al.191 Paper Sweden 361 consecutive breast cancer
patients attending the breast
cancer outpatient clinic at
Karolinska University Hospital
Solna for outpatient visits
between April and May 2005
First year after primary
breast cancera
0.696 (95% CI
0.634 to 0.747)
First year after
recurrence
0.779 (95% CI
0.700 to 0.849)
Second and following
years after primary
breast cancer/recurrence
0.779 (95% CI
0.745 to 0.811)
Metastatic disease 0.685 (95% CI
0.620 to 0.735)
continued
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TABLE 83 Summary of EQ-5D health state valuations in identified studies (continued )
Author
Publication
type Country Population
Health state
description
EQ-5D
valuation for
health state
Naik et al.206 Paper Canada 1759 ambulatory cancer survivors
at the Princess Margaret Cancer
Centre (mixed cohort with various
cancer types, 282 patients with
breast cancer)
Breast local/regional 0.82 (SE 0.01)
Breast distant/metastatic 0.75 (SE 0.03)
Yousefi et al.205 Paper Iran 163 patients with breast cancer
who attended the breast cancer
subspecialty clinic affiliated with
the Breast Cancer Research
Center (BCRC), in Tehran, Iran
First year after primary
breast cancer
0.674 (SD 0.201)
First year after
recurrence
0.718 (SD 0.139)
Second and following
years after primary
breast cancer/recurrence
0.730 (SD 0.221)
Metastatic disease 0.552 (SD 0.227)
SD, standard deviation.
a Lidgren et al.191 also report EQ-5D utility scores for patients receiving adjuvant hormone therapy of 0.824 (n = 79, 95% CI
0.785 to 0.857).
TABLE 84 Health utilities applied in the EAG model
Health state/event Duration applied in model
Mean
utility SE Source
Recurrence free Indefinite 0.824 0.018 Lidgren et al.191
Distant metastases Indefinite 0.685 0.029
Disutility distant metastases Indefinite –0.14 0.11 Calculated using
difference method
Local recurrence Once-only QALY loss applied on
transition to distant recurrence state
–0.108 0.04 (assumed) Campbell et al.193
Chemotherapy AEs Once-only QALY loss applied in first
cycle
–0.038 0.004 (assumed)
AML Indefinite 0.26 0.04 (assumed) Younis et al.192
TABLE 85 Test costs assumed in the EAG analysis
Test Cost Comments
Oncotype DX
(excluding PAS)
£2580 Tests carried out in Genomic Health laboratory in USA. Cost includes sample handling and
customer service
Prosignaa £1970 NanoString Technologies submitted a cost per Prosigna test based on conducting the test in
a NHS laboratory, which included the laboratory costs (£240), the list price for Prosigna kits
(£1650), cost of the nCounter System (£194,600) and was based on 2500 samples per lifetime
of the nCounter System
EndoPredicta £1500 Tests carried out in Myriad’s laboratory in Munich
IHC4 £203 IHC4 submitted a document outlining the time and equipment necessary to conduct the test in
2014 prices. The total cost of the test (£198) was uplifted using the HCHS index195
MammaPrint £2326 Converted from Euros to UK Pounds Sterling assuming an exchange rate of 1.15
a Alternative costs per test due to NHS testing explored in sensitivity analyses.
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
304
TABLE 86 Adjuvant chemotherapy costs applied in the EAG model
Regimen
Proportion of
women receiving
regimen
Costs
Central line Drug Delivery
Supportive
medicines
Medical
oncology
Specialist
nurse review Blood tests Toxicity Total
FEC100-T (3+ 3 cycles) 0.25 £18.17 £306.84 £1284.58 £435.64 £450.03 £613.10 £62.32 £378.20 £3548.88
TC (4 cycles) 0.20 £18.17 £52.80 £856.39 £15.91 £310.81 £408.74 £41.55 £144.83 £1849.19
FEC75 (6 cycles) 0.45 £18.17 £346.38 £1284.58 £80.77 £310.81 £613.10 £62.32 £245.91 £2962.05
FEC100-Pw (3 + 3 cycles) 0.10 £18.17 £274.53 £2569.16 £435.89 £450.03 £613.10 £124.64 £378.20 £4863.72
FEC100-Pw, fluorouracil, epirubicin, cyclophosphamide and weekly paclitaxel; FEC100-T, fluorouracil, epirubicin, cyclophosphamide and docetaxel; FEC75, fluorouracil, epirubicin and
cyclophosphamide; TC, docetaxel and cyclophosphamide.
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TABLE 88 Cusumano et al.167 post-test chemotherapy probabilities (node negative and node positive)
Test risk classification
Post-test chemotherapy probability
Node negative Node positive
Low risk 0.05 0.36
High risk 0.92 0.99
TABLE 89 Penault-Llorca et al.162 post-test chemotherapy probabilities (LN0)
Test risk classification Post-test chemotherapy probability
Low risk 0.01
High risk 0.87
TABLE 87 Endocrine therapy costs applied in the EAG model
Endocrine therapy
Proportion
of patients
Dosage
(per day) Product Price per pack
Annual
cost Source
Tamoxifen 0.40 20mg 30 × 20-mg tablet
(various manufacturers)
£2.88 £35.06 BNF194
Anastrozole 0.20 1 mg 28 × 1-mg tablet
(various manufacturers)
£1.08 (NHS Drug
Tariff price)
£14.09
Letrozole 0.20 2.5 mg 28 × 2.5-mg tablet
(Alliance Healthcare)
£2.52 £32.87
Exemestane 0.20 25mg 30 × 25-mg tablet
(various manufacturers)
£5.71 (NHS Drug
Tariff price)
£69.52
TABLE 90 Baseline probability of chemotherapy adjusted by oncotype DX Breast Recurrence Score183
(LN0, intermediate clinical risk)
Oncotype DX risk classification Probability (no test)
Low risk Confidential information has been removed
Intermediate risk Confidential information has been removed
High risk Confidential information has been removed
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TABLE 91 Risk classification probabilities and 10-year DMFI probabilities for RSPC (from TransATAC analysis46)
Test risk classification Classification probability 10-year DMFI
LN0, NPI ≤ 3.4
Low risk 0.89 0.978
Intermediate risk 0.09 0.839
High risk 0.02 0.635
LN0, NPI > 3.4
Low risk 0.52 0.858
Intermediate risk 0.30 0.817
High risk 0.18 0.762
TABLE 92 Prosigna risk classification and distant metastases probabilities derived from Gnant and Filipits104 (LN+)
Test risk classification Classification probability 10-year DMFS
Low risk 0.04 1.00
Intermediate risk 0.34 0.94
High risk 0.62 0.76
TABLE 93 EndoPredict Clinical risk classification and distant metastases probabilities derived from Dubsky et al.120 (LN+)
Test risk classification Classification probability 10-year DMFS
Low risk 0.24 0.95
High risk 0.76 0.72
TABLE 94 MammaPrint risk classification and distant metastases probabilities derived from van ’t Veer et al.91 (LN0)
Test risk classification Classification probability 10-year DMFS
Low risk 0.71 0.93
High risk 0.29 0.85
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Appendix 9 External Assessment Group post-test
chemotherapy use survey disseminated to UK Breast
Cancer Group members
The following questionnaire was circulated via e-mail to members of the UKBCG.
Questionnaire: Use of adjuvant chemotherapy for breast cancer based on the results of
genomic/immunohistochemical tests 
A team of researchers at the University of Sheffield is undertaking an assessment of the clinical and 
cost-effectiveness of alternative risk stratification tests for ER-positive, HER2-negative women with
early breast cancer. The cost-effectiveness analysis element of this work requires estimates of the 
proportion of patients who go on to receive adjuvant chemotherapy based on the results of these tests.
Please consider the following three populations of women with ER-positive, HER2-negative with
early breast cancer: 
(1) Node-negative NPI<3.4
(2) Node-negative NPI>3.4
(3) Node-positive (1-3 nodes)
Based on your own subjective opinion, please estimate the probability that a woman in each of these 
subgroups and with each genomic/immunohistochemical test result would go on to receive adjuvant
chemotherapy. Please complete both Tables 1 and 2. 
Table 1: Chemotherapy decisions based on risk score for tests which give 3 classifications
(e.g. Oncotype DX, Prosigna)
Risk score Probability patient with test result would receive chemotherapy 
(1) Node-negative 
NPI<3.4
(2) Node-negative 
NPI>3.4
(3) Node-positive 
(1-3 nodes) 
Low-risk PLEASE COMPLETE PLEASE COMPLETE PLEASE COMPLETE
Intermediate-risk PLEASE COMPLETE PLEASE COMPLETE PLEASE COMPLETE
High-risk PLEASE COMPLETE PLEASE COMPLETE PLEASE COMPLETE
Table 2: Chemotherapy decisions based on risk score for tests which give 2 classifications
(e.g. MammaPrint and EndoPredict) 
Risk score Probability patient with test result would receive chemotherapy 
(1) Node-negative 
NPI<3.4
(2) Node-negative 
NPI>3.4
(3) Node-positive (1-3
nodes) 
Low-risk PLEASE COMPLETE PLEASE COMPLETE PLEASE COMPLETE
High-risk PLEASE COMPLETE PLEASE COMPLETE PLEASE COMPLETE
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Survey results 
Eleven oncologists completed the questionnaire. The mean probabilities obtained from the survey are 
presented in Tables 3 and 4.
Table 3: Chemotherapy decisions based on risk score for tests which give 3 classifications
(e.g. Oncotype DX, Prosigna)
Risk score Probability patient with test result would receive chemotherapy 
(1) Node-negative 
NPI<3.4
(2) Node-negative 
NPI>3.4
(3) Node-positive 
(1-3 nodes) 
Low-risk 0% 4% 41%
Intermediate-risk 20% 41% 72%
High-risk 77% 91% 95%
Table 4: Chemotherapy decisions based on risk score for tests which give 2 classifications
(e.g. MammaPrint and EndoPredict) 
Risk score Probability patient with test result would receive chemotherapy 
(1) Node-negative 
NPI<3.4 
(2) Node-negative 
NPI>3.4
(3) Node-positive 
(1-3 nodes) 
Low-risk 1% 14% 36%
High-risk 74% 91% 96%
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Appendix 10 Modelled chemotherapy use
with and without tumour profiling tests
(External Assessment Group model)
Subgroup Test No test Net change
Oncotype DX vs. current practice
LN0 NPI ≤ 3.4 0.076 0.072 0.004
LN0 NPI > 3.4 0.273 0.430 –0.157
LN1–3 0.337 0.627 –0.290
IHC4+C vs. current practice
LN0 NPI ≤ 3.4 0.030 0.072 –0.042
LN0 NPI > 3.4 0.355 0.430 –0.075
LN1–3 0.554 0.627 –0.073
Prosigna vs. current practice
LN0 NPI ≤ 3.4 0.075 0.072 0.003
LN0 NPI > 3.4 0.435 0.430 0.005
LN1–3 0.709 0.627 0.082
EPClin vs. current practice
LN0 NPI ≤ 3.4 0.140 0.072 0.068
LN0 NPI > 3.4 0.438 0.430 0.008
LN1–3 0.603 0.627 –0.024
MammaPrint vs. current practice
MINDACT overall population 0.319 0.466 –0.148
mAOL high risk 0.445 0.772 –0.327
mAOL low risk 0.191 0.159 0.033
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Appendix 11 External Assessment Group
cost-effectiveness acceptability curves
Cost-effectiveness acceptability curves
Oncotype DX versus current practice
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Node positive (one to three nodes)
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Node-negative Nottingham Prognostic Index score of > 3.4
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Prosigna versus current practice
Node-negative Nottingham Prognostic Index score of ≤ 3.4
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Node positive (one to three nodes)
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Node-negative Nottingham Prognostic Index score of > 3.4
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MammaPrint versus current practice
Overall MINDACT population
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Modified Adjuvant! Online low-risk subgroup
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Appendix 12 Additional economic analyses
undertaken after submission of the original External
Assessment Group report
This appendix contains additional economic analyses undertaken after submission of the original EAGreport.
Cost-effectiveness of chemotherapy by risk subgroup
During the consultation on the EAG report and the Diagnostic Consultation Document, it was suggested
that the EAG model is predisposed to find giving chemotherapy to all patients a clinically effective and
cost-effective use of resources. This interpretation of the model is inaccurate. In the interests of clarity,
Table 95 presents the results of an analysis comparing 100% chemotherapy versus 0% chemotherapy using
the EAG model. As shown in the table, the strategy involving the indiscriminate use of chemotherapy is
dominated by the no-chemotherapy option for patients with a NPI of ≤ 3.4 (i.e. chemotherapy generates
fewer QALYs at a greater cost). Chemotherapy appears to have a favourable clinical effectiveness and
cost-effectiveness profile within the LN0, NPI > 3.4 and LN+ subgroups.
Quality-adjusted life-year shortfall analysis to account for missing
adverse events
In the light of the uncertainties associated with the analysis presented in Chapter 3, Independent economic
evaluation, the EAG undertook a further analysis that presents the QALY shortfall associated with each test
achieving an ICER of £20,000 and £30,000 per QALY gained, based on the deterministic version of the
EAG model (Tables 96–101). Other things being equal, this additional analysis may further inform the
appraisal committee’s deliberations around whether or not other factors that cannot be reliably quantified
might have a sufficient impact on the ICERs of the tumour profiling tests to change the interpretation of
the model results.
Within each analysis, the QALY shortfall represents the additional number of incremental QALYs that
would need to be accrued, given the currently quantified estimates of the incremental QALYs gained for
the test and its incremental cost, in order for each test to achieve an ICER at a particular threshold
(λ = £20,000 per QALY gained or λ = £30,000 per QALY gained). In health economic terms, this QALY
shortfall is equivalent to net clinical benefit. The NICE Diagnostic Appraisal Committee may find it useful
to consider whether the expected magnitude of the health losses avoided by reducing chemotherapy use
via tumour profiling tests that are not captured in the EAG model is likely to be equal to or greater than
TABLE 95 Cost-effectiveness of chemotherapy vs. no chemotherapy
Subgroup Option QALYs Costs Incremental QALYs Incremental costs ICER
LN0, NPI ≤ 3.4 100% chemotherapy 13.83 £7454 –0.04 £3670 Dominated
No chemotherapy 13.87 £3784 – – –
LN0, NPI > 3.4 100% chemotherapy 12.85 £11,700 0.27 £2316 £8449
No chemotherapy 12.58 £9384 – – –
LN+ 100% chemotherapy 12.63 £12,668 0.35 £2011 £5787
No chemotherapy 12.28 £10,658 – – –
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TABLE 96 The QALY shortfall analysis: oncotype DX (prognostic benefit only)
Oncotype DX (prognostic)
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
Incremental QALYs 0.01 –0.02 –0.07
Incremental costs £1317 £869 £647
ICER £120,144 Dominated Dominated
QALY shortfall to achieve ICER of
£20,000/QALY gained
0.05 0.06 0.10
QALY shortfall to achieve ICER of
£30,000/QALY gained
0.03 0.04 0.09
Proportion of patients avoiding
chemotherapy owing to testing
0.00 0.16 0.29
Proportion of patients with unaccounted
AEs (assumption based on consultation
responses)
0.25 0.25 0.25
Proportion of patients tested avoiding
chemotherapy with unaccounted AEs
N/A – more get
chemotherapy in test group
0.04 0.07
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £20,000/QALY
N/A – more get
chemotherapy in test group
1.49 1.44
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £30,000/QALY
N/A – more get
chemotherapy in test group
1.12 1.29
N/A, not applicable.
TABLE 97 The QALY shortfall analysis: oncotype DX (predictive benefit)
Oncotype DX (predictive)
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
Incremental QALYs 0.04 0.27 0.09
Incremental costs £1211 –£364 –£68
ICER £34,245 Dominating Dominating
QALY shortfall to achieve ICER of
£20,000/QALY gained
0.03 N/A – ICER already
below threshold
N/A – ICER already
below threshold
QALY shortfall to achieve ICER of
£30,000/QALY gained
0.01 N/A – ICER already
below threshold
N/A – ICER already
below threshold
Proportion of patients avoiding
chemotherapy owing to testing
0.00 0.16 0.29
Proportion of patients with unaccounted
AEs (assumption based on consultation
responses)
0.25 0.25 0.25
Proportion of patients tested avoiding
chemotherapy with unaccounted AEs
N/A – more get
chemotherapy in test group
0.04 0.07
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TABLE 97 The QALY shortfall analysis: oncotype DX (predictive benefit) (continued )
Oncotype DX (predictive)
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £20,000/QALY
N/A – more get
chemotherapy in test group
N/A – ICER already
below threshold
N/A – ICER already
below threshold
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £30,000/QALY
N/A – more get
chemotherapy in test group
N/A – ICER already
below threshold
N/A – ICER already
below threshold
N/A, not applicable.
TABLE 98 The QALY shortfall analysis: IHC4+C
IHC4+C
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
Incremental QALYs 0.01 0.01 0.05
Incremental costs £22 –£89 –£269
ICER £2752 Dominating Dominating
QALY shortfall to achieve ICER of
£20,000/QALY gained
N/A – ICER already below
threshold
N/A – ICER already
below threshold
N/A – ICER already
below threshold
QALY shortfall to achieve ICER of
£30,000/QALY gained
N/A – ICER already below
threshold
N/A – ICER already
below threshold
N/A – ICER already
below threshold
Proportion of patients avoiding
chemotherapy owing to testing
0.04 0.08 0.07
Proportion of patients with unaccounted
AEs (assumption based on consultation
responses)
0.25 0.25 0.25
Proportion of patients tested avoiding
chemotherapy with unaccounted AEs
0.01 0.02 0.02
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £20,000/QALY
N/A – ICER already below
threshold
N/A – ICER already
below threshold
N/A – ICER already
below threshold
QALY loss for patients avoiding
chemotherapy with unaccounted AEs
required to achieve shortfall at
λ = £30,000/QALY
N/A – ICER already below
threshold
N/A – ICER already
below threshold
N/A – ICER already
below threshold
N/A, not applicable.
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TABLE 99 The QALY shortfall analysis: Prosigna
Prosigna
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
Incremental QALYs 0.02 0.07 0.07
Incremental costs £1891 £1713 £1967
ICER £89,693 £25,857 £28,666
QALY shortfall to achieve ICER of £20,000/QALY gained 0.07 0.02 0.03
QALY shortfall to achieve ICER of £30,000/QALY gained 0.04 N/A – ICER
already below
threshold
N/A – ICER already
below threshold
Proportion of patients avoiding chemotherapy owing to
testing
0.00 –0.01 –0.08
Proportion of patients with unaccounted AEs (assumption
based on consultation responses)
0.25 0.25 0.25
Proportion of patients tested avoiding chemotherapy with
unaccounted AEs
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy in
test group
QALY loss for patients avoiding chemotherapy with
unaccounted AEs required to achieve shortfall at
λ = £20,000/QALY
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy in
test group
QALY loss for patients avoiding chemotherapy with
unaccounted AEs required to achieve shortfall at
λ = £30,000/QALY
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy in
test group
N/A, not applicable.
TABLE 100 The QALY shortfall analysis: EPClin
EPClin
Subgroup
LN0, NPI < 3.4 LN0, NPI > 3.4 LN1–3
Incremental QALYs 0.01 0.03 0.06
Incremental costs £1686 £1401 £1185
ICER £141,848 £46,482 £21,489
QALY shortfall to achieve ICER of £20,000/QALY gained 0.07 0.04 0.00
QALY shortfall to achieve ICER of £30,000/QALY gained 0.04 0.02 N/A – ICER already
below threshold
Proportion of patients avoiding chemotherapy owing to
testing
–0.07 –0.01 0.02
Proportion of patients with unaccounted AEs (assumption
based on consultation responses)
0.25 0.25 0.25
Proportion of patients tested avoiding chemotherapy with
unaccounted AEs
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
0.01
QALY loss for patients avoiding chemotherapy with
unaccounted AEs required to achieve shortfall at
λ = £20,000/QALY
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
0.69
QALY loss for patients avoiding chemotherapy with
unaccounted AEs required to achieve shortfall at
λ = £30,000/QALY
N/A – more get
chemotherapy
in test group
N/A – more get
chemotherapy
in test group
N/A – ICER already
below threshold
N/A, not applicable.
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this estimated QALY shortfall. It should be noted that this analysis is predicated on the commentators’
assumption that the adverse effects of chemotherapy have been underestimated in the EAG’s model.
However, the EAG model suggests that with the exception of IHC4+C, all tests increase chemotherapy use
in at least some subgroups (see Appendix 10); where this is the case, changing the balance of the net
health gains and losses of chemotherapy will produce less favourable ICERs for the tumour profiling tests.
It should also be noted that any potential underestimation of QALY losses only apply to those patients who
would have received chemotherapy and who would have experienced associated late effects who now do
not receive chemotherapy owing to the tumour profiling test result and thus avoid these late effects.
The QALY shortfall analysis operates as follows. As shown in Table 96, within the LN0 NPI > 3.4 group,
oncotype DX (assuming prognostic benefit only) is estimated to lead to –0.02 QALYs and additional costs
of £869 compared with no testing, hence it is expected to be dominated by no testing. In this subgroup,
oncotype DX would need to make up a further 0.06 QALYs in order to achieve an ICER of £20,000 per
QALY gained given its incremental cost [£869/(0.06 + –0.02) = £20,000]. Within this subgroup, the EAG
model suggests that the probability of receiving chemotherapy is reduced by 16% owing to the use of
oncotype DX. Assuming that 25% of these patients experience late effects of chemotherapy that are not
accounted for within the EAG model, this means that 4% (0.16 × 0.25) of those forgoing chemotherapy
will avoid late effects. The overall QALY shortfall of 0.06 QALYs and the probability of avoiding late effects
of 0.04 means that each patient who would have experienced a late effect of chemotherapy would have
had to have lost 1.49 QALYs (0.06/0.04) due to that AE in order for oncotype DX to be cost-effective at a
threshold of £20,000 per QALY gained.
The results for this analysis are summarised in the following sections.
TABLE 101 The QALY shortfall analysis: MammaPrint
MammaPrint
Subgroup
MINDACT
ITT
MINDACT
high risk MINDACT low risk
Incremental QALYs 0.01 –0.04 0.01
Incremental costs £1757 £1380 £2415
ICER £134,059 Dominated £399,182
QALY shortfall to achieve ICER of £20,000/QALY gained 0.07 0.11 0.11
QALY shortfall to achieve ICER of £30,000/QALY gained 0.05 0.09 0.07
Proportion of patients avoiding chemotherapy owing to testing 0.15 0.33 –0.03
Proportion of patients with unaccounted AEs (assumption based on
consultation responses)
0.25 0.25 0.25
Proportion of patients tested avoiding chemotherapy with
unaccounted AEs
0.04 0.08 N/A – more get
chemotherapy in
test group
QALY loss for patients avoiding chemotherapy with unaccounted AEs
required to achieve shortfall at λ = £20,000/QALY
2.03 1.39 N/A – more get
chemotherapy in
test group
QALY loss for patients avoiding chemotherapy with unaccounted AEs
required to achieve shortfall at λ = £30,000/QALY
1.23 1.11 N/A – more get
chemotherapy in
test group
N/A, not applicable.
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Oncotype DX (prognostic benefit assumed) (see Table 96)
l For the LN0, NPI ≤ 3.4 subgroup, the analysis is not relevant as more patients receive chemotherapy in
the test group.
l For the LN0, NPI > 3.4 subgroup, each patient who avoids chemotherapy and avoids experiencing a late
AE not quantified in the EAG model would have to save 1.49 QALYs due to the unquantified AE in
order for oncotype DX to have an ICER of £20,000 per QALY gained. Assuming a threshold of £30,000
per QALY gained, the equivalent value is 1.12 QALYs per patient.
l In the LN1–3 subgroup, each patient who avoids chemotherapy and avoids experiencing a late AE not
quantified in the EAG model would have to save 1.44 QALYs due to the unquantified AE in order for
oncotype DX to have an ICER of £20,000 per QALY gained. Assuming a threshold of £30,000 per
QALY gained, the equivalent value is 1.29 QALYs per patient.
Oncotype DX (predictive benefit assumed) (see Table 97)
l In the LN0, NPI ≤ 3.4 subgroup, the analysis is not relevant as more patients receive chemotherapy in
the test group.
l In the LN0, NPI > 3.4 subgroup, the analysis is not relevant as the test dominates.
l In the LN1–3 subgroup, the analysis is not relevant as the test dominates.
IHC4+C (see Table 98)
l In the LN0, NPI ≤ 3.4 subgroup, the analysis is not relevant as the ICER is already below £20,000 per
QALY gained.
l In the LN0, NPI > 3.4 subgroup, the analysis is not relevant as the test dominates.
l In the LN1–3 subgroup, the analysis is not relevant as the test dominates.
Prosigna (see Table 99)
l In the LN0, NPI ≤ 3.4 subgroup, the analysis is not relevant as the test increases chemotherapy use.
l In the LN0, NPI > 3.4 subgroup, the analysis is not relevant as the test increases chemotherapy use.
l In the LN1–3 subgroup, the analysis is not relevant as the test increases chemotherapy use.
EndoPredict Clinical (see Table 100)
l In the LN0, NPI ≤ 3.4 subgroup, the analysis is not relevant as the test increases chemotherapy use.
l In the LN0, NPI > 3.4 subgroup, the analysis is not relevant as the test increases chemotherapy use.
l In the LN1–3 subgroup, the analysis is not relevant at a threshold of £30,000 per QALY gained as the
ICER is below this. Each patient who avoids chemotherapy and avoids experiencing a late AE not
quantified in the EAG model would have to save 0.69 QALYs due to the unquantified AE in order for
EPClin to have an ICER of £20,000 per QALY gained.
MammaPrint (see Table 101)
l In the MINDACT ITT subgroup, each patient who avoids chemotherapy and avoids experiencing a late
AE not quantified in the EAG model would have to save 2.03 QALYs due to the unquantified AE in
order for MammaPrint DX to have an ICER of £20,000 per QALY gained. Assuming a threshold of
£30,000 per QALY gained, the equivalent value is 1.23 QALYs per patient.
l In the MINDACT high-risk subgroup, each patient who avoids chemotherapy and avoids experiencing a
late AE not quantified in the EAG model would have to save 1.39 QALYs due to the unquantified AE in
order for MammaPrint to have an ICER of £20,000 per QALY gained. Assuming a threshold of £30,000
per QALY gained, the equivalent value is 1.11 QALYs per patient.
l In the MINDACT low-risk subgroup, the analysis is not relevant as the test increases chemotherapy use.
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Additional analyses of oncotype DX versus usual practice including
chemotherapy benefit based on naive indirect comparisons of Study B20,
Study B14 and TransATAC: lymph node-negative, Nottingham Prognostic
Index > 3.4 subgroup
Table 102 presents estimated HRs for chemotherapy versus no chemotherapy based on naive indirect
comparisons of Study B20,50 Study B1449 and TransATAC.46
Table 103 presents additional economic comparisons of oncotype DX versus usual practice including
chemotherapy benefit based on naive indirect comparisons of Study B20,50 B1449 and TransATAC.46 In each
analysis, the modelled HR was calibrated against the estimates presented in Table 102. All analyses are
based on the deterministic version of the EAG model.
TABLE 102 Hazard ratios for chemotherapy benefit by oncotype DX risk score based on naive indirect comparisons
of Study B20, Study B14 and TransATAC
Oncotype DX risk group
10-year DMFS
Estimated HRNo chemotherapy (%) Chemotherapy (%)
B20 vs. B14
Low 93.20 95.60 0.64
Intermediate 85.70 89.10 0.75
High 69.50 88.10 0.35
B20 vs. TransATAC
Low 94.90 95.60 0.86
Intermediate 87.70 89.10 0.88
High 77.20 88.10 0.49
TABLE 103 Additional analyses of oncotype DX vs. usual practice including chemotherapy benefit based on naive
indirect comparisons of Study B20, B14 and TransATAC: LN0, NPI > 3.4 subgroup
Option QALYs Costs Incremental QALYs Incremental costs ICER (per QALY gained)
Chemotherapy benefit based on indirect comparison of B20 and B14
Oncotype DX 12.82 £10,664 0.03 £682 £24,334
No test 12.79 £9981 – – –
Chemotherapy benefit based on indirect comparison of B20 and TransATAC
Oncotype DX 12.74 £10,989 0.06 £525 £8150
No test 12.68 £10,465 – – –
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